UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 1 of 280 PROTOCOL RA0043 AMEN DMENT 9  
A MULTICENTER, OPEN -LABEL STUDY TO ASSES S THE 
PHARMACOKINETICS, SA FETY, AND EFFICACY O F 
CERTOLIZUMAB PEGOL I N CHILDREN AND 
ADOLESCENTS WITH MOD ERATELY TO SEVERELY 
ACTIVE POLYARTICULAR -COURSE JUVENILE IDI OPATHIC 
ARTHRITIS  
PASCAL ( Pediatric Arthritis Study of Certolizum Ab pego L) 
PHASE [ADDRESS_887498] -Number: 2009 -018027 -33 
IND Number : 9869  
UCB BIOSCIENCES GmbH  
Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Protocol /Amendment Number  Date  Type of amendment  
Final  14 Jan 2010  N/A 
Amendment 1  26 Aug 2011  Substantial  
Amendment 2  02 Jul 2012  Nonsubstantial  
Amendment 3  06 May 2013  Substantial  
Amendment 4  01 Aug 2013  Substantial  
Amendment 5  20 Jan 2014  Substantial  
Amendment 6  17 Sep 2015  Nonsubstantial  
Amendment 7  22 Sep 2016  Substantial  
Amendment 8  24 Jun 2019  Substantial  
Amendment 9  27 Apr 2020  Substantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed 
on, reproduced, published or otherwise used without the express permission of UCB . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887499] INFORMATION  
Sponsor  
UCB BIOSCIENCES GmbH  
Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Clinical Program Director  
Name:   
[CONTACT_2761]:  [ADDRESS_887500]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003] 
Phone:  
Fax:  
 
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  UCB  
[ADDRESS_887501]  
Slough  
SL1 3WE   
Phone:  
Fax: 
 
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
[LOCATION_013]  
Phone:  
Fax: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 3 of 280 Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB  
[ADDRESS_887502]  
Slough  
SL1 3WE  
Phone:   
Fax: N/A 
 
Clinical Monitoring Contract Research Organization  
Name:  [CONTACT_67645], Inc.  
Address:  [ADDRESS_887503], Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003] 
Phone:  +[PHONE_443]  
Fax: +[PHONE_444]  
 
Medical Monitor (all regions)  
E-mail:  [EMAIL_12548]  
 
Medical Monitor North America  
Name:  
[CONTACT_7626]:  
Fax: 
 
Medical Monitor Europe  
Name:  
[CONTACT_7626]:  
Fax: 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 4 of 280 SERIOUS ADVERSE EVENT REPORTING  
 
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003] and Canada:  +[PHONE_299] or +[PHONE_300]  
E-mail  Global: [EMAIL_311]   
 
 
 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887504] OF ABBREVIATION S ................................ ................................ ................................ .. 11 
1 SUMMARY  ................................ ................................ ................................ .....................  15 
2 INTRODUCTION  ................................ ................................ ................................ ...........  18 
3 STUDY OBJECTIVES  ................................ ................................ ................................ .... 20 
3.1 Primary study objectives  ................................ ................................ ..............................  20 
3.2 Secondary study objective  ................................ ................................ ...........................  20 
3.3 Other objectives  ................................ ................................ ................................ ...........  20 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 21 
4.1 Primary variables  ................................ ................................ ................................ .........  21 
4.1.1  Pharma cokinetic and immunological variables  ................................ ...................  21 
4.1.2  Safety variables  ................................ ................................ ................................ .... 21 
4.2 Secondary variables  ................................ ................................ ................................ ..... 21 
4.3 Other variables  ................................ ................................ ................................ .............  21 
5 STUDY DESIGN  ................................ ................................ ................................ .............  23 
5.1 Study description  ................................ ................................ ................................ .........  23 
5.1.1  Study duration per study participant  ................................ ................................ .... 24 
5.1.2  Planned number of study participants and sites  ................................ ...................  24 
5.1.3  Anticipated regions and countries  ................................ ................................ ....... 24 
5.2 Schedule of study assessments ................................ ................................ .....................  25 
5.3 Schematic diagram  ................................ ................................ ................................ ....... 29 
5.4 Rationale for study design and selection of dose  ................................ .........................  30 
5.4.1  Study design  ................................ ................................ ................................ .........  30 
5.4.2  Dose sel ection  ................................ ................................ ................................ ...... 30 
[IP_ADDRESS]  Original CZP dose regimen  ................................ ................................ ....... 31 
[IP_ADDRESS]  Reduced CZP dose regimen  ................................ ................................ ...... [ADDRESS_887505] AWAL OF STUDY PARTIC IPANTS  ...........................  34 
6.1 Inclusion criteria  ................................ ................................ ................................ ..........  34 
6.2 Exclusion criteria  ................................ ................................ ................................ .........  35 
6.3 Retesting and rescreening  ................................ ................................ ............................  39 
6.4 Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ ...............  39 
6.5 Withdrawal criteria  ................................ ................................ ................................ ...... 40 
7 STUDY TREATMENTS  ................................ ................................ ................................ . 42 
7.1 Description of IMP  ................................ ................................ ................................ ...... 42 
7.2 Treatments to be administered  ................................ ................................ .....................  42 
7.2.1  Procedure for dose change (Protocol Amendment 9)  ................................ ..........  44 
7.3 Packaging  ................................ ................................ ................................ .....................  45 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 6 of 280 7.4 Labeling  ................................ ................................ ................................ .......................  45 
7.5 Handling and storage requirements  ................................ ................................ .............  45 
7.6 Drug accountability  ................................ ................................ ................................ ...... 46 
7.7 Proced ures for monitoring study participant compliance  ................................ ............  46 
7.8 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 47 
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  ..........................  47 
7.8.2  Rescue medication  ................................ ................................ ...............................  48 
7.8.3  Proh ibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  .........................  [ADDRESS_887506] to follow up  ................................ ................................ ................................ ..........  49 
7.10  Enrollment and numbering of study participants  ................................ .........................  50 
8 STUDY PROCEDURES BY [CONTACT_16990]  ................................ ................................ ...............  50 
8.1 Visit 1 (Week -4 to 0) Screening  ................................ ................................ .................  50 
8.2 Visit 2 (Week 0) Baseline  ................................ ................................ ............................  52 
8.3 Visits 3 and 4 (Weeks 1 and 2)  ................................ ................................ ....................  53 
8.4 Visits 5 to 10 (Weeks 4, 8, 12 , 16, 20, and 24)  ................................ ............................  54 
8.5 Visits 11 and continuing (Week 32 and every 8 weeks thereafter)  .............................  55 
8.6 Unscheduled Visit  ................................ ................................ ................................ ........  57 
8.6.1  Unscheduled Visit related to dose change  ................................ ...........................  57 
8.7 Early Discontinuation/End of Treatment Visit  ................................ ............................  [ADDRESS_887507]  ................................ ................................ ................................ . 65 
10.4  Immediate reporting of AEs ................................ ................................ .........................  65 
10.5 Anticipated serious adverse events  ................................ ................................ ..............  66 
10.6  Laboratory measurements  ................................ ................................ ............................  66 
10.7  Other safety measurements  ................................ ................................ ..........................  69 
10.7.1  Vital signs  ................................ ................................ ................................ ............  69 
10.7.2  Growth (height and weight)  ................................ ................................ .................  69 
10.7.3  Tanner stages  ................................ ................................ ................................ ....... 70 
10.7.4  Physical examination  ................................ ................................ ...........................  70 
10.7.5  Demographics, JIA history, prior JIA medication, and general medical and 
procedure history  ................................ ................................ ................................ . 71 
10.7.6  Reproductive potential and birth control  ................................ .............................  71 
10.7.7  Pregnancy testing  ................................ ................................ ................................ . 71 
10.7.8  Autoantibody (ANA and anti -dsDNA antibodies) concentrations  ......................  71 
10.7.9  Assessment and management of TB and TB risk factors  ................................ .... 71 
[IP_ADDRESS]  Physical examination  ................................ ................................ .................  72 
[IP_ADDRESS]  IGRA test conversion  ................................ ................................ ................  72 
[IP_ADDRESS]  Latent TB infection  ................................ ................................ ...................  73 
[IP_ADDRESS] Active TB or NTMB infection  ................................ ................................ .. 73 
[IP_ADDRESS]  TB assessment by [CONTACT_658244]  (TST)  .............................  73 
[IP_ADDRESS]  TB assessment by [CONTACT_13190] x -ray ................................ ................................ ... 74 
[IP_ADDRESS]  TB risk factors via the TB questionnaire  ................................ ...................  74 
[IP_ADDRESS]  TB management  ................................ ................................ ........................  75 
11 ASSESSMENT OF EFFICA CY AND HEALTH OUTCOM ES VARIABLES  ............  76 
11.1  PedACR30, PedACR50, PedACR70, and PedACR90 clinical response  ....................  76 
11.2  PRINTO/PRCSG standard joint examination  ................................ ..............................  76 
11.3  Number of joints with active arthritis and number of joints with limitation of 
range of motion  ................................ ................................ ................................ ............  77 
11.4  Physician’s Global Assessment of Disease Activity (VAS)  ................................ ........  77 
11.5 Childhood Health Assessment Questionnaire (CHAQ)  ................................ ...............  77 
11.6  Parent’s Assessment of Arthritis Pain (VAS)  ................................ ..............................  78 
11.7  Parent’s Global Assessment of Overall Well -Being (VAS)  ................................ ........  78 
11.8  C-reactive protein (CRP)  ................................ ................................ .............................  78 
11.9  JADAS  ................................ ................................ ................................ .........................  79 
11.10  Clinically Inactive Disease and clinical remission  ................................ ......................  79 
11.11  Duration of morning stiffness (DMS)  ................................ ................................ ..........  80 
11.12  Faces Pain Scale -Revised (FPS -R) ................................ ................................ ..............  80 
11.13  Patient’s Assessment of Arthritis Pain (JIA Pain VAS)  ................................ ..............  81 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 8 of 280 11.14  Fatigue Assessment Scale (NRS) ................................ ................................ .................  81 
11.15  Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey  ........  82 
12 STUDY MANAGEMENT AND  ADMINISTRATION  ................................ .................  82 
12.1  Adherence to protocol  ................................ ................................ ................................ .. 82 
12.2  Monitoring  ................................ ................................ ................................ ...................  82 
12.2.1  Definition of source data  ................................ ................................ .....................  83 
12.2.2  Source data verification  ................................ ................................ .......................  83 
12.3  Data handling  ................................ ................................ ................................ ...............  84 
12.3.1  Case re port form completion  ................................ ................................ ...............  84 
12.3.2  Database entry and reconciliation  ................................ ................................ ........  84 
12.3.3  Study participant screening and enrollment log/Study participant 
identification code list  ................................ ................................ ..........................  84 
12.4  Termination of the study  ................................ ................................ ..............................  84 
12.5  Archiving and data retention  ................................ ................................ ........................  85 
12.6  Audit and inspection  ................................ ................................ ................................ .... 85 
12.7  Good Clinical Practice  ................................ ................................ ................................ . 86 
13 STA TISTICS  ................................ ................................ ................................ ...................  86 
13.1  Definition of analysis sets  ................................ ................................ ............................  86 
13.2  General statistical considerations  ................................ ................................ .................  86 
13.2.1  Data presentation  ................................ ................................ ................................ . 86 
13.2.2  Multicenter studies  ................................ ................................ ...............................  87 
13.2.3  Coding dictionaries  ................................ ................................ ..............................  87 
13.3  Planned safety analyses ................................ ................................ ................................  87 
13.4  Planned PK, PD, and immunological variable analysis  ................................ ...............  88 
13.5  Planned efficacy and health outcomes analyses  ................................ ..........................  89 
13.6  Handling of dropouts or missing data  ................................ ................................ ..........  90 
13.7  Interim analysis and data monitoring  ................................ ................................ ...........  91 
13.8  Determination of sample size  ................................ ................................ .......................  92 
14 ETHICS AND REGULATOR Y REQUIREMENTS  ................................ ......................  93 
14.1  Informed consent  ................................ ................................ ................................ .........  93 
14.2  Study participant identification cards  ................................ ................................ ..........  94 
14.3  Institutional Review Boards and Independent Ethics Committees  ..............................  95 
14.4  Study participant privacy  ................................ ................................ .............................  95 
14.5  Protocol amendments  ................................ ................................ ................................ ... 96 
15 FINANCE, INSURANCE, AND PUBLICATION  ................................ .........................  96 
16 REFERENCES  ................................ ................................ ................................ ................  96 
17 APPENDICES  ................................ ................................ ................................ .................  98 
17.1  Childhood Health Assessment Questionnaire (CHAQ)  ................................ ...............  99 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 9 of 280 17.2  Parent’s Assessment of Arthritis Pain (VAS)  ................................ ............................  101 
17.3  Parent’s Global Assessment of Overall Well -Being (VAS)  ................................ ...... 101 
17.4  Faces Pain Scale -Revised  ................................ ................................ ..........................  102 
17.5  Patient’s Assessment of Arthritis Pain (JIA Pain VAS, acute version)  .....................  103 
17.6  Patient’s Assessment of Arthritis Pain (JIA Pain VAS, standard version)  ................  103 
17.7  Fatigue Assessment Scale (NRS) ................................ ................................ ...............  103 
17.8  Juvenile Arthritis School Attendance and Ca regiver Work Productivity Survey  ...... 104 
17.9  TB questionnaire  ................................ ................................ ................................ ........  110 
17.10  Liver Safety – Suggested Actions and Follow -up Assessments  ................................  111 
17.10.1  Evaluation of PDILI  ................................ ................................ ..........................  111 
[IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  ....................  114 
[IP_ADDRESS]  Immediate action: determination of IMP discontinuation  .......................  114 
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  .........................  114 
[IP_ADDRESS]  Follow -up evaluation  ................................ ................................ ...............  [ADDRESS_887508] OF TABLES  
Table  5-1 Schedule of study assessments ................................ ................................ .........  25 
Table  5-2 PK estimates of CZP exposure in adult study participants with RA 
based on population PK modeling  ................................ ................................ ... 32 
Table  6-1 Prohibited medications at entry (Baseline)  ................................ ......................  36 
Table  7-1 Dosing administration of CZPa ................................ ................................ ........  43 
Table  10-1 Anticipated serious adverse events for JIA population ................................ .... 66 
Table  10-2 Laboratory measurements  ................................ ................................ ................  68 
Table  13-1 PK simulation results for 125 -study participant study sample size  .................  93 
Table  17‒1:  Required investigations and follow up for PDILI ................................ ..........  112 
Table  17‒2:  PDILI laboratory measurements  ................................ ................................ .... 115 
Table  17‒3:  PDILI information to be collected  ................................ ................................ . 116 
Table  17‒1  Proposed revised dosing recommendation based on PopPK model 
simulations  ................................ ................................ ................................ ..... 169 
Table  17‒[ADDRESS_887509]  
EAIR  exposure -adjusted incidence rate  
ECG  electrocardiogram  
ECLIA  electrochemiluminescen ce immuno assay  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 12 of 280 ELISA  enzyme -linked immunosorbent assay  
ERA  enthesitis -related arthritis  
ES Enrolled Set  
ETN  etanercept  
Fab′ fragment antigen binding  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FPS-R Faces Pain Scale -Revised  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
HBcAb  hepatitis B core antibody  
HBsAb  hepatitis B surface antibody  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
ia intra-articular  
IB Investigator’s Brochure  
IBD inflammatory bowel disease  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IGRA  interferon -gamma release assay  
im intramuscular  
IMP investigational medicinal product  
INH isonicotinic acid hydrazide/isoniazid  
IRB institutional review board  
iv intravenous(ly)  
IXRS  interactive voice/web response system  
JADAS  Juvenile Arthritis Disease Activity Score  
JIA juvenile idiopathic arthritis  
LOCF  last observation carried forward  
LOM  limitation of motion  
LTB  latent tuberculosis  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 13 of 280 LTBI  latent tuberculosis infection  
MAR  missing at random  
MCP  metacarpal  
MedDRA® Medical Dictionary of Regulatory Activities  
MSD  Meso Scale Discovery  
MTP  metatarsophalangeal  
MTX  methotrexate  
NRS  numeric rating scale  
NSAID  nonsteroidal anti-inflammatory drug  
NTMB  nontuberculous mycobacteria  
OC observed case  
PD Pharmacodynamic(s)  
PDILI  potential drug -induced liver injury  
PedACR30, 50, 70, 90  American College of Rheumatology Pediatric 30%, 50%, 70%, 90%  
PEG  polyethylene glycol  
PFS prefilled syringe(s)  
PIP proximal interphalangeal  
PK pharmacokinetics  
PK-PD Pharmacokinetic -Pharmacodynamic  
PK-PP Pharmacokinetic Per -Protocol  
POM  pain on motion  
PopPK  population pharmacokinetic  
PRN  as needed  
PRINTO/PRCSG  Paediatric Rheumatology INternational Trials Organisation/ Pediatric 
Rheumatology Collaborative Study Group  
Q2W, Q4W  every 2 weeks, every 4 weeks  
RA rheumatoid arthritis  
RBC  red blood cell  
RDC  remote data capture  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
sc subcutaneous(ly)  
SDV  source data verification  
SOP standard operating procedures  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 14 of 280 SS Safety Set  
TB tuberculosis  
TNF  tumor necrosis factor  
TNFα  tumor necrosis factor alpha  
[LOCATION_003]  [LOCATION_002] of America  
VAS  visual analog scale  
WBC  white blood cell  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 15 of 280 1 SUMMARY  
This is a Phase 3, multicenter, open -label study to assess the pharmacokinetics (PK), safety, 
and efficacy of certolizumab pegol (CDP870, CZP, Cimzia®) in children and adolescents 
with moderately to severely active polyarticular -course juvenile idi opathic arthritis (JIA).  
Certolizumab pegol, the investigational medicinal product (IMP), is a humanized antibody 
fragment antigen binding (Fab′), with specificity for human tumor necrosis factor alpha 
(TNFα), conjugated to polyethylene glycol (PEG). The d rug intended for use in this study is 
the liquid formulation in a prefilled syringe (PFS).  
The study population will consist of study participants 2 to 17 years of age upon enrollment 
with a minimum weight of 10kg (22lb). Study participants must have had onset of signs and 
symptoms consistent with polyarticular -course JIA and initiation of JIA treatment for at least 
6 months prior to Baseline. Active polyarticular -course  JIA disease is defined as ≥5  joints 
with active arthritis  including : polyarthritis rhe umatoid factor -positive, polyarthritis 
rheumatoid factor -negative, extended oligoarthritis, juvenile psoriatic arthritis, and 
enthesitis -related arthritis (ERA).  Study participants cannot have had active uveitis within the 
last [ADDRESS_887510] 1  disease -modifying antirheumatic drug (DMARD).  
The study consists of a Screening Period of up to 4 weeks; eligible study participants will 
then enter an o pen-label Treatment Period which will continue until the approval of the 
marketing application for the indication of polyarticular -course JIA in the study participant’s 
country or region or until further notice from UCB. A Final Visit will be conducted [ADDRESS_887511] dose of study medication.  
Approximately 195 study participants are planned to be screened to enroll 156 study 
participants in this study, as follows:  
 A minimum of 10 study participants will  be enrolled on the reduced CZP dose regimen 
(Prot ocol Amendment 5) in each weight range of 10 to <20kg (22 to <44lb), 20 to <40kg 
(44 to <88lb), and ≥40kg (≥88lb).  
 A minimum of 10 study participants will be enrolled in each age category of 2 to 5  years, 
6 to 11 years, and 12 to 17 years, irrespective of  the dose regimen.  
 A minimum of 25  study participants will be enrolled who receive CZP as monotherapy 
(ie, study participants with established intolerability or inadequate response to MTX),  
irrespective of the dose regimen . 
 A minimum of [ADDRESS_887512] 5  study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44  to <88lb), and ≥40kg (≥88lb)  following 
Protocol Amendment [ADDRESS_887513] completed 
the Week  24 (Visit  10) assessments.  
Certolizumab pegol will be administered as a fixed dose based on weight throughout the 
study consisting of 3  loading doses at Weeks 0, 2, and 4, followed by [CONTACT_65119] 
Q2W. The original minimum and maximum loading doses in the study were CZP 100mg 
Q2W and CZP  400mg Q2W, respectively, and the original minimum and maximum 
maintenance doses we re CZP  50mg Q2W and CZP  200mg Q2W, respectively. Based on an 
interim PopPK analysis of RA0043 data, the minimum and maximum loading doses in the 
study were adjusted to CZP 50mg Q2W and CZP  200mg Q2W, respectively, and the 
minimum and maximum maintenance do ses were adjusted to CZP  50mg Q4W and 
CZP 100mg Q2W, respectively, following implementation of Protocol Amendments 4 and 5.  
However, it was later determined that there were  deficiencies detected with the use of the 
bioanalytical assay within RA0043 , which rendered the PK data for the PopPK analysis and 
simulations that informed the dose reduction in Protocol Amendment 4 and 5 unusable from a 
regulatory standpoint. Accordingly, PK samples were no longer collected for study 
participants on the reduced CZP dos e regimen following implementation of Protocol 
Amendment 8.  
An electrochemiluminescence immuno assay (ECLIA) method, for which selectivity had 
previously been assessed in the RA matrix, has now been validated to meet the standards set 
in the regulatory gui dance for analytical procedures and methods validations for drugs and 
biologics.  
Based on [ADDRESS_887514] 163 participants enrolled in RA0043, both the 
original and reduced dose regimens showed safety profiles similar to the approved  CZP dose 
regimen in the adult RA population. The overall clinical response in this analysis (taking both 
dose regimens into account) was American College of Rheumatology Pediatric 30% 
(PedACR30)  and PedACR50 responses of 77.3% and 67.5%, respectively at W eek 12. The 
response from the original dose regimen was 75.6% for PedACR30 and 64.1% for 
PedACR50. PedACR50 response demonstrates a highly clinically relevant decrease in 
disease activity.  
Therefore, in order to adequately assess the exposure levels and cl inical experience of CZP in 
JIA at both the reduced and original CZP dose regimens and also adequately support the 
safety assessment of the original CZP dosing regimen, as more of the safety data collected in 
the study to date has been on the reduced dose,  [ADDRESS_887515] plasma concentrations of 
CZP and anti -CZP antibodies analyzed using  the ECLIA method. In addition, PK and ADA 
samples (for which sufficient volume is available) collected in this study prior to Protocol 
Amendment  9 will be analyzed with the ECLIA method. The collective ECLIA -based PK 
data for this study will form the basi s of any future CZP modeling and simulation work.  
The primary objectives of the study  are to evaluate the PK and safety including the 
immunogenicity of CZP administered subcutaneously  (sc) in children and adolescents with 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 17 of 280 moderate to severe  polyarticular -course JIA. The primary PK and immunological variables 
are CZP plasma concentrations and anti -CZP antibody levels at Week 16 and Week 48.  
The primary safety variables are the incidence of serious treatment -emergent adverse events 
(TEAEs) and TEAEs leading to permanent withdrawal of IMP. Other safety variables to be 
assessed are the incidence of TEAEs, vital signs and measurements of laboratory parameters 
including hematology, biochemistry, and urinalysis. Physical examination findings (except 
joint examinat ion) are recorded in the case report form (CRF) only at Screening. Subsequent 
physical examinations are performed to assess clinically significant changes and thus, only 
abnormal findings are recorded in the CRF as AEs. Tanner stages (except growth) and 
growth (height, weight) over the course of the study will be assessed. Autoantibody 
(antinuclear antibodies [ANA] and anti -double -stranded deoxyribonucleic acid [anti -dsDNA] 
antibodies) concentrations will be evaluated. The secondary objective of the study i s to assess 
the effectiveness of CZP on the clinical response in children and adolescents with moderate 
to severe polyarticular -course JIA.  
The following efficacy variables are defined as secondary variables: PedACR30, PedACR50, 
PedACR70, and PedA CR90 response rates at Week 16 (compared to Baseline). Other 
efficacy and health outcomes variables include: PedACR30, PedACR50, PedACR70, and 
PedACR90 response rates at other timepoints than Week 16 (compared to Baseline), change 
from Baseline in number o f joints with active arthritis, change from Baseline in number of 
joints with limitation of range of motion, change from Baseline in Physician’s Global 
Assessment of Disease Activity (visual analog scale [VAS]), change from Baseline in 
Childhood Health Assessment Questionnaire (CHAQ, parent/caregiver reported) total score, 
change from Baseline in Parent's Assessment of Arthritis Pain (VAS), change from Baseline 
in Parent’s Global Assessment of Overall Well -Being (VAS), ratio to Baseline in C -reactive 
protein (CRP), change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS), 
percentage  of study participants meeting criteria of Clinically Inactive Disease (CID) and 
clinical remission on medication (CRM), time to CID, time to CRM, change from Baseline in 
duration of morning stiffness (DMS), change from Baseline in Faces Pain Scale -Revised 
(FPS -R, child reported, ages 5 to 11  years), change from Baseline in Patient’s Assessment of 
Arthritis Pain (JIA Pain VAS, child reported, ages 12 to 17 years ), change from Baseline in 
Fatigue Assessment Scale, and Juvenile Arthritis School Attendance and Caregiver Work 
Productivity Survey (parent/caregiver reported).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 18 of 280 2 INTRODUCTION  
Certolizumab pegol (CDP870, CZP, Cimzia®) is approved in the [LOCATION_002] of Ame rica 
([LOCATION_003]), the European Union, and a number of other countries worldwide for the treatment of 
moderately to severely active RA in adults.  
Juvenile idiopathic arthritis is the clinical presentation of persistent arthritis (≥6 weeks in 
duration) of unknown  etiology due to chronic inflammation of the synovium (Ravelli and 
Martini, 2007; Nigrovic and White, 2006). Juvenile idiopathic arthritis is the most commonly 
diagnosed rheumatic disease affecting children less than 16  years of age with a prevalence of 
approximately 100 in 100,000 children (Zitelli et al, 2012). Disease onset is typi[INVESTIGATOR_58015] 
5 years of age but rarely before 6  months, and  females are affected approximately twice as 
frequently as males. Juvenile idiopathic arthritis leads to significant func tional and emotional 
disability with 50% of affected children continuing to suffer from persistent inflammation 
and disability as adults.  
The disease is characterized by B -cell, T -cell, and macrophage infiltration and expansion 
which leads to the release o f proinflammatory cytokines and promotes synovial proliferation, 
resulting in thickened pannus and subsequently joint destruction. Patients with 
polyarticular -course JIA have ≥5  inflamed joints over the course of the disease . For the 
purpose of this study,  polyarticular -course is defined as ≥5 joints at the time of enrollment. In 
addition to the articular manifestations, children with JIA commonly present with 
constitutional symptoms such as anorexia, weight loss, and growth failure.  
The introduction of TNF -antagonists represented a major advance in the drug treatment of 
RA for adults and subsequently, JIA in children and adolescents. Two TNF -antagonists, 
etanercept (ETN) and adalimumab (ADA), are currently registered in both the [LOCATION_003] and 
Europe for the treat ment of JIA. The therapeutic response to these available TNF -antagonists 
is variable. This is also true for tolerability and is in keepi[INVESTIGATOR_658211]. Therefore, a medical need remains for 
additional ef fective TNF -antagonists in the treatment of JIA.  
TNFα blockers appear to be less effective in patients with systemic JIA compared to other 
JIA subtypes (Lovell et  al, 2000). Recent evidence suggests that, unlike other JIA subtypes, 
abnormalities in the cyt okines IL -1 and IL -6 play a major role in the pathogenesis of systemic 
JIA (Vastert et al, 2009). The IL -6 blocker tocilizumab is currently approved in the EU for 
systemic JIA (Tocilizumab [RoActemra®] Summary of Product Characteristics, 2010).  
Certolizuma b pegol is a humanized antibody antigen -binding fragment (Fab′), with 
specificity for human TNFα, which is conjugated to PEG. Certolizumab pegol has a high 
affinity for TNFα with a Kd of 0.9x10-10M and has been shown to be an effective 
TNF -inhibitor, preve nting the development of arthritis as assessed by [CONTACT_658245] a transgenic mouse model of progressive arthritis. Certolizumab pegol 
does not neutralize TNF beta (lymphotoxin) and does not effect antibody -dependent 
cell-medi ated cytotoxicity (ADCC) or activate complement -mediated lysis in vitro.  
Single -dose and subchronic toxicity studies in animal models indicate that CZP was well 
tolerated and had no safety issues. Genotoxicity (in vitro and in vivo) and reproductive 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 19 of 280 toxic ity (animal models) studies support the safety of the product, demonstrating no adverse 
effects from CZP.  
Single intravenous (iv) and sc doses of CZP have been shown to have predictable 
dose-related exposure with an approximately linear relationship betwee n the dose 
administered and both the maximum plasma concentration (C max) and the area under the CZP 
plasma concentration versus time curve (AUC). The terminal elimination phase half -life is 
approximately [ADDRESS_887516] good 
bioavailability (~80%) when given sc.  
No clinically meaningful drug -drug interactions between CZP and methotrexate (MTX) or its 
metabolite, [ADDRESS_887517] shown that 
concomitant administration of M TX (or other immunosuppressants), corticosteroids, 
aminosalicylic acid analogs, nonsteroidal anti -inflammatory drugs (NSAIDs), analgesics, or 
anti-infectives do not impact the PK of CZP. Age and gender had no effect on the PK of CZP 
in these studies. The i nfluence of renal impairment was not studied as almost 80% of the 
study participants had a normal creatinine clearance and less than 2% of the study 
participants exhibited moderate to severe renal impairment.  
The overall clinical efficacy of CZP studied bo th as monotherapy as well as concomitantly 
with MTX in MTX -inadequate responders, in the treatment of adult study participants with 
moderate to severe active RA, was demonstrated in four Phase  3 placebo -controlled RA 
studies. The dosing regimens tested inc luded CZP 400mg sc at Weeks  0, 2, and 4 followed by 
[CONTACT_18322] 200mg or CZP 400mg given Q2W with MTX and CZP 400mg every 4 weeks with and 
without MTX. Inhibition of the progression of structural damage was demonstrated in the two 
Phase  3 studies in which it was e valuated. Significant improvements in physical function, 
health -related quality of life (including pain and tiredness), and productivity within and 
outside the home were demonstrated with CZP compared with the control groups in all four 
Phase  [ADDRESS_887518] 
therapy and for this population as a whole and demonstrate that CZP has a fav orable 
risk-to-benefit profile.  
The risks of the present study are essentially those of experiencing an AE following 
administration of CZP and for progressive disability if the study participant does not respond 
to CZP. As a therapeutic class, currently av ailable TNF -antagonists are known to be 
associated with serious infections, particularly reactivation of tuberculosis (TB) and 
opportunistic fungal infections. An association has also been reported with TNF -antagonist 
therapy and the development of lymphom a and leukemia especially in children and 
adolescents, although it is not clear whether there is a causal relationship as confounding 
factors exist (eg,  the increased risk of lymphoma and leukemia associated with autoimmune 
diseases and immunosuppression) themselves. Other cancer types also have been reported in 
association with TNF -antagonist use, but the causal relationship for these is unclear as well. 
Other serious AEs that have been infrequently reported in patients treated with currently 
available TNF -antagonists including CZP include congestive heart failure, drug -induced 
lupus, demyelinating disorders, and pancytopenia.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 20 of 280 In a placebo -controlled clinical study of study participants with RA, no meaningful difference 
was detected in antibody response  to vaccine between CZP and placebo treatment groups 
when the pneumococcal polysaccharide vaccine and influenza vaccine were administered 
concurrently with CZP. Similar proportions of study participants developed protective levels 
of anti -vaccine antibodies be tween CZP and placebo treatment groups. Study participants 
receiving MTX had a lower humoral response compared with study participants not receiving 
MTX, with or without CZP. The clinical significance of this is unknown. Certolizumab pegol 
does not suppres s the humoral immune response to the pneumococcal polysaccharide vaccine 
or influenza vaccine.  
No data are available on the response to live vaccinations or the secondary transmission of 
infection by [CONTACT_658246]. Live  or live attenuated 
vaccines should not be administered concurrently with CZP.  
Additional information on the nonclinical and clinical data for CZP in RA is available in the 
current version of the CZP Investigator’s Brochure (IB).  
Conducting placebo -control led studies in pediatric populations requires special consideration. 
These include ethical concerns associated with denying active treatment to a population of 
patients that cannot make their own fully -informed choices about healthcare, the enrollment 
difficulties commonly encountered for placebo -controlled pediatric studies, and the limited 
size of the patient population from which to recruit. Studies in JIA are no exception for these 
considerations.  
For the 2 TNF -antagonists (ETN and ADA) approved in the [LOCATION_003] and Europe for the 
treatment of JIA, similarities between the adult RA and the JIA population were shown in the 
placebo -controlled clinical studies with respect to efficacy, safety, and dosing. In light of 
these results and the efficacy of CZP demonstr ated in the 4 adequate and well -controlled 
studies in adult RA, it is appropriate to extrapolate these efficacy data to the intended JIA 
population if similar results are obtained for PK and safety in JIA as seen for adult RA. The 
opi[INVESTIGATOR_658212] -label PK/safety data is acceptable for additional members  of the class of 
TNF -antagonists.  
3 STUDY OBJECTIVES  
3.1 Primary study objectives  
The primary objectives of the study are to evaluate the PK and safety including the 
immunogenicity of CZP administered sc in children and adolescents with moderate to severe  
polyarticular -course JIA. 
3.2 Secondary study objective  
The secondary objective of the  study is to assess the effectiveness of CZP on the clinical 
response in children and adolescents with moderate to severe polyarticular -course JIA. 
3.3 Other objectives  
Other objectives of the study are to further assess safety as well as efficacy and health 
outcomes.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 21 of 280 4 STUDY VARIABLES  
See Section 13.1 for the definition of analysis sets.  
4.1 Primary variables  
4.1.1  Pharmacokinetic and immunological variables  
Certol izumab pegol plasma concentrations and anti -CZP antibody levels at Week 16 and 
Week 48 will be assessed and data will be summarized.  
4.1.2  Safety variables  
The primary safety variables will be the incidence of serious TEAEs and TEAEs leading to 
permanent withdra wal of IMP.  
Adverse events will be solicited at every visit, recorded and coded according to Medical 
Dictionary for Regulatory Activities (MedDRA®) criteria.  
4.2 Secondary variables  
Efficacy will be assessed by [CONTACT_658247]30, PedACR50, PedACR70, and PedACR90 
response rates at Week 16 as compared to Baseline (see Section 11.1 for definition).  
4.3 Other variables  
Other PK and immunological variables are:  
 Certolizumab pegol plasma concentrations and anti -CZP antibody levels at other study 
timepoints  
Other safety variables are:  
 Incidence of TEAEs, TEAEs of interest, TEAEs by [CONTACT_182811], TEAEs by [CONTACT_926], and 
TEAEs by [CONTACT_159464]  
 Clinical laboratory values (hematology, biochemistry, and urinalysis) will be collected 
and assessed at every visit except Visi ts 3 and  4 and Unscheduled Visits.  
 Vital sign abnormalities will be evaluated at every visit.  
 Assessments of study participant’s developmental stages and growth (height, weight) will 
be performed to determine Tanner stages at Baseline, every 24  weeks there after, and the 
Early Discontinuation/End of Treatment Visit (weight at every visit through Final Visit). 
For study participants enrolled prior to Protocol Amendment [ADDRESS_887519] not reached Tanner stage V . 
 Autoantibody (antinuclear antibodies [ANA] and anti -double -stranded deoxyribonucleic 
acid [anti -dsDNA] antibodies) concentrations will be evaluated at  Baseline (testing for 
anti-dsDNA antib odies only if ANA is positive), Weeks 16 and 48, and at the Early 
Discontinuation/End of Treatment Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 22 of 280 Other efficacy and health outcomes variables are:  
 PedACR30, PedACR50, PedACR70, and PedACR90 response rates at every visit except 
Week 16 and Final Vi sit as compared to Baseline (see Section 11.1 for definition).  
 Change from Baseline in number of joints with active arthritis at every visit except  Final 
Visit . 
 Change from Baseline in number of joints with limitation of range of motion at every 
visit except Final Visit.   
 Change from Baseline in Physician’s Global Assessment of Disease Activity (VAS) at 
every visit except Final Visit.  
 Change from Bas eline in CHAQ at every visit except Final Visit . 
 Change from Baseline in Parent's Assessment of Arthritis Pain (VAS) at every visit 
except Final Visit . 
 Change from Baseline in Parent’s Global Assessment of Overall Well -Being (VAS) at 
every visit except Fin al Visit . 
 Ratio to Baseline in CRP at every visit except Final Visit . 
 Change from Baseline in JADAS at every visit except Final Visit .  
 Percentage of study participants with Clinically Inactive Disease (CID) , as defined in 
Section  11.[ADDRESS_887520] -Baseline visit except Final Visit . 
 Percentage of study participants with clinical remission on medication (CRM), as defined 
in Section  11.[ADDRESS_887521] -Baseline visit from Week 24 onwards except Final Visit . 
 Time (in days) to CID.  
 Time (in days) to CRM.  
 Change from Baseline in DMS at every visit  except Final Visit . 
 Change from Baseline in FPS-R (child -reported, ages 5  to 11 years), daily during the first 
week of treatment ; Weeks 4, 12, 16, 24, and then every 8  weeks thereafter through the 
Early Discontinuation/End of Treatment Visit.  For study participants enrolled prior to 
Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 
8 weeks following implementation of Protocol Amendment 8.  
 Change from Baseline in JIA Pain VAS, daily during the first 7 days of the study (acut e 
and standard versions); and at Weeks 4, 12, 16, 24, and then every 8  weeks thereafter 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
participants ages 12 to 17 years.  For study participants enrolled prior to Protoco l 
Amendment 9, visit frequency changes to every 16 weeks instead of every 8 weeks 
following implementation of Protocol Amendment 8 . 
 Change from Baseline in Fatigue Assessment Scale at every visit except Weeks 12 and 
20, and Final Visit . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 23 of 280  Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey responses 
at Baseline, Week 4, and every visit thereafter except Final Visit.  
5 STUDY DESIGN  
5.1 Study description  
This is a Phase 3, multicenter, open -label study to assess the PK, safety, and efficacy of  CZP 
in children and adolescents with moderately to severely active polyarticular -course JIA.  
Please refer to Study Schedule of Assessments in Section 5.2 for visit -specific procedures and 
to Section 5.3 for a schematic representation of the study.  
The overall study consists of a Screening Period of up to 4 weeks (between Weeks -4 to 0 
[Visits 1 and 2]) and an open -label Treatment Period which will continue until the approval 
of the marketing application for the polyarticular -course JIA indication in the study 
participant’s country or region  or until further notice from UCB. A Final Visit will be 
conducted [ADDRESS_887522] dose of study medication.  
A Screening Visit is used to initiate assessments of eligibility. Certolizumab pegol will be 
administered as a fixed dose based on weight throu ghout the study (see Table 7 -1 for doses 
administered and Section  5.4.2  for the rationale for the different dose regimens). At Baseline 
(Week 0, Visi t 2) eligible study participants will begin with 3 loading doses of CZP at Weeks 
0, 2, and 4 followed by a maintenance dose for the duration of the study. After Week 4 
(Visit  5), home -based CZP administration by [CONTACT_658248]/caregiver wi ll be 
permitted between scheduled study visits.  
Interim analyses were performed as described in Section  13.7. A full interim analysis will be 
performed  after all active study participants have completed the Week  24 (Visit 10) 
assessments.  
Pharmacokinetic data from this study that were assayed with an enzyme -linked 
immunosorbent assay (ELISA) technique will not be used for submission to the Food and 
Drug  Administration (FDA) to complete the Pediatric Research Equity Act commitment, 
primarily due to deficiencies detected with the use of the bioanalytical assay within RA0043 . 
All study participants enrolled following Protocol Amendment [ADDRESS_887523] plasma 
concentrations of CZP and anti -CZP antibodies analyzed using an ECLIA method that meets 
current regulatory standards. In addition, PK and ADA samples (for which sufficient volume 
is available) collected in this study prior to Protocol Amendment 9 will be ana lyzed with the 
ECLIA method.  The collective ECLIA -based PK data for this study will form the basis of 
any future CZP modeling and simulation work.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 24 of 280 5.1.1  Study duration per study participant  
For each study participant, there will be a Screening Period of up to 4 weeks (Weeks -4 to 0). 
Eligible study participants will subsequently initiate open -label treatment with CZP at 
Baseline (Week 0, Visit  2) and be permitted to continue until the approval of the marketing 
application for the polyarticular -course JIA indicati on in the study participant’s country or 
region, or until further notice from UCB. The Final Visit will be conducted [ADDRESS_887524] study participant’s Final Visit.  
First Study participant, First Visit – 1Q [ADDRESS_887525] Visit – 3Q 2021  
5.1.2  Planned number of study participants and sites  
Approximately 195 study participants are planned to be screened at about 55 centers in order 
to enroll 156  study participants in this study, as follows:  
 A minimum of 10 study participants will be enrolled on the reduced CZP dose regimen in 
each weight ran ge of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), and ≥40kg 
(≥88lb) (See Section  7.2 for the doses administered in the study and Section  [IP_ADDRESS]  for 
the rationale for the reduced CZP dose regimen).  
 A minimum of 10 study participants will be enrolled in each age category of 2 to 5 years, 
6 to 11 years, and 12 to 17 years, irrespective of the dose regimen.  
 A minimum of 25 study participants will be enrolled who receive CZP as monotherapy 
(ie, study participants with established intolerability or inadequate response to MTX) , 
irrespective of  the dose regimen . 
 A minimum of 10 study participants with ERA will be enrolled, irrespective of the dose 
regimen.  
 The enrollment per site is limited to a maximum of [ADDRESS_887526] 5 study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44 t o <88lb), and ≥40kg (≥88lb) (See Section  7.2 
for the doses administered in the study and Section  [IP_ADDRESS]  for the rationale for the original 
CZP dose regimen).   
Each of these categories is assessed independently. For instance, a 12kg, 3 -year old study 
participant unable to tolerate MTX contributes to the enrollment goals for the 10 to <20kg 
(22 to <44lb) weight group, the 2 - to 5-year-old age group, and the CZP as monotherapy 
group.  
5.1.3  Anticipated regions and countries  
The regions planned for participation in this study are North and South America and Russia, 
with possible extension to other regions.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 25 of 280 5.2 Schedule of study assessments  
Table  5-1 Schedule of study assessments  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 16, 
(17(u)), 20, 24  32 and every 
8 weeks 
thereafter (z) Unsch.  
Visit(b) Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a) 1 2 3 4 5 to 10  11 onwards    FV 
Written informed consent/assent  X         
Assessment of inclusion/exclusion criteria  X X        
Demography, JIA history, prior JIA medication, 
general medical and procedure history  X         
Vital signs(d) X X X X X X X X X 
Height  X(e) X   X(f) X(f)   X(f)  
Weight(g)  X(e) X X X X X  X X 
Tanner stages (except growth)   X   X(f) X(f)   X(f)  
Physical examination(h) X X   X X  X X 
TB questionnaire  X X   X(i) X(i)  X(i)  
Hematology/biochemistry/urinalysis(j)  X(k) X(l)   X X  X X 
Reproductive potential and birth control  X X   X X  X X 
Pregnancy testing(m) X X   X(m) X  X X 
C-reactive protein(j) X X X X X X  X  
TB screening(n) and chest x -ray(o) X     X(n)    
PRINTO/PRCSG standard joint examination  X X X X X X  X  
Physician’s Global Assessment of Disease Activity  X X X X X X  X  
CHAQ -parent reported  X X X X X X  X  
Parent’s Assessment of Arthritis Pain  X X X X X X  X  
Parent’s Global Assessment of Overall Well -Being  X X X X X X  X  
Clinically Inactive Disease and clinical remission(p)    X X X X  X  
Duration of morning stiffness   X X X X X  X  
JADAS   X X X X X  X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 26 of 280 Table  5-1 Schedule of study assessments  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 16, 
(17(u)), 20, 24  32 and every 
8 weeks 
thereafter (z) Unsch.  
Visit(b) Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a) 1 2 3 4 5 to 10  11 onwards    FV 
Faces Pain Scale -Revised(q)  X   X X  X  
Patient’s Assessment of Arthritis Pain(r), acute   X        
Patient’s Assessment of Arthritis Pain(r), standard   X   X(r) X  X  
Fatigue Assessment Scale   X X X X(s) X  X  
Juvenile Arthritis School Attendance and Caregiver 
Work Productivity Survey (parent/caregiver -
reported)   X   X X  X  
Concomitant medications and procedures(t) X X X X X X X X X 
Adverse events  X X X X X X X X X 
IXRS contact  X X X X X X  X X 
CZP plasma concentrations   X X  X(u)  X(v)    
Anti-CZP antibodies   X X  X(u)  X(v)    
Autoantibodies (ANA and anti -dsDNA 
antibodies)(j)  X(w)   X(x) X(x)  X  
CZP administration(y)  X  X X X    
ANA=antinuclear antibody; anti -dsDNA=anti -double -stranded deoxyribonucleic acid; BCG=Bacille Calmette -Guérin; CHAQ=Childhood Health Assessment 
Questionnaire; CZP=certolizumab pegol; Disc=discontinuation; IGRA=interferon -gamma release assay; IXRS=interactiv e voice/web response system; 
JADAS=Juvenile Arthritis Disease Activity Score; JIA= juvenile idiopathic arthritis; PRINTO/PRCSG=Paediatric Rheumatology INt ernational Trials 
Organisation/Pediatric Rheumatology Collaborative Study Group; TB=tuberculosis; TST= tuberculin skin test; Unsch=Unscheduled  
a Screening Visit must be completed at least 4 to 12 working days prior to the Baseline Visit, depending on regional requiremen ts and laboratory assessments 
required for the study participant (please refer to Section 10.6 and the laboratory manual). For all other visits, the Visit window is ±[ADDRESS_887527] be assessed at every Unscheduled Visit. Other PK and safety assessments 
should be performed as related to nature of the visit. For Unscheduled Visits related to the dose changes, se e Sections 7.2.1  and 8.6.1 . For these Un scheduled 
Visits, the same visit window applies, ie, ±3 days.  
c Final Visit should be performed 12 weeks after the final dose of CZP.  
d Pulse, systolic/diastolic blood pressure, and temperature to be measured within approximately 15 minutes prior to dosing and  in addition (pulse and blood 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 27 of 280 Table  5-1 Schedule of study assessments  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 16, 
(17(u)), 20, 24  32 and every 
8 weeks 
thereafter (z) Unsch.  
Visit(b) Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a) 1 2 3 4 5 to 10  11 onwards    FV 
pressure only) approximately [ADDRESS_887528] year will be collected via parent -/self-report, if not available from medical records.  
f Height and Tann er stages to be measured at Week  24 and 48,  every 24 weeks thereafter (for study participants enrolled prior to Protocol Amendment 9, 
Tanner stages assessment will be performed every [ADDRESS_887529] not reached Tanner 
stage V ) and at Early Discontinuation/E nd of Treatment.  
g From Week [ADDRESS_887530] the CZP dose as needed according to Table 7-1. 
h Physical examination findings (except joint examination) are recorded in the CRF only at Screening. Subsequent physical exami nations are to be recorded in 
the source documentation and clinically significant findings recorded as AEs.  
i TB questionnaire to be completed at Weeks 12 and 24 and every 16 weeks thereafter, and Early Discontinuation/End of Treatment . If the Investigator 
suspects latent TB or active TB, TB testing and/or a chest x -ray should be performe d as outlined in Section  10.7.9 . 
j Hematology/biochemistry/urinalysis will be performed by a central laboratory, except urine dipsticks, which will be done locally at the site. Study 
participants do not have to be fasting.  
k At Screening, laboratory testing includes testing for hepatitis B core antibody, hepatitis B surface antibody, hepatitis B su rface antigen, hepatitis C virus 
antibody , and HIV 1/[ADDRESS_887531] will not be allowed in the study (except for anti -hepatitis B surface positive 
only, in case study participant is immune due to well -documented hepatitis B vaccination or isolated false -positive anti -hepatitis B core test confirmed with a 
confirmatory test such as hepatitis B virus deoxyribonucleic acid [DNA]). A positive hepatitis C antibody test will be confir med by a confirmatory test (such 
as hepatitis C virus ribonucleic acid [RNA]) and those with a positive confirmatory test will not be allowed in the study.  
l At Baseline, hematology/chemistry/urinalysis only need to be done if in the Investigator’s opi[INVESTIGATOR_658213] a change in the s tudy participant’s status 
compared to the Screening Visit.  
m Pregnanc y testing for postmenarcheal female study participants. Serum testing by a central laboratory at Screening and urine testing locally at the site at 
Baseline, Weeks 8, 16, 24, and every visit thereafter.  
n TB screening: Interferon -gamma release assay (IGRA) t esting (QuantiFERON®) is required to be performed by [CONTACT_658249] 
[ADDRESS_887532] and IGRA testing at Screening is mandatory for study participants less than 5 years of age in this study unless written 
documenta tion of BCG vaccination is available (refer to Section 6.2 [exclusion criterion  11] and Section  10.7.9 ). Following implementation of Protocol 
Amendment  7, IGRA testing (QuantiFERON) should be done once a year (approximately every 48  weeks) for all study participants.  
o Chest radiographic imaging is done at Screening and results must be available at Baseline  before first drug administration, unless a chest x -ray or CT is 
available within [ADDRESS_887533] -Baseline visit from Week 24 onwards only.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 28 of 280 Table  5-1 Schedule of study assessments  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 16, 
(17(u)), 20, 24  32 and every 
8 weeks 
thereafter (z) Unsch.  
Visit(b) Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a) [ADDRESS_887534] week (Baseline and Day 1 to Day 7, to be collected at Week 1). In addition, to be 
completed at Weeks 4, 12, 16, 24, and then every 8  weeks thereafter  (for study participants enrolled prior to Protocol Amendment 9, visi t frequency changes 
to every 16 weeks instead of every 8 weeks following implementation of Protocol Amendment 8)  through the End of Treatment/Early Discontinuation Visit.  
r For study participants ages [ADDRESS_887535] week (at Baseline and Day 1 to Day 7, to be collected at 
Week 1). In addition, standard VAS version to be completed at Baseline, Weeks 4, 12, 16, 24, and then every 8  weeks thereafter (for study participants 
enrolled prior to Protocol Amendme nt 9, visit frequency changes to every 16 weeks instead of every 8 weeks following implementation of Protocol 
Amendment 8)  through the End of Treatment/Early Discontinuation Visit for study participants ages 12 to 17 years.  
s Fatigue Assessment Scale perform ed at Weeks 4, 8, 16, and 24.  
t Concomitant procedures are collected starting at Baseline.  
u CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 24. A postdose CZP plasma sample will be collected at 
approximately 5  to 7 days  following the Week 16 Visit (ie, requires an additional clinic site visit for blood collection at Week 17). Samples for CZP p lasma 
concentration and anti -CZP antibodies will be collected as separate samples.  
v CZP plasma concentration and anti -CZP antibodi es to be measured at Weeks 32, 40, 48, and every 24 weeks thereafter for study participants enrolled 
following Protocol Amendment 9. For study participants enrolled prior to Protocol Amendment 9, samples for CZP plasma concent ration and anti -CZP 
antibodies  will no longer be collected.  Samples for CZP plasma concentration and anti -CZP antibodies will be collected as separate samples.  
w At Baseline, testing for anti -dsDNA antibodies will only be done if ANA is positive.  
x ANA and anti -dsDNA antibodies performed at Week 16 and Week 48.  
y After Week 4 (Visit 5) study participants/caregivers may administer CZP Q2W (or Q4W for the lowest weight group) at home betw een scheduled study 
visits. See Section 7.2 regarding training and option for continued site administration.  
z For study participants enrolled prior to Protocol Amendment 9, on -site CZP administration, safety sampling, and efficacy assessment frequency chan ges to 
every 16 weeks instead of every 8 weeks following implementation of Protocol Amendment 8 , provided that compliance is maintained with the CZP dosing 
schedule using at -home administration. The option to come to the site for CZP administration between  scheduled visits is available as needed.    
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 29 of 280 5.3 Schematic diagram  
 
 
 
 
 
a 
a Following Week 32, visits will be every 8 weeks. For study participants enrolled prior to Protocol Amendment 9, visit 
frequency changes to every 16 weeks instead of every 8 weeks following implementation of Protocol Amendment 8.  
b The futility analysis of PedACR30 after all study participants on the reduced CZP dose completed Week 16 has 
already been completed. A further futility analysis will not be performed using the additional study participants that 
will be enrolled on the ori ginal CZP dose regimen following the implementation of Protocol Amendment 9.   b 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 30 of 280 5.4 Rationale for study design and sel ection of dose  
5.4.1  Study design  
Following the US approval of CZP for the treatment of moderately to severely active RA in 
adults, the FDA has required a postmarketing pediatric study. The following open -label study 
has been accepted to fulfill the FDA postmark eting requirement to investigate CZP PK, 
dosing, safety, and immunogenicity in the pediatric population (2 to 17  years old, inclusive) 
with JIA.  
Conducting placebo -controlled studies in pediatric populations requires special consideration. 
These include e thical concerns associated with denying active treatment to a population of 
patients that cannot make their own fully -informed choices about healthcare, the enrollment 
difficulties commonly encountered for placebo -controlled pediatric studies, and the limi ted 
size of the patient population from which to recruit. Studies in JIA are no exception for these 
considerations.  
Currently, 2 TNF -antagonists (ETN and ADA) have been approved in the [LOCATION_003] and Europe 
for the treatment of JIA. For both TNF -antagonists, similarities between the adult RA and the 
JIA population were shown in the placebo -controlled clinical studies with respect to effica cy, 
safety and dosing. Through extensive interactions between the FDA and external experts, 
culminating in a collaborative workshop in October 2019 entitled “Accelerating Drug 
Development for polyarticular Juvenile Idiopathic Arthritis (pJIA)”, a therapeut ic bridging 
approach from RA to pJIA was strongly supported for TNF -α inhibitors based on the 
relationship between RA and pJIA and the extensive knowledge of TNF -α inhibitors as 
therapeutic agents in these two po pulations. This approach (based on "Pharmaco kinetic (PK) 
matching") directs that the therapeutic effect of TNF -α inhibitors (such as CZP) in pJIA 
patients can be expected if the pediatric systemic exposure for the drug is within the 
therapeutic range for adult RA patients.  
Study RA0043 is being und ertaken in support of the pJIA Pediatric Research Equity Act 
(PREA) requirement for CZP. The pJIA development program for CZP will be based on PK 
data generated with the newly validated MSD ECLIA method for pediatric study participants 
in (Section  7.2 and Section  5.4.2 ). To enable this approach, an additional 30  study 
participants will be enrolled in RA0043 following Protocol Amendment 9 at the original CZP 
dosing regimen.  
Central to application of this approach is the existence of a reference systemic exposure (PK) 
range which is associated with  therapeutic benefit of the drug in adult RA population. A 
supporting adult reference PK dataset for "PK matching" in the pJIA program will also need 
to be based on data generated with the ECLIA method. Accordingly, a separate study is being 
undertaken in order to generate ECLIA -based CZP PK data for CZP in adults with RA.    
5.4.2  Dose selection  
The original minimum and maximum loading doses in the study were CZP 100mg Q2W and 
CZP 400mg Q2W, respectively, and the original minimum and maximum maintenance doses 
were CZP  50mg Q2W and CZP  200mg Q2W, respectively (see Section  [IP_ADDRESS]  for the 
rationale for the original CZP dose regimen). Based on an interim PopPK analysis of RA0043 
data, the minimum and maximum loading doses in the study were adjusted to CZP 50mg 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 31 of 280 Q2W and CZ P 200mg Q2W, respectively, and the minimum and maximum maintenance 
doses were adjusted to CZP  50mg Q4W and CZP  100mg Q2W, respectively, following 
implementation of Protocol Amendments 4 and 5 (see Section  [IP_ADDRESS]  for the rationale for the 
reduced CZP dose regimen).  
However, it was later determined that there were deficiencies detected with the use of the 
bioanalytical assay within RA0043,  which rendered  the PK data for the PopPK analysis and 
simulations that informed the dose reduction in Protocol Amendment 4 and 5  unusable from a 
regulatory standpoint . Accordingly, PK samples were no longer collected for study 
participants on the reduced CZP dose regime n following implementation of Protocol 
Amendment 8.  
An ECLIA method, for which selectivity had previously been assessed in the RA matrix, has 
now been validated to meet the standards set in the regulatory guidance for analytical 
procedures and methods val idations for drugs and biologics (FDA, Guidance for Industry – 
Bioanalytical Method Validation, 2018). The ECLIA assay consists of a homogeneous 
bridging immunoassay on the MSD platform.  
Based on 24 -week interim results from RA0043 (Section  13.7), both the original and reduced 
dose regimens showed safety profiles similar to the approved CZP dose regimen in the adult 
RA population. The overall clinical r esponse in the study (taking both dose regimens into 
account) was PedACR30 and PedACR50 responses of 77.3% and 67.5%, respectively at 
Week 12. The response from the original dose regimen was 75.6% for PedACR30 and 64.1% 
for PedACR50. PedACR50 response demo nstrates a highly clinically relevant decrease in 
disease activity.  
Therefore, in order to adequately assess the exposure levels and clinical experience of CZP in 
pJIA at both the reduced and original CZP dose regimens and also adequately support the 
safet y assessment of the original CZP dosing regimen, as more of the safety data collected in 
the study to date has been on the reduced dose, [ADDRESS_887536] plasma concentrations of 
CZP and anti -CZP antibodies analyzed using the ECLIA method. In addition, PK and ADA 
samples (for which sufficient volume is available) collected in this study pr ior to Protocol 
Amendment  9 will be analyzed with the ECLIA method. The collective ECLIA -based PK 
data for this study will form the basis of any future CZP modeling and simulation work.  
[IP_ADDRESS]  Original CZP dose regimen  
The recommended dosing regimen for CZP in ad ult study participants with moderate to 
severe RA is CZP 400mg sc at Weeks 0, 2, and 4 followed by [CONTACT_18322] 200mg Q2W thereafter. 
This dose regimen was evaluated for safety and efficacy in 2 double -blind, placebo -
controlled, Phase 3 clinical studies (C87027 and  C87050) a nd supported by [CONTACT_658250]/pharmacodynamic (PD) modeling (C87079). The PK/PD model estimated EC 50 Cavg 
plasma concentration (the CZP concentration that produces one -half of the maximum effect 
for ACR20 response) to be 16.8µg/mL (95% confidence  interval [CI] = 10.2 to 23.4).  
Population PK analysis on data from adult study participants with RA (C87068) showed that 
there was a less than proportional inverse relationship between body weight and PK. The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887537] of extreme body weights on PK  exposure in 
typi[INVESTIGATOR_658214]  5-2. 
Table  5-2 PK estimates of CZP exposure in adult study participants with RA 
based on population PK modeling  
Body weight (kg)  Cmax (µg/mL)  Ctrough  (µg/mL)  AUC (µg.day/mL)  
40 53 34 616 
70 41 22 457 
120 33 14 334 
AUC=area under the curve; C max=maximum serum concentration; C trough=trough serum concentration; 
CZP=certolizumab pegol; PK=pharmacokinetic; RA=rheumatoid arthritis  
The therapeutic plasma concentration of CZP in children and adolescents  with JIA was 
expected to be similar to that required for the adult population with RA. In adults with RA, 
effective plasma concentrations are achieved with doses of CZP 400mg at Weeks 0, 2, and 4, 
followed by [CONTACT_18322] 200mg Q2W thereafter. The intention in RA0 043 is to study the equivalent 
dose regimen in children and adolescents with JIA. Initial predictions, based on allometric 
scaling of PK data from adults, suggested that this could be ac hieved by [CONTACT_658251] 20 to <40kg (44 to <88lb) to 
CZP 200mg at Weeks 0, 2, and 4 followed by [CONTACT_18322] 100mg Q2W (ie, 50% of the 
recommended adult dose), and by [CONTACT_658252] 25% of the adult dose for 
study participants with body weights 10 to <20kg (22 to <44lb) (ie, CZP  100mg at Weeks 0, 
2, and 4 followed by [CONTACT_18322] 50mg Q2W).  
The original choice of dose and the weight -based dose -adjustment algorithm was supported 
by [CONTACT_658253]/PD exposure response model developed in adult RA study participants, corrected for 
pediatric demographics (C87079 addendum [ADDRESS_887538] 2008). Results of these simulations 
showed that all age groups exhibit similar exposures (C max and AUC T) to those o f adults over 
the Week 14 to Week 16 dosing interval, with the pediatric/adult ratio of the median 
predicted values of PK parameters ranging from 1.03 to 1.19 for C max and from 0.97 to 1.18 
for AUC T. The similarities in exposures were reflected in the prob ability of ACR20 response, 
which are similar for all age groups at Week  16 (pediatric/adult ratio of the median predicted 
values ranging from 1.08 to 1.10). These simulations were performed upon the assumption 
that disease progression and response rate for  a given exposure are similar in children and 
adults.  
The original CZP dose regimen is the regimen that will be used for study participants 
enrolled following Protocol Amendment 9.  
[IP_ADDRESS]  Reduced CZP dose regimen  
Interim CZP plasma concentration data available at the time of Protocol Amendment [ADDRESS_887539] been performed.  
Results of an interim PopPK analysis conducted following Protocol Amendment 3 (in 
Jun 2013) suggested that while observed CZP plasma concentrations remained in the adult 
range, they were at the upper end of the distribution. Simulations predicted that for some 
study participants in RA0043 receiving the originally determined loading doses u p to Week 4 
(Visit 5), plasma concentrations were likely to exceed the range previously seen in adult 
study participants receiving CZP 400mg Q2W. Furthermore, plasma concentrations of study 
participants receiving the originally determined maintenance dose after Week 4 (Visit 5) were 
predicted to exceed the concentration range observed in adults receiving CZP 200mg Q2W. 
Based on these findings, the dosing regimen was changed with Protocol Amendments 4 and 
5, and the doses to be administered were reduced by 5 0% for all weight groups. This dose 
change was intended to achieve plasma concentrations that were similar to the effective 
concentrations observed in previous studies in adult study participants with RA.  
Subsequently, the maintenance doses in this study were reduced with Protocol Amendment  4 
so that study participants with body weights between 20 and <40kg (44 to <88lb) received 
CZP 50mg Q2W, and study participants with body weights of ≥40kg (≥88lb) received 
CZP 100mg Q2W (see Table 7 -1). The optimal main tenance dose estimated in the PopPK 
model for the lowest weight group was CZP  25mg Q2W, however, the lowest available dose 
size is CZP  50mg. Thus, study participants with body weights of 10  to <20kg (22 to <44lb) 
received CZP  50mg Q4W to achieve this 50% r eduction. In addition, with Protocol 
Amendment 5, the loading dose in the study was reduced by 50% for newly enrolled study 
participants, so that study participants with body weights of 10 to <20kg (22 to <44lb) 
received CZP 50mg at Weeks 0, 2, and 4, stud y participants with body weights between 20 to 
<40kg (44 to <88lb) received CZP  100mg at Weeks 0, 2, and 4, and study participants with 
body weights ≥40kg (≥88lb) will receive CZP  200mg at Weeks 0, 2, and 4.  
The rationale behind selecting the equivalent of  the adult therapeutic dose was based on the 
following:  
 There is no metabolic rationale to expect a difference in the PK/PD of CZP in a younger 
population, particularly as there is no involvement of cytochrome  P450.  
 Evaluation of a previous anti -TNF antibo dy (CDP571, a whole antibody) in a pediatric 
population (administered iv) confirmed that the PK and safety were similar to that of an 
adult population.  
 Doses in excess of CZP 400mg (up to CZP 800mg) have been administered to healthy 
adult study participant s and study participants with RA without any dose -limiting 
toxicities being identified.  
 A conservative approach to dose reduction was chosen because the body weight of 
pediatric study participants may be influenced largely by [CONTACT_658254].  
However, it was later determined that there were deficiencies detected with the use of the 
bioanalytical assay within RA0043 , which rendered the PK data for the PopPK analysis and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 34 of 280 simulation s that informed the dose reduction in Protocol Amendment 4 and 5  unusable from a 
regulatory standpoint . Study participants enrolled prior to the implementation of Protocol 
Amendment 9 can remain on the reduced CZP dose or may be switched to the original CZ P 
dose at the discretion of the Investigato r and in consultation with the medical monitor . 
Additiona l dose changes are not allowed (Section  7.2.1 ).  
[ADDRESS_887540] be met:  
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved 
written Informed Conse nt form is signed and dated by [CONTACT_658255](s) or legal representative. The Consent form or a specific Assent form, where 
required, will be signed and dated by [CONTACT_122256].  
2. Study participant/legal representative/parent is considered re liable and capable of 
adhering to the protocol, visit schedule or medication intake according to the judgment of 
the Investigator.  
3. Study participant must be able and willing to comply with the requirements of the study.  
4. Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2).  
5. Study participants must weigh ≥10kg (22lb) at Baseline (Visit 2).  
6. Study participants must have had onset of signs and symptoms consistent with a diagnosis 
of JIA (according to the International League of Associatio ns for Rheumatology 
Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at 
least 6 months prior to Baseline (Visit  2). Eligible JIA categories include: polyarthritis 
rheumatoid factor -positive, polyarthritis rheumatoi d factor -negative, extended 
oligoarthritis, juvenile psoriatic arthritis, and ERA.  
7. Study participants must have active polyarticular -course disease, defined as ≥[ADDRESS_887541] (nonbiologic or biologic). For example, study participant had prior inadequate 
response to MTX (based on the Investigator’s clinical judgment).  
9. If the study participant is using MTX, then the  study participant must have been on MTX 
for a minimum of [ADDRESS_887542] 1 month before Screening at ≥10 to ≤15mg/m2 per week. If the study participant is 
not using MTX, then the treatment mu st have been previously withdrawn for documented 
reasons of intolerability or inadequate response.  
10. If the study participant is using oral corticosteroid therapy, the dose must have been stable 
for at least 7  days prior to the Baseline arthritis assessment  at a maximum dose of 10mg 
or 0.2mg/kg prednisone (or equivalent) per day, whichever is the smaller dose.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 35 of 280 6.2 Exclusion criteria  
Study participants are not permitted to enroll in the study if any one of the following criteria 
is met:  
1. Study participant has previously been exposed to more than 2 biologic agents.  
2. Study participant previously failed to respond to treatment with more than one tumor 
necrosis factor alpha (TNFα) antagonist drug. Lack of response to treatment is defined as 
no clinical disease impro vement within the first 12 weeks of treatment. (Study 
participants who demonstrated clinical response within [ADDRESS_887543] response after 12  weeks of treatment are eligible.)  
3. Study participant is currently receiving or has rec eived any experimental (biological or 
non-biological) therapy (within or outside a clinical study) in the 3 months or 5  half-lives 
prior to Baseline (Visit 2), whichever is longer.  
4. Study participant had previous treatment with a biological therapy for JIA that resulted in 
a severe hypersensitivity reaction or an anaphylactic reaction.  
5. Study participant previously participated in this study or has previously been treated with 
CZP (whether in a study or not).  
6. Study participant has received any prohibited medi cation as detailed in  Table  6-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 36 of 280 Table  6-1 Prohibited medications at entry (Ba seline)  
Drug class  Prohibited dose  Exclusion criteria  
Oral corticosteroids  Any dose greater than 10mg 
or 0.2mg/kg prednisone (or 
equivalent) per day, 
whichever is the smaller dose  Any change in dose in the 7 days prior to 
the Baseline arthritis assessment.  
im/iv/ia corticosteroids  Any dose  Use within 28 days prior to the Baseline 
arthritis assessment.  
Non-biologic DMARDs 
(eg, sulfasalazine, 
hydroxychloroquine,  
cyclosporine)  Any dose 
For MTX, any dose <10 or 
>15mg/m2 per week  Use within 28 days prior to the Baseline 
arthritis assessment.  
For MTX, any change in dose in the 
1 month prior to Screening.  
Use of cyclosporine within 7 days prior to 
the Baseline arthritis assessment.  
Use of leflunomide within 6 months prior 
to the Baseline arthritis assessment if a 
cholestyramine washout is not performed 
(and 28  days prior if performed).  
Biologic DMARDs  Any dose  Prior or current exposure to more than 
2 biologic DMARDs and/or primary 
failure (defined as a complete lack of 
response) to more than 1 TNF inhibitor.  
Use of anakinra or rilonacept within 
7 days prior to the Baseline arthritis 
assessment.  
Use of etanercept within 28 days prior to 
the Baseline arthritis assessment.  
Use of adalimumab within 56 days prior 
to the Baseline arthritis assessment.  
Use of infliximab or abatacept within 
60 days prior to the Baseline arthritis 
assessment.  
Use of rituximab within 180 days prior to 
the Baseline arthritis assessment.  
Use of any other bi ological response 
modifier therapy (eg , tocilizumab, 
canakinumab) within 90  days or 
5 half-lives prior to the Baseline arthritis 
assessment, whichever is longer.  
(All aforementioned drugs are prohibited 
during the study.)  
DMARDs=disease -modifying antirheu matic drugs; ia=intra -articular; im=intramuscular; iv=intravenous; 
JIA=juvenile idiopathic arthritis; TNF=tumor neucrosis factor  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 37 of 280 7. Study participant has a history of systemic JIA, with or without systemic features.  
8. Study participant has a secondary, noninflammatory type of rheumatic disease or of joint 
pains (eg,  fibromyalgia) that in the Investigator’s opi[INVESTIGATOR_658215].  
9. Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, 
inflammatory bowel disease -related).  
10. Study participant has active uveitis or a history of active uveitis within the preceding 6 
months.  
11. Participant has:  
a. Known active TB disease  
b. History of active TB involving any organ system  
c. History of or current l atent tuberculosis infection (LTBI)  
d. High risk of exposure to TB infection  
e. Current nontuberculous mycobacterial (NTMB) infection or history of NTMB 
infection. For further information relating to definitions of known active TB, past 
history of TB, LTBI, high risk of acquiring TB infection and NTMB infection , refer 
to Section  10.7.9  (Assessment and management of TB and TB risk fact ors). 
12. Study participant has a current sign or symptom which may indicate infection (eg, fever, 
cough), a history of chronic or recurrent infections within the same organ  system (more 
than 3  epi[INVESTIGATOR_658216]/antivirals during the 12 months pri or to Screening 
[Visit  1]), had a recent (within the 6  months prior to Screening [Visit 1]) serious or 
life-threatening infection (including herpes zoster), or is at a high risk of infection in the 
Investigator’s opi[INVESTIGATOR_1649] (eg,  study participants with leg ul cers, indwelling urinary catheter, 
and persistent or recurrent chest infections or permanently bed -ridden or wheelchair 
bound).  
13. Study participant has a history of or current hepatitis B or C virus or HIV 1/2 or has any 
of the following laboratory abnormal ities during the Screening Period:  
a. Hepatitis B surface (HBs) antigen, hepatitis B core (HBc) antibody (except for 
isolated, false -positive anti -HBc confirmed with a confirmatory test such as hepatitis 
B virus [HBV] -deoxyribonucleic acid [DNA] [refer to Table  5-1 footnote k and 
Section  10.6 (Clinical La boratory Tests) table footnote c]): Positive to any of these  
b. Hepatitis C virus (HCV) positive: defined as hepatitis C antibody (anti -HCV Ab) 
positive confirmed via a confirmatory test (for example, HCV polymerase chain 
reaction)  
c. HIV antigen or antibody: Po sitive to either test  
14. Study participant has received any live, including attenuated, vaccination within 8 weeks 
prior to Baseline (Visit 2) and/or is scheduled for live  vaccination during the course of 
study participation. Non -live vaccinations are permitted at any time prior to and during 
the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 38 of 280 15. Study participant has a history of chronic alcohol or drug abuse based on the 
Investigator’s clinical judgment within the last [ADDRESS_887544] dose of study medication (or longer if required by 
[CONTACT_427]). Female study participants of childbearing p otential (ie, 
postmenarcheal) must have a negative result at Screening and Baseline (Visits 1 and 2) 
pregnancy tests to be eligible for study entry.  
17. Study participant is a sexually active female of childbearing potential (ie, 
postmenarcheal) and is not practicing or will not agree to practice an effective means of 
birth control. For postmenarcheal female study participants not currently sexually active, 
the study participant and parent or legal representative should agree that the study 
participant will employ an effective means of birth control consistently and correctly 
should the study participant become sexually active. Effective methods of birth control 
are: oral/parenteral/implantable hormonal contraceptives (stable at least 2 months prior to 
Screen ing (Visit 1) if initiated prior to entering the study) or a combination of barrier and 
spermicide. Study participants must agree to use effective  contraception during the study 
and for [ADDRESS_887545] dose of study medication (or longer if requi red by [CONTACT_13125]). Male study participants who are sexually active must agree to ensure they or 
their female partner(s) uses adequate contraception during the study and for [ADDRESS_887546] dose of study medi cation (or longer if 
required by [CONTACT_427]). (Sexually active means engaging in sexual intercourse, 
regardless of frequency).  
18. Study participant has a history of an adverse reaction to PEG.  
19. Study participant has a history of a lymphoproliferative di sorder including lymphoma or 
signs and symptoms at any time suggestive of lymphoproliferative disease.  
20. Study participant has a concurrent malignancy, or a history of any malignancy.  
21. Study participant has a current or recent history (within 6 months prior t o Screening [Visit 
1]) of severe, progressive, and/or uncontrolled renal, hepatic, hematological, 
gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease 
including blood dyscrasia (eg, pancytopenia, aplastic anemia), demyelinatin g disease (eg, 
multiple sclerosis, myelitis, optic neuritis).  
22. Study participant has any other medical or psychiatric condition that, in the opi[INVESTIGATOR_58901], could jeopardize or would compromise the study participant’s 
ability to part icipate in the study or which otherwise make the study participant unsuitable 
for inclusion in the study.  
23. Study participant has any clinically significant laboratory abnormalities which, in the 
Investigator’s judgment, would make the study participant unsu itable for inclusion in the 
study, with specific exclusion of study participants with values of: liver function tests that 
are >2×upper limit of normal (ULN), serum creatinine that are >1.5 ×ULN, and white 
blood cells that are <3.0x109/L or 3000/mm3. 
24. Study  participant is wheelchair -bound at the time of enrollment.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 39 of 280 25. Study participant with a history of or active systemic/respi[INVESTIGATOR_658217], 
parasitic, or mycotic pathogens including but not limited to histoplasmosis, coccidiosis, 
paracoccidiosi s, pneumocystis, blastomyces, and aspergillus.  
Radiographic evidence suggestive of any of these infections is sufficient grounds for 
exclusion.  
6.3 Retesting and rescreening  
Retesting of laboratory assessments within the Screening Period is allowed as per the  
following:  
 Study participants with isolated exclusionary laboratory assessments at Screening may 
have this laboratory assessment repeated once if, in the Investigator’s opi[INVESTIGATOR_1649], the value 
is not reflective of the study participant’s previous clinical and laboratory pattern. 
Retesting must be completed within the stated Screening Period. If the repeat values are 
within the acceptable ranges of the study and the study participant remains eligible during 
the Baseline Visit (Week 0), the study participant may be dosed.  
Rescreening is only allowed after consultation with the Medical Monitor as per the following:  
 Study participants who failed Screening (eg, due to transient out -of-range safety 
laboratory values or in the Investigator’s judgment mild acute illness , eg, a cold) may be 
rescreened after complete recovery of the mild acute illness and/or normalization of the 
out-of-range safety laboratory values.  
 Study participants who fulfilled all eligibility criteria but were registered as Screen 
failures due to sus pension of enrollment as of 17 Jul 2013 are allowed to be rescreened.  
 Rescreening might be allowed more than once but not in case of repeated occurrence of 
the same illness. All Screening assessments must be repeated as applicable in case of 
Rescreening. T he maximum duration of the Rescreening Period is [ADDRESS_887547] only be scheduled after an appropriate time period after the initial 
Screening Visit allowing for repetition of blood collection (depending on local 
requirements for maxi mum blood volumes; depending on study participant weight).  
 All study participants who failed to be enrolled within the Screening Period of [ADDRESS_887548] be registered as Screen Failure in the interactive voice/web response system (IXRS). 
Study participants approved to be rescreened must be registered with a new study 
participant number.  
6.4 Liver Chemistry Stoppi[INVESTIGATOR_658218] -induced liver injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all co ncomitant medications and herbal supplements 
that are not medically necessary should be discontinued. The PDILI criteria below require 
immediate and permanent discontinuation of IMP:  
 Participants with either of the following:  
- ALT or AST ≥5xULN  
- ALT or AST  ≥3xULN and coexisting total bilirubin ≥2xULN  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 40 of 280 The PDILI criterion below requires immediate discontinuation of IMP:  
 Participants with ALT or AST ≥3xULN who exhibit temporally associated symptoms 
of hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, 
and right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever 
(without clear alternative cause), rash, and eosinophilia (ie, >5%).  
The PDILI criterion below allows participants to continue on IMP at the di scretion of the 
Investigator:  
 Participants with ALT or AST ≥3xULN (and ≥2x baseline) and <5xULN, total 
bilirubin <2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of 
hepatitis (eg, fatigue, nausea, vomiting, right upper quadrant pain  or tenderness).  
Evaluation of PDILI must be initiated as described in Section  17.[ADDRESS_887549] be discontinued immediately.  
Investigators should attempt to obtain information on participants in the case of IMP 
discontinuation to complete the final evaluation. P articipants with PDILI should not be 
withdrawn from the study until investigation and monitoring are complete. All results of 
these evaluations and observations, as well as the reason(s) for IMP discontinuation and 
participant withdrawal (if applicable), m ust be recorded in the source documents. The eCRF 
must document the primary reason for IMP discontinuation.  
6.5 Withdrawal criteria  
Study participants are free to withdraw from the study at any time, without prejudice to their 
continued care. Where possible, s tudy participants discontinuing study medication should be 
encouraged to remain in the study.  
A study participant may withdraw from the study at any time at his/her own request, or may 
be withdrawn at any time at the discretion of the investigator for safe ty, behavioral, 
compliance, or administrative reasons.  
If the study participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of consent.  
If a study participan t withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records.  
See the Schedule of Activities for data to be collected at the time of study discontinuation and 
follow -up and for any further evaluations that need to be completed.  
Study participants should be withdrawn from the study if any of the following events occur:  
1. Study participant or legal representative withdraws his/her consent.  
2. The sponsor or a regul atory agency requests withdrawal of the study participant.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887550] be permanently  discontinued from study medication (but not 
necessarily from the study) if any of the following occurs:  
1. Study participant/caregiver is noncompliant with the s tudy procedures or medications in 
the opi[INVESTIGATOR_12182].  
2. A study participant considered as having either a suspected new LTBI or who develops 
active TB or NTMB infection during the study (including but not limited to, conversion 
demons trated by [CONTACT_14234] -gamma release assay  [IGRA ] or other diagnostic means) must 
be immediately discontinued from IMP (refer to Section  [IP_ADDRESS]  for further details).  
a) The study participant must be permanently withdrawn from the study if further 
examinations result in a diagnosis of active TB, NTMB infection , or if the study 
participant is diagnosed with LTBI. An Early Discontinuation visit must be  scheduled 
as soon as possible, but not later than the next regular visit.  
Any confirmed diagnosis or suspi[INVESTIGATOR_1884] a latent or active TB infection is a reportable 
event. Either type of infection must be reported as an adverse event of special interest 
(AES I) and must be captured on an AE report form, ticking the appropriate AESI and, if 
applicable, serious adverse event (SAE) field(s) on the form to clearly indicate the level 
of seriousness. A UCB TB follow -up form also must be completed. Confirmed active T B 
is an SAE and must be captured on an SAE report form and provided to the Sponsor in 
accordance with SAE reporting requirements. As with all SAEs, periodic follow -up 
reports should be completed as per protocol requirements until such time as the TB 
infect ion resolves.  
3. Study participant is found to be persistently noncompliant (missing 2 or more consecutive 
scheduled CZP doses or missing 3 or more doses over a 12 -month period), the Sponsor in 
conjunction with the Investigator will make a decision as to whether the study participant 
should be withdrawn from the study (see Section 7.7).  
This rule does not apply when CZP is discontinued if the study participant is in  CRM or if 
CZP is temporarily discontinued due to an AE. In the case of temporary discontinuation 
due to an AE, the Sponsor in conjunction with the Investigator will make a decision as to 
whether the study participant should be withdrawn from the study.  
4. Study participant takes prohibited concomitant medications as defined in this protocol 
(see Section  7.8.3 ). 
Study participants may be discontinued fr om study medication (but not necessarily from the 
study) if any of the following occurs, but may be restarted after consultation with the Medical 
Monitor:  
1. Study participant develops an illness that would interfere with continued participation (eg, 
malignan cies).  
2. If there is a positive pregnancy test, study medication will be held. If there is confirmed 
pregnancy, study medication must be discontinued until end of the pregnancy. In case the 
study participant intends to breastfeed after a pregnancy study medi cation must be further 
discontinued until end of breastfeeding.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 42 of 280 Investigators should attempt to obtain information  on study participants, in the case of 
withdrawal or discontinuation. All results of these evaluations and observations, together 
with a narr ative description of the reason(s) for removing the study participant, must be 
recorded in the source documents. For study participants considered as lost to follow -up the 
Investigator should make an effort (at least 1 phone call and 1 written message to t he study 
participant), and document his/her effort (date and summary of the phone call and copy of the 
written message in the source documents) to complete the final evaluation. The CRF must 
document the primary reason for withdrawal or discontinuation.  
Investigators should contact [CONTACT_658256] a study participant in advance.  
7 STUDY TREATMENTS  
7.1 Description of IMP  
Supplies of CZP will be provided by [CONTACT_658257] a CZP 200mg/mL solution for single sc 
injection, in  a single use PFS for sc injection (administered in accordance wit h Table 7-1). 
Each PFS contains an extractable volume of 0.25mL, 0.5mL, or 1mL of CZP  solution.  
The IMP will be supplied under the responsibility of UCB. The frequency at which the IMP 
will be supplied to each individual center will be adapted based on the recruitment capacity 
of that center, availability, and expi[INVESTIGATOR_658219]. Study  medication supplies will be 
managed by [CONTACT_658258].  
7.[ADDRESS_887551] weight group on the reduced CZP regimen who will receive the 
maintenance dose Q4W. The loading dose, maintenance dose, and range of exposures in each 
weight category for both the original and reduced CZP regimens are presented in Table 7-1. 
Study participants start with 3  loading doses of CZP at Weeks 0, 2, and 4 followed by a 
maintenance dose for the duration of the study. After Week  4 (Visit  5), home -based CZP 
administration by [CONTACT_658248]/caregiver will be permitted between 
scheduled study visits.  
A study participant’s dosing category will only be changed after the confirmation of a weight 
change by [CONTACT_658259] a scheduled clinic visit.   
The study participant will receive the dose of the next weight category once their weight 
crosses the 40kg/88lb boundary or crosses the 20kg/44lb boundary at a scheduled clinic visit. 
The study participant will continue on  the dose of the new weight category regardless of 
potential decrease of the weight below the boundary. In case of significant weight 
fluctuations the Investigator should contact [CONTACT_658260] (eg, if related 
to AE).  
The injection should be administered at either the lateral abdominal wall or upper outer thigh.  
Treatment of the injection site with an anesthetic cream prior to dosing is permitted.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 43 of 280 Table 7-1 Dosing administration of CZPa  
Weight range  Loading dose – Weeks 0, 2, and 4  
(mg/kg dose range)  
IMP Description  Maintenance – Week 6 and onwards  
(mg/kg dose range)  
IMP Description  
Original CZP regimen  
10 to <20kg  
(22 to <44lb)  100mg Q2W  
(5-10mg/kg)  
1 x 0.5mL inj  50mg Q2W  
(2.5-5mg/kg)  
1 x 0.25 mL inj  
20 to <40kg  
(44 to <88lb)  200mg Q2W  
(5-10mg/kg)  
1 x 1mL inj  100mg Q2W  
(2.5-5mg/kg)  
1 x 0.5mL inj  
≥40kg  
(≥88lb)  400mg Q2W  
(<10mg/kg)  
2 x 1mL inj  200mg Q2W  
(<5mg/kg)  
1 x 1mL inj  
Reduced CZP regimen  
10 to <20kg  
(22 to <44lb)  50mg Q2W  
(2.5-5mg/kg)  
1 x 0.25mL inj  50mg Q4W  
(2.5-5mg/kg)  
1 x 0.25mL inj  
20 to <40kg  
(44 to <88lb)  100mg Q2W  
(2.5-5mg/kg)  
1 x 0.5mL inj  50mg Q2W  
(1.25 -2.5mg/kg)  
1 x 0.25mL inj  
≥40kg  
(≥88lb)  200mg Q2W  
(<5mg/kg)  
1 x 1mL inj  100mg Q2W  
(<2.5mg/kg)  
1 x 0.5mL inj  
CZP=certolizumab pegol; inj =injection; Q2W=every 2 weeks; Q4W=every 4 weeks  
Note: A study participant should change dosing category during the course of the study if their weight crosses 
the 40kg/88lb boundary or crosses the 20kg/44lb boundary.  
a Note that the original CZP regimen describes the dosing administration of CZP prior to the implementation of 
Protocol Amendments 4 and 5 and for study participants enrolled following the implementation of Protocol 
Amendment 9. The reduced CZP regimen  describes the dosing administration of CZP after implementation of 
Protocol Amendment s 4 and 5 . Refer to Section 7.2.1 for the procedure to be taken f or study participants who 
are undergoing a  dose change.   
Site staff will administer the study participant’s injection at Week [ADDRESS_887552] injection technique. At Weeks 2 and 4, study participants/caregivers may administer 
the study medication under the supervision of the site staff to ensure that the study 
medication is being properly and safely injected. Once study participants/ caregivers have 
been trained, the study medication may be administered at home. Prior to CZP administration 
at home, study participants/caregivers will be trained by [CONTACT_658261] c orrect sc injection technique including 
0.25m L, 0.5m L, and 1m L injections, as appropriate. If administered  at home, the study 
participant/caregiver is requested to document the container number, date, and time point of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 44 of 280 administration of study medication an d return this documentation together with any 
used/unused or partially used containers at the next scheduled clinic visit. Study participants 
who are unable to self -administer the study treatment or those without a family 
member/friend/caregiver who can he lp, will not be withdrawn from the study but may 
continue to visit the site for study treatment administration between regular scheduled visits. 
In addition, if needed, home dosing can be performed by [CONTACT_658262]. Study participants will have the option to either switch to home -based CZP injection or 
switch back to administration at the study site at anytime during the study.  
The m ethod of injection (ie, qualified site personnel -injection at study site; injection by [CONTACT_658263]/caregiver or qualified health care professional at the study site or at home) 
and the site of injection (abdomen, thigh) will be recorded in the CR F at each visit.  
Study participants achieving clinical remission on medication (CRM), ie, after 6 months of 
continuous CID, may discontinue CZP treatment at the Investigator’s discretion following 
consultation with the Sponsor to confirm remission status. Study participants who have 
discontinued CZP due to achieving CRM will be allowed to remain in the study and continue 
with scheduled study visits. Study participants not maintaining persistent CID following 
achievement of CRM will be allowed to resume CZP treatment at any time at the 
Investigator’s discretion and consultation with the Sponsor. If a study participant is on 
concomitant MTX treatment, the Investigator may decide to decrease and ultimately 
discontinue the MTX dose after complete discontinuation  of CZP. Study participants not 
maintaining persistent CID following achievement of CRM and resuming treatment will 
restart the fixed -dose CZP dosing based on their current weight with [ADDRESS_887553] weight group on the reduced CZP regimen  for the duration of the study 
(see Table 7-1). 
7.2.1  Procedure f or dose change (Protocol Amendment 9)  
Following Protocol Amendment 9, study participants will only be enrolled on the original 
CZP dose regimen. With Protocol Amendment 4, the maintenance dose in the study was 
reduced by 50% for all weight groups (not appl icable for study participants enrolled on the 
reduced CZP dose regimen per Protocol Amendment  5). Participants on the reduced CZP 
dose regimen can remain on the reduced CZP dose or may be switched to the original CZP 
dose regimen  at the discretion of the I nvestigator  and in consultation with the medical 
monitor . Additional dose changes are not allowed. The procedure for dose change is as 
follows:   
 The timepoint of the dose change is the next scheduled time of injection after the 
Informed Consent form relate d to the dose change was signed. In case the next scheduled 
injection was planned for home dosing, the study participant will be requested to return to 
the clinic for an Unscheduled Visit for signing the Informed Consent form related to the 
dose change, ad ministration of CZP, and to dispense the new supplies. Unused IMP 
dispensed previously needs to be returned.  
In case the study participant is not able to visit the site for that next scheduled injection, 
then the dose change must be performed at the next s cheduled injection.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 45 of 280  Study participants will be monitored at least every 4  weeks over a period of 12  weeks 
after the dose change, either at the regularly scheduled visits or at additional Unscheduled 
Visits. The Unscheduled Visits will be scheduled to match  with the dosing schedule, ie, 
the study medication will be administered at the day of the Unscheduled Visit. The 
Investigator should consult with the Medical Monitor in case of any questions related to 
the timing of the dose change or the Unscheduled Visi ts.   
 Study participants undergoing the dose change at an Unscheduled Visit between the 
regular visits will be required to return at the latest after [ADDRESS_887554] every 4  weeks over a period of 12  weeks .  
 At Unscheduled Visits when the dose change occurs and following the dose change, the 
following will be assessed: AEs, concomitant medications and procedures, vital signs, 
hematology/biochemistry, as well as CRP, PRINTO/PRCSG standard joint examination, 
Physician’s Global Assessment of Disease Activity, CHAQ, and Parent’s Global 
Assessment of Overall Well -Being to determine PedACR response rates. Assessments at 
regular visit s will be done as scheduled, except for PK sampling (see below).  
7.3 Packaging  
Certolizumab pegol is packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They are suitably packaged in such a 
way as to protect the IMPs from deterioration during transport and storage.  
7.4 Labeling  
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will in clude 
any locally required statements. If necessary, labels will be translated into the local language. 
Details on Labeling will be provided in the Pharmacy manual.  
7.5 Handling and storage requirements  
The Investigator (or designee) is responsible for the saf e and proper storage of IMP at the 
site. All IMPs must be stored in a secured, limited access area between 2  and 8°C (35.6  and 
46.4°F) and protected from light.  
Appropriate storage conditions must be ensured either by [CONTACT_658264] g a temperature log in accordance with local requirements, but at least once a day 
with minimum and maximum temperatures reached over the time interval. A temperature 
out-of-range can be noted during storage at a site or during shipment at any time during the 
study.  
In case a temperature out -of-range is noted during storage at a site, it must be immediately 
communicated to the Clinical Program Manager (CPM) (or designee) via the monitor before 
further use of the IMP. Site personnel have to complete the tem perature excursion form 
during storage and fax it together with the temperature log form to the monitor. The monitor 
immediately has to inform Clinical Trial Supplies (CTS) at UCB who will place the affected 
medication in quarantine during the evaluation o f the temperature excursion.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887555] at th e site.  
For IMP dispensed to the study participant/caregiver for injection at home, the Investigator 
(or designee) will instruct the study participant/caregiver to store the IMP following the 
instructions on the label.  
7.[ADDRESS_887556] (due to breakage or wastage), not used, disposed of at the  study 
site, or returned to the Sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for 
UCB (or designee) to review.  
Periodically and at the end of the stud y, all unused and expi[INVESTIGATOR_149325] (PFSs 
and containers) will be collected and sent to the Sponsor (or designee) for destruction. All 
used PFSs will be disposed of by [CONTACT_658265] (sharps) container 
directly after the  administration. For CZP administration at home, the study 
participant/caregiver will receive a disposal (sharps) container in order to return used PFSs to 
the site for disposal. All containers of the used PFSs must be kept until the accountability is 
checked by [CONTACT_658266].  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The Investigator may assign some of the Investigator’s duti es for drug accountability at the 
study site to an appropriate pharmacist/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
7.[ADDRESS_887557] be done in the study participant’s presence in order to obtain 
explanations regarding discrepancies in compliance with the dosing regimen. Drug 
accountability must be recorded on the Drug Accountability form.  
If a study participant is found to be persistently noncompliant (missing 2 or more consecutive 
scheduled CZP doses or missing 3 or more doses over a 12 -month period), the Sponsor in 
conjunction with the Investigator will make a decision as to whether the study participant 
should be withdrawn from the study.  
This rule does not apply when CZP is discontinued if the study pa rticipant is in CRM or if 
CZP is temporarily discontinued due to an AE. The study participant will continue with 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 47 of 280 scheduled study visits even if not dosed. In the case of temporary discontinuation due to an 
AE, the Sponsor in conjunction with the Investigat or will make a decision as to whether the 
study participant should be withdrawn from the study.  
7.8 Concomitant medication(s)/treatment(s)  
The sections below describe the following categories of concomitant medications/treatments: 
concomitant medications that  are permitted during the study, rescue medications that are 
allowed before Week  16, rescue medications that are allowed after Week  [ADDRESS_887558] udy. 
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following are permitted:  
 MTX, if being used:  
 Must have been stable for at least 1 month before Screening (Visit 1) at ≥10 to 
≤15mg/m2 per week.  
 During the study, an increase is allowed  only after Week 16 and to a maximum dose 
of 15mg/m2 per week.  
 Prior to Week 16, route of administration must not change. After Week 16, the route 
of administration may be changed.  
 During the study, the MTX dose may be decreased, but not discontinued. 
Methotrexate may be discontinued only for documented reasons of intolerance or 
toxicity, or in study participants who achieve CRM (persistent CID over a period of 6 
months, as defined in Section 11.10) and only after discontinuation of CZP.  
 Study participants  who do not maintain persistent CID following achievement of 
CRM can reinitiate therapy with MTX.  
 Scheduled and as needed (PRN) use of NSAIDs, cyclooxygenase -2 (COX -2) inhibitors, 
acetaminophen (paracetamol), and other analgesics are permitted.  
 Folic aci d or folinic acid.  
 Topi[INVESTIGATOR_8823] (eg, lidocaine/prilocaine creams, licensed NSAID creams).  
 Corticosteroids:  
 At study entry, the dose should have been stable for at least 7 days prior to the 
Baseline joint examination  at a maximum dose of 10mg or 0.2mg/kg prednisone (or 
equivalent) per day, whichever is the smaller dose.  
 During the study, the dose of oral corticosteroids may be decreased but not initiated or 
increased above 10mg or 0.2mg/kg prednisone (or equivalent) per day, whichever is 
the sm aller dose. The dose must be stable in the 7 days prior to a joint examination.  
 Initiation of topi[INVESTIGATOR_658220].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 48 of 280  Intra -articular (ia) corticosteroids may be administered no more frequently than every 
4 months and no more than up to 3 times in 1 year and only into up to 2  joints at a 
single time point.  
 Any joint injected with ia corticosteroids will be excluded from the efficacy analysis 
for a period of 3 months.  
 Intravenou s (iv) corticosteroid use is permitted only for stress dosing for the purposes 
of surgery.  
 Oral/parenteral/implantable hormonal contraceptives (stable for at least 2 months prior to 
Screening [Visit 1] if initiated prior to entering the study).  
 Non-live an d therefore permitted vaccinations include: intramuscular polio, Hepatitis A, 
Hepatitis B, pneumococcal conjugate vaccine (PCV), pneumococcal polysaccharide 
vaccine (PPSV), diphtheria -tetanus -pertussis (DTaP/DTP), Hemophilus influenzae type b 
(Hib), inject able (but not nasal) influenza, meningococcus, and human papi[INVESTIGATOR_27509]. 
The effectiveness of vaccines administered while on CZP treatment is currently unknown. 
(Live or live attenuated vaccines are prohibited during the course of the study.)  
7.8.2  Rescue medic ation  
Rescue medication use is defined as any initiation of treatment or increase in dose of a 
medication used to treat JIA (in addition to the IMP) that is considered to impact the efficacy 
analyses. A study participant requiring rescue medication after f irst administration of IMP is 
considered as a treatment failure from that time point forward for the purpose of efficacy 
analyses. Exception: A study participant initiating rescue medication use after the Week 56 
visit will not be considered a treatment fa ilure and the efficacy data will be analyzed as 
observed without imputation.  
A study participant requiring rescue medication may remain on study medication if the 
benefit/risk assessment of the study participant’s continued participation is still favorable  
based on the Investigator’s clinical assessment.  
The use of rescue medication should be specifically avoided during the first 4 months 
(16 weeks) of treatment, if possible.  
The following medications are defined as rescue medication in the first 16 weeks of this 
study:  
 Initiation of MTX (if not being used at study entry), or increase of MTX above Baseline.  
 Initiation of oral corticosteroids, or increase above Baseline.  
The following medications are defined as rescue medication after Week 16:  
 Initiation of  MTX (if not being used at study entry), and increase of MTX above 15mg/m2 
per week at any time.  
 Initiation of oral corticosteroids, or increase to >10mg or 0.2mg/kg prednisone (or 
equivalent) per day, whichever is the smaller dose.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 49 of 280 The following medicatio ns are defined as rescue medication when given at any time during 
the study:  
 Injection of intra -articular (ia) corticosteroids into more than 2 joints at a single time 
point.  
 Injection of intra -articular (ia) corticosteroids into the same joint more freque ntly than 
3 times in a 12 -month period.  
 Intravenous (iv) corticosteroids (any dose), if not used for stress dosing for the purposes 
of surgery.  
 Intramuscular (im) corticosteroids.  
Use of the following medications only results in efficacy data at the next scheduled visit 
being treated as missing/nonresponse:  
 Higher than Baseline dose of NSAIDs and COX -2 inhibitors including PRN use within 
72 hours prior to scheduled study visit.  
 Higher than Baseline dose of analgesics or opi[INVESTIGATOR_658221] 48  hours 
prior to scheduled study visit.  
 Any increase in dose of oral corticosteroids within [ADDRESS_887559] be recorded on the CRF. Rescue 
medication will not be supplied by [CONTACT_1034].  
7.8.3  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
See Table  6-1 for prohibitions prior to study entry. The following are prohibited at any time 
during the study:  
 Nonbiologic DMARDs (other than MTX; see Section 7.8.1 ) and biologic DMARDs.  
 Any experimental (biological or non -biological) therapy (within or outside a clinical 
study).  
 Live and live attenuated vaccinations including, but not limited to, oral polio, chicken pox 
(varicella), measles -mumps -rubella (MMR), nasal influenza, and rotavirus. No data are 
available on the response to live vaccinations or the secondary transmission of infection 
by [CONTACT_658246].  
The concomitant use of these must result in the study participant’s immediate discontinuation 
of CZP dosing and the study participant must be withdrawn from the study.  
7.[ADDRESS_887560] to follow up, the Investigator should make an effort 
(at least 1 phone call and 1 written messag e to the participant), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source 
documents), to complete the final evaluation.  
A participant will be considered lost to follow -up if he or she repeatedly f ails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887561] be taken if a participant fails to return to the clinic for a required 
study visit:  
 The site must attempt to contact [CONTACT_288949]/or 
shou ld continue in the study.  
 Before a participant is deemed lost to follow up, the Investigator or designee must 
make every effort to regain contact [CONTACT_6635] (at least 1 phone call and 1 
written message to the participant), and document his/her e ffort (date and summary of 
the phone call and copy of the written message in the source documents), to complete 
the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the  participant, must be recorded 
in the source documents. The eCRF must document the primary reason for 
withdrawal.  
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost t o follow -up documented in the 
eCRF . 
7.[ADDRESS_887562] the IXRS and provide brief details 
of the study participant to be enrolled, eg, age, weight, and concomitant MTX  use. The 
Investigator will enter the unique study participant number assigned to each study participant, 
based on a predefined range of study participant numbers assigned to the Investigator’s site. 
This unique study participant number will be required in  all communications between the 
Investigator (or designee) and the IXRS regarding a particular study participant. The IXRS 
will allocate container numbers to the study participants based on the unique study participant 
number during the course of the study . Study participant numbers and container numbers will 
be tracked via the IXRS and also will be required to be entered into the CRF.  
The IXRS will allocate containers of study medication as appropriate to the visit schedule.  
[ADDRESS_887563] in the timeframe as described in the study schedule 
(Schedule of study assessments,  Section  5.2). The accep table window between all the study 
visits is +/-3 days relative to Baseline  (Week 0, Visit 2).  
8.1 Visit 1 (Week -4 to 0) Screening  
Prior to any study activities and at least 4 days prior to the Baseline Visit (Visit 2), study 
participants and parent(s)/legal representative, as applicable, will be asked to read and sign an 
Informed Consent/Assent Form that has been approved  by [CONTACT_2717]/IEC and which complies 
with regulatory requirements. Study participants and parent(s)/legal representative will be 
given adequate time to consider any information concerning the study given to them by [CONTACT_25309]. As part of the  informed consent procedure, study participants and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 51 of 280 parent(s)/legal representative will be given the opportunity to ask the Investigator any 
questions regarding potential risks and benefits of participation in the study.  
Assessments at this visit will incl ude: 
 Obtain written informed consent/assent  
 Assessment of inclusion/exclusion criteria  
 Demographic data including date of birth, gender, and race/ethnicity  
 JIA history and prior JIA medication  
 Review of general medical and procedure history, concomitant di seases, and previous and 
concomitant medications  
 Vital signs  
 Height*  
 Weight*  
 Physical examination  
• TB questionnaire  
 Hematology/biochemistry/urinalysis (including hepatitis and HIV testing)  
 Reproductive potential and birth control  
 Pregnancy (serum) test for postmenarcheal females  
 CRP  
 Chest radiographic imaging and results must be available at Baseline before first IMP 
administration unless a chest X -ray or CT scan is available from 2 months prior to 
Screening.   
 TB screening: TST and IGRA for study participants from 2 to 4  years of age (unless the 
study participant is located in a country with high TST positivity and/or written 
documentation for BCG vaccination is available) or IGRA (to be performed by [CONTACT_658267]) for study participants from [ADDRESS_887564] may be positive 
due to BCG vaccination, however, UCB will not permit enrollment of pediatric study 
participants < 5 years old into the study with out written approval from a physician with 
expertise in pediatric TB**  
 TB questionnaire (study participant and parent/caregiver)**  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessment of Arthritis Pain (VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 52 of 280  Adverse events  
 IXRS contact (to register study participant with unique study participant number)  
*Change in height and weight over the last [ADDRESS_887565] year will be collected 
via parent -/self-report, if not available from medical records.  
**For details of TB screening and testing, see Section  10.7.9 . 
8.2 Visit 2 (Week 0) Baseline  
 Assessment of inclusion/exclusion criteria  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes  after dosing)  
 Height  
 Weight (measurement used to determine CZP dose according to Table 7-1) 
 Tanner stages (except growth)  
 Physical examination  
 TB ques tionnaire (study participant and parent/caregiver)  
 Hematology/biochemistry/urinalysis (only if in the Investigator’s opi[INVESTIGATOR_658213] a 
change in the study participant’s status compared to the Screening Visit, ie, any valid 
result from hematology, biochemi stry, or urinalysis obtained at the Screening Visit will 
be used as the Baseline value)  
 Reproductive potential and birth control  
 Pregnancy (urine) test for postmenarcheal females  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessment of Arthritis Pain (VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 DMS  
 JADAS  
 FPS-R for study participants ages 5 to 11  years  (at Baseline and daily assessment on Day 
1 to Day  7) 
 JIA Pain VAS for study participants ages 12 to 17  years ; acute and standard versions 
(both at Baseline and daily assessment of the acute version on Day  1 to Day  7)  
 Fatigue Assessment Scale  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 53 of 280  Juvenile Arthritis School Attendance and Caregiver Work Productiv ity Survey  
 Concomitant medications and procedures  
 Adverse events  
 IXRS contact (to receive assigned container number[s])  
 CZP plasma concentrations  
 Anti-CZP antibodies  
 Autoantibodies (ANA antibodies and, if ANA is positive, anti -dsDNA antibodies)  
 CZP administration (Injection by [CONTACT_658268].)  
Documentation of the assessment of all 6 core set measures of PedACR response 
(PRINTO/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VA S], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
UCB or designee for immediate review  of completeness, while the study participant is 
still on site.  
8.3 Visits 3 and 4 (Weeks 1 and 2)  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing)  
 Weight (at Week 2 measurement used to reassess CZP dose according to Table 7-1) 
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessment of Arthritis Pain ( VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 Collection of JIA Pain VAS or FPS -R completed on Day 1 to Day 7  
 Clinically Inactive Disease  
 DMS  
 JADAS  
 Fatigue Assessment Scale  
 Concomitant medications and procedures  
 Adverse events  
 IXRS contact  
 CZP plasma concentrations (Week 1 only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 54 of 280  Anti-CZP antibodies (Week 1 only)  
 CZP administration  (Week 2 only. Self/or parent/caregiver -administration under the 
supervision of the site staff for training.)  
8.4 Visits 5 to 10 (Weeks 4, 8, 12, 16, 20, and 24)  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing)  
 Height (Week 24 only)  
 Weight (measurement used to reassess CZP dose according to Table 7-1) 
 Tanner stages (except growth; Week 24 only)  
 Physical examination  
 TB questionnaire (study participant and parent/caregiver) (Weeks 12 and 24 only)  
 Hematology/biochemistry/urinalysis  
 Reproductive potential and birth control  
 Pregnancy (urine) test for postmenarcheal females (Weeks 8, 16, and 24 only)  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessme nt of Arthritis Pain (VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 Clinically Inactive Disease  
 Clinical remission on medication (at Week 24 only)  
 DMS  
 JADAS  
 FPS-R for study participants ages 5 to 11 years  (Weeks 4, 12, 16, and 24 only)  
 JIA Pain VAS (standard version, Weeks 4, 12, 16, and 24 only for study participants ages 
12 to 17 years ) 
 Fatigue Assessment Scale (Weeks 4, 8, 16, and 24 only)  
 Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey  
 Concomitant medicati ons and procedures  
 Adverse events  
 IXRS contact (Assignment of all required study medication until next scheduled visit.)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 55 of 280  CZP plasma concentrations (predose at Weeks 4, 12, 16, and 24.  
Study participants will return to the clinic site for a postdose CZP pl asma sample  
approximately 5 to 7 days following the Week 16 visit .) 
 Anti-CZP antibodies (predose at Weeks 4, 12, 16, and 24)  
 Autoantibodies (ANA and anti -dsDNA antibodies) (Week 16 only)  
 CZP administration (At Week 4, self/parent/caregiver -administration under the 
supervision of the site staff for training. After Week  4, administration of study medication 
either by [CONTACT_8786] [for those not performing home -based administration] or 
self/parent/caregiver -administration under supervision of site personnel  to ensure proper 
injection technique.)  
Between scheduled visits (Weeks 6, 10, 14, 18, 22, 26, 28, 30), CZP will be administered at 
home by [CONTACT_658248]/caregiver or study participants may visit the site for 
CZP administration by [CONTACT_3655] p ersonnel.  
Documentation of the Week 24  assessment of all 6 core set measures of PedACR response 
(PRINTO/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [ VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
UCB or designee for immediate review of completeness, while the study participant is 
still on site.  
8.5 Visits 11 and continuing (Week 32 and every 8 weeks 
thereafter )  
For study participants enrolled prior to Protocol Amendment 9, visit frequency changes to 
every 16 weeks instead of every 8 weeks following implementation of Protocol 
Amendment  8, provided that compliance is maintained with the CZP dosing schedule using 
at-home administration.   
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing)  
 Height (Week 48 and every 24 weeks thereafter ; for study participants enrolled prior to 
Protocol  Amendment 9, height assessment will be performed every 48 weeks following 
Protocol Amendment 8 ) 
 Weight (measurement used to reassess CZP dose according to Table 7-1) 
 Tanner stages (except growth; for study participants enrolled prior to Protocol 
Amendment 9, Tanner stages assessment will be performed every [ADDRESS_887566] not reached Tanner s tage 
V) 
 Physical examination  
 TB screening once a year (at least every  48 weeks)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 56 of 280  TB questionnaire (study participant and parent/caregiver) (Week 40 and every 16 weeks 
thereafter)  
 Hematology/biochemistry/urinalysis  
 Reproductive potential and birth control  
 Pregnancy (urine) test for postmenarcheal females  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessment of Arthritis Pain (VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 Clinically Inactive Disease  
 Clinical remission on medication  
 DMS  
 JADAS  
 FPS-R for study participants ages 5 to 11  years  
 JIA Pain VAS (standard version, ages 12 to 17  years ) 
 Fatigue Assessment Scale  
 Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey  
 Concomitant medications and procedures  
 Adverse events  
 IXRS contact (Assignment of all required study medication until next scheduled visit.)  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendment 9 only; Weeks 32, 40, and 48 and every 24  weeks thereafter)  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only; Weeks 32, 40, and 48 and every 24  weeks thereafter)  
 Autoantibodies (ANA and anti -dsDNA antibodies ) (Week 48 only)  
 CZP administration (Administration of study medication either by [CONTACT_658269]/parent/caregiver -administration under supervision of site personnel to ensure properly 
performed.)  
Between scheduled visits (starting at Week 34), CZP will be administered at home by [CONTACT_658270]/caregiver or study  participants may visit the site for CZP 
administration by [CONTACT_658271].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 57 of 280 8.6 Unscheduled Visit  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and bloo d 
pressure only] approximately 30 minutes after dosing, if dosing is applicable)  
 Concomitant medications and procedures  
 Adverse events  
Other PK and safety assessments should be performed as related to nature of the visit.  
8.6.[ADDRESS_887567] every 4  weeks over a period of 12  weeks 
after the dose change, either at the regularly scheduled visits o r at additional Unscheduled 
Visits.  
The following will be assessed at this visit:  
 Administration of study medication  
 Adverse events  
 Concomitant medications and procedures  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing)  
 Hematology/biochemistry  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 IXRS contact, if applicable  
8.7 Early Discontinuation/End of Treatment Visit  
 Vital signs  
 Height  
 Weight  
 Tanner stages (except growth)  
 Physical examination  
 TB questionnaire (study participant and parent/caregiver)  
 Hematology/biochemistry/urinalysis  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 58 of 280  Reproductive p otential and birth control  
 Pregnancy (urine) test for postmenarcheal females  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Assessment of Arthritis Pain (VAS)  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 Clinically Inactive Disease  
 Clinical remission on medication  
 DMS  
 JADAS  
 FPS-R for study participants ages 5 to 11  years  
 JIA Pain VAS (standard version ages 12 to 17  years ) 
 Fatigue Assessment Scale  
 Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey  
 Concomitant medications and procedures  
 Adverse events  
 IXRS contact (to register study participant visit)  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendm ent 9 only  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only)  
 Autoantibodies (ANA and anti -dsDNA antibodies)  
8.8 Final Visit  
The final visit is to be completed by [CONTACT_512460] 12 weeks after the final dose of 
CZP. 
 Vital signs  
 Weight  
 Physical examination  
 Hematology/biochemistry/urinalysis  
 Reproductive potential and birth control  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 59 of 280  Pregnancy (urine) test for postmenarcheal females  
 Concomitant medications and procedures  
 Adverse events  
 IXRS contact (to deactivate the  study participant)  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendment 9 only)  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only)  
9 ASSESSMENT OF PHARMA COKINETICS AND 
IMMUNOLOGICAL V ARIABLES  
Blood samples will be collected predose to determine plasma concentrations of CZP and 
anti-CZP antibodies at Baseline (Week 0), Weeks 4, 12, 16, 24, 32, 40, 48, and then every 
24 weeks thereafter; the Early Discontinuation/End of Treatment Visit, and the Final Visit 
[ADDRESS_887568] dose of study medication. For study participants enrolled prior to 
Protocol Amendment 9, samples for CZP plasma concentration and anti -CZP antibodies will 
no longer be collected. In addition, blood samples will b e collected 5  to 7 days after dosing at 
Baseline (ie, at Week 1, Visit 3) and  Week 16 (ie, return of study participant to clinic site at 
Week 17) to determine postdose plasma concentration.  
All of these blood draws (except for postdose samplings at Week 1  and after Week 16) will 
be performed prior to any study medication administration, where applicable, and all of them 
coincide with the blood collection times for the assessment of hematology and clinical 
chemistry parameters, so that no additional blood d raws are required at these visits except at 
Week 1 (Visit 3) and the postdose sampling following Week 16 (Visit 8). Time and date of 
each blood draw will be documented on the CRF.  
Instructions on blood sample collection, processing, storage, and labeling/shippi[INVESTIGATOR_261452].  
Blood samples to determine plasma concentrations of CZP and anti -CZP antibodies will be 
analyzed by a specialty laboratory. All study participants enrolled following Protocol 
Amendment [ADDRESS_887569] plasma concentrations of CZP and anti -CZP antibodies analyz ed 
using an ECLIA method that meets current regulatory standards. In addition, PK and ADA 
samples (for which sufficient volume is available) collected in this study prior to Protocol 
Amendment  [ADDRESS_887570] a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of a n IMP, whether or not related to the IMP.  
In order to ensure complete safety data collection, all AEs occurring during the study 
(ie, after signing the Informed Consent Form), including any pretreatment and posttreatment 
periods required by [CONTACT_760], m ust be reported in the CRF even if no IMP was 
administered but specific study procedures were conducted. This includes all AEs not present 
prior to the initial visit and all medical conditions or AEs which recurred or worsened after 
the initial visit.  
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile k nown to the 
Investigator from the study participant’s history or the period preceding Baseline.  
10.1.2  Procedures for reporting and recording AEs  
The study participant/caregiver will be given the opportunity to report AEs spontaneously. A 
general prompt will also  be given at each study visit to detect AEs, for example:  
“Did you notice anything unusual about your (your child’s) health (since your last 
visit)?”  
In addition, the Investigator should review any self -assessment procedures (eg, diary cards) 
employed in t he study to identify potential AEs.  
10.1.[ADDRESS_887571] medical terminology, rather than recording individual symptoms or signs, where 
possible. If a diagno sis/syndrome is eventually determined, relevant signs and symptom AEs 
should be consolidated under the diagnosis/syndrome rather than continued to be listed 
individually. The CRF and source documents should be consistent. Any discrepancies 
between the stud y participant’s own words on his/her own records (eg, diary card) and the 
corresponding medical terminology should be clarified in the source documentation.  
Details for completion of the Adverse Event CRF (including judgment of relationship to 
study medica tion) are described in the CRF instructions.  
10.1.[ADDRESS_887572] to follow -
up.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 61 of 280 If an AE is still ongoing at the end of the study for a study participant, follow -up should be 
provided until the AE resolves/reaches a stable level of sequelae, the Investigator no longer 
deems that it is clinically significant, or the study participant is  lost to follow -up. If no 
follow -up is provided, the Investigator must provide a justification. Follow -up of any ongoing 
AE is continued until the end of the study for a study participant (Final Visit) or until the 
study participant is lost to follow -up. 
10.1.5  Rule for repetition of an AE  
An increase in the intensity of an AE (or an ongoing medical condition at the study onset) 
should lead to the repetition of the AE being reported with:  
 The outcome date of the first AE that is not related to the natural course o f the disease 
being the same as the start date of the repeated AE, and the outcome of “worsening”,  
 The AE verbatim term being the same for the first and repeated AE, so that the repeated 
AE can be easily identified as the worsening of the first one,  
 Chan ge in intensity or severity being recorded.  
10.1.[ADDRESS_887573] are selected based on findings from the IMP clinical program to 
date, potential risks generally associated with biologic immunomodulators, or findings from 
other medicines with a related mechanism of action. There are no specific AE reporting 
requirements beyond those specified for AEs and SAEs in the protocol; however, special 
monitoring, additional data collection activities, and/or enhanced signal detection activities 
(within UCB) are in place. The reporting requirements for events relating to TB are as 
follows:  
 IGRA test conversions defined as a positive or indeterminate (and confirmed 
indeterminate on repeat) should be reported as AEs. The AE term would need to be 
updated with final diagnosis once available.  
 LTBI must be reported as an AE. Follow -up reports sho uld be completed as per 
protocol requirement until the LTBI resolves.  
 Confirmed active TB is always considered a SAE and must be reported per SAE 
reporting instruction in the study protocol. Follow -up reports should be completed as 
per protocol requiremen t until TB infection resolves.  
10.1.[ADDRESS_887574] be discontinued as soon as 
pregnancy is known (by [CONTACT_417712]). Study participants can remain in the study 
under observation and should attend to scheduled visits regularly as their condition allows.  
The Investigator must inform the study participant of information currently known about 
potential risks and abo ut available treatment alternatives .  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887575] consent via th e Partner Pregnancy Consent Form. If the partner agrees to 
provide additional information, the Pregnancy Report and Outcome Form will be forwarded 
to the study participant’s partner (or parent/caregiver if study participant underaged) for 
completion.  
The pregnancy will be documented on the Pregnancy Report and Outcome Form provided to 
the Investigator. The progression of the pregnancy and the eventual birth (if applicable) must 
be followed -up using the Pregnancy Report and Outcome form in which the Investi gator has 
to report on the health of the mother and of the child. The health of the child must be 
followed for [ADDRESS_887576] that follow -up is continued for a period longer  
than 30 days.  
A pregnancy becomes a serious adverse event (SAE) in the following circumstances: 
miscarriage, abortion, or anomaly/birth defect of the child. A pregnancy is considered as an 
SAE in case of contraceptive failure (eg, pi[INVESTIGATOR_658222] a pproximately the same time 
each day without having been forgotten or with use of permanent contraceptive devices). 
Those serious events must be additionally reported using the Investigator SAE report form.  
10.1.[ADDRESS_887577]  
For the purposes of reporting, any suspected transmission of an infectious agent via the study 
medication should be considered as an SAE; such cases must be reported immediately, 
recorded in the AE module of the CRF, and followed as an y other SAE. Any organism, virus, 
or infectious particle (eg, prion protein transmitting transmissible spongiform 
encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.  
10.1.9  Overdose of IMP  
Excessive dosing of IMP (beyond that prescrib ed in the protocol and including overdose) 
should be recorded in the appropriate CRF module. Since excessive dosing may be 
symptomatic, in that the excessive dosing results in clinical signs and symptoms, or the 
excessive intake may itself be a symptom, an y SAE or nonserious AE associated with 
excessive dosing must be followed as any other serious or nonserious AE.  
10.1.10  Ongoing safety data review and oversight  
This study will be performed using remote data capture (RDC). The Investigator is 
responsible for the prompt reporting of accurate, complete, and legible data in the electronic 
CRFs. Laboratory data will be regularly transferred electronically to the Sponsor for 
incorporation with the Investigator -entered data.  
Adverse event and laboratory data will period ically be reviewed by [CONTACT_658272]. Regular monitoring of all 
safety data collected during CZP clinical studies is performed as described in the Safety 
Signal Detection in the Ongoing Cl inical Trials Charter for CZP. The data from this study 
will be reviewed separately, in the context of all CZP data, and in the context of data coming 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887578] (DSMB) 
will periodicall y review emerging safety and efficacy data (see Section 13.7). The DSMB 
will function and meet on a regular basis as per the agreed upon charter.  
The Sponsor Study Physician or medically qualified designee/equivalent will conduct an 
ongoing review of SAEs and perform ongoing SAE reconciliations in collaboration with the 
Patient Safety and Data Management representatives.  
10.[ADDRESS_887579] meet 1 or more of the following criteria:  
 Death.  
 Life-threatening.  
◦ Life-threatening does not include a reaction that mig ht have caused death had it 
occurred in a more severe form.  
 Significant or persistent disability/incapacity.  
 Congenital anomaly/birth defect (including that occurring in a fetus).  
 Important medical event that, based upon appropriate medical judgment, may j eopardize 
the study participant and may require medical or surgical intervention to prevent 1 of the 
other outcomes listed in the definition of an SAE: allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias th at do not result 
in inpatient hospi[INVESTIGATOR_059], pregnancy due to contraceptive failure, or the development of 
drug dependency or drug abuse.  
 Initial inpatient hospi[INVESTIGATOR_318].  
 A study participant admitted to a hospi[INVESTIGATOR_307], even if released on the same day, meets the 
criterion initial inpatient hospi[INVESTIGATOR_059]. An emergency room visit that results in 
admission to the hospi[INVESTIGATOR_658223]. However, emergency room visit s that do not result in admission to the hospi[INVESTIGATOR_261414], instead, should be evaluated for 1 of the other 
criteria in the definition of an SAE (eg, life -threatening adverse experience, important 
medical event).  
Hospi[INVESTIGATOR_658224] (eg, preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested in 
an unusual or uncharacteristic manner) do not qualify for reporting. Preplanned sur gery or 
elective surgery must be verified in source document prior to Baseline (eg, timing and type of 
procedure). For example, if a study participant has a condition recorded on his/her medical 
history and later has a preplanned surgery for this condition , it is not appropriate to record the 
surgery or hospi[INVESTIGATOR_658225]. Please note that, if the pre -existing condition has worsened or manifested in an 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887580] be verified in source document prior to 
Baseline (eg, timing and type of procedure). If a hospi[INVESTIGATOR_658226] (at Week  0), it will not be classified as either an 
AE or SAE. This also applies to a scheduled elective surgery where no AE is present. A 
noncomplicated, preplanned elective surgery will not be considered an AE or SAE even if it 
involves  hospi[INVESTIGATOR_059]. However, if a hospi[INVESTIGATOR_122221] a result of an AE, 
this will be considered to be an SAE.  
10.2.[ADDRESS_887581] be informed within 24 hours of receipt of this information 
by [CONTACT_779]  (see contact [CONTACT_658273]). The Investigator must forward to UCB (or its representative) a duly completed 
Investigator SAE Report form provided by [CONTACT_18338], even if the data are incomplete, or if it is 
obvious that more data will be needed in order to draw any conclusions. Information recorded 
on this form will be entered into the pharmacovigilance database.  
An Investigator SAE Report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English.  
Additional information (eg, autopsy or laboratory reports) received by [CONTACT_658274] [ADDRESS_887582] and report to UCB (or its representative) 
any SAEs (even if the Investigator is certain that they are in no way associated with the IMP), 
up to [ADDRESS_887583] expedited reporting, even if the AE does not fulfill the 
expedited reporting criteria of “serious,” “unexpected,” and “associated with the us e of the 
drug.”  
Adverse events of special interest include:  
 Potential Hy’s Law  
 Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnor mality (ie, without waiting for any additional etiologic 
investigations to have been concluded). Follow -up information should be reported if 
an alternative etiology is identified during investigation and monitoring of the 
participant.  
 Serious infections, i ncluding opportunistic infections  
 Malignancies, including lymphoma  
 Congestive heart failure  
 Demyelinating -like disorders  
 Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leukopenia  
 Serious bleeding events  
 Lupus and lupus -like syndrom e  
 Serious skin reactions (eg, Stevens -Johnson syndrome, toxic epi[INVESTIGATOR_59373], and 
erythema multiforme)  
Adverse events of  special  interest must be reported immediately by [CONTACT_737] (see 
Section  10.4).  
The purpose of the AESI  is to identify and capture product specific AEs/reactions requiring 
expedited reporting or close monitoring by 1 or more regulatory authorities or close 
monitoring required by [CONTACT_18338]. This tool will help ensure that specific special reporting 
requirements fr om regulatory authorities and safety topi[INVESTIGATOR_658227], processed, reported, and monitored. The process also allows for 
detection of safety signals, signal evaluation, and the assessment of changes in the 
benefi t-risk ratio of UCB products/compounds, based on all safety and benefit -risk 
information available for the protection of the patient.  
10.[ADDRESS_887584] be reported immediately via use of the SAE form (see Study 
Contact [CONTACT_658275]):  
 SAE: AE that the Investigator classifies as serious by [CONTACT_658276] (see 
Section 10.2.1 ) regardless o f causality  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 66 of 280  Suspected transmission of an infectious agent via a medicinal product  
 AE of interest (see Section 10.3) 
10.[ADDRESS_887585] does not change the Investigator’s obligation to report all serious AEs (including 
Anticipated SAEs) as detailed in Section 10.2.2 . 
Table  10-1 Anticipated serious adverse events for JIA population  
Preferre d Term  
Juvenile idiopathic arthritis  
10.6 Laboratory measurements  
Hematology, biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32 and every 8 weeks thereafter ( for study participants enrolled 
prior to Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 
8 weeks following implementation of Protocol Amendment 8 ), the Early Discontinuation/End 
of Treatment Visit, and the Final Visit [ADDRESS_887586] dose of study medicati on. At 
Week 1, only CRP and PK samples will be collected and at Week 2, only CRP samples will 
be collected. In addition, hematology, biochemistry, and CRP samples will be collected at 
Unscheduled Visits for study participants undergoing a dose change (Sect ion 7.2.1  and 
Section  8.6.1 ).  
Retesting of laboratory assessments within the Screening Period is allowed in case of isolated 
exclusionary laboratory assessments  at Screening if, in the Investigator’s opi[INVESTIGATOR_1649], the value is 
not reflective of the study participant’s previous clinical and laboratory pattern (see 
Section  6.3). In addition, retesting within the Screening  Period is allowed in case of reporting 
failure of laboratory results (eg, issues with transportation of samples).  
Study participants do not have to fast.  
Laboratory criteria and collection details are provided in the laboratory manual.  
For blood sampling  on PK and immunological variables see Section 9. 
Measures to minimize distress and pain have been considered for this study in line with the 
“Ethic al Considerations for Clinical Trials on Medicinal Products Conducted with the 
Paediatric Population” (European Medicines Agency, 2008) and the “Guidance for Industry – 
E11 Clinical Investigation of Medicinal Products in the Pediatric Population” (FDA, 200 0). 
Unless in the Investigator’s opi[INVESTIGATOR_658213] a change in the study participant’s status, any 
valid laboratory result obtained at the Screening Visit on hematology, chemistry, and 
urinalysis can be used as the Baseline value, which will avoid the repea ted collection of these 
specific samples at Baseline.  Only samples for CRP , PK, and immunological variables will 
then be collected at Baseline (Week 0).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 67 of 280 A qualified central laboratory capable of handling small sample/tube sizes will be used in this 
study. The planned total blood volumes collected at a single time point (visit) will vary 
between 2mL and 9mL. The highest blood sampling frequency will occur during the first 
4 weeks of the study. The maximum total volume collected during this period will be 
approximately 24mL (at the first 4 study visits).  
In addition , treatment of the venipuncture site with an anesthetic cream prior to blood 
sampling is permitted.  
The TB assessment by [CONTACT_658277]; additional 
blood  sampling of approximately 3mL will be required at Screening.  
If the result of the IGRA test is indeterminate, the test may be repeated once. If positive or 
indeterminate on retest, the study participant must not be enrolled (Section  [IP_ADDRESS] ).  
For study participants from [ADDRESS_887587] and IGRA testing will be performed 
(except for study participants with documented BCG vaccination) as desc ribed in 
Section  [IP_ADDRESS].[ADDRESS_887588] positivity, only 
IGRA should be performed (Section  [IP_ADDRESS].2 ). The TST may be positive due to BCG 
vaccination, however, UCB will not permit enrollment of pediatric study participants 
<5 years old into the study with out written approval from a physician with expertise in 
pediatric TB. IGRA testing should be done once a year (approximately every 48 weeks) for 
all study participants.   
The central laboratory will analyze and assess blood and urine samples for the followi ng 
(except dip stick test and urine pregnancy test); other PK assessments may be periodically 
performed as per Section  9: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 68 of 280 Table  10-2 Laboratory measurements  
Hematology  Serum biochemistry  Urinalysis  
Red blood cells  
Hemoglobin  
Hematocrit  
Platelets  
White blood cells  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Sodium  
Potassium  
Chloride  
Bicarbonate  
Total calcium  
Inorganic phosphorus  
Creatinine kinase  
Glucose  
Creatinine  
Uric acid  
Urea  
Total protein  
Albumin  
Alkaline phosphatase  
Gamma glutamyl transferase  
Aspartate aminotransferase  
Alanine aminotransferase  
Lactate dehydrog enase  
Bilirubin  
Total cholesterol  
CRP 
Autoantibodies (ANA and 
anti-dsDNA antibodies)  pH(a) 
Protein(a) 
Glucose(a)  
Blood(a) 
Microscopy (WBC, RBC, casts, 
crystals, bacteria) (Microscopy 
will be performed only when 
there are abnormalities on 
dipstick)(a) 
  Serum and urine pregnancy 
test(b) 
 
Hepatitis screening(c) 
HBcAb  
HBsAb  
HBsAg  
HCVAb  
HBV DNA, if applicable  
HCV RNA, if applicable  
TB screening(d) 
IGRA,  
TST 
HIV Screening  
HIV antigen or antibody  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 69 of 280 ANA=antinuclear antibody; anti -dsDNA antibodies=double -stranded deoxyribonucleic acid antibody; 
BCG=Bacille Calmette -Guérin; CRP=C -reactive protein; DNA=deoxyribonucleic acid; HBcAb=hepatitis 
B core antibody; HBsAb=hepatitis B surface antibody; HBsAg=hepatitis B surface antigen; HBV=hepatitis  
B virus; HCV=hepatitis C virus; HIV= human immunodeficiency virus ; IGRA=interferon -gamma release 
assay; RBC=red blood cells; TB= tuberculosis; TST=tuberculin skin test; WBC=white blood cells  
Note: The Screening Visit must be completed at least 4 to 12 worki ng days prior to the Baseline Visit, 
depending on regional requirements and laboratory assessments required for the study participant (refer to 
laboratory manual for country -specific requirements). In case HBV DNA  or TB IGRA is to be analyzed, 
the Baseline  Visit can be performed at the earliest 12 days after the Screening Visit (6 working days in 
Russia). Study participants can only be enrolled into the study after all laboratory results of the Screening 
Visit have been confirmed.  
a Urine dipsticks will be d one locally at the site; only abnormalities will be reported. In case of 
abnormalities on dipstick, microscopy will be performed by [CONTACT_2237].  
b Serum pregnancy tests will be performed at Screening by [CONTACT_2237] (see Section 10.7.7 ). 
At Baseline, Weeks 8, 16, 24, and every visit thereafter, urine pregnancy tests will be performed 
locally.  
c At Screening, laboratory testing includes testing for hepatitis B core antibody, hepatitis B surface 
antibody, hepatitis B surface antigen, hepatitis C virus antibody , and HIV 1/[ADDRESS_887589] will not be allowed in the study (except for anti -hepatitis B po sitive only, in case 
study participant is immune due to well -documented hepatitis B vaccination or isolated false -positive 
anti-HBc test confirmed with a confirmatory test such as hepatitis B virus deoxyribonucleic acid 
[HBV -DNA]). A positive hepatitis C a ntibody test will be confirmed by a confirmatory test (such as 
HCV RNA) and those with a positive confirmatory test will not be allowed in the study.  
d For TB testing refer to Section 10.7.9 . IGRA is performed by [CONTACT_6626].  
10.7 Other safety measurements  
10.7.1  Vital signs  
Vital signs will be measured within approximately 15  minutes prior to dosing and in addition 
(pulse and blood pre ssure only) approximately [ADDRESS_887590] 5  minutes prior and during the 
collection of blood pressure and pulse rate measurements. Vital signs are as follows:  
 Pulse  
 Systolic/d iastolic blood pressure measurement  
 Temperature  
Vital signs will be measured at Screening, Baseline, every visit (including all Unscheduled 
Visits) through the Early Discontinuation/End of Treatment Visit, and the Final Visit 
[ADDRESS_887591] dose o f study medication.  
10.7.2  Growth (height and weight)  
Height will be recorded at Screening, Baseline,  every 24 weeks thereafter ( for study 
participants enrolled prior to Protocol Amendment 9, the height  assessment will be performed 
every 48 weeks following Protoc ol Amendment 8), and the Early Discontinuation/End of 
Treatment Visit . Height will be recorded after the shoes have been removed. Height should 
preferably be measured with a wall -mounted stadiometer.   
At Screening, change in height and weight over the last  [ADDRESS_887592] year will 
be collected via parent -/self-report, if not available from medical records.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 70 of 280 Weight will be recorded after removal of shoes and heavy clothing. Weight will be measured 
at Screening, Baseline, and every visit through th e Early Discontinuation/End of Treatment 
Visit, and the Final Visit [ADDRESS_887593] dose of study medication.  
Results of the weight measurement will be used to determine the study participant’s CZP 
dose as specified in Table 7-1. 
10.7.3  Tanner stages  
Assessments of study participants’ developmental stages on external genitalia and pubic hair 
(boys) and on breast and pubic hair (girls) will be performed  to determine Tanner stages 
(Marshall and Tanner, 1969; Marshall and Tanner, 1970). These assessments  will be 
performed at Baseline and every 24 weeks thereafter, and the Early Discontinuation/End of 
Treatment Visit. For study participants  enrolled prior t o Protocol Amendment 9, Tanner 
stages assessment will be performed every [ADDRESS_887594] not reached Tanner stage V.  
10.7.4  Physical examination  
Physical examinations (except joint examination) will be performed at Screening, Baseline, 
Week 4, every visit thereafter through the Early Discontinuation/End of Treatment Visit, and 
the Final Visit [ADDRESS_887595] dose of study medication. Physic al examination 
findings will be recorded in the CRF only at Screening. Details of the subsequent physical 
examinations should be recorded in the source documentation. Clinically relevant changes in 
subsequent physical examinations will be recorded as AEs.  
The following body systems will be examined:  
 General appearance  
 Ear, nose, and throat  
 Eyes  
 Hair and skin  
 Respi[INVESTIGATOR_696]  
 Cardiovascular  
 Gastrointestinal  
 Musculoskeletal  
 Hepatic  
 Neurological  
 Mental status  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 71 of 280 10.7.5  Demographics, JIA history, prior JIA medication, and g eneral 
medical and procedure history  
Demographic data, JIA history including prior medication, general medical and procedure 
history (including any prior chest radiographs), and concomitant diseases will be recorded by 
[CONTACT_658278]. 
10.7.6  Reproductive potential and birth control  
Reproductive potential of all study participants will be assessed by [CONTACT_658279], Baseline, and every visit thereafter except at Visits 3 and 4 and at Unscheduled 
Visits. If the study parti cipant is not of reproductive potential, the reason will be recorded (eg, 
prepubescent, pre -menarcheal). If the study participant is of reproductive potential and is 
sexually active, the method of birth control used will be recorded. Sexually active study 
participants (male and female) must use effective contraceptive measures (see Section 6.2, 
Exclusion Criterion 17).  
10.7.7  Pregnancy testing  
Pregnancy testing for all postmenarcheal female study participants (regardless of sexual 
activity) will consist of serum testing at Screening and urine testing at all other applicable 
visits. For female study participants who start menstruating during the study, uri ne pregnancy 
testing will be performed starting at the next applicable visit. Pregnancy testing must be 
carried out at Screening, Baseline, and every visit thereafter except at Unscheduled Visits 
(unless deemed necessary by [CONTACT_737]).  
10.7.8  Autoantibody (ANA and anti -dsDNA antibodies) concentrations  
Autoantibodies (ANA and anti -dsDNA antibodies) will be assessed at Baseline ( testing for 
anti-dsDNA antibodies only if ANA is positive), Weeks 16 and 48, and the Early 
Discontinuation/End of Treatment Visit.  
All of these blood draws will coincide with the blood collection times for the assessment of 
hematology and clinical chemistry parameters, so that no additional blood draws are required.  
10.7.9  Assessment and management of TB and TB risk factors  
As TNF inhibitors are known to be associated with significant risk of reactivation of LTBI or 
previously treated active TB, appropriate rigorous precautions are being taken within the 
protocol  (see Section  6.2 [Exclusion Criterion 11] and Section  6.4 [Withdrawal Criterion  2]). 
Study participants with known active TB disease, at high risk of acquiring TB infection, or 
with past or current LTBI or current or history of NTMB infection are excluded from the 
study.  
a. Known TB infection whether present or past is defined as:  
 Active TB infection or clinical signs and symptoms strongly suggestive of TB 
(pulmonary or extra pulmonary).  
 History of active TB infection involving any organ system or findings in other organ 
systems  consistent with TB infection.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 72 of 280  Any evidence by [CONTACT_658280] 's medical history.  
b. High risk of acquiring TB infection is defined as:  
 Known cl ose exposure (eg, sleepi[INVESTIGATOR_368739]) to another person with active 
TB infection within 3 months prior to Screening.  
 Time spent within 3 months prior to Screening in a healthcare delivery setting or 
institution where individuals infected with TB are  housed or where the risk of 
transmission of infection is high.  
c. LTBI is defined as an infection by [CONTACT_658281]:  
 A positive IGRA (or 2 indeterminate IGRAs), AND  
 Chest imaging (or other imaging) negative for TB infection, AND  
 Absence of  signs, symptoms (eg, evidence of organ -specific involvement), or physical 
findings suggestive of TB infection.  
d. Pulmonary NTMB infection is defined as a group of lung infections caused by 
[CONTACT_658282] . 
[IP_ADDRESS]  Physical examination  
The investigator should consider all potential sites of infection when assessing for TB during 
the physical examination and other evaluations and based on the study participant’s medical 
or social history.  
The most common primary foc us of TB is the lung. Other sites may include gastrointestinal 
system, bones/joints, lymph glands and meninges etc. However, in immune compromised 
patients and/or patients treated with TNF inhibitors, extra -pulmonary manifestations of TB 
are common compare d to normal population.  
Some common symptoms that the study participant may present are dependent on the 
primary focus of infection and may include cough, blood in sputum, night sweats, 
lymphadenitis, joint pain/swelling, spi[INVESTIGATOR_18262], headache/confusi on, abdominal pain 
(mimicking IBD) etc. Unusual presentations should always be considered.  
[IP_ADDRESS]  IGRA test conversion  
Tuberculosis test conversion is defined as a positive or indeterminate (and confirmed 
indeterminate on repeat) IGRA result for the current test when previous IGRA test results 
were negative. All study participants with positive or indeterminate IGRA test results must 
immediately stop IMP administration. In case of an IGRA test conversion, the study 
participant must be considered as having either a  suspected new latent or an active TB 
infection and be promptly referred to an appropriate specialist (eg, pulmonologist, infectious 
disease specialist) for further evaluation. Additional assessments (eg, blood tests or IGRA, 
chest X -rays, or other imaging ) should be performed where medically relevant and 
documented. Such conversions should be reported as AEs as described in the protocol. The 
AE term would need to be updated with final diagnosis once available.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 73 of 280 [IP_ADDRESS]  Latent TB infection  
In case the evaluation by [CONTACT_658283] a new LTBI, the study 
participant must permanently stop IMP and be withdrawn from the study. A TB prophylactic 
therapy in accordance with applicable clinical guidelines might be initiated, if considered 
appropriate.  
Once withdrawn from study treatment, study participants should return for the Early 
Discontinuation Visit and complete all early discontinuation assessments, and complete an 
Final Visit ([ADDRESS_887596] dose of IMP). LTBI must be reported as an AE. Fo llow-up 
reports should be completed as per protocol requirement until such time as the LTBI resolves.  
[IP_ADDRESS]  Active TB or NTMB infection  
Study participants who develop active TB or NTMB  infection during the study must be 
withdrawn from the study. The study partic ipant must be immediately discontinued from 
study medication and an Early Discontinuation Visit must be scheduled as soon as possible, 
but no later than the next scheduled visit. The study participant should be encouraged to keep 
the Final Visit as specifi ed by [CONTACT_760]. Treatment should be started immediately.  
Note that study participants with history of or active NTMB infection are excluded from the 
study regardless of prior or current therapy for this condition.  
Confirmed active TB is always considered an SAE. UCB’s process requires that these must 
be captured on an SAE report form and provided to the Sponsor in accordance with SAE 
reporting requirements. Follow -up reports should be completed as per protocol requirement 
until such time as the TB infection resolves.  
[IP_ADDRESS]  TB assessment by [CONTACT_658244]  (TST)  
During the Screening Period, the TB assessment by [CONTACT_658284] (17  years and under). The IGRA (QuantiFERON®-TB GOLD In -Tube test) is the 
protocol -required method of screening for TB. A UCB validated central laboratory shall be 
responsible for interpreting the results of IGRA. The central laboratory must provide UCB 
with all assay values (both measured and calculated) in accordance with the approved test 
label or package insert. The IGRA negative result is as defined by [CONTACT_206000]’s manufacturer. If a 
central laboratory is not easily accessible for IGRA, UCB will determine whether the test 
should be performed by a qualified local laboratory.  
If the result of the IGRA test is indeterminate, the test may be repeated once. If positive or 
indeterminate on retest, the study participant may not be enrolled. The retest must be done 
during the protocol -defined Screening window.  
For study participants [ADDRESS_887597] is optional in some regions/locations, 
based on local guidelines or requirements taking into account the prevalence of TB in such 
countries.  
In countries with high bacillus Calmette -Guerin (BCG) vaccination or high TST positivit y, it 
is not recommended to do the TST. The TST may be positive due to BCG vaccination. UCB 
will not permit enrollment of pediatric study participants without advice from physician with 
expertise in pediatric TB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887598] is defined as an induration of ≥5mm occurring 48 to 72  hours after 
intradermal injection with 5 tuberculin units (TU) of either TST -S or 2TU of TST -RT23. The 
test must be performed and read by a TST qualified health care professional (per local 
guidelines). The exact measurement of t he observed induration (in mm) must be documented 
in the study participant’s medical record at the same time that it is read. Documentation must 
include the date and time the test was performed, the testing field (site), and the date and time 
the test was read.  
During the conduct of the study, the TB assessment by [CONTACT_658285]’s discretion. The TST test should not be repeated during the conduct of the study.  
The test results will be reported as positive, negative , or indeterminat e and must be reviewed 
by [CONTACT_18408], radiologist, or a pulmonologist. If the assessment by [CONTACT_658286], the study participant must undergo appropriate study -
specified withdrawal procedures. The retest duri ng Screening must be done during the 
protocol -defined Screening window.  
[IP_ADDRESS]  TB assessment by [CONTACT_13190] x -ray 
Chest radiographic imaging is done at Screening and results must be available at Baseline 
before first drug administration, unless a chest x -ray or CT is a vailable within [ADDRESS_887599] be clear of signs of TB infection (previous or current) 
before first study medication administration. The chest x -ray should be repeated only if the 
TB test was confirmed positive or any fur ther evidence is suggestive of potential TB infection 
(eg, exposure). Radiographic findings suggestive of inactive TB or active TB may include but 
are not limited to: api[INVESTIGATOR_18304], pleural thickening, pulmonary nodules, fibrotic scars, 
calcified granulo mas, upper lobe infiltrates, cavitations and pleural effusions, calcified lung 
nodules, calcified hilar lymph nodes, and pericardial calcification.  
The chest imaging must be negative for old or recent TB infection as determined by a 
qualified radiologist a nd/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest x -ray must be documented in the source documents and the eCRF as an 
AE. 
[IP_ADDRESS]  TB risk factors via the TB questionnaire  
The TB questionnaire “Evaluation of signs and symptom s of tuberculosis” should be 
completed accurately and filed as a critical source document. The questionnaire will assist 
with the identification of study participants who may require therapy for TB. It will be 
completed as outlined in the schedule of asses sments ( Table  5-1). 
A “Yes” response to any of the questions in the TB questionnaire during the study should 
trigger further assessments to determine if the study participant has either LTBI or active TB 
infect ion and must be withdrawn from the study (see below for details). As an example, a 
study participant who answers “Yes” at Screening to the question “Has the participant been in 
close (eg, sleepi[INVESTIGATOR_368739]) contact [CONTACT_41022] , or an 
individual who has recently been treated for TB? ” should not be allowed in the study pending 
further assessments (including TB specialist consult) to determine if the study participant has 
either LTBI or active TB infection. In case of any doubt, U CB recommends seeking the 
opi[INVESTIGATOR_1101] a TB specialist before starting or continuing study medication intake.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 75 of 280 [IP_ADDRESS]  TB management  
For inclusion in the study, see Section  6.2 (Exclusion Criteria).  
[IP_ADDRESS].[ADDRESS_887600] (pulmonologist or infectious disease specialist) for 
further evaluation and appropriate clinical management. Study participants must be 
withdrawn and scheduled to return for the Early Disco ntinuation Visit as soon as possible but 
no later than the next scheduled study visit and complete all Early Discontinuation Visit 
assessments. The study participant should be encouraged to complete the Final Visit 
([ADDRESS_887601] dose of IMP).  
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study and compliant TB treatment shall be followed.  
[IP_ADDRESS].2  Tuberculosis testing during the study for study participants above 
and below 5 years of age  
Upon signing the updated Informed Consent form, all study participants need to undergo TB 
testing as described below.  
Study participants above 5 years of age  
IGRA testing (QuantiFERON) should be done once a year (approximately every 48 weeks) 
for all study participants from 5 to 17 years of age as described in Section  [IP_ADDRESS] . 
Study participants below [ADDRESS_887602] be negative to be 
eligible for study inclusion (Note that some antihistaminics have the potential to interact with 
the TST response and render it negative). If either test is positive, the study participant should 
be ref erred to a TB specialist and the study participant must not initiate IMP. If the IGRA 
become s positive during the study , the IMP administration must be stopped and study 
participants should be referred to TB specialist.  
In countries with high BCG vaccinat ion or high TST positivity, it is not recommended to do 
the TST. The TST may be positive due to BCG vaccination, however UCB will not permit 
enrollment of pediatric study participants <5 years of age  into a study without written 
approval from a physician w ith expertise in pediatric TB.  
IGRA testing (QuantiFERON) should be done once a year (approximately every 48 weeks) 
for all study participants below [ADDRESS_887603] (ie, no validated test performance 
with a smaller blood volume). Therefore, if a maximum cumulative blood draw volume is 
cited by [CONTACT_2717]/EC for a pediatric clinical study, exceptions may be made for other clinical 
lab assessments in order to accommod ate the IGRA volume requirement.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 76 of 280 11 ASSESSMENT OF EFFICA CY AND HEALTH OUTCOM ES 
VARIABLES  
11.1 PedACR30, PedACR50, PedACR70, and PedACR90 clinical 
response  
The PedACR30, PedACR50, PedACR70, and PedACR90 clinical responses rates 
(Giannini  et al, 1997; Lovell et al, 2008) at every visit compared to Baseline (except the Final 
Visit) will be assessed. The assessments are based on a 30%, 50%, 70%, and 90% or greater 
improvement in at least 3 of the 6 core set measures with no more than 1  of the remaining 
worsened by >30% . The 6 core set measures are:  
 Number of joints with active arthritis (joints with swelling not due to deformity or 
inactive synovitis, or joints with limitation of motion with pain, tenderness, or both)  
 Number of joints with limitation of range of motion  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ completed by [CONTACT_308489] (Appendix 17.1) 
 Parent’s Global Assessment of Overall Well -Being (VAS) (Appendix 17.3) 
 Acute phas e reactant (CRP)  
Documentation of the assessment of all 6 core set measures will be submitted to UCB or 
designee for immediate review of completeness at Week 0 (Baseline)  and Week 24, while 
the study participant is still on site.  
11.2 PRINTO/PRCSG standard join t examination  
The following 75 joints are to be examined for swelling, pain on motion (POM), tenderness, 
and limitation of motion (LOM) by [CONTACT_737], another delegated physician, or an 
appropriately qualified medical professional (based on local req uirements) who has had 
documented training on how to perform these assessments correctly. Preferably the same 
assessor should evaluate the study participant at each arthritis assessment, as per 
PRINTO/PRCSG guidelines. The individual with this delegated du ty must be listed on 
Form  1572.  
 Upper body (6) - bilateral temporomandibular, sternoclavicular, and acromioclavicular 
joints  
 Upper extremity (34) - bilateral shoulders, elbows, wrists, metacarpals (MCP I, II, III, IV, 
and V), proximal interphalangeals (PIP  I, II, III, IV, and V) and distal interphalangeals 
(DIP II, III, IV, and V)  
 Lower extremity (30) - bilateral hips, knees, ankles, subtalar, tarsi, metatarsophalangeals 
(MTP I, II, III, IV, and V), and proximal interphalangeals (PIP I, II, III, IV, and V)  
 Spi[INVESTIGATOR_1304] (5) – cervical spi[INVESTIGATOR_050], thoracic spi[INVESTIGATOR_050], and lumbar spi[INVESTIGATOR_050], and bilateral sacroiliac joints  
The assessment for LOM is made on [ADDRESS_887604]. The hip, subtalar, cervical spi[INVESTIGATOR_050], thoracic spi[INVESTIGATOR_050], lumbar spi[INVESTIGATOR_050], 
and sacroiliac joints are excluded. Artificial and ankylosed joints are excluded from both 
tenderness and swelling assessments.  
Joint assess ment will be based on a 2 -point scale as unaffected (Grade 0) and affected 
(Grade  1). 
These assessments are completed at Screening, Baseline, and every visit (including 
Unscheduled Visits that are related to dose change) through the Early Discontinuation/E nd of 
Treatment Visit.  
11.3 Number of joints with active arthritis and number of joints 
with limitation of range  of motion  
The change in the number of joints with active arthritis and the change in the number of 
joints with limitation of range of motion will be  assessed. Joint and joint motion assessments 
will be performed as part of the PRINTO/PRCSG standard joint examination.  
11.4 Physician’s Global Assessment of Disease Activity (VAS)  
The Investigator will assess the overall status of the study participant with re spect to their JIA 
signs and symptoms and functional capacity using a 0 to 100mm VAS where 0 is “very good, 
asymptomatic and no limitation of normal activities” and 100 is “very poor, very severe 
symptoms which are intolerable and inability to carry out al l normal activities.”  
The Physician’s Global Assessment of Disease Activity (VAS) will be completed at 
Screening, Baseline, and every visit (including Unscheduled Visits that are related to dose 
change) through the Early Discontinuation/End of Treatment Vi sit. 
11.5 Childhood Health Assessment Questionnaire (CHAQ)  
The Childhood Health Assessment Questionnaire (CHAQ) is an adaptation of the Health 
Assessment Questionnaire -Disability Index (HAQ -DI), which is a questionnaire developed to 
assess physical function in adults (Singh et al, 1994). The CHAQ was developed specifically 
as a measure of function for children with juvenile RA and the population evaluated for the 
development of this questionnaire comprised study participants between ages 1 to 19 years 
old with J IA. The CHAQ is a parent/caregiver -reported questionnaire and the recall period is 
“the past week.”  
The disability section of the CHAQ uses 30 questions (5 -point Likert scale) to assess 
8 domains of daily living, namely dressing & grooming, arising, eating, walking, hygiene, 
reach, grip, and activities. In addition to the questions on activities of daily living, there are 
[ADDRESS_887605] 1  question that is relevant to children of all ages. Further, to eliminate 
discrepancies int roduced by [CONTACT_658287], parents/caregivers are asked to note 
only those difficulties that are caused by [CONTACT_119181]. The question with the highest score 
determines the score for that functional area. If aids or devices are used or help is needed t o 
complete tasks in a certain area, a minimum score of 2 is recorded for the corresponding 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 78 of 280 functional area. The scores for each of the 8 functional areas or domains are averaged to 
calculate the Disability Index which yields a score of 0 representing “no d isability” to 3 
representing “very severe disability.”  
A copy of the CHAQ is provided in Appendix 17.1. The CHAQ will be completed by [CONTACT_211296]/caregivers at Screening, Baseline, and every visit (including Unscheduled Visits that 
are related to dose change) through the Early Discontinuation/End of Treatment Visit. 
Preferably, the same parent/caregiver should complete the questionnaires for  each visit. The 
questionnaire will not be collected if the study participant is not living with a parent/caregiver 
at least part -time, ie, if the parent/caregiver is not able to answer the questions appropriately. 
The questionnaire should be checked by [CONTACT_658288].  
11.6 Parent’s  Assessment of Arthritis Pain (VAS)  
In the Parent’s Assessment of Arthritis Pain (VAS), the parent/caregiver is asked the 
following question “How much pain do you think your child has had because of his or her 
illness  in the past week?” The parent/caregiver should then place a mark on a 100mm 
horizontal line to indicate the severity of the pain. This VAS 100mm line has as anchors 0mm 
representing “No  Pain” and 100mm, “Very Severe Pain.”  
The Parent’s Assessment of Arthr itis Pain (VAS) is provided in Appendix 17.2. The Pain 
(VAS) will be completed at Screening, Baseline, and every visit through the Early 
Discontinua tion/End of Treatment Visit. Preferably, the same parent/caregiver should 
complete the scale for each visit. The scale will not be completed if the study participant is 
not living with a parent/caregiver at least part -time, ie, if the parent/caregiver is n ot able to 
answer the question appropriately. The scale should be checked by [CONTACT_658289].  
11.7 Parent’s Global Assessment of Overall Well -Being (VAS)  
In the Parent’s Global Assessment of Overall Well -Being (VAS), the parent/caregiver is 
asked the following question “Considering all the ways that arthritis affects your child, rate 
how your child is doing on the following scale by [CONTACT_1299] a mark on the line.” The 
parent/caregiver should then place a mark on a 100mm horizontal line ranging from 0 “Very 
well” to 100 “Very poor.”  
The Parent’s Global Assessment of Overall Well -Being (VAS) is provided in Appendix 17.3. 
The Parent’s Global Asse ssment of Overall Well -Being (VAS) will be completed at 
Screening, Baseline, and every visit (including Unscheduled Visits that are related to dose 
change) through the Early Discontinuation/End of Treatment Visit. Preferably, the same 
parent/caregiver shou ld complete the scale for each visit. The scale will not be completed if 
the study participant is not living with a parent/caregiver at least part -time, ie, if the 
parent/caregiver is not able to answer the question appropriately. The scale should be check ed 
by [CONTACT_658290].  
11.8 C-reactive protein (CRP)  
The acute phase reactant CRP will be analyzed by [CONTACT_2237]. Samples will be 
collected at Screening, Baseline, and every visit (including Unscheduled Visits that are 
related to dos e change) through the Early  Discontinuation/End of Treatment Visit. Values 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 79 of 280 will be used in determining PedACR clinical response, JADAS, CID and CRM, and ratio to 
Baseline in CRP.  
11.9 JADAS  
The change in the JADAS from Baseline will be assessed. The JADAS -71 is  a composite 
disease activity score based on a 71 -joint count and includes the measures (normalized as 
needed): Physician’s Global Assessment of Disease Activity (VAS) (0 to 10), the Parent’s 
Global Assessment of Overall Well -Being (VAS) (0 to 10), the act ive joint count (0  to 71), 
and CRP (0  to 10) (Consolaro et al, 2009; Nordal et al, 2010).  
The JADAS will be completed at Screening, Baseline, and every visit through the Early 
Discontinuation/End of Treatment Visit.  
Values of CRP will be normalized to a 0  to 10 scale as follows: if CRP is expressed in mg/dl, 
any values above 10 are converted to 10. If expressed in mg/L, the value will be first divided 
by 10 and then any values above 10 will be converted to 10.  
Values below the minimum threshold for the met hod used for CRP determination are 
converted to 0.  
The JADAS is calculated as the linear sum of the scores of the 4  components with a total 
score range of 0 to 101.  
11.10  Clinically Inactive Disease and clinical remission  
Criteria for Clinically Inactive Disease  (CID) are defined as follows (Wallace et  al, 2011):  
 No joints with active arthritis*  
 No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to 
JIA 
 No active uveitis as defined by [CONTACT_658291] W orking 
Group**  
 ESR or CRP within normal limits in the laboratory where tested or, if elevated, not 
attributable to JIA  
 Physician’s Global Assessment of Disease Activity score of best possible on the scale 
used (0mm on the 100mm VAS)  
 Duration of morning st iffness of ≤[ADDRESS_887606] be met.  
* Note: The American College of Rheumatology defines a joint with active arthritis as a joint 
with swelling not due to bony enlargement or, if no swelling is present, limitation of motion 
accompanied by [CONTACT_658292]/or tenderness. An isolated finding of pain on 
motion, tenderness, or limitation of motion on joint examination may be present only if 
explained by [CONTACT_658293], such as trauma.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 80 of 280 ** Note: The Standardization of Uveitis Nomenclature Working Group defines inactive 
anterior uveitis as “grade zero cells,” indicating <1 cell in field sizes of 1mm by a 1mm slit 
beam.  
Clinical remission on medication (CRM) is defined as criteria for CID achieved for at least 
6 continuous months (Wallace et al, 2004; Wallace et al, 2009).  
Clinically Inactive Disease will be assessed at every post -Baseline visit except the Final Visit. 
Clinical remission on medication wi ll be assessed at every post -Baseline visit from Week 24 
onwards, except the Final Visit.  
Study participants achieving CRM, ie, after 6 months of continuous CID, may discontinue 
CZP treatment at the Investigator’s discretion following consultation with the Sponsor to 
confirm remission status. Study participants who have discontinued CZP due to achieving 
CRM will be allowed to remain in the study and continue with scheduled study visits. Study 
participants not maintaining persistent CID following achievement of CRM will be allowed 
to resume CZP treatment at any time at the Investigator’s discreti on and consultation with the 
Sponsor. If a study participant is on concomitant MTX treatment, the Investigator may decide 
to decrease and ultimately discontinue the MTX dose after complete discontinuation of CZP. 
Study participants not maintaining persiste nt CID following achievement of CRM and 
resuming treatment will restart the fixed -dose CZP dosing based on their current weight with 
[ADDRESS_887607] weight group 
on the reduced dose regimen, who will receive the maintenance dose Q4W.  
11.11  Duration of morning stiffness (DMS)  
Morning stiffness is defined by [CONTACT_658294] (even 
if not in the morning) and the time the study participant is as limber as he/she will be during a 
day involving typi[INVESTIGATOR_572771]. The study participant/caregiver will be asked the following 
question (Kirwan and Reeback, 1986):  
“How long does it take, from th e time you (your child) wake up, for you (your child) to 
become as limber as you (your child) will be?”  
For those experiencing relief, the actual hours elapsed should be recorded no matter how 
long. The duration in hours and minutes will be recorded. For t hose study participants with 
unrelenting stiffness, 24 hours should be recorded.  
Duration of morning stiffness will be assessed at Baseline and at every visit through the Early 
Discontinuation/End of Treatment Visit.  
11.12  Faces Pain Scale -Revised (FPS -R) 
The Fa ces Pain Scale -Revised (FPS -R) is a self -reported measure used to assess the intensity 
of children’s pain (Hicks et al, 2001). The original version of the scale consists of 7 faces 
increasing in pain intensity and approximating equal intervals as assessed by [CONTACT_7683] 
(Bieri  et al, 1990). Children have to select a level on the scale that matches their own pain. A 
numerical value is associated with the different levels on the scale. The FPS -R was adapted 
from the FPS in order to make scoring possible on the w idely accepted 0 to 10 metric. It 
includes 6 faces (instead of 7). This tool has been validated for children aged [ADDRESS_887608] week of the study; at  Weeks 4, 12, 16, 24, and then every 8  weeks 
thereafter (for study participants enro lled prior to Protocol Amendment 9, visit frequency 
changes to every 16 weeks instead of every 8 weeks following implementation of Protocol 
Amendment 8 ) through the Early Discontinuation/End of Treatment Visit . The questionnaire 
should be checked by [CONTACT_3725] p ersonnel for completeness.  
11.13  Patient’s Assessment of Arthritis Pain (JIA Pain VAS)  
In the JIA Pain VAS, study participants aged 12 years or older are asked the following 
question “How much pain have you had because of your illness today (acute version)/in th e 
past week (standard version)?” (as applicable). The study participant should then place a 
mark on a 100mm horizontal line to indicate the severity of the pain. This VAS 100mm line 
has as anchors 0mm representing “No  Pain” and 100mm, “Very Severe Pain.”  
Both versions of the JIA Pain VAS are provided in Appendix 17.5 and Appendix 17.6. The 
Pain (VAS) will be completed at Baseline (acute and standard versions), daily during the first 
week of treatment (acute version); Weeks 4, 12, 16, 24, and then every 8  weeks thereafter  
(for study participants enrolled prior to Protocol Amendment 9, visit frequency changes to 
every 16 weeks instead of every 8 weeks following implementation of Protocol 
Amendment  8) through the Early Discontinuation/End of Treatment Visit (standard version). 
The scale should be ch ecked by [CONTACT_658290] . 
11.14  Fatigue Assessment Scale (NRS)  
The study participant’s level of tiredness (fatigue) will be assessed by [CONTACT_658295] (numeric rating scale [NRS]) where the parent/caregiver are asked the following 
question:  
"Please rate your child's fatigue (weariness, tiredness) during the past week on a scale of 
0 to 10" where 0 is "No fatigue" and 10 is "Fatigue as bad as you can imagine."  
The recall period for this instrument is the past week.  
The Fatigue Assessm ent Scale is provided in Appendix 17.7. The Fatigue Assessment Scale 
will be assessed at Baseline, Weeks 1, 2, 4, 8, and then every 8  weeks thereaft er (for study 
participants enrolled prior to Protocol Amendment 9, visit frequency changes to every 16 
weeks instead of every 8 weeks following implementation of Protocol Amendment 8 ) and the 
Early Discontinuation/End of Treatment Visit. Preferably, the sa me parent/caregiver should 
complete the scale for each visit. The scale will not be completed if the study participant is 
not living with a parent/caregiver at least  part-time, ie, the parent/caregiver is not able to 
answer the question appropriately. The scale should be checked by [CONTACT_658289].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 82 of 280 11.15  Juvenile Arthritis School Attendance and Caregiver Work 
Productivity Survey  
The Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey is a 
parent/caregiver -reported self -admi nistered questionnaire, which captures information related 
to the impact of the disease on the child’s ability to participate in school and 
social/after -school activities and evaluate the impact of disease on the parent or caregiver’s 
productivity at their  paid work and in the household. The same parent/caregiver should 
complete the questionnaire at each visit. The recall period, for the questions relating to the 
child’s school attendance and parent/caregiver’s work productivity, is the past 4 weeks. This 
survey collects information related to eg,  the child’s attendance to school, number of school 
days missed due to the disease, number of school days impacted due to the disease, level of 
difficulty in performing school activities, the parent or caregiver’s e mployment status, 
number of days missed from work due to the child’s disease, number of days with work 
productivity reduced by [CONTACT_658296]’s disease, days with no household work due 
to child’s disease, days with productivity within household reduced by [CONTACT_658297]’s disease. For further information please see the instructions provided on the worksheet.  
The Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey 
(parent/caregiver) will be assessed at Baseline, Week  4 and every visit through the Early 
Discontinuation/End of Treatment Visit. The full questionnaire and instructions are provided 
in Appendix 17.8. 
12 STUDY MANAGEMENT AND  ADMINISTRATION  
12.1 Adherence to protocol  
The Investigator should not deviate from the protocol. In medical emergencies, the 
Investigator may use his/her medical judgment and may remove a study participant from 
immediate hazard before n otifying UCB (or its representative) and the IRB/IEC in writing 
regarding the type of emergency and the course of action taken.  
12.2 Monitoring  
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring Standard 
Operating Procedures (SOPs), ICH -GCP guidelines, and applicable regulatory requirements, 
and to ensure that study initiation, conduct, and closure are adequate. Monitoring of the study 
may be delegated by [CONTACT_18410] a contract research organization (CRO) or a contract monitor.  
The Investigator  and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to so urce 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Investigator will allow UCB (or designee) to periodically review all CRFs and 
corresponding source documents (eg, hospi[INVESTIGATOR_658228] r each study 
participant). Monitoring visits will provide UCB (or designee) with the opportunity to 
evaluate the progress of the study, verify the accuracy and completeness of CRFs, ensure that 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 83 of 280 all protocol requirements, applicable authorities regulations and Investigator’s obligations are 
being fulfilled, and resolve any inconsistencies in the study records.  
12.2.[ADDRESS_887609] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] 
(such as removable self -stick notes). Photocopi[INVESTIGATOR_658229]. 
Source documents are original records in which raw data are first recorded. These may 
include hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, 
printouts, pharmacy records, care records, ECG or other printouts, completed scales, or 
Quality of Life Questionnaires, for example. Source documents should be kept in a secure, 
limited access area.  
Some data will be recorded directly in the CRF and will not appear in a source document as 
defined in the Source Data Verification (SDV) form.  
Source documents that are computer -generated and stored electronically do not need to be 
printed if the electronic medical record system at the investigational site is 21CFR Part [ADDRESS_887610] be printed for 
review by [CONTACT_2037] (eg, ECG reports). Once printed, these copi[INVESTIGATOR_658230] a permanent part of the study participant’s source 
documents. The Investigator wi ll authorize the monitor to compare the content of the printout 
and the data stored in the computer to ensure all data are consistent.  
Electronic data records such as Holter monitor records or electroencephalogram records must 
be saved and stored as instru cted by [CONTACT_18338] (or designee).  
12.2.[ADDRESS_887611] to being accurate, complete, and 
verifiable from source docu ments (eg, study participant files, recordings from automated 
instruments, tracings [ECG], x -ray films, laboratory notes).  
The procedures for conducting SDV on computerized study participant records (if the system 
is 21CFR Part 11 compliant) are the same as those for paper records. Source data verification 
is performed by [CONTACT_658298].  
All data reported on the CRF should be supported by [CONTACT_18412], unless otherwise 
specified in Section 12.2.[ADDRESS_887612] be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) must be reappro ved by [CONTACT_737].  
The Investigator should maintain a list of personnel authorized to enter data into the 
electronic CRF.  
Detailed instructions will be provided in the CRF Completion Guidelines.  
12.3.2  Database entry and reconciliation  
Case report forms/ext ernal electronic data will be entered/loaded in a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning 
checks will be used in addition to manual review to check for discrepancies and to ensure 
consistency  of the data. The data are entered into the electronic CRFs once and are 
subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes 
in the database once the data has been saved initially into the sy stem or electronically loaded. 
Regular backups of the electronic data will be performed.  
12.3.3  Study participant screening and enrollment log/Study participant 
identification code list  
The study participant’s screening and enrollment will be recorded in the stud y participant 
screening and enrollment log.  
The Investigator will keep a study participant identification code list. This list remains with 
the Investigator and is used for unambiguous identification of each study participant.  
The study participant’s conse nt and enrollment in the study must be recorded in the study 
participant’s medical record. These data should identify the study and document the dates of 
the study participant’s participation.  
12.4 Termination of the study  
A futility analysis of the PedACR30 re sponse rate was performed after all active study 
participants on the reduced CZP dose had completed the Week 16 (Visit 8) assessments. If 
less than 50% of the study population enrolled on the reduced CZP dose regimen (Protocol 
Amendment 5) achieved a PedAC R30 response at Week 16, the study was to be 
discontinued. The futility analysis confirmed that ≥50% of the study population enrolled on 
the reduced CZP dose regimen achieved a PedACR30 response at Week 16. A further futility 
analysis will not be performed  using the additional participants that will be enrolled on the 
original CZP dose regimen following the implementation of Protocol Amendment 9.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887613] to quality or quantity.  
If the study is prematu rely terminated or suspended, UCB (or its representative) will inform 
the Investigators/institutions, and the regulatory authority(ies) of the termination or 
suspension and the reason(s) for the termination or suspension, in accordance with applicable 
regulatory requirement(s). The IRB/IEC should also be informed and provided with reason(s) 
for the termination or suspension by [CONTACT_12942]/institution, as 
specified by [CONTACT_8146](s). In addition, arrangements will be made 
for the return of all unused investigational products and other material in accordance with 
UCB procedures for the study.  
12.[ADDRESS_887614]. These 
documents should be retained for a longer period; however, if required by [CONTACT_40006](s) or by [CONTACT_18415] (ICH -GCP Guideline, 
Section  4.9.5). The Investigator will cont act UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study -related files to a 
location other  than that specified in the Sponsor’s study master file.  
12.[ADDRESS_887615] been protected, that enrolled study participants (ie, 
signing consent and undergoing study procedures) are appropriate for the study, and that all 
data relevant for the evaluation of the IMP have been processed and reported in compliance 
with the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, 
ICH/GCP, and applicable regulatory requirements.  
The Investigator will provide dire ct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will 
immediately inform UCB (or designee).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 86 of 280 12.7 Good Clinical Practice  
Noncompliance with the protocol, ICH/GCP, or loca l regulatory requirements by [CONTACT_3786], institution, institution staff, or designees of the Sponsor will lead to prompt 
action by [CONTACT_18418]. Continued noncompliance may result in the termination 
of the site’s involvement in the study.  
13 STATISTICS  
A description of statistical methods is presented below and will be described in more detail in 
the Statistical Analysis Plan (SAP). Any deviations from the final SAP, as well as changes 
from the protocol, will be detailed in the Clinical Study  Report.  
13.1 Definition of analysis sets  
 The Enrolled Set (ES) will consist of all study participants who have given informed 
consent.  
 The Safety Set (SS) will consist of all study participants in the ES who have received at 
least 1  dose of study medication.  
 The Full Analysis Set (FAS) will consist of all study participants in the SS who have a 
valid Baseline and valid post -Baseline efficacy measurement.  
 The Pharmacokinetic Per -Protocol (PK -PP) Population is a subset of the SS consisting of 
those study parti cipants who took at least 1 dose of study medication, provided 
measurable plasma samples (with recorded sampling time) on at least 1 occasion and who 
had no important protocol deviations affecting the PK parameters, as confirmed during a 
preanalysis review  prior to locking the database. This population will be used for the 
PopPK model and for all presentations of plasma concentration and PK data.  
 The Pharmacokinetic -Pharmacodynamic (PK -PD) Population will consist of all study 
participants in the SS who hav e at least [ADDRESS_887616] nonmissing pretreatment measurement.  
13.2.1  Data presentation  
For safety and efficac y analyses, study participants will be grouped by [CONTACT_658299] (10  to <20kg [22 to <44lb], 20 to <40kg [44 to <88lb], and ≥40kg [≥88lb]). Selected 
analyses will also group study participants by [CONTACT_658300], concomitant MTX 
use, and anti -CZP antibody status. Subgroups defined by [CONTACT_658301]. Two CZP dosing regimen subgroups will be defined as follows:  
 Original CZP dose regimen: includes all study participants in the SS who began treatment 
in accordan ce with the original dosing regimen defined for the study (3 loading doses of 
CZP at Weeks 0, 2, and 4 [minimum=100mg Q2W, maximum=400mg Q2W] followed 
by a maintenance dose for the duration of the study [minimum=50mg Q2W, 
maximum=200mg Q2W]). This subgroup  includes all study participants who began the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 87 of 280 study with this CZP dose regimen and received 1 or more doses of this regimen, 
regardless of any subsequent switch to the reduced CZP dose regimen.  
 Reduced CZP dose regimen: includes all study participants in the SS who began 
treatment in accordance with the reduced dosing regimen defined for the study (3 loading 
doses of CZP at Weeks 0, 2, and 4 [minimum=50mg Q2W, maximum=200mg Q2W] 
followed by a maintenance dose for the duration of the study [minimum=50mg Q4W , 
maximum=100mg Q2W]). This subgroup includes all study participants who began the 
study with this CZP dose regimen and received [ADDRESS_887617] of frequency tables for categorical variables. For continuous 
variables, descriptive statistics (number of available observations, mean, median, standard 
deviation, minimum and maximum) will be presented.  
For those parameters likely to have a skew ed distribution (eg, CRP), geometric means with 
associated coefficients of variation and/or quartiles may be presented.  
13.2.2  Multicenter studies  
Approximately 55 centers are planned to enroll the original 156 study participants into this 
study. A subset of thes e centers will be used to enroll the additional 30 study participants 
following Protocol Amendment 9. The enrollment per site is limited to a maximum of 
12 study participants.  
13.2.3  Coding dictionaries  
Medications will be coded with the World Health Organizatio n Drug Dictionary and AEs will 
be coded according to MedDRA®. In both cases, the version used will be that current to the 
Sponsor at the time of data capture.  
13.[ADDRESS_887618], TEAEs by [CONTACT_182811], TEAEs by [CONTACT_926], and TEAEs by 
[CONTACT_159464]. The primary summaries of safety will in clude all study participants in 
the SS, regardless of CZP dose. Safety variables will be summarized overall and separately 
for the 2 CZP dose regimens (original  CZP dose regimen, reduced CZP dose regimen).  
Safety summaries will include presentations of AE s, extent of exposure, laboratory values 
(hematology and biochemistry), vital signs, concomitant medications and procedures, and 
autoantibody (ANA and anti -dsDNA antibodies) concentrations. Urinalysis results will be 
listed. Tanner stages will be presented  by [CONTACT_17203]. Growth as measured by [CONTACT_658302] a comparative population and this may include an assessment 
of any change after treatment with CZP.  
For AEs, the exposure -adjusted incidence rate (EAIR) will also be calculated. For EAIR, the 
numerator will be the total number of study participants experiencing a particular AE. The 
denominator will be study participant -years, ie, the total summation of i ndividual study 
participant -years at risk up to the first occurrence of the given AE for study participants with 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887619] 16  weeks of study medication exposure will be summarized separately for the 2 CZP 
dose reg imens (original CZP dose regimen, reduced CZP dose regimen). This analysis will be 
repeated, excluding any study participants who switched from the original to the reduced 
CZP dose regimen prior to Week 16. Selected safety summaries will be presented overa ll and 
by [CONTACT_658303], as well as by [CONTACT_654] (2 to 5 years, 6 to 11  years, and 12  to 17 years), 
by [CONTACT_658304], and by [CONTACT_14181] -CZP antibody status.  
13.[ADDRESS_887620] modeling (NONMEM) software. The model will be parameterized in terms of 
clearance, volume of distribution, and absorption rate constant. Details of the PopPK 
modeling procedures will be de scribed in a separate data analysis plan. The pediatric PopPK 
model will be combined with PD data (PedACR) and if the data allow, an exposure response 
relationship will be derived. These modeling analyses and results will be reported separately.  
All study participants enrolled following Protocol Amendment [ADDRESS_887621] plasma CZP 
concentrations and anti -CZP antibodies analyzed using the ECLIA method. In addition, PK 
and ADA samples (for which sufficient volume is available) collected in this study prior to 
Protocol Amendment 9 will be analyzed with the ECLIA method.  
Data from the ECLIA method will constitute the study's main PK and anti -CZP antibody 
evaluations. As such, PK and anti -CZP antibody data generated with the original ELI SA 
method will be reported a s Listings. Plasma CZP concentration data generated by [CONTACT_658305] (geometric mean, arithmetic mean, minimum, 
maximum, standard deviation and % coefficient of variation) by [CONTACT_658306] (original 
CZP dose regimen  or reduced CZP dose regimen) for each PK sampling visit. Plasma 
concentration time curves will be plotted, along with respective individual anti -CZP antibody 
titers where available, separately for study participants who began treatment according to the 
original CZP dose regimen or the reduced CZP dose regimen, overall, and by [CONTACT_658307]. Subgroup analyses will include study participants enrolled with Protocol 
Amendment 9 and those treated up to the Week 16 timepoint under the original maintenance  
dosing regimen. Where available, individual ECLIA -based anti -CZP antibody data will be 
tabulated by [CONTACT_658308] (all study participants, 2 to 5 years, 6 to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 89 of 280 11 years, and 12 to 17 years). In addition, safety and efficacy profiles b y antibody titers (or 
titer categories) may be investigated.  
In addition, the effect of concomitant use of MTX versus monotherapy on CZP plasma 
concentration and incidence of anti -CZP antibodies will be evaluated.  
13.5 Planned efficacy and health outcomes anal yses  
Summary statistics will be presented for efficacy and health outcomes variables using the 
FAS.  
All efficacy and health outcomes variables results will be presented overall and separately for 
the 2 CZP dose regimens ( original  CZP dose regimen, reduced  CZP dose regimen).  
The following efficacy variables are defined as secondary variables in this study:  
 PedACR30, PedACR50, PedACR70, and PedACR90 response rates at Week  16 as 
compared to Baseline.  
The following efficacy variables are defined as other varia bles:  
 PedACR30, PedACR50, PedACR70, and PedACR90 response rates at every visit except 
Week  16 and Final Visit as compared to Baseline.  
For PedACR30, PedACR50, PedACR70, and PedACR90, results will be presented overall 
and by [CONTACT_658303], as well as by [CONTACT_654] (2 to 5  years, 6 to 11 years, and 12  to 
17 years), by [CONTACT_658304], and by [CONTACT_14181] -CZP antibody status.   
 Change from Baseline in number of joints with active arthritis at every visit except Final 
Visit.  
 Change from Baseline in number of joint s with limitation of range of motion at every 
visit except Final Visit.  
 Change from Baseline in Physician’s Global Assessment of Disease Activity (VAS) at 
every visit except Final Visit.  
 Change from Baseline in CHAQ at every visit except Final Visit.  
 Chang e from Baseline in Parent's Assessment of Arthritis P ain (VAS) at every visit 
except Final Visit.  
 Change from Baseline in Parent’s Global Assessment of Overall Well -Being (VAS) at 
every visit except Final Visit.  
 Ratio to Baseline in CRP at every visit exce pt Final Visit.  
 Change from Baseline in JADAS at every visit except Final Visit. The JADAS is a 
composite disease activity score including the Physician’s Global Assessment of Disease 
Activity, the Parent’s Global Assessment of Overall Well -Being, the acti ve joint count, 
and CRP.  
 Percentage of study participants with Clinically Inactive Disease (CID) , as defined in 
Section  11.[ADDRESS_887622] -Baseline visit except Final Visit . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 90 of 280  Percentage of study participants with clinical remission on medication (CRM), as defined 
in Section  11.[ADDRESS_887623] -Baseline visit from Week 24 onwards except Final Visit . 
 Time (in days) to CID.  
 Time (in days) to CRM.  
 Change from Baseline in DMS at every visit except Final Visit . 
 Change from Baseline on FPS -R (child -reported, for study participants ages 5 to 11 
years), daily during the first 7 days of treatment; Weeks 4, 12, 16, 24, and then every 
8 weeks thereafter ( for study participants enrolled prior to Protocol Amendment 9, visit  
frequency changes to every 16 weeks instead of every 8 weeks following implementation 
of Protocol Amendment 8 ) through the Early Discontinuation/End of Treatment Visit.   
 Change from Baseline in JIA Pain VAS, daily during the first week of the study (acute  
and standard versions); Weeks 4, 12, 16, 24, and then every 8  weeks thereafter (for study 
participants enrolled prior to Protocol Amendment 9, visit frequency changes to every 16 
weeks instead of every 8 weeks following implementation of Protocol Amendmen t 8) 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
participants ages 12 to 17 years.  
 Change from Baseline in Fatigue Assessment Scale at every visit except Weeks 12 and 
20, and Final Visit.  
 Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey responses 
at Baseline, Week 4, and every visit thereafter except Final Visit.  
13.6 Handling of dropouts or missing data  
For all binary efficacy endpoints assessing response, study participants who withdraw early  
will be considered as non -responders from that time point onwards. The exception is efficacy 
data for study participants who withdraw after Week 56: Per Protocol Amendment  7, these 
will not be imputed (as nonresponse or missing) and will be analyzed as ob served.  
For continuous efficacy endpoints, missing assessments will be imputed using the last 
observation carried forward (LOCF) approach. These summaries will be supported by 
[CONTACT_658309] (OC) analyses. Per Protocol Amendment  7, missing assessments after  Week [ADDRESS_887624] of medications which would 
result in data at only the next scheduled visit (and not all subsequent visits) being treated as 
missing/non -response. These data will then be imputed as for any other missing data.  The 
exception is any rescue medication use that is initiated after Week 56: Per Protocol 
Amendment  7, efficacy data after any rescu e medication use initiated after Week 56 will not 
be imputed (as nonresponse or missing) and will be analyzed as observed.  
Missing or partial dates for safety evaluations will be imputed and full details of these 
algorithms will be presented in the SAP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887625] nonmissing pretreatment 
measurement, therefore if available, data from the Screening vis it will be used as Baseline 
values, if these data are missing at Week 0.  
No further imputations of any other missing data are planned (eg, efficacy data missing at 
random [MAR]).  
13.7 Interim analysis and data monitoring  
A futility analysis of the PedACR30 resp onse rate was performed after all active study 
participants enrolled on the reduced CZP dose had completed the Week 16 (Visit 8) 
assessments. If less than 50% of the study population enrolled on the reduced CZP dose 
regimen (Protocol Amendment 5) achieved a PedACR30 response at Week 16, the study was 
to be discontinued. The futility analysis confirmed that ≥50% of the study population enrolled 
on the reduced CZP dose regimen achieved a PedACR30 response at Week 16. Given the 
descriptive nature of the data p resentations, there were no statistical implications of this 
interim analysis. A further futility analysis will not be performed using the additional study 
participants  that will be enrolled on the original CZP dose regimen following the 
implementation of Protocol Amendment 9.  
In addition to the futility analysis, several interim analyses were planned, including interim 
analyses of PK data, and full interim analyses of PK, immunogenicity, safety, and efficacy 
endpoints, as described below.  
Interim analyses  of PK data  
Per original protocol, if the pediatric plasma concentrations demonstrate that the geometric 
mean and median concentrations are below the adult 5th percentile or above the 95th 
percentile, the PK data will be used to re -evaluate the weight -based dose adjustment 
algorithm for pediatric study participants. Interim CZP plasma concentration data available at 
the time of Protocol Amendment 3 indicated that no change to the dosing algorithm was 
required. The protocol stated that  if future interim anal yses, which may include PopPK,  
indicate that plasma concentrations of JIA study participants are outside of the exposure 
range observed in previous adult RA studies, a revised pediatric dose algorithm will be 
derived. Any change in dose regimen will requir e a protocol amendment prior to 
implementation.  
An interim analysis of PK data conducted following Protocol Amendment 3 compared CZP 
plasma concentration data from this study with CZP plasma concentrations observed 
previously in adult study participants wi th RA. Interim analysis of CZP plasma 
concentrations was started when 6  study participants in 1  of the age groups completed 
Week  12 (Visit 7). Comparisons were made between the Week 12 geometric mean and 
median values for the pediatric and adult study part icipants, as well as between the individual 
pediatric data and the adult 5th and 95th percentile and minimum and maximum observed 
values.  
Based on results of this interim PopPK analysis (also described in Section  5.1), the dosing 
regimen was changed with Protocol Amendments 4 and 5, and the doses to be administered 
were reduced by 50% for all weight groups. This change was intended  to achieve plasma 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 92 of 280 concentrations similar to the effective concentrations observed in previous studies in adult 
study participants with RA.  
Interim analyses of PK, immunogenicity, safety, and efficacy endpoints  
An interim analysis of PK, immunogenicity, safety, and efficacy endpoints was performed 
after all active study participants that were enrolled and treated prior to implementation of 
Protocol Amendment 9 had completed the Week  24 (Visit 10) assessments, and the results 
were reported separately. A n interim analysis, incl uding all enrolled participants, for all PK, 
immunogenicity, safety, and efficacy endpoints will be performed after all active study 
participants, including those enrolled following the implementation of Protocol 
Amendment  9, have completed the Week  24 (Vi sit 10) assessments.  
Further interim analyses may be performed  at the Sponsor’s discretion as required.  
A DSMB will periodically review emerging safety and efficacy data. The DSMB members 
will be independent of the Sponsor and Investigators. The DSMB membe rs will be informed 
by [CONTACT_658310] (or designee) of all SAEs at the time of expedited 
reporting and will periodically review emerging safety data (eg, SAEs, AEs, safety laboratory 
data) and efficacy data, as applicable, during the cou rse of the study. Based on the safety 
data, the DSMB can recommend modifying/stoppi[INVESTIGATOR_10098].  
13.[ADDRESS_887626] 12 months 
continuous exposure to CZP. Assuming a dropout rate of approximately 20%, it was 
originally determined that 125 study participants would need to be enrolled. At the time of 
Protocol Amendment 5, 78 study participants had been enrolled according to the original 
CZP dose regimen, and it was planned to enroll a further 78 study participants on the reduced 
CZP dose regimen, so that a comparable number of study participants on the reduced CZP 
dose regimen s could be analyzed. Thus, the total number of study participants planned to be 
enrolled was increased to 156 study participants. Assuming a Screening failure rate of 25%, it 
is planned to screen [ADDRESS_887627] 5 study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), and ≥40kg (≥88lb).  
Prior to the start of st udy conduct, simulations using the adult population PK model in 
pediatric study participants with JIA suggested that the planned sample size of 125 study 
participants was adequate for PK assessment purposes. Individual apparent clearance (CL/F) 
and volume of distribution (V/ F) were simulated for a total of 125  study participants (using 
the same approach presented in C87079 report addendum [ADDRESS_887628] 2008 performed for 
190 study participants). In all age groups, the standard errors of both PK parameters, CL/F 
and V/F, relative to their mean were substantially <20%, with values ranging from 5.5 to 
7.0% for CL/F and from 4.6 to 7.5% for V/F. A tabular summary of the results is presented 
below.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 93 of 280 Table  13-1 PK simulation results for 125 -study participant study sample size  
Parameter  Age group (years)  Mean  Standard error  Standard error/ 
Mean (%)  
CL/F  4 to 8  0.253  0.015  6.0 
 9 to 12  0.356  0.025  7.0 
 13 to 17  0.432  0.024  5.5 
V/F 4 to 8  2.90 0.134  4.6 
 9 to 12  4.80 0.358  7.5 
 13 to 17  6.80 0.334  4.9 
CL/F=apparent clearance; PK=pharmacokinetic; V/F=apparent volume of distribution  
Data from all 186 study participants will be included in the final PopPK analysis, and 
therefore should allow CL/F and V/F to be determined with sufficient precision.  
14 ETHICS AND REGULATOR Y REQUIREMENTS  
14.1 Informed consent  
Adequate information will be provided to the study participant and his/her parent(s)/legally 
acceptable representative(s) in both oral  and written form and consent will be obtained in 
writing prior to performance of any study specific procedure. The content and process of 
obtaining informed consent will be in accordance with all applicable regulatory and IRB/IEC 
requirements.  
All IRBs wh ich oversee US research must be registered with the FDA.  
UCB will provide a sample informed consent form, child assent form, and study participant 
information sheet. The final consent form must be approved by [CONTACT_1201]/IEC and should 
contain the applicable I CH-GCP elements in a language readily understood by [CONTACT_114812] (ie,  lay terminology).  
If the informed consent form is amended during the study, the Investigator (or the Sponsor, if 
applicable) must follow all applicable regulatory requirements p ertaining to the approval of 
the amended informed consent form by [CONTACT_1201]/IEC and use of the amended form.  
For the US sites a Health Insurance Portability and Accountability Act (HIPAA) agreement 
will be provided if required by [CONTACT_122308].  
The Investigator or designee should fully inform the study participant about all pertinent 
aspects of the study including the fact that the protocol has been granted the approval of the 
IRB/IEC and local regulatory authorities if required.  
Study participants a nd their parent(s)/legally acceptable representative(s) will be informed of 
the purpose of the study in unambiguous language they easily understand. Their participation 
is voluntary and they can at any time decide to stop their participation without any in fluence 
on their future care or treatment. The study participants and their parent(s)/legally acceptable 
representative(s) must be informed about the main procedures used to guarantee their 
anonymity, especially during the analysis of their personal data. Study participants and their 
parent(s)/legally acceptable representative(s) should be able to ask any questions about the 
study and to receive relevant answers.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 94 of 280 After having received extensive information about the purpose and risks of the study and 
having  had enough time to consider participation in the study, the study participant’s 
parent(s)/ legally acceptable representative(s) or legal guardian must give their written 
consent by [CONTACT_658311]. This form will also be signe d and 
dated by [CONTACT_658312]. 
If applicable, a child assent form may be used. This form will also be dated and signed by [CONTACT_658313]. Obtaining of consent (and child assent, where applicable) will be confirmed in 
the study participant’s medical records. The study participant’s parent(s)/legally acceptable 
representative(s) will receive a copy of  the signed and dated consent form (and child assent, 
where applicable) and the original will be filed in the Investigator’s Study File.  
The study participants and their parent(s)/legally acceptable representative(s) may withdraw 
their consent to participa te in the study at any time. A study participant is considered as 
enrolled in the study when his/her parent(s)/legally acceptable representative(s) has signed 
the informed consent form (and child assent, where applicable). A CRF must not be started, 
nor ma y any study specific procedure be performed for a given study participant, without 
having obtained his/her parent’s or legally acceptable representative’s written consent to 
participate in the study.  
If any new information that could influence the study pa rticipant’s decision to stay in the 
study becomes available, this information will be transmitted to the study participant’s 
parent(s)/legally acceptable representative(s) without delay. In addition, the informed consent 
form (and child assent form where a pplicable) must be amended accordingly or a separate 
consent form (and child assent form where applicable) be created and submitted to the 
IRB/IEC for approval prior to being implemented for reconsent (and child assent) of all 
ongoing study participants in  the study and for use in obtaining consent from all 
parent(s)/legally acceptable representative(s) of study participants (and child assent) who 
enter the study from that point forward.  
Adequate information will be provided to the study participant and his /her parent(s)/legally 
acceptable representative(s) in both oral and written form and consent (and child assent) will 
be obtained in writing prior to performance of any study specific procedure. The content and 
process of obtaining informed consent (and ch ild assent) will be in accordance with all 
applicable regulatory and IRB/IEC requirements.  
14.2 Study participant identification cards  
Upon signing the informed consent form and child assent form (as applicable), the study 
participant or legal representative wi ll be provided with a study participant identification card 
in the language of the study participant. The Investigator will fill in the name [CONTACT_658366] [CONTACT_3031]. The Investigator will instruct the study 
participant/legal representative to keep the card with them at all times.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 95 of 280 14.3 Institutional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local 
regulations, ICH -GCP, and in accordance with the ethical  principles that have their origin in 
the Declaration of Helsinki.  
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies 
with the requirements of the current ICH -GCP version or applicable country -specific 
regulations will  be responsible for the initial and continuing review and approval of the 
clinical study. Prior to initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_261423], informed consent form, IB, Investigator’s curriculum vitae (if applicable) , 
advertisement (if applicable), and all other study participant -related documents to be used for 
the study to the IRB/IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsib le IRB/IEC for the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human study participants or others, and any 
protocol deviations, to eliminate immediate hazards t o study participants.  
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the study 
participants. For minor changes to a previously approved pr otocol during the period covered 
by [CONTACT_59001], it may be possible for the Investigator to obtain an expedited review 
by [CONTACT_1201]/IEC as allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the 
Investigator will  be responsible for submitting periodic progress reports to the IRB/IEC 
(based on the Committee’s requirements), at intervals appropriate to the degree of study 
participant risk involved but no less than once per year. The Investigator should provide a 
final report to the IRB/IEC following study completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators, in accordance with applicable regulatory 
requirements. The appropri ate IRB/IEC will also be informed by [CONTACT_223493], as specified by [CONTACT_59002]. 
Where applicable, Investigators are to provide the Sponsor (or its representative) with 
evidence of such  IRB/IEC notification.  
14.4 Study participant privacy  
UCB staff (or designee) will affirm and uphold the study participant’s confidentiality. 
Throughout this study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_658314].  
The Investigator agrees that representatives of UCB, its designee, representatives of the 
relevant IRB/IEC, or representatives of regulatory authorities will be allowed to review that 
portion of the study participant’s primary medica l records that directly concerns this study 
(including, but not limited to, laboratory test result reports, ECG reports, admission/discharge 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 96 of 280 summaries for hospi[INVESTIGATOR_1684] a study participant’s study participation, 
and autopsy reports f or deaths occurring during the study).  
14.[ADDRESS_887629] be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to 
being implemented.  
15 FINANCE, INSURANCE, AND PUBLICATION  
Insurance covera ge will be handled according to local requirements.  
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements as applicable.  
16 REFERENCES  
Bieri D, Reeve RA, Champi[INVESTIGATOR_98249], Addicoat L, Ziegler JB. The Faces Pain Scale fo r the 
self-assessment of the severity of pain experienced children: development, initial validation, 
and preliminary investigation for ratio scale properties. Pain. 1990;41:139 -50. 
Centers for Disease Control and Prevention. http:www.cdc.gov/TB/topic/testi ng/default.htm. 
Accessed 03 Sep 2012.  
Consolaro A, Ruperto N, Bazso A, Pi[INVESTIGATOR_40963] A, Magni -Manzoni S, Filocamo G et al. 
Development and validation of a composite disease activity score for juvenile idiopathic 
arthritis. Arthritis Rheum. 2009;61:658 -66. 
Europ ean Medicines Agency. Ethical Considerations for Clinical Trials on Medicinal 
Products Conducted with the Paediatric Population.2008. 
http://ec. europa.eu/health/files/eudralex/vol -10/ethical_considerations_en.pdf. Accessed 
13 Jul 2011.  
FDA Guidance for Industry – Bioanalytical Method Validation. 2018.  
FDA. Guidance for Industry – E11 Clinical Investigation of Medicinal Products in the 
Pediatric Population. 2000. 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf. Accessed 
13 Jul 2011.  
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition 
of improvement in juvenile arthritis.  Arthritis Rheum. 1997;40:[ADDRESS_887630] PA, van Korlaar I, Goodenough B. The F aces Pain 
Scale -Revised: toward a common metric in pediatric pain measurement. Pain. 
2001;93(2):173 -83. 
International League of Associations for Rheumatology Classification of Juvenile Idiopathic 
Arthritis: Second Revision, Edmonton. J Rheumatol. 2004;31(2 ):[ADDRESS_887631] Health Assessment modified to assess disability in British 
patients with rheumatoid arthritis. Br J Rheumatol. 1986;25:206 –9. 
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept 
in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology 
Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763 -9. 
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or 
without methotr exate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810 -20.  
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 
1969;44(235):291 -303. 
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in boys. Arch Dis Child. 
1970;45(239):13 -23. 
Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis 
Rheum. 2006;55:208 -16. 
Nordal E,  Zak M, Berntson L, Aalto K, Peltoniemi S, Nielsen S, et al. Validation of the 
Juvenile Arthrit is Disease Activity Score (JADAS) based on C -reactive protein in a 
population -based Nordic cohort of juvenile idiopathic arthritis. Pediatric Rheumatology 
European Society Congress, Valencia, Spain. 2010: Poster abstract; p.164.  
Ravelli A, Martini A. Juven ile idiopathic arthritis. Lancet. 2007;369:767 -78. 
Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with 
juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761 -9. 
Tocilizumab (RoActemra®), Summary of Product Chara cteristics. [COMPANY_002] Registration 
Limited, [LOCATION_008]. July 2010.  
Vastert SJ, Kuis W, Grom AA. Systemic JIA: New Developments in the Understanding of 
the Pathophysiology and Therapy. Best Pract Res Clin Rheumatol. 
2009  October;23(5):[ADDRESS_887632] categories of juvenile 
idiopathic arthritis. Arthritis Care Res. 2011;63:[ADDRESS_887633] categories of juvenile idiopathic arthritis. Arthritis Rheum. 
2009;60([ADDRESS_887634]):[ADDRESS_887635] 
categories of juvenile idiopathic arthritis. J Rheum. 2004;31:2290 -4. 
Zitelli B, McIntire S, Nowalk A. Zitelli and Davis’ Atlas of pediatric physical diagnosis, 6th 
edition. Chapter 7: Rheumatology, Section: Juvenile Idiopathic Arthritis. Elsevi er Health 
Sciences, 2012, 264.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 98 of 280 17 APPENDICES  
Scales in the appendix are intended for information only and are not to be copi[INVESTIGATOR_658231]. The actual CRF page may differ in format or presentation from what is 
contained in the protocol appendix.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 99 of 280 17.1 Childhood Health Assessment Questionnaire (CHAQ)  
1 CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE  
2 
 
 
 
 
 
 
  
In this section we are interested in learning how your child's illness affects his/her ability to function in daily life. Please feel free 
to add any comments on the back of this page. In the followin g questions, please check the one response which best describes your 
child's usual activities (averaged over an entire day) OVER THE PAST WEEK . ONLY NOTE THOSE DIFFICULTIES OR 
LIMITATIONS WHICH ARE DUE TO ILLNESS . If most children at your child's age are n ot expected to do a certain activity, 
please mark it as "Not Applicable". For example, if your child has difficulty in doing a certain activity or is unable to do it 
because he/she is too young but not because he/she is RESTRICTED BY [CONTACT_121991], please mark i t as "NOT Applicable".  
 
       
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 100 of 280 © Singh G:  Arthritis Rheum 1994; 37:[ADDRESS_887636] [EMAIL_12549]  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 101 of 280 17.2 Parent’s Assessment of Arthritis Pain (VAS)  
 
17.3 Parent’s Global Assessment of Overall Well -Being (VAS)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
 Confidential  Page 102 of 280 17.4 Faces Pain Scale -Revised  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 103 of 280 17.5 Patient’s Assessment of Arthritis Pain  
(JIA Pain VAS, acute version)  
 
17.6 Patient’s Assessment of Arthritis Pain  
(JIA Pain VAS, standard version)  
 
17.7 Fatigue Assessment Scale (NRS)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 104 of 280 17.8 Juvenile Arthritis School  Attendance and Caregiver Work 
Productivity Survey  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 105 of 280  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 106 of 280  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 107 of 280  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 108 of 280  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 109 of 280  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 110 of 280 17.9 TB questionnaire  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 111 of 280 17.10  Liver Safety – Suggested Actions and Follow -up Assessments  
17.10.[ADDRESS_887637] be reported as AEs and reported to the study site and sponsor within 24 hours of learning of 
their occurrence. Any PDILI event that meets the crit erion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  10.3), and, if applicable, also reported as an 
SAE (see Section 10.2). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  17‒1 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section  [IP_ADDRESS] ). The local 
hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepa tologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section  [IP_ADDRESS] ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.  
All initial tests resulting in abnormal he patic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever poss ible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
[ADDRESS_887638] not occur.  
Table  17‒1 summarizes the approach to investigate PDILI.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 112 of 280 Table  17‒1: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptoms a of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULN b NA Hepatology consult.c 
Medical Monitor 
must be notified 
within 24  hours 
(eg, by [CONTACT_67600]) and participant 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section  [IP_ADDRESS]
); recommended 
to occur at the 
site with HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or ret urn to within baseline 
values.d ≥8xULN  NA NA 
≥3xULN  NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.  
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  [IP_ADDRESS] ). Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).  
≥5xULN 
(and ≥2x 
baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48  hours 
at the site with 
HCP (see 
Section  [IP_ADDRESS]
). Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 113 of 280 ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophili a (>5%), 
rash, and fever (without clear alternative cause).  
b If the p articipant also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.  
c Details provided in Section  [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hep atologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by [CONTACT_58982]. Determination of stabi lization is at the discr etion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 114 of 280 [IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the participant must be discussed with the Medical 
Monitor as soo n as possible. If required, the participant must also be discussed with the local 
hepatologist. The local hepatologist is the expert usually consulted by [CONTACT_261512]. This would usually be a 
hepatologist, but may be a gastroenterologist. If determined necessary, this discussion should 
be followed by a full hepatology assessment (see Section  [IP_ADDRESS] ) and SAE report (if 
applicable).  
[IP_ADDRESS]  Immediate action: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepati tis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) 
to immediate and permanent discontinuation (see Section  6.4 and Table  17‒1 for details).  
When IMP is discontinued, all concomitant medications and h erbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any 
medically required concomitant medication known to  be hepatotoxic to a suitable alternative.  
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events 
when there is a reasonable possibility  that they may have been caus ed by [CONTACT_261514]  17‒2 (laboratory measurements) and Table  17‒3 (additional information). Results of 
the laboratory measurements and information collected are to be submitted to the sponsor on 
the corresponding eCRFs. If the medical history of the participant indicates a requirement f or 
other assessments not included below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid 
results, a concurrent sample should also be se nt to the central laboratory whenever possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 115 of 280 The following measurements are to be assessed:  
Table  17‒2: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation  
Additional  Prothrombin time/INR a 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal  
a Measured only for participants with ALT >8xULN, elevations in total  bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 116 of 280 The following additional information is to be collected:  
Table  17‒3: PDILI information to be collected  
New or updated information  
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
 History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
 Adverse reactions to drugs  
 Allergies  
 Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
 Recent travel  
 Progression of malignancy involving the liver (Note: Metastatic diseas e to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tend erness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Result s of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
[IP_ADDRESS]  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  17‒1. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 117 of 280 17.11  Protocol Amendment 1  
The version of the protocol dated 14 Jan 2010 was submitted to FDA on 28 Jan 2010. This 
version has not been submitted to any other regulatory authorities, IRBs/IECs, or 
Investigators. Therefore the integrated protocol contains only the rationale for the amendment 
and a general summary of changes. The detailed changes to the protocol dated [ADDRESS_887639] typographical errors.  
Modifications and changes  
Global changes  
The following changes were made throughout the protocol:  
 The Sponsor name [CONTACT_658367] “SCHWARZ BIOSCIENCES GmbH – A 
Member of the UCB Group of Companies” to “UCB BIOSCIENCES GmbH.”  
 The assessments of vital signs and laboratory parameters previously included in the 
primary safety variable have been redefined as “other” safety variables. The primary 
safety variable is the incidence of AEs.  
 The assessment of the effectiveness of CZP o n the clinical response in children and 
adolescents with moderate to severe polyarticular -course JIA was added as a secondary 
objective.  
 In line with the change above, a few efficacy variables formerly listed as “exploratory” 
have been redefined as “second ary” (PedACR30, PedACR50, PedACR70, and 
PedACR90 response rates at Week 16) or “other” variables (all other efficacy variables).  
 An additional study objective has been added to reflect the “other” variables.  
 The study population was further defined to incl ude study participants with polyarticular -
course JIA except systemic JIA. In addition, the term “polyarticular -course JIA” for the 
studied indication replaces “polyarticular JIA.”  
 The study population was further defined to include a minimum number of stud y 
participants in each body weight and age class, to include a minimum number of study 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 118 of 280 participants with ERA, and to include a minimum number of study participants who 
receive CZP as monotherapy.  
 The exclusion criteria have been reordered to group arthrit is-related criteria and medical 
history -related criteria.  
 Text describing planned interim analyses has been updated to reflect full interim analyses 
at Week 16 and Week 56, instead of Week 24.  
 A study stoppi[INVESTIGATOR_658232], stating that the study w ill be discontinued if less 
than 50% of the study population achieves PedACR30 response at Week 16.  
 For the comparison of PK data with previously observed plasma concentrations from 
adult study participants with RA, at least 20 study participants instead o f 15 study 
participants (minimum of 6 instead of 4  study participants in each age group) are required 
to have completed Week 12 (Visit 7).  
 The protocol has been updated with current terminology used in the rheumatology 
community with regard to “Clinically Inactive Disease (CID)” and “clinical remission.”  
 “Juvenile Arthritis School Attendance and Caregiver Work Productivity Survey” replaces 
“productivity measure.”  
 The Patient’s Assessment of Arthritis Pain questionnaire (“How much pain have you had 
because  of your illness today/in the past week?”) has been separated into an acute 
version, which will be used daily during the first week of treatment (“How much pain 
have you had because of your illness today?”) and a standard version (“How much pain 
have you h ad because of your illness in the past week?”).  
 The following assessments have been removed throughout the protocol: erythrocyte 
sedimentation rate, respi[INVESTIGATOR_1487], thyroid function, and rheumatoid factor.  
 “Tanner stage (pubertal maturity only)” has been  changed to “Tanner stages (except 
growth)” for clarity.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887640] information for SAE reporting were 
updated.  
The format and style of the document was changed to comply with UCB’s new document 
authoring software; these changes are not specifically noted.  
Modifications and changes  
Specific changes  
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 26 Aug 2011. The changes are displayed in the order of 
appearance.  
Change #1  
Under SPONSOR DECLARATION,  the name [CONTACT_658368]:  
 
Has been changed to:  
 
Change #[ADDRESS_887641] details of the Clinical 
Program Director:  
Clinical Program Director  
Name:   
[CONTACT_2761]:  [ADDRESS_887642]  
Smyrna, GA [ZIP_CODE]  
[LOCATION_003]  
Phone:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887643] been changed to:  
Clinical Program Director  
Name:   
[CONTACT_2761]:  [ADDRESS_887644]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:   
Change #[ADDRESS_887645] information for SAE 
reporting (24h) and safety related issues:  
 Phone  Europe and Rest  of the World:  [PHONE_301] 68  
[LOCATION_003] & Canada : +[PHONE_13625]  
Has been changed to:  
 Phone  Europe, [LOCATION_003] & Canada, and Rest of the World:  [PHONE_301] 68  
Change #4  
Section 5.1.3 Anticipated regions and countries:  
The regions planned for participation in this study are North America and Western Europe, 
with possible extension to other regions.  
Has been changed to:  
The regions planned for participation in this study are North and South America and Russia, 
with possible extension to other regions.  
Change #[ADDRESS_887646] paragraph has been removed:  
In addition, the study is proposed to fulfill the requirements for a pediatric investigation plan 
in compliance with the European pediatric regulation, with the objective to develop and make 
CZP available in the pediatric JIA population in the EU.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887647] the updated recommendations of 
various national guidelines (eg, CDC diagnosis of latent TB infection, 
http://www.cdc.gov/TB/topic/tes ting/default.htm). This guideline includes the preference of 
use of [COMPANY_003] testing over IGRA in children below the age of 5 years. With the implementation 
of Protocol Amendment 3, [COMPANY_003] testing will be mandatory for study participants from 2 to 4 
years of age i n this study, unless the study participant has received a BCG vaccination, and 
IGRA testing will be required for study participants from 5 to 17  years of age.  
In addition, the assessment of vital signs (especially the measurement of blood pressure) was 
adapted to the current UCB standard of safety assessment for CZP studies, in order to follow 
a consistent process in the collection of safety data across the UCB development program, 
and lactate dehydrogenase was added to complete the panel of laboratory par ameters.  
A DSMB will be implemented to conform with the standards for pediatric clinical studies. 
The DSMB will review emerging safety data from the study and will replace the 
study -specific Safety Review Committee. Activities will be defined in the DSMB c harter.  
Furthermore, this substantial amendment introduces a full interim analysis at Week 24 
involving a complete data analysis for the inclusion in the marketing application for the JIA 
indication. At the same time, the planned analysis at Week 16 has be en reduced to an analysis 
of the PedACR30 response rate required to confirm adequate response of the study 
population to CZP treatment and to confirm continuation of RA0043.  
Key revisions also include modifications of the following eligibility criteria:  
 Eligibility criteria related to the diagnosis of JIA (inclusion criterion 6) have been revised 
for clarity.  
 Use of DMARDS and MTX (inclusion criteria 8 and 9) has been revised for clarity.  
 TB exclusion criteria (exclusion criterion 11 and withdrawal criter ia 3 and 4) have been 
updated to comply with the revised UCB policy.  
 Exclusion criterion 13 (hepatitis screening panel) has been revised for clarity.  
 Follow -up period for pregnancy and contraception (exclusion criteria 16 and 17) has been 
adapted to allow for compliance with local requirements.  
 An exclusion criterion for infections (exclusion criterion 25) has been added.  
In addition, the Per Protocol Set was deleted given that efficacy variables are secondary in 
this study, and an additional PK -PD Populati on was defined.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 122 of 280 Further revisions were made to clarify study -related procedures (eg, the process of analyzing 
CZP plasma concentrations in the first cohort of study participants and the completion of 
parent -reported questionnaires), to clarify the CZP assa y methodology, and to correct errors 
in the previous protocol version (eg, in relation to the components of the PedACR). In 
addition, the definition of the Physician’s Global Assessment criterion for CID and CRM was 
changed to conform with the most current  standard as defined by [CONTACT_293149] (2011).  
The sentence that the pediatric PopPK model may be combined with PD data (PedACR) for 
an exposure response relationship has been moved from the variables section into the section 
on the assessment of pharmacok inetics and immunological variables as it represents an 
analysis rather than a variable.  
References to the findings of the interim analysis of plasma concentration data from the 
clinical study of CZP in children and adolescents with Crohn’s disease (C87035 ) have been 
removed from the protocol because of the differences between C87035 and the present study 
(ie, differences in dose interval and potential for impact of disease characteristics on 
clearance), and in consideration of the more relevant plan for an  interim analysis of plasma 
concentration data from the present study in children and adolescents with JIA, as described 
in this protocol.  
The reference to the JADAS has been changed from “JADAS -75” to “JADAS” and it has 
been clarified that for the purpose  of this study, 71 joints will be included in the analysis in 
line with the PRINTO/PRCSG joint assessment used in this study.  
In addition, administrative and editorial changes have been made, eg, to update study 
personnel and correct typographical errors.  
Modifications and changes  
Global changes  
The following changes have been made throughout the protocol:  
 All procedures related to TB detection and monitoring have been updated in order to 
comply with the revised UCB TB Task Force policy and company -wide 
recommendations that are based on international guidelines. This applies to eligibility 
criteria, withdrawal criteria, and timing and descriptions of related assessments 
throughout the protocol. In the tabular schedule of study assessments and the description  
of study procedures by [CONTACT_765], TB -related assessments have been grouped for clarity.  
 References to the findings of an interim analysis of plasma concentration data from 
C87035 in children and adolescents with Crohn’s disease have been removed throughout 
the protocol.  
 “Study participant and parent/caregiver” has been added throughout the “Study 
procedures by [CONTACT_765]” section for the TB questionnaire. This global change is not listed 
under the specific changes.  
 The following terminology changes have been made t hroughout the protocol; these global 
changes are not listed under the specific changes:  
 “QuantiFERON” has been replaced by “IGRA” in line with the updated TB policy.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 123 of 280  The reference to the JADAS has been changed from “JADAS -75” to “JADAS” 
throughout the pro tocol.  
 “IVRS phone call” has been changed to “IXRS contact” to account for the use of an 
interactive voice/web response system.  
 References to Global Clinical Safety and Pharmacovigilance (GCSP) have been 
changed to “Drug Safety.”  
Specific changes  
This se ction displays the modifications in this amendment compared with the previous 
version of the protocol dated 02 Jul 2012. The changes are displayed in the order of 
appearance.  
Change #1  
On the SPONSOR DECLARATION page, the name [CONTACT_658369]:  
 
Has been changed to:  
 
Change #2  
On the SPONSOR DECLARATION page, the name [CONTACT_658368]:  
 
Has been changed to:  
 
Change #[ADDRESS_887648] details of the Clinical 
Program Director:  
Name:   
[CONTACT_2761]:  [ADDRESS_887649]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887650] been changed to:  
Name:   
[CONTACT_2761]:  [ADDRESS_887651]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
Change #[ADDRESS_887652] details of the Clinical 
Trial Biostatistician:  
Name:   
[CONTACT_2761]:  [ADDRESS_887653]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
Have been changed to:  
Name:   
[CONTACT_2761]:  [ADDRESS_887654]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
Change #[ADDRESS_887655] INFORMATION, the name [CONTACT_658370]:  
Name:  
[CONTACT_7626]:  
Fax: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 125 of 280 Has been changed to:  
Name:  
[CONTACT_7626]:  
Fax: 
Change #[ADDRESS_887656] details:  
Serious Adverse Event reporting (24h) and safety related issues  
 Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003]:  +[PHONE_299]  
Canada:  +[PHONE_1063]  
 Phone  Europe, [LOCATION_003] & Canada, and Rest of the World:  [PHONE_301] [ADDRESS_887657] been changed to:  
Serious adverse event reporting (24h)  
 Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003]:  +[PHONE_299]  
Canada:  +[PHONE_1063]  
 E-mail  Global: [EMAIL_311]   
Change #[ADDRESS_887658] been added:  
CDC  
DSMB  
IBD 
IGRA  Centers for Disease Control and Prevention  
Data and Safety Monitoring Board  
inflammatory bowel disease  
interferon -gamma release assay  
IXRS   interactive voice/web response system  
LTB  
NTMB  
PK-PD 
SDV  latent tuberculosis  
nontuberculous mycobacteria  
Pharmacokinetic -Pharmacodynamic  
source data verification  
Change #[ADDRESS_887659] been removed:  
GCSP  Global Clinical Safety and Pharmacovigilance  
IVRS  interactive voice response system  
PPS Per Protocol Set  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 126 of 280 Change #[ADDRESS_887660] paragraph, the second sentence:  
Study participants must have had polyarticular -course JIA for at least 6 months prior to 
Baseline.  
Has been changed to:  
Study  participants must have had onset of signs and symptoms consistent with polyarticular -
course JIA and initiation of JIA treatment for at least 6 months prior to Baseline.  
Change #10  
Section 1 Summary, the following has been added below the fifth paragraph:  
An interim analysis of the American College of Rheumatology Pediatric 30% (PedACR30) 
response rate will be performed after all active study participants have completed the Week 
16 (Visit  8) assessments. The study will be discontinued if less than 50% of th e study 
population achieves a PedACR30 response at Week 16.  
Change #11  
Section 1 Summary, the seventh paragraph:  
Full interim analyses will be performed after all active study participants have completed the 
Week  16 (Visit  8) assessments and after all acti ve study participants have completed the 
Week 56 (Visit  14) assessments.  
Has been changed to:  
Full interim analyses will be performed after all active study participants have completed the 
Week  24 (Visit  10) assessments, as well as after all active study participants have completed 
the Week 56 (Visit  14) assessments. The study will continue until the approval of the 
marketing application for the polyarticular -course JIA indication in the study participant’s 
country or region, or until discontinuation of th e study based on the Week 16 analysis of 
response, or until further notice from UCB.  
Change #12  
Section 1 Summary, the following sentence has been moved from the seventh paragraph to 
the new text below the fifth paragraph:  
The study will be discontinued if  less than 50% of the study population achieves at least an 
American College of Rheumatology 30% (PedACR30) response rate at Week 16.  
Change #13  
Section 1 Summary, the eighth paragraph:  
Certolizumab pegol will be administered as a fixed dose based on weigh t every 2 weeks 
(Q2W) throughout the study consisting of 3 loading doses at Weeks 0, 2, and 4 
(minimum=100mg, maximum=400mg) followed by a treatment dose (minimum=50mg, 
maximum=200mg). Once at least 20 study participants (minimum 6 study participants in 
each age group: 2 to 5  years, 6 to 11 years, and 12 to 17 years) have completed Week 12 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 127 of 280 (Visit 7), PK data will be compared with plasma concentrations observed previously in 
studies conducted in adult study participants with rheumatoid arthritis (RA). Interi m data 
from an ongoing clinical study in children and adolescents with Crohn’s disease (ages 6 to 17 
years) confirm that the weight -based dose adjustment for pediatric study participants with 
Crohn’s disease leads to similar plasma concentrations as observ ed previously in adult study 
participants with Crohn’s disease. However, if plasma levels of JIA study participants are not 
consistent with those observed in previous adult RA studies, the dosing algorithm may be 
changed via a protocol amendment.  
Has been changed to:  
Certolizumab pegol will be administered as a fixed dose based on weight every 2 weeks 
(Q2W) throughout the study consisting of 3  loading doses at Weeks 0, 2, and 4 
(minimum=100mg, maximum=400mg) followed by a treatment dose (minimum=50mg, 
maxim um=200mg). Interim analysis of PK data will compare plasma concentration data from 
this study with CZP plasma concentrations observed previously in adult study participants 
with rheumatoid arthritis (RA). This CZP plasma concentration analysis will be done  on an 
ongoing basis throughout the study, starting when [ADDRESS_887661] completed Week  12 (Visit 7). Interim CZP plasma concentration data available at the 
time of Protocol Amendment 3 indicate that no change to the dosing  algorithm is required. If 
future analyses indicate that plasma levels of JIA study participants are outside of the 
exposure range observed in previous adult RA studies, the dosing algorithm may be changed 
via a protocol amendment.  
Change #[ADDRESS_887662] paragraph, the second sentence:  
Other exploratory efficacy and health outcomes variables include: …  
Has been changed to:  
Other efficacy and health outcomes variables include: …  
Change #[ADDRESS_887663] paragraph, the following variabl e has been removed:  
Shifts by [CONTACT_658315] #[ADDRESS_887664] paragraph, the following variable:  
Number of study participants meeting criteria of Clinically Inactive Disease (CID) and 
clinical remission on medication (CRM)  
Has been changed to:  
Percentage of study participants meeting criteria of Clinically Inactive Disease (CID) and 
clinical remission on medication (CRM)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 128 of 280 Change #[ADDRESS_887665] sentence:  
Certolizumab pegol (CDP870, CZP, Cimzia®) is approv ed in the [LOCATION_002] of America 
([LOCATION_003]), the European Union, and a number of other countries worldwide for the treatment of 
moderate to severe active RA in adults.  
Has been changed to:  
Certolizumab pegol (CDP870, CZP, Cimzia®) is approved in the United S tates of America 
([LOCATION_003]), the European Union, and a number of other countries worldwide for the treatment of 
moderately to severely active RA in adults.  
Change #[ADDRESS_887666] sentence:  
In a placebo -controlled clinical s tudy of study participants with RA, no difference was 
detected in antibody response to vaccine between CZP and placebo treatment groups when 
the pneumococcal polysaccharide vaccine and influenza vaccine were administered 
concurrently with CZP.  
Has been cha nged to:  
In a placebo -controlled clinical study of study participants with RA, no meaningful difference 
was detected in antibody response to vaccine between CZP and placebo treatment groups 
when the pneumococcal polysaccharide vaccine and influenza vaccine  were administered 
concurrently with CZP.  
Change #19  
Section 4.3 Other variables, the following has been removed at the beginning of the section:  
Other pharmacodynamic (PD) variables are:  
 The pediatric PopPK model will be combined with PD data (PedACR) and  if the data 
allow, an exposure response relationship will be derived.  
Change #20  
Section 4.3 Other variables, under “Other efficacy and health outcomes variables,” the ninth 
bullet has been removed:  
 Shifts by [CONTACT_658316].  
Change #21  
Section  5.1 Study description, the fourth and fifth paragraphs:  
Full interim analyses will be performed:  
 After all active study participants have completed the Week 16 (Visit 8) assessments  
 After all active study participants have completed the Week 56 (Visit 14)  assessments  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 129 of 280 If less than 50% of the study population achieves at least PedACR30 response at Week 16, 
the study will be discontinued.  
Have been changed to:  
An interim analysis of PedACR30 response rates will be performed after all active study 
participants  have completed the Week 16 (Visit 8) assessments. If less than 50% of the study 
population achieves a PedACR30 response at Week 16, the study will be discontinued.  
Full interim analyses will be performed:  
 After all active study participants have completed  the Week  24 (Visit 10) assessments  
 After all active study participants have completed the Week 56 (Visit 14) assessments  
Change #[ADDRESS_887667] 3 paragraphs:  
Once at least 20 study participants (minimum 6 study participants in  each age group: 2 to 5 
years, 6 to 11 years, and 12 to 17 years) have completed Week 12 (Visit 7), PK data will be 
compared with plasma concentrations observed previously in adult study participants with 
RA. 
This CZP plasma concentration analysis may be d one in [ADDRESS_887668] 20 study 
participants in total complete Week 12 (Visit 7) before [ADDRESS_887669] completed Week 12 (Visit 7).  
The therapeutic plasma concentration of CZP in children and adolescen ts is expected to be 
similar to that required for the adult population (see Section 5.4.2). If plasma concentrations 
are not consistent with those observed in previous studies with adults, the dosing algorithm 
may be changed via a protocol amendment. This study will continue during the PK analysis. 
All study participants assessed in this analysis will continue treatment after Week 12 (Visit 
7). 
Have been changed to:  
Interim analysis of PK data will compare CZP plasma concentration data from this study with 
plasma concentrations observed previously in adult study participants with RA. This plasma 
concentration analysis will be done on an ongoing basis throughout the study, starting when 
[ADDRESS_887670] completed Week  12 (Visit  7).  
The therapeutic plasma concentration of CZP in children and adolescents is expected to be 
similar to that required for the adult population (see Section  5.4.2). Interim CZP plasma 
concentration data available at the time of Protocol Amendment [ADDRESS_887671] udy will continue during the PK analysis. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 130 of 280 All study participants assessed in this analysis will continue treatment after Week 12 (Visit 
7). 
Change #[ADDRESS_887672] line:  
Planned Last Study participant, First Visit – 2Q 2013  
Has been changed to:  
Planned Last Study participant, First Visit – 3Q/4Q 2013  
Change #[ADDRESS_887673] sentence:  
Approximately 167 study participants will be screened at about 70 ce nters in order to enroll 
125 study participants in this study.  
Has been changed to:  
Approximately 167 study participants will be screened at about 55 centers in order to enroll 
125 study participants in this study.  
Change #25  
Section 5.2 Schedule of study assessments, Table 5 -1, Week 17 with footnote “u” has been 
added in the second header row, sixth column:  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 16, 
(17(u)), 20, 
24 32 and every  
8 weeks 
thereafter  Unsch.  
Visit(b) Early Disc/  
End of 
Treatment  Final  
Visit(c) 
Change #26  
Section 5.2 Schedule of study assessments, Table 5 -1, the row for “TB questionnaire” has 
been moved below the row for “TB screening.”  
Change #27  
Section 5.2 Schedule of study assessments, Table 5 -1, the row “TB screening”:  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 
16, 20, 24  32 and every  
8 weeks 
thereafter  Unsch.  
Visit(b) Early Disc/  
End of 
Treatment  Final  
Visit(c
) 
Visit (+/ -3 days)(a) 1 2 3 4 5 to 10  11 onwards    FV 
TB screening(n)  X     X(o)    
 Has been changed to:  
Study period  Screening  Baseline         
Week  -4 to 0(a) 0 1 2 4, 8, 12, 
16, 17u, 
20, 24  32 and every  
8 weeks 
thereafter  Unsch.  
Visit(b) Early Disc/  
End of 
Treatment  Final  
Visit(c
) 
Visit (+/ -3 days)(a) 1 2 3 4 5 to 10  11 onwards    FV 
TB screening(n) and chest x -ray(o) X         
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 131 of 280 Change #28  
Section 5.2 Schedule of study assessments, footnote “a” in Table 5 -1: 
a Screening Visit must be completed at least 4 days prior to the Baseline Visit. For all other visits, the Visit 
window is ±3 days relative to Baseline.  
Has been changed to:  
a Screening Visit must be completed at least 4 to 12 working days prior to the Baseline Visit, depending on 
regional requirements and laboratory assessments required f or the study participant (please refer to Section 
10.6 and the laboratory manual). For all other visits, the Visit window is ±3  days relative to Baseline.  
Change #29  
Section 5.2 Schedule of study assessments, footnote “d” in Table 5 -1: 
d Pulse, systolic/d iastolic blood pressure, and temperature to be measured within approximately 15 minutes 
prior to dosing.  
Has been changed to:  
d Pulse, systolic/diastolic blood pressure, and temperature to be measured within approximately 15  minutes 
prior to dosing  and in addition (pulse and blood pressure only) approximately 30 minutes after dosing.  
Change #30  
Section 5.2 Schedule of study assessments, footnotes “i,” “j,” and “k” in Table 5 -1: 
i TB questionnaire to be completed at Weeks 12 and 24, every 16 weeks thereafte r, and Early 
Discontinuation/End of Treatment.  
j Analyses will be performed by a central laboratory. Study participants do not have to be fasting.  
k At Screening, laboratory testing includes testing for HBcAb, HBsAb, HBsAg, and HCVAb. In addition, 
HBV DN A is required for study participants with only positive HBcAb (negative HBsAg and HBsAb) or 
with only positive HBsAg. Rescreening on 1 additional occasion within the Screening Period is allowed 
after consultation with the Medical Monitor in case of isolate d exclusionary laboratory results, if, in the 
Investigator’s opi[INVESTIGATOR_1649], the value is not reflective of the study participant’s previous clinical and laboratory 
pattern. In addition, retesting within the Screening Period is allowed after consultation with the  Medical 
Monitor in case of reporting failure of laboratory results (eg, issues with transportation of samples).  
Have been changed to:  
i TB questionnaire to be completed at Weeks 12 and 24, every 16 weeks thereafter, and Early 
Discontinuation/End of Treatm ent. If the Investigator suspects reactivation of TB or active TB, TB testing 
and/or a chest x -ray should be performed.  
j Analyses will be performed by a central laboratory, except urine dipsticks, which will be done locally at the 
site. Study participants  do not have to be fasting.  
k At Screening, laboratory testing includes testing for HBcAb, HBsAb, HBsAg, and HCVAb. In addition, 
HBV DNA is required for study participants with only positive HBcAb (negative HBsAg and HBsAb) or 
with only positive HBsAg. Ret esting on 1 additional occasion within the Screening Period is allowed in 
case of isolated exclusionary laboratory results, if, in the Investigator’s opi[INVESTIGATOR_1649], the value is not reflective 
of the study participant’s previous clinical and laboratory pattern. In addition, retesting within the Screening 
Period is allowed in case of reporting failure of laboratory results (eg, issues with transportation of 
samples).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 132 of 280 Change #31  
Section 5.2 Schedule of study assessments, footnotes “m,” “n,” and “o” in Table 5 -1: 
m Pregnancy testing for postmenarcheal female study participants. Serum testing by a central laboratory at 
Screening and urine testing at Baseline, Weeks 8, 16, 24, and every visit thereafter.  
n Performed ≤3 months within Screening. [COMPANY_003] tests should be read by a trained health care worker between 
48 and 72 hours after injection. QuantiFERON testing is required to be performed by [CONTACT_658317] a documented history of severe positive [COMPANY_003] reaction or a documented history of 
Bacille  Calmette -Guérin (BCG) vaccination. 
o TB screening to be done at Week 48 and yearly (every 48 weeks) thereafter.  
Have been changed to:  
m Pregnancy testing for postmenarcheal female study participants. Serum testing by a central laboratory at 
Screening and urine testing locally at the site at Baseline, Weeks 8, 16, 24, and every visit thereafter.  
n TB screening if not performed within 3 months of Screening: Interferon -gamma release assay (IGRA) 
testing (QuantiFERON®) is required to be performed by [CONTACT_64295] l lab for all study participants from 5 to 
17 years of age. [COMPANY_003] testing is mandatory for study participants from 2 to 4 years of age in this study unless 
written documentation of BCG vaccination is available (refer to Section 6.2 [exclusion criterion 11 ] and 
Section  10.7.9).  
o A chest radiograph (anterior -posterior view at minimum, but preferably anterior -posterior and lateral) must 
be taken if the study participant has a positive IGRA/[COMPANY_003] testing at Screening  or, if written documentation 
of BCG vaccinat ion is available for study participants ages 2 to 4 years, a TB questionnaire indicating an 
increased study participant’s risk of exposure or infection with TB. If a study participant has had a recent 
radiograph of the chest within approximately [ADDRESS_887674]/pulmonary 
physician who is specifically required to look for evidence of active TB or inactive TB. Refer to 
Section  [IP_ADDRESS].[ADDRESS_887675] x -rays.  
Change #32  
Section 5.2 Schedule of study assessments, footnote “u” in Table 5 -1: 
u CZP plasma level and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 24. A postdose CZP 
plasma sample will be co llected at approximately 5 to 7 days following the Week 16 Visit (ie, requires an 
additional clinic site visit at Week 17).  
Has been changed to:  
u CZP plasma level and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 24. A postdose CZP 
plasma sam ple will be collected at approximately 5 to 7 days following the Week 16 Visit (ie, requires an 
additional clinic site visit for blood collection at Week 17).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 133 of 280 Change #33  
Section 5.3 Schematic diagram:  
 
Has been changed to:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 134 of 280 Change #[ADDRESS_887676] sentence has been removed:  
Interim data from the ongoing clinical study in children and adolescents with Crohn’s disease 
(ages 6 to 17 years) confirm that the weight -based dose adjustment for pediatric study 
participants with Crohn’s d isease leads to similar plasma concentrations as observed 
previously in adult study participants with Crohn’s disease.  
Change #35  
Section 6.1 Inclusion criteria, inclusion criterion 6:  
6. Study participants must have had a diagnosis of JIA (according to th e International League 
of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) for 
at least 6 months prior to Baseline (Visit  2). Eligible JIA categories include: polyarthritis 
rheumatoid factor -positive, polyarthritis rheum atoid factor -negative, extended 
oligoarthritis, juvenile psoriatic arthritis, and ERA.  
Has been changed to:  
6. Study participants must have had onset of signs and symptoms consistent with a diagnosis 
of JIA (according to the International League of Associations for Rheumatology 
Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at 
least 6 months prior to Baseline (Visit  2). Eligible JIA categories include: polyarthritis 
rheumatoid factor -positive, polyarthritis  rheumatoid factor -negative, extended 
oligoarthritis, juvenile psoriatic arthritis, and ERA.  
Change #36  
Section 6.1 Inclusion criteria, inclusion criterion 8:  
8. Study participants must have had an inadequate response to, or intolerance to, at least [ADDRESS_887677] (nonbiologic and biologic).  
Has been changed to:  
8. Study participants must have had an inadequate response to, or intolerance to, at least [ADDRESS_887678] (nonbiologic or biologic). For example, study participant had prior inadequate 
response to MTX (based on the Investigator’s clinical judgment).  
Change #37  
Section 6.1 Inclusion criteria, inclusion criterion 9:  
9. If the study participant is using MTX, then the dose must have been stable for at least 1 
month before Screening at ≥10 to ≤15mg/m2 per week. If the study participant is not using 
MTX, then the treatment must have been previously withdrawn for documented reasons of 
intolerability or inadequate response.  
Has been changed to:  
9. If the study participant is using MTX, then the study part icipant must have been on MTX 
for a minimum of [ADDRESS_887679] 1 month before Screening at ≥10 to ≤15mg/m2 per week. If the study participant is 
not using MTX, then the treatment must have bee n previously withdrawn for documented 
reasons of intolerability or inadequate response.  
Change #38  
Section 6.2 Exclusion criteria, exclusion criterion 6, the exclusion criterion for biologic 
DMARDs infliximab and abatacept in Table 6 -1 Prohibited medicatio ns at entry (Baseline):  
Use of infliximab or abatacept within 84 days prior to the Baseline arthritis assessment.  
Has been changed to:  
Use of infliximab or abatacept within 60 days prior to the Baseline arthritis assessment.  
Change #39  
Section 6.2 Exclusio n criteria, exclusion criterion 11:  
11. Known TB disease, high risk of acquiring TB infection, or latent TB infection:  
a. Known TB disease of either Study participant or Caregiver  
 Currently active TB disease or clinical signs and symptoms suspi[INVESTIGATOR_58917].  
 Prior history of active TB disease involving any organ system (clinically 
documented).  
 Chest radiograph evidence of past active TB disease (not clinically 
documented), which could include api[INVESTIGATOR_658233], pleural thickening, 
calcified lung nodules, cal cified hilar lymph nodes, pericardial calcification.  
a. High risk of acquiring TB infection  
 Known exposure of Study participant or Caregiver to another person with 
active TB disease <3 months prior to Screening.  
 High risk of future exposure of Study participant or Caregiver to another person 
with active TB disease (eg, time spent in an institutional setting).  
b. Latent TB infection - Study participants who don’t meet criteria “a=known TB 
disease” or “b=high risk of acquiring TB infection” but do meet any of the 
following, regardless of prior TB treatment : 
 Currently purified protein derivative ([COMPANY_003]) positive (+) (test must be performed 
≤3 months prior to Screening).  
OR 
 An alternative to the [COMPANY_003] skin test must be used if study participants meet the 
followin g criteria:  
◦ Study participants with documented history of severe positive [COMPANY_003] 
reaction, eg, necrosis, blistering, anaphylactic shock, or ulcerations (test 
performed >3  months prior to Screening), or  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 136 of 280 ◦ Study participants with previous documented history of B acille Calmette -
Guérin (BCG) vaccination.  
 
If any one of these [ADDRESS_887680] a 
QuantiFERON® test conducted at Screening. If the result of the QuantiFERON 
is indeterminate, the test may be repeated once; if positive or i ndeterminate on 
retest, the study participant is excluded. The retest must be conducted in the 
allowable Screening window.  
◦ Study participants with QuantiFERON (performed ≤3 months prior to 
Screening) positive or indeterminate are excluded.  
 Exception from exclusion 11c is permitted only if treatment for latent TB infection is 
initiated or has been initiated at least 1 month prior to study medication administration 
and treatment is still ongoing at the time of study entry.  
 A positive [COMPANY_003] is defined as ≥5mm o f induration 48 to 72 hours after intradermal 
injection of 5TU of [COMPANY_003] -S or 2TU of [COMPANY_003] -RT23 regardless of the study participant’s 
history of BCG vaccination.  
 Reports of [COMPANY_003] results not taken at Screening but (performed ≤3 months prior to 
Baseline and) repor ted from elsewhere must be documented with exact induration 
measurement and date.  
 Treatment for latent TB infection includes eg, isonicotinic acid hydrazide/isoniazid 
(INH) therapy for 9  months (with vitamin B6); another latent TB infection treatment 
regim en should be considered if the study participant is living in or has emigrated 
recently from a country with a high endemic rate of INH -resistant or multi -drug-
resistant TB.  
Has been changed to:  
11. Study participants with known TB infection, at high risk o f acquiring TB infection, or 
latent TB (LTB) infection are excluded:  
a. Known TB infection whether present or past is defined as:  
 Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] 
(pulmonary or extra -pulmonary)  
 History of active TB infecti on involving any organ system or findings in other 
organ systems consistent with TB infection  
 Any evidence by [CONTACT_658318]’s 
medical hi story  
b. High risk of acquiring TB infection is defined as:  
 Known exposure of Study participant or Caregiver to another person with 
active TB infection within the 3  months prior to Screening  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 137 of 280  Time spent in a healthcare delivery setting or institution where ind ividuals 
infected with TB are housed and where the risk of transmission of infection to 
Study participant or Caregiver is high  
c. Latent TB infection (unless appropriate prophylaxis is initiated prior to study 
treatment according to Section  [IP_ADDRESS].1 and con tinued to completion of 
prophylaxis) is defined as:  
Absence of signs, symptoms (ie, evidence of organ -specific involvement), or 
physical findings suggestive of TB infection with a positive interferon -gamma 
release assay (IGRA [QuantiFERON]) test (or [ADDRESS_887681] results) 
or positive [COMPANY_003] (where the [COMPANY_003] skin test is approved for use by [CONTACT_18338]; mandatory 
for ages 2 to 4  years in this study) or, if written documentation of Bacille 
Calmette -Guérin (BCG) vaccination is available for study participants a ges 2 to 
4 years, a TB questionnaire indicating an increased study participant’s risk of 
exposure or infection with TB, and a chest x -ray (or other imaging) without 
evidence of TB infection.  
Note: If available, respi[INVESTIGATOR_58918] (Centers of Disease Control and Prevention [CDC] diagnosis of 
LTB infection, http://www.cdc.gov/TB/topic/testing/default.htm).  
Refer to Section 10.7.9 for additional information on TB definition and clinical signs, 
diagnos is, documentation, and treatment.  
Study participants with a history of or active infection with nontuberculous mycobacteria 
(NTMB) are excluded from this study.  
Change #40  
Section 6.2 Exclusion criteria, exclusion criterion 12:  
12. Study participant has a current sign or symptom which may indicate infection (eg, fever, 
cough), a history of chronic or recurrent infections (more than 3 epi[INVESTIGATOR_658234]/antivirals during the 12 months prior to Screening [Visit 1]), had a recent 
(within the 6 mont hs prior to Screening [Visit 1]) serious or life -threatening infection 
(including herpes zoster), or is at a high risk of infection in the Investigator’s opi[INVESTIGATOR_1649] (eg, 
study participants with leg ulcers, indwelling urinary catheter, and persistent or recurr ent 
chest infections or permanently bed -ridden or wheelchair bound).  
Has been changed to:  
12. Study participant has a current sign or symptom which may indicate infection (eg, fever, 
cough), a history of chronic or recurrent infections within the same orga n system (more 
than 3  epi[INVESTIGATOR_658216]/antivirals during the 12 months prior to Screening 
[Visit  1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or 
life-threatening infection (including herpes zoster), or is at a high risk of infection in the 
Investigator’s opi[INVESTIGATOR_1649] (eg, study participants with leg ulcers, indwelling urinary catheter, 
and persistent or recurrent chest infections or permanently bed -ridden or wheelchair 
bound).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 138 of 280 Change #41  
Section 6.2 Exclusion criteri a, exclusion criterion 13:  
13. Study participant with known concurrent viral hepatitis or known positivity to hepatitis B 
surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or known human 
immunodeficiency virus (HIV) infection.  
Has been changed to : 
13. Study participant with known concurrent viral hepatitis or known positivity for hepatitis 
B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or known human 
immunodeficiency virus (HIV) infection. At Screening, a hepatitis panel result whic h 
indicates immunity due to hepatitis B vaccination is not considered an exclusion criterion.  
Change #42  
Section 6.2 Exclusion criteria, exclusion criterion 16:  
16. Study participant is breast -feeding, pregnant or plans to become pregnant during the study 
or within [ADDRESS_887682] dose of study medication. Female study participants 
of childbearing potential (ie, postmenarcheal) must have a negative result at Screening 
and Baseline (Visits 1 and 2) pregnancy tests to be eligible for study entry.  
Has been changed to:  
16. Study participant is breast -feeding, pregnant or plans to become pregnant during the study 
or within [ADDRESS_887683] dose of study medication (or longer if required by 
[CONTACT_427]). Female study participants of ch ildbearing potential (ie, 
postmenarcheal) must have a negative result at Screening and Baseline (Visits 1 and 2) 
pregnancy tests to be eligible for study entry.  
Change #43  
Section 6.2 Exclusion criteria, exclusion criterion 17:  
17. Study participant is a sexually active female of childbearing potential (ie, 
postmenarcheal) and is not practicing or will not agree to practice an effective means of 
birth control. For postmenarcheal female study participants not currently sexually active, 
the study participant  and parent or legal representative should agree that the study 
participant will employ an effective means of birth control should the study participant 
become sexually active. Acceptable methods of birth control are: 
oral/parenteral/implantable hormonal c ontraceptives (stable at least 2 months prior to 
Screening (Visit 1) if initiated prior to entering the study) or a combination of barrier and 
spermicide. Study participants must agree to use adequate contraception during the study 
and for [ADDRESS_887684] agree to ensure they or their female partner(s) uses adequate 
contraception during the study and for [ADDRESS_887685] dose of s tudy medication. (Sexually active means engaging in sexual intercourse, 
regardless of frequency).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 139 of 280 Has been changed to:  
17. Study participant is a sexually active female of childbearing potential (ie, 
postmenarcheal) and is not practicing or will not agree to practice an effective means of 
birth control. For postmenarcheal female study participants not currently sexually active, 
the study participant and parent or legal representative should agree that the study 
participant will employ an effective means of birth control should the study participant 
become sexually active. Acceptable methods of birth control are: 
oral/parenteral/implantable hormonal contraceptives (stable at least 2 months prior to 
Screening (Visit 1) if initiated prior to entering the study)  or a combination of barrier and 
spermicide. Study participants must agree to use adequate contraception during the study 
and for [ADDRESS_887686] dose of study medication (or longer if required by [CONTACT_13125]). Male study participants who a re sexually active must agree to ensure they or 
their female partner(s) uses adequate contraception during the study and for [ADDRESS_887687] dose of study medication (or longer if 
required by [CONTACT_427]). (Se xually active means engaging in sexual intercourse, 
regardless of frequency).  
Change #44  
Section 6.2 Exclusion criteria, exclusion criterion 24:  
24. Study participant is wheelchair -bound.  
Has been changed to:  
24. Study participant is wheelchair -bound at th e time of enrollment.  
Change #45  
Section 6.2 Exclusion criteria, a new exclusion criterion 25 has been added:  
25. Study participant with a history of or active systemic/respi[INVESTIGATOR_658217], 
parasitic, or mycotic pathogens including but not limited to histoplasmosis, coccidiosis, 
paracoccidiosis, pneumocystis, blastomyces, and aspergillus.  
Radiographic  evidence suggestive of any of these infections is sufficient grounds for 
exclusion.  
Change #46  
Section 6.3 Rescreening:  
6.3 Rescreening  
Rescreening is allowed after consultation with the Medical Monitor as per the following:  
 Study participants with isolat ed exclusionary laboratory assessments at Screening may 
have this laboratory assessment repeated once if, in the Investigator’s opi[INVESTIGATOR_1649], the value 
is not reflective of the study participant’s previous clinical and laboratory pattern. 
Retesting must be comp leted within the stated Screening Period. If the repeat values are 
within the acceptable ranges of the study and the study participant remains eligible during 
the Baseline Visit (Week 0), the study participant may be dosed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 140 of 280  Study participants who failed Sc reening (eg, due to transient out -of-range safety 
laboratory values or in the Investigator’s judgment mild acute illness, eg, a cold) may be 
rescreened after complete recovery of the mild acute illness and/or normalization of the 
out-of-range safety labora tory values.  
Has been changed to:  
6.3 Retesting and rescreening  
Retesting of laboratory assessments within the Screening Period is allowed as per the 
following:  
 Study participants with isolated exclusionary laboratory assessments at Screening may 
have this  laboratory assessment repeated once if, in the Investigator’s opi[INVESTIGATOR_1649], the value 
is not reflective of the study participant’s previous clinical and laboratory pattern. 
Retesting must be completed within the stated Screening Period. If the repeat values ar e 
within the acceptable ranges of the study and the study participant remains eligible during 
the Baseline Visit (Week 0), the study participant may be dosed.  
Rescreening is only allowed after consultation with the Medical Monitor as per the following:  
 Study participants who failed Screening (eg, due to transient out -of-range safety 
laboratory values or in the Investigator’s judgment mild acute illness, eg, a cold) may be 
rescreened after complete recovery of the mild acute illness and/or normalization of t he 
out-of-range safety laboratory values.  
 Study participants with LTB infection, indicated by [CONTACT_658319] (or TB questionnaire indicating an increased risk of exposure or infection 
with TB for study participants ages  2 to 4 years with documented BCG vaccination) and a 
chest imaging without evidence of TB infection at Screening, may be rescreened after 
initiation of treatment for latent TB. Prior to first study medication administration, TB 
treatment must have been ong oing for at least [ADDRESS_887688] be continued until 
completion of 9  months of therapy (refer to Section  10.7.9).  
 Rescreening might be allowed more than once but no t in case of repeated occurrence of 
the same illness. All Screening assessments must be repeated as applicable in case of 
Rescreening. The maximum duration of the Rescreening Period is [ADDRESS_887689] only be scheduled after an appropr iate time period after the initial 
Screening Visit allowing for repetition of blood collection (depending on local 
requirements for maximum blood volumes; depending on study participant weight).  
 All study participants who failed to be enrolled within the S creening Period of [ADDRESS_887690] be registered as Screen Failure in the interactive voice/web response system (IXRS). 
Study participants approved to be rescreened must be registered with a new study 
participant number.  
Change #[ADDRESS_887691] withdrawal criterion:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 141 of 280 3. Study participant develops confirmed latent or active TB once enrolled or discontinues 
treatment for latent TB prematurely or is noncompliant with anti -TB therapy in the 
Investigator’s or Sponsor’s opi[INVESTIGATOR_658235] (see Section 10.7.9).  
Has been changed to:  
3. Study participant who develops confirmed reactivation of latent or active TB or NTMB 
infection during the study (inc luding, but not limited to, conversion demonstrated by 
[CONTACT_658320], eg, TB questionnaire, during the course of the 
study) must be withdrawn.  
Change #[ADDRESS_887692] been renumbered:  
4. Study participant who prematurely discontinues treatment for LTB, or, in the opi[INVESTIGATOR_352159], is noncompliant with anti -TB therapy must be withdrawn.  
Change  #[ADDRESS_887693] sentence:  
In addition, study participants will have the option to either switch to home -based CZP 
injection or switch back to administration at the study site at anytime during the study.  
Has been changed to:  
In addition, if needed, home dosing can be performed by [CONTACT_658321]. Study participants will have th e option to either switch to home -based CZP injection or 
switch back to administration at the study site at anytime during the study.  
Change #50  
Section 7.2 Treatments to be administered, the fifth paragraph:  
The method of injection (ie, qualified site per sonnel -injection at study site; injection by [CONTACT_658263]/caregiver at the study site or at home) and the site of injection (abdomen, 
thigh) will be recorded in the CRF at each visit.  
Has been changed to:  
The method of injection (ie, qualified sit e personnel -injection at study site; injection by [CONTACT_658263]/caregiver or qualified health care professional at the study site or at home) 
and the site of injection (abdomen, thigh) will be recorded in the CRF at each visit.  
Change #[ADDRESS_887694] sentence:  
The tear -off section will be removed and attached to the CRF at the time of study medication 
administration to the study participant and the main section will remain affixed to the 
individual container.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 142 of 280 Has been changed to:  
The tear -off section will be removed and attached to the source document at the time of study 
medication administration to the study participant and the main section will remain affixed to 
the individual container.  
Change #52  
Section 7.8 .1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]), the first bullet:  
 MTX, if being used:  
 Must have been stable for at least 1 month before Screening (Visit 1) at ≥10 to 
≤15mg/m2 per week.  
 The maximum dose allowed during the study is 15mg/m2 per week.  
 Prior to Week 16, route of administration must not change. After Week 16, the route 
of administration may be changed.  
 During the study, the MTX dose may be decreased, but not discontinued (except for 
documented reasons of intolerance or toxicit y, or in association with study 
participants achieving CRM and after CZP was discontinued).  
 After discontinuation, MTX treatment can be restarted.  
Has been changed to:  
 MTX, if being used:  
 Must have been stable for at least 1 month before Screening (Visit 1) at ≥10 to 
≤15mg/m2 per week.  
 During the study, an increase is allowed only after Week 16 and to a maximum dose 
of 15mg/m2 per week.  
 Prior to Week 16, route of administration must not change. After Week 16, the route 
of administration may be changed.  
 During the study, the MTX dose may be decreased, but not discontinued. 
Methotrexate may be discontinued only for documented reasons of intolerance or 
toxicity, or in study participants who achieve CRM and only after discontinuation of 
CZP.  
 Study participant s who do not achieve persistent CRM status can reinitiate therapy 
with MTX.  
Change #53  
Section 7.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]), the fifth bullet:  
 Corticosteroids:  
 At study entry, the dose should have been stable for at least 7 days prior to the 
Baseline joint examination  at a maximum dose of 10mg or 0.2mg/kg prednisone (or 
equivalent) per day, whichever is the smaller dose.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 143 of 280  During the study, the dose of oral cortico steroids may be decreased but not initiated or 
increased above 10mg or 0.2mg/kg prednisone (or equivalent) per day, whichever is 
the smaller dose. The dose must be stable in the 7 days prior to a joint examination.  
 Intra -articular (ia) corticosteroids may be administered no more frequently than every 
4 months and no more than up to 3 times in 1 year and only into up to 3  joints at a 
single time point.  
 If [ADDRESS_887695] been injected (limited to 3 joints at a single time point), 
this/these joint(s) mu st be excluded from the PRINTO/PRCSG standard joint 
examination.  
 Intravenous (iv) corticosteroid use is permitted only for stress dosing for the purposes 
of surgery.  
Has been changed to:  
 Corticosteroids:  
 At study entry, the dose should have been stable fo r at least 7 days prior to the 
Baseline joint examination  at a maximum dose of 10mg or 0.2mg/kg prednisone (or 
equivalent) per day, whichever is the smaller dose.  
 During the study, the dose of oral corticosteroids may be decreased but not initiated or 
increased above 10mg or 0.2mg/kg prednisone (or equivalent) per day, whichever is 
the smaller dose. The dose must be stable in the 7 days prior to a joint examination.  
 Initiation of topi[INVESTIGATOR_658236] g the course of the study.  
 Intra -articular (ia) corticosteroids may be administered no more frequently than every 
4 months and no more than up to 3 times in 1 year and only into up to 2  joints at a 
single time point.  
 Any joint injected with ia corticostero ids will be excluded from the efficacy analysis 
for a period of 3 months.  
 Intravenous (iv) corticosteroid use is permitted only for stress dosing for the purposes 
of surgery.  
Change #54  
Section 7.8.2 Rescue medication, the fourth and fifth paragraphs:  
The following medications are defined as rescue medication in the first 16 weeks of this 
study:  
 Initiation of MTX (if not being used at study entry), or increase of MTX above Baseline.  
 Initiation of oral corticosteroids, or increase of oral corticosteroids abo ve Baseline.  
 Injection of intra -articular (ia) corticosteroids into more than 3 joints at a single time 
point.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 144 of 280  Injection of intra -articular (ia) corticosteroids into the same joint more frequently than 
3 times in a 12 -month period.  
 Intravenous (iv) corticosteroids (any dose), if not used for stress dosing for the purposes 
of surgery.  
 Intramuscular (im) corticosteroids.  
The following medications are defined as rescue medication for the remainder of the study:  
 Initiation of MTX (if not being used at study entry), and increase of MTX above 15mg/m2 
per week at any time.  
 Initiation of oral corticosteroids, or increase to >10mg or 0.2mg/kg (whichever is the 
smaller dose).  
 Injection of intra -articular (ia) corticost eroids into more than 3 joints at a single time 
point.  
 Injection of intra -articular (ia) corticosteroids into the same joint more frequently than 
3 times in a 12 -month period.  
 Intravenous (iv) corticosteroids (any dose), if not used for stress dosing for the purposes 
of surgery.  
 Intramuscular corticosteroids (im).  
Have been changed to:  
The following medications are defined as rescue medication in the first 16 weeks of this 
study:  
 Initiation of MTX (if not being used at study entry), or increase of MTX abov e Baseline.  
 Initiation of oral corticosteroids, or increase above Baseline .  
The following medications are defined as rescue medication after Week 16:  
 Initiation of MTX (if not being used at study entry), and increase of MTX above 15mg/m2 
per week at any t ime. 
 Initiation of oral corticosteroids, or increase to >10mg or 0.2mg/kg prednisone (or 
equivalent) per day, whichever is the smaller dose.  
The following medications are defined as rescue medication when given at any time during 
the study:  
 Injection of in tra-articular (ia) corticosteroids into more than 2 joints at a single time 
point.  
 Injection of intra -articular (ia) corticosteroids into the same joint more frequently than 
3 times in a 12 -month period.  
 Intravenous (iv) corticosteroids (any dose), if not  used for stress dosing for the purposes 
of surgery.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 145 of 280  Intramuscular (im) corticosteroids.  
Change #55  
Section 7.9 Enrollment and numbering of study participants, the second sentence:  
The IVRS will provide the Investigator with the unique study participant number assigned to 
each study participant.  
Has been changed to:  
The Investigator will enter the unique study participant number assigned to each study 
participant, based on a predefi ned range of study participant numbers assigned to the 
Investigator’s site.  
Change #56  
Section 8.1 Visit 1 (Week -4 to 0) Screening, the tenth bullet has been moved below the 
bullet “TB screening”:  
 TB questionnaire  
Change #57  
Section 8.1 Visit 1 (Week -4 to 0) Screening, a new bullet has been added above the 15th 
bullet “TB screening”:  
 Chest x -ray (only for study participants with positive IGRA or [COMPANY_003] testing)**  
Change #58  
Section 8.1 Visit 1 (Week -4 to 0) Screening, the 15th bullet:  
 TB screening if not p erformed within 3 months of Screening: [COMPANY_003] skin test (or 
QuantiFERON required to be performed by [CONTACT_658322] a 
documented history of severe positive [COMPANY_003] reaction or a documented history of BCG 
vaccination)  
Has been changed to: 
 TB screening if not performed within 3 months of Screening: [COMPANY_003] skin test for study 
participants from 2 to 4  years of age (unless written documentation for BCG vaccination 
is available) or IGRA (to be performed by [CONTACT_6626]) for study participant s from 5  to 
17 years of age)**  
Change #59  
Section 8.1 Visit 1 (Week -4 to 0) Screening, the last bullet:  
 IVRS phone call (to receive study participant number assignments)  
Has been changed to:  
 IXRS contact (to register study participant with unique study pa rticipant number)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 146 of 280 Change #60  
Section 8.1 Visit 1 (Week -4 to 0) Screening, the note at the end of the section:  
*Change in height and weight over the last [ADDRESS_887696] year will be collected 
via parent -/self-report, if available from medical r ecords.  
Has been changed to:  
*Change in height and weight over the last [ADDRESS_887697] year will be collected 
via parent -/self-report, if not available from medical records.  
Change #61  
Section 8.1 Visit 1 (Week -4 to 0) Screening, a new note ha s been added at the end of the 
section for chest x -ray, TB screening, and TB questionnaire:  
**For details of TB screening and testing, see Section 10.7.9.  
Change #62  
Section 8.2 Visit 2 (Week 0) Baseline, the 19th and 20th bullets:  
 FPS-R for study participants ages 5 to 11  years  (at Baseline and daily assessment during 
the first 7  days of treatment)  
 JIA Pain VAS for study participants ages 12 to 17  years ; acute and standard versions 
(both at Baseline and daily assessment of the acute version during the first 7 days of 
treatment)  
Has been changed to:  
 FPS-R for study participants ages 5 to 11  years  (at Baseline and daily assessment on Day 
1 to Day  7) 
 JIA Pain VAS for study participants ages 12 to 17  years ; acute and standard versions 
(both at Baseline and daily assessment of the acute version on Day  1 to Day  7)  
Change #63  
Section 8.2 Visit 2 (Week 0) Baseline, the paragraph at the end of the section:  
Documentation of the assessment of all 6 core set measu res of PedACR response 
(PRINTO/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and DMS) will be submitted to 
UCB or designee for immediate review of completeness, while the study participant is 
still on site.  
Has been changed to:  
Documentation of the assessment of all 6 core set measures of PedACR response 
(PRINTO/PRCSG standard joint examinatio n, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 147 of 280 UCB or designee for immediate review of comp leteness, while the study participant is 
still on site.  
Change #64  
Section 8.3 Visits 3 and 4 (Weeks 1 and 2), the ninth bullet:  
 Collection of JIA Pain VAS or FPS -R completed during the first 7 days of treatment   
Has been changed to:  
 Collection of JIA Pain  VAS or FPS -R completed on Day 1 to Day 7  
Change #65  
Section 8.4  Visits 5 to 10 (Weeks 4, 8, 12, 16, 20, and 24), the paragraph at the end of the 
section:  
Documentation of the Week 16  assessment of all 6 core set measures of PedACR response 
(PRINTO/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and DMS) will be submitted to 
UCB or designee for  immediate review of completeness, while the study participant is 
still on site.  
Has been changed to:  
Documentation of the Week 16  and Week 24 assessment of all 6 core set measures of 
PedACR response (PRINTO/PRCSG standard joint examination, Physician’s Gl obal 
Assessment of Disease Activity [VAS], CHAQ -parent reported, Parent’s Assessment of 
Arthritis Pain [VAS], Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) 
will be submitted to UCB or designee for immediate review of completeness, while t he 
study participant is still on site.  
Change #66  
Section 8.5  Visits 11 and continuing (Week 32 and every 8 weeks thereafter), the eleventh 
bullet has been removed:  
 TB screening is to be repeated every [ADDRESS_887698] be performed. 
(QuantiFERON required to be performed by [CONTACT_658322] a 
documented history of severe positive [COMPANY_003] reaction or a documented history of BCG 
vaccinatio n) (Week 48 and every 48 weeks thereafter).  
Change #67  
Section 8.5  Visits 11 and continuing (Week 32 and every 8 weeks thereafter), the paragraph 
at the end of the section:  
Documentation of the Week 56  assessment of all 6 core set measures of PedACR respo nse 
(PRINTO/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and DMS) will be submitted to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 148 of 280 UCB or designee for immediate review of completeness, while the study participant is 
still on site.  
Has been changed to:  
Documentation of the Week 56  assessment of all 6 core set measures of PedACR response 
(PRINTO/PRCSG standard joint examination, Physicia n’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
UCB or designee for immediate review of completeness, w hile the study participant is 
still on site.  
Change #[ADDRESS_887699], fourth, 
and fifth paragraphs:  
Once at least 20 study participants (minimum 6 study participants in each age group: 2 to 5 
years, 6 to 11 years, and 12 to 17 years) have completed Week 12 (Visit 7), PK data will be 
compared with plasma concentrations observed previously in adult study p articipants with 
RA.  
This CZP plasma concentration analysis may be done in [ADDRESS_887700] 20 study 
participants in total complete Week 12 (Visit 7) before [ADDRESS_887701] completed Week 12 (Visit 7).  
If plasma concentrations are not consistent with those observed in previous studies with 
adults, the dosing algorithm may be changed via a protocol amendment. This study will 
continue during the PK analysis. All study participants assessed in this analysis  will continue 
treatment after Week 12 (Visit 7).  
Have been changed to:  
Plasma concentration data for CZP from this study will be compared with plasma 
concentrations observed previously in adult study participants with RA, as described in 
Section  13.7. Thi s plasma concentration analysis will be done on an ongoing basis throughout 
the study, starting when [ADDRESS_887702] completed Week  12 
(Visit 7).  
Interim CZP plasma concentration data available at the time of Protocol Amend ment 3 
indicate that no change to the dosing algorithm is required. If future analyses indicate that 
plasma concentrations are outside of the exposure range of those observed in previous studies 
with adults, the dosing algorithm may be changed via a protoc ol amendment, and if necessary 
additional interim analyses including PopPK, may be performed. This study will continue 
during the PK analysis. All study participants assessed in this analysis will continue treatment 
after Week 12 (Visit 7).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 149 of 280 Change #69  
Section 9 Assessment of pharmacokinetics and immunological variables, the following 
sentence has been added below the fourth paragraph:  
The final pediatric PopPK model will be combined with PD data (PedACR) and if the data 
allow, an exposure -response relations hip will be derived.  
Change #70  
Section 9 Assessment of pharmacokinetics and immunological variables, the following has 
been added at the end of the section:  
These plasma samples may be used additionally for analyses of CZP and its constituent 
moieties usi ng alternative assay methods. The results of the analyses of CZP and its 
constituent moieties from alternative methods may be reported separately.  
Change #71  
Section 10.1.8 Ongoing safety data review and oversight, second paragraph, the fourth and 
fifth se ntences:  
In addition, there will be a study -specific Safety Review Committee consisting of the UCB 
study physician, the UCB study GCSP representative, and an external pediatric 
rheumatologist experienced in the field and clinical studies in pediatrics and familiar with 
safety issues in this population. A charter will be developed to address the logistics of such a 
committee.  
Has been changed to:  
In addition, a Data and Safety Monitoring Board (DSMB) will periodically review all 
emerging safety data (see Sec tion 13.7). The DSMB will function and meet on a regular basis 
as per the agreed upon charter.  
Change #[ADDRESS_887703] sentence:  
The Sponsor Study Physician or medically qualified designee/equivalent wil l conduct an 
ongoing review of SAEs and perform ongoing SAE reconciliations in collaboration with the 
GCSP representative.  
Has been changed to:  
The Sponsor Study Physician or medically qualified designee/equivalent will conduct an 
ongoing review of SAEs an d perform ongoing SAE reconciliations in collaboration with the 
Drug Safety and Data Management representatives.  
Change #[ADDRESS_887704]:  
10.[ADDRESS_887705]/compound.  
 Adverse events of special interest must be reported immediately by [CONTACT_737] (s ee 
Section 10.4). The following are AEs of special interest for this study:  
 Serious infections, including opportunistic infections  
 Malignancies, including lymphoma  
 Congestive heart failure  
 Demyelinating -like disorders  
 Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leukopenia  
 Serious bleeding events  
 Lupus and lupus -like illness  
 Serious skin reactions (eg, Stevens -Johnson syndrome, toxic epi[INVESTIGATOR_59373], and 
erythema multiforme)  
The purpose of the  AE of special interest list is to identify and capture product specific 
AEs/reactions requiring expedited reporting or close monitoring by 1 or more regulatory 
authorities or close monitoring required by [CONTACT_18338]. This tool will help ensure that specific 
speci al reporting requirements from regulatory authorities and safety topi[INVESTIGATOR_658237], processed, reported, and monitored. The process also 
allows for detection of safety signals, signal evaluation, and the assessm ent of changes in the 
benefit -risk ratio of UCB products/compounds, based on all safety and benefit -risk 
information available for the protection of the patient.  
Has been changed to:  
10.[ADDRESS_887706] expedited reporting, even if the AE does not 
fulfill the expedited reporting criteria of “serious,” “unexpected,” and “associated with the 
use of the drug.”  
Adverse events of interest include:  
 Serious infections, including opportunistic infections  
 Malignancies, including lymphoma  
 Congestive heart failure  
 Demyelinating -like disorders  
 Aplastic anemia, pancytopenia, thrombocytopenia, neutropenia, and leukopenia  
 Serious bleed ing events  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 151 of 280  Lupus and lupus -like syndrome  
 Serious skin reactions (eg, Stevens -Johnson syndrome, toxic epi[INVESTIGATOR_59373], and 
erythema multiforme)  
Adverse events of interest must be reported immediately by [CONTACT_737] (see 
Section  10.4).  
The purpose  of the AE of interest list is to identify and capture product specific AEs/reactions 
requiring expedited reporting or close monitoring by 1 or more regulatory authorities or close 
monitoring required by [CONTACT_18338]. This tool will help ensure that specific specia l reporting 
requirements from regulatory authorities and safety topi[INVESTIGATOR_658227], processed, reported, and monitored. The process also allows for 
detection of safety signals, signal evaluation, and the assessme nt of changes in the 
benefit -risk ratio of UCB products/compounds, based on all safety and benefit -risk 
information available for the protection of the patient.  
Change #[ADDRESS_887707] bullet:  
 AE of special interest (s ee Section 10.3)  
Has been changed to:  
 AE of interest (see Section 10.3)  
Change #[ADDRESS_887708] and second paragraphs:  
Hematology, biochemistry, urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32, every 8 weeks thereafter, the Early Discontinuation/End of 
Treatment Visit, and the Final Visit [ADDRESS_887709] dose of study med ication. At 
Weeks 1 and 2, CRP samples will be collected only.  
Retesting within the Screening Period is allowed after consultation with the Medical Monitor 
in case of reporting failure of laboratory results (eg, issues with transportation of samples).  
Have been changed to:  
Hematology, biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32, every 8 weeks thereafter, the Early Discontinuation/End of 
Treatment Visit, and the Final Visit [ADDRESS_887710] dose of study medication. At 
Week 1, only CRP and PK samples will be collected and at Week 2, only CRP samples will 
be collected.  
Retesting of laboratory assessments within the Screening Period is allowed in case of isolated 
exclusionary laboratory assessments at Screening if, in the Investigator’s opi[INVESTIGATOR_1649], the value is 
not reflective of the study participant’s previous clinical and laboratory pattern (see Section 
6.3). In addition, retesting within the Screening Period is allowed in case of reportin g failure 
of laboratory results (eg, issues with transportation of samples).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 152 of 280 Change #76  
Section 10.6 Laboratory measurements, the following sentence has been added at the end of 
the sixth paragraph:  
Only samples for CRP , PK, and immunological variables wil l then be collected at Baseline 
(Week 0).  
Change #77  
Section 10.6 Laboratory measurements, seventh paragraph, the second sentence:  
The planned total blood volumes collected at a single time point (visit) will not exceed 
approximately 8mL.  
Has been changed to: 
The planned total blood volumes collected at a single time point (visit) will vary between 
2mL and 9mL.  
Change #78  
Section 10.6 Laboratory measurements, the eighth to tenth paragraphs:  
In addition, treatment of the veinpuncture site with an anesthetic cream prior to dosing is 
permitted.  
If QuantiFERON testing is required to be performed by [CONTACT_6626] (for study participants 
with documented history of severe positive [COMPANY_003] reaction or previous documented history of 
BCG vaccination, see Section 6.2) ad ditional blood sampling of approximately 3ml will be 
required at Screening.  
If the result of the QuantiFERON is indeterminate, the test may be repeated once. The retest 
must be conducted in the allowable Screening window. Study participants with 
QuantiFERO N (performed ≤3 months prior to Screening) positive or indeterminate are 
excluded.  
Have been changed to:  
In addition, treatment of the venipuncture site with an anesthetic cream prior to blood 
sampling is permitted.  
If IGRA testing is required to be perfor med by [CONTACT_6626] (for all study participants from 
5 to 17  years of age, see Section 6.2) additional blood sampling of approximately 3mL will 
be required at Screening.  
If the result of the IGRA is indeterminate, the test may be repeated once. The ret est must be 
conducted in the allowable Screening window. Study participants with IGRA (performed ≤3 
months prior to Screening) positive or indeterminate and a chest x -ray confirmative of TB 
infection are excluded (see Section [IP_ADDRESS]).  
For study particip ants from 2 to 4 years of age, [COMPANY_003] testing will be performed locally (except 
for study participants with documented BCG vaccination) as described in Section [IP_ADDRESS].3.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 153 of 280 Change #79  
Section 10.6 Laboratory measurements, the sentence above the table and Table  10-2 
Laboratory measurements:  
The central laboratory will analyze and assess blood and urine samples for the following 
(except urine pregnancy test):  
Table 10 -2 Laboratory measurements  
Hematology  Serum biochemistry  Urinalysis  
Red blood cells  
Hemoglobin  
Hematocrit  
Platelets  
White blood cells  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Sodium  
Potassium  
Chloride  
Bicarbonate  
Total calcium  
Inorganic phosphorus  
Creatinine kinase  
Glucose  
Creatinine  
Uric acid  
Urea  
Total protein  
Albumin  
Alkaline phosphatase  
Gamma glutamyl tranferase  
Aspartate aminotransferase  
Alanine aminotransferase  
Bilirubin  
Total cholesterol  
CRP 
Autoantibodies (ANA and 
anti-dsDNA antibodies)  pH 
Protein  
Glucose  
Blood  
Microscopy (WBC, RBC, casts, 
crystals, bacteria) (Microscopy  
will be performed only when 
there are abnormalities on 
dipstick)  
Serum pregnancy test(a) 
 
Hepatitis screening(b) 
HBcAb  
HBsAb  
HBsAg  
HCVAb  
HBV DNA, if applicable  
TB screening(c) 
QuantiFERON  
ANA=antinuclear antibody; anti -dsDNA antibodies=double -stranded deoxyribonucleic acid antibody; 
CRP=C -reactive protein; HBcAb=hepatitis B core antibody; HBsAb=hepatitis B surface antibody; HBsAg=hepatitis 
B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C virus; RBC=red blood cells; WB C=white blood cells  
a Serum pregnancy tests will be performed at Screening by [CONTACT_2237] (see Section 10.7.7). At 
Baseline, Weeks 8, 16, 24, and every visit thereafter, urine pregnancy tests will be performed locally.  
b Study participants will be tested for hepatitis at Screening. HBV DNA is required for study participants with 
only positive HBcAb (negative HBsAg and HBsAb) or only positive HBsAg  
c Only study participants with documented history of severe positive [COMPANY_003] reaction or previous documented 
history of BCG vaccination, see Section 6.2.  
Note: Other pharmacokinetic assessments may be periodically performed as per Section [ADDRESS_887711] been changed to:  
The central laboratory will analyze and assess blood and urine samples for the following 
(except dip stick test and urine pregnancy test); other PK assessments may be periodically 
performed as per Section 9:  
Table 10 -2 Laboratory measurements  
Hematology  Serum biochemistry  Urinalysis  
Red blood cells  
Hemoglobin  
Hematocrit  
Platelets  
White blood cells  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Sodium  
Potassium  
Chloride  
Bicarbonate  
Total calcium  
Inorganic phosphorus  
Creatinine kinase  
Glucose  
Creatinine  
Uric acid  
Urea  
Total protein  
Albumin  
Alkaline phosphatase  
Gamma glutamyl transferase  
Aspar tate aminotransferase  
Alanine aminotransferase  
Lactate dehydrogenase  
Bilirubin  
Total cholesterol  
CRP 
Autoantibodies (ANA and 
anti-dsDNA antibodies)  pH(a) 
Protein(a) 
Glucose(a)  
Blood(a) 
Microscopy (WBC, RBC, casts, 
crystals, bacteria) (Microscopy 
will be performed only when 
there are abnormalities on 
dipstick)(a) 
Serum and urine pregnancy 
test(b) 
 
Hepatitis screening(c) 
HBcAb  
HBsAb  
HBsAg  
HCVAb  
HBV DNA, if applicable  
TB screening(d) 
IGRA (ages 5 -17 years ),  
[COMPANY_003] (ages 2 -4 years)  
ANA=antinuclear antibody; anti -dsDNA antibodies=double -stranded deoxyribonucleic acid antibody; BCG=Bacille 
Calmette -Guérin; CRP=C -reactive protein; DNA=deoxyribonucleic acid; HBcAb=hepatitis B core antibody; 
HBsAb=hepatitis B surface antibody; HBsAg=hepat itis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis C 
virus; IGRA=interferon -gamma release assay; RBC=red blood cells; TB=tuberculosis; WBC=white blood cells  
Note: The Screening Visit must be completed at least 4 to 12 working days prior to the Ba seline Visit, depending on 
regional requirements and laboratory assessments required for the study participant  (refer to laboratory manual for 
country -specific requirements). In case HBV DNA or TB IGRA is to be analyzed, the Baseline Visit can be 
performed  at the earliest 12 days after the Screening Visit (6 working days in Russia). Study participants can only be 
enrolled into the study after all laboratory results of the Screening Visit have been confirmed.  
a Urine dipsticks will be done locally at the site;  only abnormalities will be reported. In case of abnormalities on 
dipstick, microscopy will be performed by [CONTACT_2237].  
b Serum pregnancy tests will be performed at Screening by [CONTACT_2237] (see Section 10.7.7). At 
Baseline, Weeks 8, 1 6, 24, and every visit thereafter, urine pregnancy tests will be performed locally.  
c Study participants will be tested for hepatitis at Screening. HBV DNA is required for study participants with 
only positive HBcAb (negative HBsAg and HBsAb) or only positive HBsAg. A hepatitis panel result which 
indicates immunity due to hepatitis B vaccination is not considered an exclusion criterion.  
d IGRA testing is required at Screening for all study participants aged 5 to 17 years; [COMPANY_003] testing is required for 
all study participants aged 2 to 4 years (except for study participants with documented BCG vaccination) .  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 155 of 280 Change #[ADDRESS_887712] sentence:  
Vital signs will be measured within approximately 15 minutes prior to dosing with study 
medication.  
Has been changed to:  
Vital signs will be measured within approximately 15 minutes prior to dosing and in addition 
(pulse and blood pressure only) approxima tely 30 minutes after dosing with study 
medication.  
Change #81  
Section 10.7.9 Assessment and management of TB and TB risk factors:  
[IP_ADDRESS]   Assessment and management of TB and TB risk factors  
As TNF -antagonists are known to be associated with significant risk of reactivation of latent 
TB, appropriate rigorous precautions are being taken within the protocol to address this. For 
inclusion in the study, see Section 6.2  (Exclusion Criterion 11).  
Study participants who develop evidence of latent or active TB du ring the study must 
immediately discontinue further administration of study medication. Once withdrawn from 
study treatment, study participants should return for the Early Discontinuation Visit, 
complete all Early Discontinuation assessments, and complete a Final Visit [ADDRESS_887713] dose of study medication.  
[IP_ADDRESS]   Tuberculosis assessments  
[IP_ADDRESS].1   Tuberculin purified protein derivative ([COMPANY_003]) skin test  
A Mantoux tuberculin skin test must be performed preferably at the Screening Visit but at 
least within [ADDRESS_887714] of injection or 
puncture. The size (diameter) of the induration is measured and recorded. The results of the 
test are assessed in accordance to the criteria set in Section 6.2 ( Exclusion Criterion 11).  
[IP_ADDRESS].[ADDRESS_887715] method of 
detecting infection with Mycobacterium tuberculosis . One -tenth milliliter of [COMPANY_003] ( ie, 5TU 
[COMPANY_003]-S or 2TU of [COMPANY_003] -RT 23, as recommended by [CONTACT_38375]) is 
injected into the inner surface of the forearm. Other areas may be used, but the forearm is 
preferred. The use of a skin area free of lesions and away from veins is reco mmended. The 
injection is made using a one -quarter - to one -half-inch (1cm), 27G needle and a tuberculin 
syringe. The tuberculin should be injected by a qualified health care worker just beneath the 
surface of the skin, with the needle bevel upward. A discr ete, pale elevation of the skin (a 
wheal) [ADDRESS_887716], tuberculin 
testing should be repeated. If a positive [COMPANY_003] is read after 72 hours, the study par ticipant will 
be considered to be TB positive. Study participants should never be allowed to read their own 
tuberculin skin tests.  
The reading should be performed in good light, with the forearm slightly flexed at the elbow. 
The basis of reading is the pr esence or absence of induration. Erythema should not be 
measured. The presence or absence of induration may be determined by [CONTACT_122317] (from a 
side view against the light as well as by [CONTACT_658323]) and by [CONTACT_23302]. The diameter of 
induration should be m easured transversely to the long axis of the forearm and recorded in 
millimeters, even for those tests classified as negative (ie, 0mm).  
An induration of 5mm or greater in response to the intradermal tuberculin skin test is 
considered to be a positive res ult and evidence for either latent or active TB. In most 
countries, the most conservative definition of positivity , ie, an induration of 5mm or greater, 
in response to the tuberculin skin test is reserved for immunocompromised study participants. 
This defi nition is to be applied here to maximize the likelihood of detecting latent TB.  
T-cell interferon gamma release assays  
A QuantiFERON®-TB GOLD must be done at the Screening Visit in those study participants 
with a documented history of severe positive [COMPANY_003] reaction or a documented history of BCG 
vaccination. Mantoux tuberculin skin testing must be done on all other study participants.  
[IP_ADDRESS].3   Tuberculosis questionnaire  
The questionnaire “Evaluation of signs and symptoms of tuberculosis” (see Appendix 17. 9) 
should be used as a source document. The questionnaire will be completed at Screening, 
Baseline, Weeks 12 and 24, every 16  weeks thereafter, and at the Early Discontinuation/End 
of Treatment Visit. The questionnaire will be completed by [CONTACT_658324], once for the study participant and once for the caregiver and appropriately 
identified (ie, labeled study participant or caregiver). The questionnaire will assist with the 
identification of study participants who may requi re therapy for TB. A study 
participant/caregiver who answers “Yes” to the question “Has the study participant/caregiver 
been in close contact [CONTACT_41022], or an individual who has recently 
been treated for TB?” at Screening is exclude d. A “Yes” response to any of the other 
questions within the questionnaire at Screening should trigger further careful assessment to 
determine if study participant has latent or active TB (see Exclusion Criterion 11, Section 
6.2). A “Yes” response to any o f the questions during the study should trigger further careful 
assessment to determine if the study participant has TB (regardless if latent or active) and has 
to be withdrawn from the study.  
Responses to the questions and the Investigator’s assessment of  the study participant’s status 
and any action taken must be recorded in the source documents.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 157 of 280 [IP_ADDRESS]   Tuberculosis management  
For inclusion in the study, see  Section 6.2 (E xclusion Criterion 11).  
It is the Sponsor’s requirement that all study participan ts who are on latent TB treatment at 
Baseline must comply with the full therapy course (see Section 6.2, Exclusion Criterion 11). 
Study participants who discontinue treatment for latent TB prematurely or who are 
noncompliant with anti -TB therapy in the Inv estigator’s or Sponsor’s opi[INVESTIGATOR_658238]. Once withdrawn from study treatment, study participants should return for the 
Early Discontinuation Visit to complete a ll early withdrawal assessments, and complete the 
Final Visit [ADDRESS_887717] dose of study medication. Confirmed active TB (ie, positive 
culture or acid -fast bacilli smear) is an SAE which must be captured on an SAE report form 
and provided to  the Sponsor in accordance with SAE reporting requirements. As with all 
SAEs, periodic follow -up reports should be completed as per protocol requirement until such 
time as the TB infection resolves. Confirmed latent TB should be recorded both as an AE and 
the reason for discontinuation from the study.  
Follow -up information of suspected and confirmed TB cases should be provided to UCB at 
least after 3, 9, and 12  months of start date of anti -TB treatment, including hematological and 
biochemical safety paramet ers, x -ray evolution data, and TB diagnostic procedures used to 
follow -up and confirm recovery of TB.  
Has been changed to:  
10.7.9    Tuberculosis guidance, testing, and screening  
[IP_ADDRESS]   Guidance  
TNFα -inhibitors are known to be associated with an increas ed risk of TB and therefore, 
precautions are taken within the protocol to mitigate this risk. Study participants who develop 
signs or symptoms that may indicate latent TB infection or active TB during the Treatment 
Period must immediately discontinue furth er administration of IMP. Additional actions 
required are provided below. The Investigator should consider all potential sites of infection 
when assessing for TB during the study participant’s history and the physical examination, 
and other evaluations. Si tes commonly infected by [CONTACT_18404]: the lungs, larynx, lymph 
glands, pleura, gastrointestinal system, genito -urinary tract (including renal), bones and 
joints, meninges, peritoneum, pericardium, and skin. This is not an exhaustive list and 
unusual present ations and areas of involvement should always be considered. Common 
symptoms that the study participant may present with include cough, blood in sputum, night 
sweats, lymphadenitis, joint pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal 
pain mimicking inflammatory bowel disease (IBD), frequent or painful urination, scrotal 
mass in men and pelvic inflammatory disease in women as well as other symptoms, or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887718] and unusual presentations should alwa ys 
be considered.  
Note that study participants with a history of NTMB or active NTMB infection are excluded 
from the study regardless of prior or current therapy.  
[IP_ADDRESS].[ADDRESS_887719] (IGRA or [COMPANY_003]) 
and chest imaging without positive findings for TB along with the absence of signs, 
symptoms, or physical findings suggestive of TB infection. If available, smears and cultures 
of secretions or tissues should also be negative. At Screening, study participants who have 
recently (defined as no more than 12 months prior to Screening) completed a full course of 
prophylaxis for LTB infection may be considered for study participation. Study participants 
who have received prophylactic therapy for LTB infection for at least 4 weeks prior to 
enrollment (initiation of CZP treatment at Baseline) and are committed to completing the full 
course of therapy, may be considered for study participation. The Investigator must provide 
documentation of duration, and start and stop date of such therapy and method of therapy (eg, 
self-administration or directly observed therapy). This evidence of treatment should be 
recorded contemporaneously with the treatment date and should be filed in t he source 
document. The Investigator must assess that the study participant’s likelihood of completing 
the therapy is high and duly record their opi[INVESTIGATOR_658239]’s record prior to 
enrolling the study participant. The Investigator must discu ss each case with the Study 
Physician or Medical Monitor prior to allowing the study participant to be screened (in event 
the LTB infection was discovered prior to study participant screening) or enrolled (if LTB 
infection was identified at Screening).  
Study participants with LTB infection, indicated by [CONTACT_658325] (or TB questionnaire indicating an increased study participant’s risk of exposure or 
infection with TB for study participants ages 2 to 4 years with docume nted BCG vaccination) 
and a chest imaging without evidence of TB infection at Screening, may be rescreened after 
initiation of treatment for latent TB and after approval of the Medical Monitor. Prior to first 
study medication administration TB treatment mu st have been ongoing for at least [ADDRESS_887720] be continued until completion of 
9 months of therapy.  
Prophylaxis may include isonicotinic acid hydrazide/isoniazid [INH] therapy (with vitamin 
B6) for 9 mon ths or any other locally approved therapy or combination regimen/therapy 
appropriate for immunosuppressed study participants. For study participants living in or 
recently emigrated (within 5 years prior to initiation of Screening) from a country or region 
with a high endemic rate of INH resistant or multidrug resistant TB, an approved 
combination therapy must be followed that is both approved for the region in which the 
infection was likely to have originated and targeted to the study participant’s specific  TB 
infection. If there is disagreement between the local guidelines and the UCB standards, the 
more stringent guidance will apply and should be considered appropriate for the study 
participant’s specific TB infection.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887721] for evalua tion. Evidence 
of LTB infection is defined as study participant’s IGRA test converts to positive or 
indeterminate (and confirmed indeterminate on repeat), or [COMPANY_003] converts to positive (this only 
applies for regions or sites where UCB has determined [COMPANY_003] may be used for screening and 
follow -up), or the study participant’s questionnaire or history and physical examination 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, 
in addition to the aforementioned tests, signs and  symptoms of organ involvement. In either 
situation, the study participant should be carefully assessed by a TB specialist for active TB 
(see Section  [IP_ADDRESS]). Study participants diagnosed with active TB or LTB infection should 
receive appropriate TB or p rophylaxis therapy respectively per local and UCB guidelines as 
described above. Any presumptive diagnosis or diagnosis of LTB infection or active TB is a 
reportable event; refer to Section  10.2.[ADDRESS_887722] be followed.  
[IP_ADDRESS]   TB screening and testing  
[IP_ADDRESS].[ADDRESS_887723] radiograph (anterior -posterior view at minimum, but preferably ante rior-posterior and 
lateral) must be taken for study participants with a positive or repeatedly indeterminate IGRA 
or [COMPANY_003] testing or TB questionnaire indicating an increased study participant’s risk of 
exposure or infection with TB (study participants 2 to 4 years of age with a written 
documentation of BCG vaccination) at Screening. If a study participant has had a recent 
radiograph of the chest within approximately [ADDRESS_887724]/pulmonary physician who is specifically required to look for evidence of active 
TB or inactive TB.  
Radiographic findings suggestive of inactive TB or active TB may include but are not limited 
to: api[INVESTIGATOR_19529] l fibrosis, pleural thickening, pulmonary nodules, fibrotic scars, calcified 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887725] x -ray (or, if  done, Computed Axial Tomography of the Chest) must be negative for 
TB infection as determined by a qualified radiologist/pulmonary physician. All chest imaging 
(particularly x -rays) should be available for review by [CONTACT_658326].  
[IP_ADDRESS].2   Interferon -gamma release assay (IGRA test)  
The IGRA (QuantiFERON®-TB GOLD In -Tube test) is the protocol -required method of 
screening for TB in study participants from [ADDRESS_887726] be done during the  protocol -defined Screening window.  
[IP_ADDRESS].3   Tuberculin Purified Protein Derivative ([COMPANY_003] skin test)  
In study participants from 2 to 4 years of age (except for study participants 2 to 4 years of age 
with a written documentation of BCG vaccination), the [COMPANY_003] skin test must be administered 
during Screening or within the [ADDRESS_887727] administration guidance:  
The [COMPANY_003] skin test should be administered by a qualified health care profession al. The 
injection is made intradermally into the inner surface of the forearm using a 27 -gauge needle 
and tuberculin syringe using one -tenth milliliter of [COMPANY_003] (5TU [COMPANY_003] -S or 2TU of [COMPANY_003] -RT 23). 
If necessary, a site on the anterior thigh may be used. The site  on the forearm used for 
administration should be free of lesions and away from superficial veins. A discrete, pale 
elevation of the skin (a wheal) [ADDRESS_887728] be interpreted by a trained health care professional between 48 and 
72 hours after administration. The reading should be done in a good light, with the  forearm 
slightly flexed at the elbow. The presence or absence of induration, as determined by 
[CONTACT_658327]. The diameter of induration 
is measured transversely to the long axis of the forearm and rec orded in millimeters. 
Erythema should not be measured. An induration greater than or equal to 5mm is considered 
positive for the purposes of this study; regardless of study participant’s history of vaccination 
with BCG. Study participants are not permitted  to read their own [COMPANY_003] skin tests. If a study 
participant fails to return within [ADDRESS_887729] should not be applied to study participants with the following history:  
 History of severe positive [COMPANY_003] reaction, or  
 History of a positive [COMPANY_003] skin test  
 History of BCG vaccination regardl ess of time since vaccination  
 History of positive IGRA test (or 2 indeterminate IGRA tests)  
[IP_ADDRESS]  TB questionnaire (evaluation of signs and symptoms associated with 
TB and guidelines for evaluating exposure risk)  
A questionnaire “Evaluation of Signs a nd Symptoms of Tuberculosis” will be provided as a 
source document (see Appendix 17.9). The questionnaire will assist study sites with the 
identification of study participants that may require prophylactic therapy for TB as well as 
suspect new cases of act ive TB. In this study, the TB questionnaire will be completed for 
study participant and parent/caregiver at the following visits: Screening, Baseline, Weeks 12 
and 24, every 16 weeks thereafter, and at the Early Discontinuation/End of Treatment Visit.  
Responses of “yes” to any of the items on the questionnaire may indicate that a study 
participant’s risk of exposure or infection with TB has increased. This should prompt the 
Investigator to further examine the circumstances and consider initiating investiga tions 
necessary to rule out infection with TB. Depending on the outcome of the investigations, the 
Investigator will determine if prophylaxis or treatment for TB is required. Any presumptive 
diagnosis or diagnosis of LTB infection or active TB is a reporta ble event; refer to Section 
10.2.2 for details. The Investigator is to complete and submit the TB follow -up form 
provided.  
Change #82  
Section 11.1 PedACR30, PedACR50, PedACR70, and PedACR90 clinical response, the 
fourth bullet:  
 CHAQ completed by [CONTACT_308489] (including the Parent's Assessment of Arthritis 
Pain [VAS]) (Appendices 17.1 and 17.2)  
Has been changed to:  
 CHAQ completed by [CONTACT_308489] (Appendix 17.1)  
Change #83  
Section 11.1 PedACR30, PedACR50, PedACR70, and PedACR90 clinical response, the 
bolded sentence at the end of the section:  
Documentation of the assessment of all 6 core set measures will be submitted to UCB or 
designee for immediate review of completeness at Week 0 (Baseline), Week 16, and 
Week  56, while the study partic ipant is still on site.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 162 of 280 Has been changed to:  
Documentation of the assessment of all 6 core set measures will be submitted to UCB or 
designee for immediate review of completeness at Week 0 (Baseline), Week 16, Week 24, 
and Week  56, while the study participa nt is still on site.  
Change #84  
Section 11.2 PRINTO/PRCSG standard joint examination, second paragraph, the second 
sentence:  
The assessment for swelling is made on [ADDRESS_887730].  
Has been changed to:  
The assessment for swelling is made on [ADDRESS_887731].  
Change #85  
Section 11.5 Childhood Health Assessment Questionnaire (CHAQ), third paragraph, the third 
sentence:  
The same parent/caregiver should complete the questionnaires for each visit.  
Has been changed to:  
Preferably, the s ame parent/caregiver should complete the questionnaires for each visit. The 
questionnaire will not be collected if the study participant is not living with a parent/caregiver 
at least part -time, ie, if the parent/caregiver is not able to answer the questio ns appropriately.  
Change #86  
Section 11.6 Parent’s Assessment of Arthritis Pain (VAS), second paragraph, the third 
sentence:  
The same parent/caregiver should complete the scale for each visit.  
Has been changed to:  
Preferably, the same parent/caregiver sho uld complete the scale for each visit. The scale will 
not be completed if the study participant is not living with a parent/caregiver at least part -
time, ie, if the parent/caregiver is not able to answer the question appropriately.  
Change #87  
Section 11.7  Parent’s Global Assessment of Overall Well -Being (VAS), second paragraph, 
the third sentence:  
The same parent/caregiver should complete the scale for each visit.  
Has been changed to:  
Preferably, the same parent/caregiver should complete the scale for each visit. The scale will 
not be completed if the study participant is not living with a parent/caregiver at least part -
time, ie, if the parent/caregiver is not able to answer the questio n appropriately.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 163 of 280 Change #88  
Section 11.9 Juvenile Arthritis Disease Activity Score 75 -joint (JADAS -75), the heading and 
the first paragraph:  
11.9 Juvenile Arthritis Disease Activity Score 75 -joint (JADAS -75) 
The change in the JADAS -75 from Baseline will b e assessed. The JADAS -75 is a composite 
disease activity score based on a 75 -joint count and includes the measures (normalized as 
needed): Physician’s Global Assessment of Disease Activity (VAS) (0 to 10), the Parent’s 
Global Assessment of Overall Well -Being (VAS) (0 to 10), the active joint count (0 to 75), 
and CRP (0 to 10) (Consolaro et al, 2009; Nordal et al, 2010).  
Have been changed to:  
11.9 JADAS  
The change in the JADAS from Baseline will be assessed. The JADAS -71 is a composite 
disease activity scor e based on a 71 -joint count and includes the measures (normalized as 
needed): Physician’s Global Assessment of Disease Activity (VAS) (0 to 10), the Parent’s 
Global Assessment of Overall Well -Being (VAS) (0 to 10), the active joint count (0 to 71), 
and CRP  (0 to 10) (Consolaro et al, 2009; Nordal et al, 2010).  
Change #[ADDRESS_887732] paragraph, the fifth 
bullet:  
 Physician’s Global Assessment of Disease Activity score of ≤5mm on a 100mm VAS  
Has been  changed to:  
 Physician’s Global Assessment of Disease Activity score of best possible on the scale 
used (0mm on the 100mm VAS)  
Change #90  
Section 11.11 Duration of morning stiffness (DMS), the second sentence:  
The study participant/caregiver will be asked the following question (Kirwan, JR and 
Reeback TS, 1986):  
Has been changed to:  
The study participant/caregiver will be asked the following question (Kirwan and Reeback, 
1986):  
Change #91  
Section 11.12 Faces Pain Scale -Revised (FPS -R), the following has bee n added at the end of 
the first paragraph:  
Study participants enrolled at 5 to 11 years of age will continue with the FPS -R when 
reaching 12  years of age. Completion of the FPS -R will not be required for study participants 
enrolled at 2 to 4  years of age i f they reach 5 years of age during the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 164 of 280 Change #92  
Section 11.13 Patient’s Assessment of Arthritis Pain (JIA Pain VAS), the first sentence:  
In the JIA Pain VAS, study participants ages 12 to 17 years are asked the following question 
“How much pain ha ve you had because of your illness today (acute version)/in the past week 
(standard version)?” (as applicable).  
Has been changed to:  
In the JIA Pain VAS, study participants aged 12 years or older are asked the following 
question “How much pain have you had  because of your illness today (acute version)/in the 
past week (standard version)?” (as applicable).  
Change #93  
Section 11.14 Fatigue Assessment Scale (NRS), fourth paragraph, the third and fourth 
sentences:  
The same parent/caregiver should complete the questionnaires for each visit. The 
questionnaire should be checked by [CONTACT_658290].  
Have been changed to:  
Preferably, the same parent/caregiver should complete the scale for each visit. The scale will 
not be completed if the study partic ipant is not living with a parent/caregiver at least part -
time, ie, the parent/caregiver is not able to answer the question appropriately. The scale 
should be checked by [CONTACT_658290].  
Change #[ADDRESS_887733] paragraph:  
For further information please see the instructions provided on the worksheet.  
Change #[ADDRESS_887734] sentence:  
Source documents that are computer -generated and stored electronically must be printed for 
review by [CONTACT_2037] (eg, ECG reports).  
Has been changed to:  
Source documents that are computer -generated and stored electronic ally do not need to be 
printed if the electronic medical record system at the investigational site is 21CFR Part [ADDRESS_887735] be printed for 
review by [CONTACT_2037] (eg, ECG reports).  
Chang e #[ADDRESS_887736] 
paragraph:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 165 of 280 The procedures for conducting SDV on computerized study participant records (if the system 
is 21CFR Part 11 compliant) are the same as those for paper re cords. Source data verification 
is performed by [CONTACT_658298].  
Change #[ADDRESS_887737] sentence:  
If, in the results of the first interim analysis, less than 50% of the study population achieves  at 
least a PedACR30 response at Week 16, the study will be discontinued.  
Has been changed to:  
If, in the results of the first interim analysis, less than 50% of the study population achieves a 
PedACR30 response at Week 16, the study will be discontinued.  
Change #98  
Section 13.1 Definition of analysis sets, the following set has been removed:  
 The Per -Protocol Set (PPS) will consist of study participants in the FAS who have 
completed a prespecified minimal exposure to the treatment regimen without any 
import ant protocol deviations that may influence the validity of the efficacy data.  
Change #99  
Section 13.1 Definition of analysis sets, the following set has been added:  
 The Pharmacokinetic -Pharmacodynamic (PK -PD) Population will consist of all study 
participa nts in the SS who have at least [ADDRESS_887738]-Baseline PedACR30 assessment.  
Change #100  
Section 13.2.1 Data presentation, the following sentence has been added at the beginning of 
the paragraph:  
For safety and efficacy analyses, study participants will be grouped by [CONTACT_658299] (10  to <20kg [22 to <44lb], 20 to <40kg [44 to <88lb], and ≥40kg [≥88lb]). Selected 
analyses will also group study participants by [CONTACT_658300], concomitant M TX 
use, and anti -CZP antibody status.  
Change #[ADDRESS_887739] sentence:  
Approximately 70 centers are planned to enroll 125 study participants into this study.  
Has been changed to:  
Approximately 55 centers are planned to enroll 125 study participants into this study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 166 of 280 Change #[ADDRESS_887740] paragraph:  
Selected safety summaries will be presented overall as well as by [CONTACT_654] (2 to 5 years, 6  to 
11 years, and 12 to 17 years) and weight strata (10 to <20kg [22 to <44lb], 20 to <40kg [44 to 
<88lb], and ≥40kg [≥88lb]) and study participants with or without concomitant MTX use. 
Safety summaries will be based upon the SS (study participants who were enrolled and took 
at least 1 dose of study medication).  
Has been changed to:  
Selected safety summaries will be presented overall and by [CONTACT_658303], as well as 
by [CONTACT_654] (2 to 5 years, 6 to 11  years, and 12  to 17 years), by [CONTACT_658304], and by 
[CONTACT_14181]-CZP antibody status. Safety summaries will be based upon the SS (study participants 
who were enrolled and took at least 1 dose of study medication).  
Change #103  
Section 13.5 Planned efficacy and health outcomes analyses, the fourth paragraph:  
For PedACR30,  PedACR50, PedACR70, and PedACR90, results will be presented overall as 
well as by [CONTACT_654] (2 to 4 years, 5 to 11 years, and 12 to 17 years) and weight strata (10 to <20kg 
[22 to <44lb], 20 to <40kg [44 to <88lb], and ≥40kg [≥88lb]) and study participants with  or 
without concomitant MTX use.  
Has been changed to:  
For PedACR30, PedACR50, PedACR70, and PedACR90, results will be presented overall 
and by [CONTACT_658303], as well as by [CONTACT_654] (2 to 5  years, 6 to 11 years, and 12  to 
17 years), by [CONTACT_658328] u se, and by [CONTACT_14181] -CZP antibody status.  
Change #104  
Section 13.5 Planned efficacy and health outcomes analyses, the eighth bullet below the 
fourth paragraph has been removed:  
 Shifts by [CONTACT_658316].  
Change #[ADDRESS_887741] and second 
sentences:  
Data collected after the taking of rescue medication will be treated as missing/non -response 
in all analyses except where specifically stated otherwise. See Section 7.8.[ADDRESS_887742] of 
medications which, if commenced after Week 16, would result in data at only the next 
scheduled visit (and not all subsequent visits) being treated as missing/non -response.  
Has been changed to:  
Data collected after the taking of rescue medication will be tr eated as missing for continuous 
efficacy endpoints and non -response for binary efficacy endpoints in all analyses except 
where specifically stated otherwise. See Section 7.8.[ADDRESS_887743] of medications which would 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 167 of 280 result in data at only the next scheduled visit (and not all subsequent visits) being treated as 
missing/non -response.  
Change #106  
Section 13.7 Planned interim analysis and data monitoring:  
Following completion of Week 12 (Visit 7) by [CONTACT_2669] 20 study participants (minimum 
6 study participants in  each age group: 2 to 5 years, 6 to 11 years, and 12 to 17 years), PK 
data will be reviewed by [CONTACT_658329]. The plasma concentration analysis may be 
done in [ADDRESS_887744] 20  study participants in total complete Week 12 (Visit 7) 
before [ADDRESS_887745] completed (see Section 
5.1). 
Comparisons will be made between the geometric mean and median values for th e pediatric 
and adult study participants, as well as between the individual pediatric data and the adult 5th 
and 95th percentile and minimum and maximum observed values.  
If the pediatric plasma concentrations demonstrate that the geometric mean and median 
concentrations are below the adult 5th percentile or above the 95th percentile, the PK data will 
be used to re -evaluate the weight -based dose adjustment algorithm for pediatric study 
participants. If necessary, a revised pediatric dose algorithm will be de rived. Any change in 
dose regimen will require a protocol amendment prior to implementation.  
Population PK or PK/PD analyses will not be performed separately on this initial [ADDRESS_887746] study participant has reached the Week 16 Visit (Visit 8, including collection of 
the Week 16 postdose blood samples), the database will be cut and a full interim analysis will 
be performed based upon 16 weeks of exposure for each individual (or all data f or those cases 
who withdrew before this timepoint). This will be used to determine whether the study will 
continue or not. Given the descriptive nature of the data presentations, there are no statistical 
implications of this interim analysis.  
A second full  interim analysis will be performed upon 56 weeks of exposure (Visit 14)  and 
will be used for the initial submission of results for regulatory purposes . 
Further interim analyses may be performed at the Sponsor’s discretion as required.  
Has been changed to:  
Interim analysis of PK data will compare CZP plasma concentration data from this study with 
CZP plasma concentrations observed previously in adult study participants with RA. This 
plasma concentration analysis will be done on an ongoing basis throughout t he study, starting 
when [ADDRESS_887747] completed Week  12 (Visit 7).  
Comparisons will be made between the Week [ADDRESS_887748] completed the Week 16 (Visit 8) assessments, an 
interim analysis of PedACR30 response rates will be performed and the study will be 
discontinued if less than 50% of the study population achieves a PedACR30 response at 
Week 16. Given the descriptive nature of the data presentations, there are no statistical 
implications of this interim analysis.  
After the last study participant has reached the Week 24 Visit (Visit 10), the database will be 
cut and a full interim analysis of all safety and efficacy endpoints will be performed based 
upon 24  weeks of exposure for each individual (or all data for those cases who withdrew 
before this timepoint).  
A second full interim analysis of all safety and efficacy endpoints will be performed based 
upon 56 weeks of exposure (Visit 14).  
Further interim analyses may be performed at the Sponsor’s discretion as required.  
A DSMB will periodically review all emergi ng safety data. The DSMB members will be 
independent of the Sponsor and Investigators. The DSMB members will be informed by [CONTACT_658330] (or designee) of all SAEs at the time of expedited reporting and 
will review periodically all emergin g safety data (eg, SAEs, AEs, safety laboratory data). 
Based on the safety data, the DSMB can recommend modifying/stoppi[INVESTIGATOR_10098].  
Change #107  
Section 16 References, the following reference has been added:  
Centers for Disease Control and Prevention. htt p:www.cdc.gov/TB/topic/testing/default.htm. 
Accessed [ADDRESS_887749] -Baseline samples in RA0043 was performed in 
combination with PK data from studies in Western (mainly Caucasian) adult study 
participants with RA and in Japanese adult study participants with RA . The interim PopPK 
analysis and subsequent simulations indicated that in all weight groups (10 to <20kg, 20 to 
<40kg, and ≥40kg), a higher exposure in terms of the maximum plasma concentratio n (C max) 
and the area under the curve (AUC) is likely to be observed in the population of children and 
adolescents with the current dosing algorithm. This difference is not due to body mass/weight 
differences alone, and therefore an additional adjustment t o the dosing algorithm to account 
for these unexplained differences is necessary in order to maintain children and adolescents 
within the adult exposure ranges. The clinical relevance in terms of efficacy or safety is 
currently unknown.  
Based on the result s of the interim PopPK analysis, new enrollment into RA0043 will be 
suspended, effective 17 Jul 2013, and the dose for study participants already enrolled in 
RA0043 will be reduced with Protocol Amendment 4. An overall dose reduction for pediatric 
study pa rticipants of 50% of the dose currently used in RA0043 is proposed to provide a 
pragmatic dosing regimen that will yield a closer match to the adult plasma concentration 
range achieved in adults with the approved label for RA (CZP  400mg at Weeks  0, 2, and 4 
followed by [CONTACT_18322]  200mg Q2W thereafter).  
A summary table of the proposed revised dosing recommendations for loading and treatment 
doses in RA0043 based on the PopPK model simulations is provided below.  
Table  17‒1 Proposed revised dosing recommendation based on PopPK 
model simulations  
Weight range  Loading dose  
(Weeks 0, 2, and 4)  Treatment dose  
(Week 6 and onwards)  
10 to <20kg (22 to <44lb)  50mg Q2W  50mg Q4W  
20 to <40kg (44 to <88lb)  100mg Q2W  50mg Q2W  
≥40kg (≥88lb)  200mg Q2W  100mg Q2W  
PopPK=population pharmacokinetic; Q2W=every 2 weeks; Q4W=every 4 weeks  
The reduced loading dose will only apply to  study participants already enrolled in RA0043 
who do not achieve persistent CID and resume CZP treatment after implementation of 
Protocol Amendment 4.  
A dose reduction of 50% can be implemented immediately by [CONTACT_658331] a study delay to acquire new drug supply. Following the change of dose, t he ≥40kg 
(≥88lb) weight group will use the 0.5ml PFS (CZP  100mg)  for treatment doses , while the 20 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 170 of 280 to <40kg (44 to <88lb ) weight group will use the 0.25ml PFS  (CZP  50mg)  for treatment 
doses . As a PFS containing 25mg is not available, the lowest body weight  category (10 to 
<20kg [22 to <44lb]) will use the 0.25ml PFS  (CZP  50mg)  administered with a [ADDRESS_887750] been 
added to the tabular schedule of study assessments to ensure that the 50% dose reduction will 
result in plasma concentrations within the target range of those observed in  adults. Additional 
Unscheduled Visits have been implemented, as required, in order to closely monitor the study 
participants over a period of [ADDRESS_887751] been made throughout the protocol:  
 The description of the dose regimen has been changed throughout the protocol to reflect 
the reduction of the treatment dose for study participants in the 3 weight categories.  
 Additional PK samples after the dose change have been added throughout the protocol.  
 The term “level” has been chang ed to “concentration” throughout the protocol for CZP 
plasma concentrations and antibody concentrations. This global change is not listed under 
the specific changes.  
 The timing of predose and postdose vital sign assessments has been added throughout 
Sectio n 8 for clarification, where applicable. This global change is not listed under the 
specific changes.  
 The following clarification has been added in the description of timepoints for efficacy 
assessments in Section 11: “(including Unscheduled Visits that ar e related to the dose 
change implemented with Protocol Amendment 4).” This global change is not listed 
under the specific changes.  
Specific changes  
This section displays the modifications in this amendment compared with the previous 
version of the protocol  dated 06 May 2013. The changes are displayed in the order of 
appearance.  
Change #1  
On the SPONSOR DECLARATION page, the name [CONTACT_658368]:  
 
Has been changed to:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 171 of 280 Change #[ADDRESS_887752] details of the Clinical 
Program Director:  
Name:   
[CONTACT_2761]:  [ADDRESS_887753]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax:  
Have been changed to:  
Name:   
[CONTACT_2761]:  [ADDRESS_887754]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax:  
Change #[ADDRESS_887755] OF ABBREVIATIONS, the following abbreviation:  
Q2W  every 2 weeks  
Has been changed to:  
Q2W, Q4W  every 2 weeks, every 4 weeks  
Change #[ADDRESS_887756] sentence : 
Certolizumab pegol will be administered as a fixed dose based on weight every 2 weeks 
(Q2W) throughout the study consisting of 3 loading doses at Weeks 0, 2, a nd 4 
(minimum=100mg, maximum=400mg) followed by a treatment dose (minimum=50mg, 
maximum=200mg).  
Has been changed to:  
Certolizumab pegol will be administered as a fixed dose based on weight throughout the 
study consisting of 3 loading doses at Weeks 0, 2, a nd 4 (minimum=50mg every 2 weeks 
[Q2W], maximum=200mg Q2W) followed by a treatment dose (minimum=50mg every 
4 weeks [Q4W], maximum=100mg Q2W). With the implementation of Protocol 
Amendment  4, the reduced loading dose applies only for already enrolled study  participants 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 172 of 280 who resume CZP treatment after nonpersistent Clinically Inactive Disease (CID). Prior to 
implementation of Protocol Amendment  4, the minimum and maximum loading doses in the 
study were CZP 100mg Q2W and CZP  400mg Q2W, respectively, and the mi nimum and 
maximum treatment doses were CZP  50mg Q2W and CZP  200mg Q2W, respectively.  
Change #5  
Section 1 Summary, eighth paragraph , the sixth and seventh sentences : 
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicat e that no change to the dosing algorithm is required. If future analyses indicate that 
plasma levels of JIA study participants are outside of the exposure range observed in previous 
adult RA studies, the dosing algorithm may be changed via a protocol amend ment.  
Has been changed to:  
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The protocol stated that if 
future analyses indicate that plasma concentrations o f JIA study participants are outside of 
the exposure range observed in previous adult RA studies, the dosing algorithm may be 
changed via a protocol amendment.  
Change #6  
Section 1 Summary, the following has been added below the eighth paragraph:  
Results o f an interim population pharmacokinetic (PopPK) analysis suggest that while 
observed CZP plasma concentrations have remained in the adult range, they have been at the 
upper end of the distribution. Simulations predict that for some study participants in RA 0043 
receiving the initially determined loading doses up to Week 4 (Visit 5), plasma 
concentrations are likely to exceed the range previously seen in adult study participants 
receiving CZP  400mg Q2W. Furthermore, plasma concentrations of study participants  
receiving the initially determined treatment dose after Week 4 (Visit 5) are predicted to 
exceed the concentration range observed in adults receiving CZP 200mg Q2W. Based on 
these findings, the dosing regimen will be changed with Protocol Amendment 4, and  the 
doses to be administered will be reduced by 50% for all weight groups. This dose change is 
intended to achieve plasma concentrations that are similar to the effective concentrations 
observed in previous studies in adult study participants with RA. Add itional assessments of 
the CZP plasma concentration after the change in dose will be performed to ensure that the 
50% dose reduction will result in plasma concentrations within the target range of those 
observed in adults.  
Change #[ADDRESS_887757] sentences:  
Certolizumab pegol will be administered as a fixed dose based on weight, Q2W throughout 
the study (see Table 7 -1). At Baseline (Week 0, Visit 2) eligible study participants will begin 
with 3  loading doses of CZP at Weeks  0, 2, and 4 (minimum=100mg, maximum=400mg) 
followed by a treatment dose for the duration of the study (minimum=50mg, 
maximum=200mg).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 173 of 280 Has been changed to:  
Certolizumab pegol will be administered as a fixed dose based on weight th roughout the 
study (see Table 7 -1). At Baseline (Week 0, Visit 2) eligible study participants will begin 
with 3  loading doses of CZP at Weeks  0, 2, and 4 (minimum=50mg Q2W, maximum=200mg 
Q2W) followed by a treatment dose for the duration of the study (mini mum=50mg Q4W, 
maximum=100mg Q2W). With the implementation of Protocol Amendment  4, the reduced 
loading dose applies only for already enrolled study participants who resume CZP treatment 
after nonpersistent CID. Prior to implementation of Protocol Amendment  4, the minimum 
and maximum loading doses in the study were CZP 100mg Q2W and CZP  400mg Q2W, 
respectively, and the minimum and maximum treatment doses were CZP  50mg Q2W and 
CZP 200mg Q2W, respectively.  
Change #[ADDRESS_887758] sentences:  
Interim CZP plasma concentration data available at the time of Protocol Amendment [ADDRESS_887759] been changed to:  
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The protocol stated that if 
future analyses indicate that plasma concentrations are outside of the exposure range 
observed in previous studies with adults, the dosing algorithm may be changed via a protocol 
amendment.  
Change #9 
Section 5.1 Study description, the following has been added at the end of the section:  
Results of an interim PopPK analysis conducted in Jun  [ADDRESS_887760] that for some study participants in RA0043 receiving the 
initially determined loading doses up to Week 4 (Visit 5), plasma concentrations are likely to 
exceed the range previously seen in adult study pa rticipants receiving CZP  400mg Q2W. 
Furthermore, plasma concentrations of study participants receiving the initially determined 
treatment dose after Week 4 (Visit 5) are predicted to exceed the concentration range 
observed in adults receiving CZP  200mg Q2W . Based on these findings, the dosing regimen 
will be changed with Protocol Amendment 4, and the doses to be administered will be 
reduced by 50% for all weight groups. This dose change is intended to achieve plasma 
concentrations that are similar to the ef fective concentrations observed in previous studies in 
adult study participants with RA. Additional assessments of the CZP plasma concentration 
after the change in dose will be performed to ensure that the 50% dose reduction will result in 
plasma concentra tions within the target range of those observed in adults.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 174 of 280 Change #[ADDRESS_887761] line:  
Planned Last Study participant, First Visit – 3Q/4Q 2013  
Has been changed to:  
Planned Last Study participant, First Vi sit – 3Q/4Q 2013 (to be confirmed)  
Change #11  
Section 5.2 Schedule of study assessments, footnotes “b,” “u,” “v,” and “y” in Table 5 -1: 
b Vital signs, concomitant medications, concomitant procedures, and AEs must be assessed at every 
Unscheduled Visit. Other PK and safety assessments should be performed as related to nature of the visit.  
 
u CZP plasma level and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 24. A postdose CZP 
plasma sample will be collected at approximately 5 to 7 days follow ing the Week 16 Visit (ie, requires 
an additional clinic site visit for blood collection at Week 17).  
v CZP plasma level and anti -CZP antibodies to be measured at Weeks 32, 40, and 48 and every 24 weeks 
thereafter.   
 
y After Week 4 (Visit 5) study particip ants/caregivers may administer CZP Q2W at home between scheduled 
study visits. See Section 7.[ADDRESS_887762] been changed to:  
b Vital signs, concomitant medications, concomitan t procedures, and AEs must be assessed at every 
Unscheduled Visit. Other PK and safety assessments should be performed as related to nature of the visit. 
For Unscheduled Visits related to the dose change with Protocol Amendment 4, see Sections 7.2.1 and 
8.6.1. For these Unscheduled Visits, the same visit window applies, ie, ±3 days.  
 
u CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 24. A postdose 
CZP plasma sample will be collected at approximately 5 to 7 days following the Week 16 Visit (ie, 
requires an additional clinic site visit for blood collection at Week 17).  For study participants already 
enrolled and treated prior to the implementation of Protocol Amendment 4 and hence undergoing a 
reduction of their do se, additional PK samples will be collected prior to dosing at the visit the dose change 
occurs and at the next 3 site visits following the dose change, ie, additional PK samples will be collected at 
the Unscheduled Visits or at the regular visits if not a lready planned per regular schedule. Afterwards, the 
regular PK sampling schedule applies.  
v CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 32, 40, and 48 and every 
24 weeks thereafter.  For study participants already enrolled and treated prior to the implementation of 
Protocol Amendment 4 and hence undergoing a reduction of their dose, additional PK samples will be 
collected prior to dosing at the visit the dose change occurs and at the next 3 site visits following the dose 
change,  ie, additional PK samples will be collected at the Unscheduled Visits or at the regular visits if not 
already planned per regular schedule. Afterwards, the regular PK sampling schedule applies.  
 
y After Week 4 (Visit 5) study participants/caregivers may a dminister CZP Q2W (or Q4W for the lowest 
weight group) at home between scheduled study visits. See Section 7.2 regarding training and option for 
continued site administration.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 175 of 280 Change #[ADDRESS_887763] and fourth sentences in the p aragraph below Table 5 -2: 
The intention is to study the equivalent dose regimen in children and adolescents, reducing 
the dose of CZP for pediatric study participants with body weights between 20 to <40kg 
(44 to <88lb) to CZP 200mg at Weeks 0, 2, and 4 fol lowed by [CONTACT_18322] 100mg Q2W (ie, 50% of 
the recommended adult dose). The dose of CZP will be reduced further to 25% of the adult 
dose for study participants with body weights 10 to <20kg (22 to <44lb) (ie, CZP 100mg at 
Weeks 0, 2, and 4 followed by [CONTACT_18322] 50mg Q2W ) (see Table 7 -1). 
Have been changed to:  
The intention in RA0043 is to study the equivalent dose regimen in children and adolescents. 
Initial predictions, based on allometric scaling of PK data from adults, suggested that this 
could be achieved by [CONTACT_658332] 20 to <40kg (44 to <88lb) to CZP 200mg at Weeks 0, 2, and 4 followed by 
[CONTACT_18322] 100mg Q2W (ie, 50% of the recommended adult dose), and by [CONTACT_658333] 25% of the adult dose for study participants with body weights 10 to <20kg (22 to <44lb) 
(ie, CZP  100mg at Weeks 0, 2, and 4 followed by [CONTACT_18322] 50mg Q2W). During the course of the 
study, results from the ongoing interim PK analysis and an interim PopPK analysis conducted 
in Jun 2013 indicated that plasma concentrations within the range previously seen in adult 
study participants receiving CZP 200mg Q2W would be achieved if the dose in RA0043 was 
reduced to 50%. Therefore, the treatment doses in this study will be reduced furth er with 
Protocol Amendment  4 so that study participants with body weights between 20 and <40kg 
(44 to <88lb) will receive CZP  50mg Q2W, and study participants with body weights of 
≥40kg (≥88lb) will receive CZP  100mg Q2W (see Table 7 -1). The optimal treatm ent dose 
estimated in the PopPK model for the lowest weight group would be CZP  25mg Q2W, 
however, the lowest available dose size is CZP  50mg. Thus, study participants with body 
weights of 10  to <20kg (22 to <44lb) will receive CZP  50mg Q4W to achieve a 50%  
reduction.  
Change #13  
Section 5.4.2 Dose selection, the paragraph at the end of the section:  
The choice of dose and the weight -based dose -adjustment algorithm is supported by 
[CONTACT_658253]/PD exposure response model developed in adult RA study participants, corrected for 
pediatric demographics (C87079 addendum [ADDRESS_887764] 2008). Results of these simulations show 
that all age groups exhibit similar exposures (C max and AUC T) to those of adults over the 
Week 14 to Week 16 dosing interval, with the pediatric/adult ratio of the median predicted 
values of PK parameters ranging from 1.03 to 1.19 for C max and from 0.97 to 1.18 for AUC T. 
The similarities in exposures are reflected in the probabi lity of ACR20 response, which are 
similar for all age groups at Week 16 (pediatric/adult ratio of the median predicted values 
ranging from 1.08 to 1.10). These simulations were performed upon the assumption that 
disease progression and response rate for a given exposure are similar in children and adults.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 176 of 280 Has been changed to:  
The original choice of dose and the weight -based dose -adjustment algorithm, prior to 
Protocol Amendment 4, was supported by [CONTACT_658334] n using the PopPK model and PK/PD exposure response model developed in adult 
RA study participants, corrected for pediatric demographics (C87079 addendum [ADDRESS_887765] 
2008). Results of these simulations showed that all age groups exhibit similar exposures 
(Cmax and AUC T) to those of adults over the Week 14 to Week 16 dosing interval, with the 
pediatric/adult ratio of the median predicted values of PK parameters ranging from 1.03 to 
1.19 for C max and from 0.97 to 1.18 for AUC T. The similarities in exposures were reflected in 
the probability of ACR20 response, which are similar for all age groups at Week 16 
(pediatric/adult ratio of the median predicted values ranging from 1.08 to 1.10). These 
simulations were performed upon the assumption that disease progression and response rate 
for a given exposure are similar in children and adults. The revised dose and weight -based 
dose adjustment algorithm was based on a PopPK analysis and simulation using data from 
[ADDRESS_887766] -Baseline plasm a concentrations of CZP available 
prior to Protocol Amendment 4.  
Change #[ADDRESS_887767] sentence:  
Throughout the study, CZP dosing is fixed dose based on weight  and given Q2W.  
Has been changed to:  
Throughout the study, CZP dosing is fixed dose based on weight  and given Q2W, with 
exception of the lowest weight group, who will receive the treatment dose Q4W following 
implementation of Protocol Amendment 4.  
Change #[ADDRESS_887768] sentence:  
Study participants start with 3  loading doses of CZP at Weeks 0, 2, and 4 (minimum=100mg, 
maximum=400mg) followed by a treatment dose for the duration of the study 
(minimum=50mg, maximum=200mg).  
Has been change d to:  
Study participants start with 3  loading doses of CZP at Weeks 0, 2, and 4 (minimum=50mg 
Q2W, maximum=200mg Q2W) followed by a treatment dose for the duration of the study 
(minimum=50mg Q4W, maximum=100mg Q2W). With the implementation of Protocol 
Amen dment 4, the reduced loading dose applies only for already enrolled study participants 
who resume CZP treatment after nonpersistent CID.  
Change #16  
Section 7.2 Treatments to be administered, Table 7 -1: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 177 of 280 Table 7 -1 Dosing administration of CZP  
Weight range  Loading dose – 
Weeks 0, 2, and 4  
(mg/kg dose range)  Treatment – 
Week 6 and onwards  
(mg/kg dose range)  
10 to <20kg  
(22 to <44lb)  100mg  
(5-10mg/kg)  
1 x 0.5mL inj  50mg  
(2.5-5mg/kg)  
1 x 0.25 mL inj  
20 to <40kg  
(44 to <88lb)  200mg  
(5-10mg/kg)  
1 x 1mL inj  100mg  
(2.5-5mg/kg)  
1 x 0.5mL inj  
≥40kg  
(≥88lb)  400mg  
(<10mg/kg)  
2 x 1mL inj  200mg  
(<5mg/kg)  
1 x 1mL inj  
CZP=certolizumab pegol; inj=injection  
Note: A study participant should only change dosing category during the course of the study if their weight 
crosses the 40kg/88lb boundary due to a weight change of >5kg (11lb) (eg, a 39.0kg study participant 
becomes 44.1kg) or crosses the 20kg/44lb boundary due to a weight change of >2.5kg (5.5lb) (eg, a 19.0kg 
study participant becomes 21.6kg).  
Has been chang ed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 178 of 280 Table 7 -1 Dosing administration of CZPa  
Weight range  Loading dose – 
Weeks 0, 2, and 4b 
(mg/kg dose range)  Treatment – 
Week 6 and onwards  
(mg/kg dose range)  
10 to <20kg  
(22 to <44lb)  50mg Q2W  
(2.5-5mg/kg)  
1 x 0.25mL inj  50mg Q4W  
(2.5-5mg/kg)  
1 x 0.25mL inj  
20 to <40kg  
(44 to <88lb)  100mg Q2W  
(2.5-5mg/kg)  
1 x 0.5mL inj  50mg Q2W  
(1.25 -2.5mg/kg)  
1 x 0.25mL inj  
≥40kg  
(≥88lb)  200mg Q2W  
(<5mg/kg)  
1 x 1mL inj  100mg Q2W  
(<2.5mg/kg)  
1 x 0.5mL inj  
CZP=certolizumab pegol; inj =injection; Q2W=every  2 weeks; Q4W=every 4 weeks  
Note: A study participant should only change dosing category during the course of the study if their weight 
crosses the 40kg/88lb boundary due to a weight change of >5kg (11lb) (eg, a 39.0kg study participant 
becomes 44.1kg) or crosses the 20kg/44lb boundary due to a weight change of >2.5kg (5.5lb) (eg, a 19.0kg 
study participant becomes 21.6kg).  
a Note that Table 7 -1 describes the dosing administration of CZP after implementation of Protocol 
Amendment 4. Refer to Section  7.2.1  for the procedure to be taken f or study participants already enrolled 
and treated prior to the implementation  of Protocol Amendment 4 , and  who are  undergoing a  dose change.  
b With implementation  of Protocol Amendment 4, the reduced loading dose applies only  for study 
participants who are already enrolled and who resume CZP treatment after nonpersistent Clinically Inactive 
Disease.  
Change #[ADDRESS_887769] sentence:  
Study participants not achieving persistent CID and resuming treatment will re -start the 
fixed -dose CZP dosing based on their current weight with 3 loading doses of CZP 
administered Q2W over 6 weeks, followed by a treatment dose administered Q2W for the 
duration of the study (see Table  7-1). 
Has been change d to:  
Study participants not achieving persistent CID and resuming treatment will re -start the 
fixed -dose CZP dosing based on their current weight with [ADDRESS_887770] weight group after implementation of Protocol Amendment 4, for the duration 
of the study (see Table 7 -1). 
Change #18  
A new subsection has been added at the end of Section 7.2 Treatments to be administered:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 179 of 280 7.2.1  Procedure for dose change  (Protocol Amendment 4)  
With Protocol Amendment 4, the treatment dose in the study will be reduced by 50% for all 
weight groups.  
 The timepoint of the dose change is the next scheduled time of injection after the 
Informed Consent form related to the dose ch ange was signed. In case the next scheduled 
injection was planned for home dosing, the study participant will be requested to return to 
the clinic for an Unscheduled Visit for signing the Informed Consent form related to the 
dose change, administration of CZP, and to dispense the new supplies. Unused IMP 
dispensed previously needs to be returned.  
In case the study participant is not able to visit the site for that next scheduled injection, 
then the dose change must be performed at the next scheduled injecti on. 
 Study participants will be monitored at least every 4  weeks over a period of 12  weeks 
after the dose change, either at the regularly scheduled visits or at additional Unscheduled 
Visits. The Unscheduled Visits will be scheduled to match with the dosing  schedule, ie, 
the study medication will be administered at the day of the Unscheduled Visit. The 
Investigator should consult with the Medical Monitor in case of any questions related to 
the timing of the dose change or the Unscheduled Visits.    
 For study  participants undergoing a dose change prior to or at Week  12 (Visit  8), and 
who return for regularly scheduled visits every 4  weeks for a period of 12 weeks after 
the dose change, no additional Unscheduled Visits will be required.  
 For study participants u ndergoing a dose change after Week  12 (Visit  8), 1 or 2 
additional Unscheduled Visits will be required.  
For example, a study participant undergoing a dose change at Week  20 (Visit  9) will 
return for a regularly scheduled visit at Week  24 (Visit  10), will require an additional 
Unscheduled Visit at Week  28, and will return for the next regularly scheduled visit at 
Week  32 (Visit  11). 
A study participant who is undergoing a dose change at Week  40 (Visit  12) will 
require an Unscheduled Visit at Week  44, will r eturn for a regularly scheduled visit at 
Week  48 (Visit  13), and will require another Unscheduled Visit at Week  52. 
 Study participants undergoing the dose change at an Unscheduled Visit between the 
regular visits will be required to return at the latest af ter [ADDRESS_887771] 
Unscheduled Visit another 4  weeks later. For example, a stud y participant undergoing 
the dose change at Week 42 at the clinic will return for an Unscheduled Visit at Week 
46, then continue with the regular visit at Week 48 (Visit 13), and return for an 
additional Unscheduled Visit at Week 52 before continuing with the regular Week 56 
visit (Visit 14).  
 At Unscheduled Visits when the dose change occurs and following the dose change, the 
following will be assessed: AEs, concomitant medications and procedures, vital signs, 
hematology/biochemistry, as well as CRP, PRINTO /PRCSG standard joint examination, 
Physician’s Global Assessment of Disease Activity, CHAQ, and Parent’s Global 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 180 of 280 Assessment of Overall Well -Being to determine PedACR response rates. Assessments at 
regular visits will be done as scheduled, except for PK samp ling (see below).  
 A predose PK sample will be collected prior to administration of CZP at the visit the dose 
change occurs. Additional predose PK sampling after the change in dose will be 
performed at the next 3 site visits, ie, additional PK samples will be collected at the 
Unscheduled Visits or at the regular visit if not already planned per regular schedule.  
Change #19  
Section 8.4  Visits 5 to 10 (Weeks 4, 8, 12, 16, 20, and 24) , the 27th bullet point:  
 CZP plasma levels and anti -CZP antibodies (Weeks 4, 12, 16, and 24 only; predose.  
Study participants will return to the clinic site for a postdose CZP plasma sample  
approximately 5 to 7 days following the Week 16 visit .) 
Has been changed to:  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 4, 12, 16, and 24 only, OR if 
a dose change is performed at the current visit OR if the study participant’s dose was 
changed during [ADDRESS_887772] 3 visits following Protocol Amendment 4; predose.  
Study participants will return to the clinic site for a postdose CZP plasma sample  
approximately 5 to 7 days following the Week 16 visit .) 
Change #20  
Section 8.5  Visits 11 and continuing (Week 32 and every 8 weeks thereafter) , the 2 7th bullet 
point:  
 CZP plasma levels and anti -CZP antibodies (Weeks 32, 40, and 48 and every 24 weeks 
thereafter)  
Has been changed to:  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 32, 40, and 48 and every 
24 weeks thereafter , OR if a dose change is performed at th e current  visit OR if the study 
participant ’s dose was changed during [ADDRESS_887773] 3 visits  following Protocol 
Amendment 4) 
Change #[ADDRESS_887774] bullet point:  
 Vital signs  
Has been changed to:  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing, if dosing is applicable)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 181 of 280 Change #22  
Section 8.6 Unscheduled Visit, a new subsection has been added at the end of the section:  
8.6.1 Unscheduled Visit rela ted to dose change (Protocol Amendment  4) 
If required, study participants will return for an Unscheduled Visit to undergo the dose 
change upon implementation of Protocol Amendment 4. Study participants will be monitored 
at least every 4  weeks over a period  of 12  weeks after the dose change, either at the regularly 
scheduled visits or at additional Unscheduled Visits.  
The following will be assessed at this visit:  
 Administration of study medication  
 CZP plasma concentrations and anti -CZP antibodies (predose)  
 Adverse events  
 Concomitant medications and procedures  
 Vital signs (within approximately 15 minutes prior to dosing and [pulse and blood 
pressure only] approximately 30 minutes after dosing)  
 Hematology/biochemistry  
 CRP  
 PRINTO/PRCSG standard joint examination  
 Physician’s Global Assessment of Disease Activity (VAS)  
 CHAQ -parent reported  
 Parent’s Global Assessment of Overall Well -Being (VAS)  
 IXRS contact, if applicable  
Change #[ADDRESS_887775] paragraph:  
For study participants already enrolled and treated prior to the implementation of Protocol 
Amendment  4 and hence undergoing a reduction of their dose, additional PK samples will be 
collected prior to  dosing at the visit the dose change occurs and at the next 3 site visits 
following the dose change, ie, additional PK samples will be collected at either Unscheduled 
Visits or regular visits if not already planned per regular schedule. Afterwards, the reg ular PK 
sampling schedule applies.  
Change #[ADDRESS_887776] and second sentences:  
Interim CZP plasma concentration data available at the time of Protocol Amendment [ADDRESS_887777] been changed to:  
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The pro tocol stated that i f 
future analyses indicate that plasma concentrations are outside of the exposure range of those 
observed in previous studies with adults, the dosing algorithm may be changed via a protocol 
amendment, and if necessary additional interim analyses including PopPK, may be 
performed.  
Change #25  
Section 9 Assessment of pharmacokinetics and immunological variables,  the following has 
been added below the fifth paragraph:  
Results of an interim PopPK analysis conducted in Jun  [ADDRESS_887778] that for some study participants in RA0043 receiving the 
initially determined loading doses up to Week 4 (Visit  5), plasma concentrations are likely to 
exceed the range previously seen in adult study participants receiving CZP  400mg Q2W. 
Furthermore, plasma concentrations of study participants receiving the initially determined 
treatment dose after Week  4 (Visit 5)  are predicted to exceed the concentration range 
observed in adults receiving CZP  200mg Q2W. Based on these findings, the dosing regimen 
will be changed with Protocol Amendment 4, and the doses to be administered will be 
reduced by 50% for all weight group s. This dose change is intended to achieve plasma 
concentrations that are similar to the effective concentrations observed in previous studies in 
adult study participants with RA. Additional assessments of the CZP plasma concentration 
after the change in d ose will be performed to ensure that the 50% dose reduction will result in 
plasma concentrations within the target range of those observed in adults.  
Change #[ADDRESS_887779] paragraph:  
In addition, hematology, biochemistry, and CRP samples will be collected at Unscheduled 
Visits related to the dose change implemented with Protocol Amendment 4.  
Change #[ADDRESS_887780] sentence:  
Vital signs will be measured at Screening, Baseline, every visit through the Early 
Discontinuation/End of Treatment Visit, and the Final Visit [ADDRESS_887781] dose of 
study medication.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 183 of 280 Has been changed to:  
Vital signs will be measured at Screening, Baseline, every vis it (including all Unscheduled 
Visits) through the Early Discontinuation/End of Treatment Visit, and the Final Visit [ADDRESS_887782] dose of study medication.  
Change #28  
Section 11.8  C-reactive protein (CRP), the third sentence:  
Values will be used in determining PedACR clinical response, JADAS, CID and CRM, ratio 
to Baseline in CRP, and shift by [CONTACT_658316].  
Has been changed to:  
Values will be used in determining PedACR clinical response, JADAS, CID and CRM, and 
ratio to Baseline in C RP. 
Change #[ADDRESS_887783] sentence:  
Study participants not achieving persistent CID and resuming treatment will re -start the 
fixed -dose CZP dosing based on their current weight with 3 loading doses of CZP 
administered Q2W over 6 weeks, followed by a treatment dose administered Q2W for the 
duration of the study.  
Has been changed to:  
Study participants not achieving persistent CID and resuming treatment will re -start the 
fixed -dose CZP dosing based on their current weight with [ADDRESS_887784] weight group, who will receive the 
treatment dose Q4W followi ng implementation of Protocol Amendment 4.  
Change #30  
Section 13.4 Planned PK, PD, and immunological variable analysis , eighth paragraph , the 
second sentence : 
Plasma concentration time curves will be plotted, overall, and by [CONTACT_658335].  
Has been changed to:  
Plasma concentration time curves will be plotted, overall, by [CONTACT_658336], and by 
[CONTACT_14181]-CZP antibody status.  Subgroup analyses will include an analysis  of the study participants 
enrolled and tr eated up to the Week 16 timepoint under the original treatment dosing 
regimen.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 184 of 280 Change #[ADDRESS_887785] sentences : 
Interim CZP plasma concentration data available at the t ime of Protocol Amendment [ADDRESS_887786] been changed to:  
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The protocol stated th at if 
future interim analyses, which may include PopPK,  indicate that plasma concentrations of 
JIA study participants are outside of the exposure range observed in previous adult RA 
studies, a revised pediatric dose algorithm will be derived.  
Change #[ADDRESS_887787]  paragraph : 
Based on results of an interim PopPK analysis conducted in Jun 2013 described in 
Section  5.1, the dosing regimen will be changed with Protocol Amendment 4, and the doses 
to be administered will be reduced by 50% for all weight groups. This change is intended to 
achieve plasma concentrations similar to the effective concentrations observed in previous 
studies in adult study participants with RA.  
The CZP plasma concentrations will be monitored on an ongoing basis following the change 
in dose regimen to confirm they are within the adult range.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 185 of 280 17.15  Protocol Amendment 5  
Rationale for the amendment  
The primary purpose of this substantial amendment is to reopen enrollment under the new 
reduced CZP dose regimen and to update the statistical analysis to account for the changes in 
the CZP dose regimen. FDA has agreed to the implementation of the reduced dosing regimen.  
Two CZP dosing regimen subgroups will be  defined as follows:  
 Original CZP dose regimen: includes all study participants in the SS who began treatment 
in accordance with the original dosing regimen defined for the study (including study 
participants who underwent a dose reduction under Amendment 4).  
 Reduced CZP dose regimen: includes all study participants in the SS who began 
treatment in accordance with the reduced dosing regimen defined for the study.  
With implementation of Protocol Amendment 5, all newly enrolled study participants will 
receiv e loading and maintenance doses that correspond to 50% of the original  CZP dose 
regimen used in RA0043. The maintenance dose of previously enrolled study participants 
was reduced with Protocol Amendment 4. The reduced CZP dose regimen as implemented 
with P rotocol Amendments 4 and 5 is based on PopPK model simulations and is provided 
below.  
Table  17‒2 Proposed revised dosing recommendation based on PopPK 
model simulations  
Weight range  Loading dose  
(Weeks 0, 2, and 4)  Maintenance dose  
(Week 6 and onwards)  
10 to <20kg (22 to <44lb)  50mg Q2W  50mg Q4W  
20 to <40kg (44 to <88lb)  100mg Q2W  50mg Q2W  
≥40kg (≥88lb)  200mg Q2W  100mg Q2W  
PopPK=population pharmacokinetic; Q2W=every 2 weeks; Q4W=every 4 weeks  
At the time of Protocol Amendment 4, 78 study participants had been enrolled and started 
treatment on the original  CZP dose regimen. To allow for a comparison of the group of 78 
study participants on the original  CZP dose regimen with a comparable group of study 
participants on the revised CZP dose regimen, a further 78  study participants are planned to 
be enrolled on the reduced CZP dose regimen. Thus, the overall number of study participants 
to be enrolled will be increased from 125 to 156. Study participants who had fulfilled the 
eligibility criteria but could not be enrolled due to the suspended enrollment as of 17  Jul 2013 
will be allowed to be rescreened.  
Key changes include the clarification that only study participants who w ill be enrolled under 
Protocol Amendment 5 and will begin treatment on the reduced CZP dose regimen will be 
taken into account for the study stoppi[INVESTIGATOR_658240] 16 PedACR30 interim 
analysis, and that a minimum number of 10  study participants in  each weight category will 
need to be enrolled for the reduced CZP dose regimen.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 186 of 280 In addition, the requirement that a study participant’s dosing category may only be changed if 
the 40kg/88lb and 20kg/44lb weight boundaries are crossed due to weight changes of >5kg 
and >2.5kg, respectively, was removed from the protocol. Applying this re quirement at the 
time of dose reduction would lead to potential underdosing of study participants who have 
just crossed the weight boundary, as they would have their doses reduced by 50% even 
though, based on their actual weight, they already fall into the  next higher weight category.  
Furthermore, additional changes have been made to the exclusion criteria and guidelines 
related to TB detection and monitoring to adapt the protocol to the current UCB standard, and 
descriptions of CID and CRM have been modifi ed for clarity.  
In addition, administrative and editorial changes have been made to update study personnel, 
update terminology, and to correct errors.  
Modifications and changes  
Global changes  
The following changes have been made throughout the protocol and  are not listed under the 
specific changes:  
 The terms “treatment dose” and “Treatment Period” have been changed to “maintenance 
dose” and “Maintenance Period” throughout the protocol.  
 The definition of the minimum number of study participants to be enrolle d in each weight 
category has been updated throughout the protocol to clarify that a minimum number of 
10 study participants on the reduced CZP dose regimen will be enrolled in each weight 
category. For the other enrollment categories (age categories, CZP monotherapy, study 
participants with ERA) the minimum enrollment numbers apply irrespective of the dose 
regimen.  
 The definition of the study stoppi[INVESTIGATOR_658241] 50% of the study population 
enrolled on the reduced CZP dose regimen (Protocol Amendment 5) achieves a 
PedACR30 response at Week 16.  
 The explanation that “With the implementation of Protocol Amendment 4, the reduced 
loading dose applies only for already en rolled study participants who resume CZP 
treatment after nonpersistent Clinically Inactive Disease (CID)” has been removed 
throughout the protocol as this is no longer applicable with implementation of Protocol 
Amendment  5.  
 The description of minimum and maximum doses under the original  CZP dose regimen 
has been updated to refer to both Protocol Amendments  4 and 5.  
 The description that the dosing regimen will be changed based on findings from an 
interim PopPK analysis and the doses to be administered will  be reduced by 50% for all 
weight groups has been updated throughout the protocol to refer to Protocol 
Amendments  4 and 5.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 187 of 280 Specific changes  
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 01 Aug 2013. The changes are displayed in the order of 
appearance.  
Change #1  
On the SPONSOR DECLARATION page, the name [CONTACT_658371]:  
 
Has been changed to:  
 
Change #[ADDRESS_887788] details of the Study 
Physician:  
Name:   
[CONTACT_2761]:  [ADDRESS_887789]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax:  
Have been changed to:  
Name:   
[CONTACT_2761]:  [ADDRESS_887790]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax:  
Change #3  
Under SERIOUS ADVERSE EVENT REPORTING, the global e -mail address:  
[EMAIL_311]  
Has been changed to:  
[EMAIL_2443]  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 188 of 280 Change #[ADDRESS_887791] OF ABBREVIATIONS, the following abbreviation has been added:  
EAIR  exposure -adjusted incidence rate  
Change #[ADDRESS_887792] sentence : 
Approximately 167 study participants will be screened to enroll 125 study participants in this 
study.  
Has been changed to : 
Approximately 195 study participants will be screened to enroll 156 study participants in this 
study.  
Change #[ADDRESS_887793] sentence : 
Additional assessments of the CZP plasma concentration after the change in dose will be  
performed to ensure that the 50% dose reduction will result in plasma concentrations within 
the target range of those observed in adults.  
Has been changed to:  
Continued analysis of CZP plasma concentrations (including additional assessments for study 
participants undergoing a dose reduction with Protocol Amendment 4) will be performed to 
confirm that the 50% dose reduction will result in plasma concentrations within the target 
range of those observed in adults.  
Change #[ADDRESS_887794] sentence:  
Additional assessments of the CZP plasma concentration after the change in dose will be 
performed to ensure that the 50% dose reduction will result in plasma concentrations within 
the target range of those observed in adults.  
Has been changed to:  
Continued analysis of CZP plasma concentrations (including additional assessments for study 
participants undergoing a dose reduction with Protocol Amendment 4) will be performed to 
confirm that the 50% dose reduction will result in plasma concentrations within the target 
range of those observed in adults.  
Change #[ADDRESS_887795] Visit dates at the end of the section : 
Plann ed First Study participant, First Visit – 1Q [ADDRESS_887796] Visit – 3Q/4Q 2013 (to be confirmed)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887797] been changed to:  
First Study participant, First Visit – 1Q [ADDRESS_887798] Visit – 1Q/2Q 2015  
Chang e #[ADDRESS_887799] and second sentences : 
Approximately [ADDRESS_887800] been changed to:  
Approximately 195 study participants will be screened at about 55 centers in order to enroll 
156 study participants in this study.  
The enrollment per site is limited to a maximum of 12 s tudy participants.  
Change #10  
Section 5.4.2 Dose selection, the paragraph below Table 5 -2 (fifth sentence onwards):  
During the course of the study, results from the ongoing interim PK analysis and an interim 
PopPK analysis conducted in Jun 2013 indicated t hat plasma concentrations within the range 
previously seen in adult study participants receiving CZP 200mg Q2W would be achieved if 
the dose in RA0043 was reduced to 50%. Therefore, the treatment doses in this study will be 
reduced further with Protocol Am endment 4 so that study participants with body weights 
between 20 and <40kg (44 to <88lb) will receive CZP 50mg Q2W, and study participants 
with body weights of ≥40kg (≥88lb) will receive CZP 100mg Q2W (see Table 7 -1). The 
optimal treatment dose estimated in the PopPK model for the lowest weight group would be 
CZP 25mg Q2W, however, the lowest available dose size is CZP 50mg. Thus, study 
participants with body weights of 10 to <20kg (22 to <44lb) will receive CZP 50mg Q4W to 
achieve a 50% reduction.  
Has be en changed to:  
During the course of the study, results from the ongoing interim PK analysis and an interim 
PopPK analysis conducted in Jun 2013 indicated that plasma concentrations within the range 
previously seen in adult study participants receiving CZP 200mg Q2W would be achieved if 
the dose in RA0043 was reduced to 50% of the original dose used in the study. Therefore, the 
maintenance doses in this study will be reduced further with Protocol Amendment 4 so that 
study participants with body weights betwe en 20 and <40kg (44 to <88lb) will receive CZP 
50mg Q2W, and study participants with body weights of ≥40kg (≥88lb) will receive CZP 
100mg Q2W (see Table 7 -1). The optimal maintenance dose estimated in the PopPK model 
for the lowest weight group would be CZ P 25mg Q2W, however, the lowest available dose 
size is CZP  50mg. Thus, study participants with body weights of 10 to <20kg (22 to <44lb) 
will receive CZP 50mg Q4W to achieve this 50% reduction. In addition, with Protocol 
Amendment 5, the loading dose in th e study will be reduced by 50% for newly enrolled study 
participants, so that study participants with body weights of 10 to <20kg (22 to <44lb) will 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 190 of 280 receive CZP 50mg at Weeks 0, 2, and 4, study participants with body weights between 20  to 
<40kg (44 to <88l b) will receive CZP  100mg at Weeks 0, 2, and 4, and study participants 
with body weights ≥40kg (≥88lb) will receive CZP  200mg at Weeks 0, 2, and 4.  
Change #[ADDRESS_887801] sentence:  
11. Study partici pants with known TB infection, at high risk of acquiring TB infection, or 
latent TB (LTB) infection are excluded:  
Has been changed to:  
11. Study participants with known TB infection, or at high risk of acquiring TB infection, are 
excluded. Study participan ts with latent TB (LTB) infection that have not received a 
minimum of 4 weeks of prophylactic treatment are only eligible following prophylaxis:  
Change #[ADDRESS_887802] sentence under “c”:  
c. Latent TB infection (unless appropriate prophylaxis is initiated prior to study 
treatment according to Section [IP_ADDRESS].1 and continued to completion of prophylaxis) 
is defined as:  
Has been changed to:  
c. Latent TB infection is defined as:  
Change #[ADDRESS_887803] bullet:  
 Study participants who fulfilled all eligibility criteria but were registered as Screen 
failures due to suspension of enrollment as of 17 Jul 2013 are allowed to be rescreened.  
Change #14  
Section 6.4 Withdrawal criteria, withdrawal criterion no.3:  
3. Study participant who develops confirmed reactivation of latent or active TB or NTMB 
infection during the study (including, but not limited to, con version demonstrated by 
[CONTACT_658320], eg, TB questionnaire, during the course of the 
study) must be withdrawn.  
Has been changed to:  
3. Study participant who develops active TB or NTMB infection during the study must be 
withdrawn.  
Change #15  
Section 7.2 Treatments to be administered, the second paragraph:  
To prevent unnecessary switching of study participants between weight categories, a study 
participant’s dosing category may only be changed after assessment of weight changes by [CONTACT_3433] e 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 191 of 280 Investigator at a scheduled clinic visit and if their weight crosses the 40kg/88lb boundary due 
to a weight change of >5kg (11lb) compared to their last weight measurement of the lower 
weight category (eg, a 39.0kg study participant becomes 44.1kg) or cr osses the 20kg/44lb 
boundary due to a weight change of >2.5kg (5.5lb) (eg, a 19.0kg study participant becomes 
21.6kg). Weight, weight change, and any change in study medication dose will be 
documented.  
Has been changed to:  
A study participant’s dosing cate gory will only be changed after the confirmation of a weight 
change by [CONTACT_314661] a scheduled clinic visit.   
The study participant will receive the dose of the next weight category once their weight 
crosses the 40kg/88lb boundary or crosses the 20 kg/44lb boundary at a scheduled clinic visit. 
The study participant will continue on the dose of the new weight category regardless of 
potential decrease of the weight below the boundary. In case of significant weight 
fluctuations the Investigator should c ontact the Medical Monitor to discuss and confirm 
potential change in dosing if medically advised or discontinuation of treatment (eg, if related 
to AE).  
Change #16  
Section 7.2 Treatments to be administered, the note below Table 7 -1: 
Note: A study partici pant should only change dosing category during the course of the study if their weight 
crosses the 40kg/88lb boundary due to a weight change of >5kg (11lb) (eg, a 39.0kg study participant becomes 
44.1kg) or crosses the 20kg/44lb boundary due to a weight ch ange of >2.5kg (5.5lb) (eg, a 19.0kg study 
participant becomes 21.6kg).  
Has been changed to:  
Note: A study participant should change dosing category during the course of the study if their weight crosses 
the 40kg/88lb boundary or crosses the 20kg/44lb boun dary.  
Change #[ADDRESS_887804] paragraph:  
Study participants achieving clinical remission on medication (CRM), ie, after 6 months of 
CID, may discontinue CZP treatment at the Investigator’s discretion following consultation 
with the Sponsor to confirm remission status. Study participants will remain in the study and 
continue with scheduled study visits. Study participants not achieving persistent CID will be 
allowed to resume CZP treatment at any time at the Inve stigator’s discretion. If a study 
participant is on concomitant MTX treatment, the Investigator may decide to decrease and 
ultimately discontinue the MTX dose after complete discontinuation of CZP. Study 
participants not achieving persistent CID and resumi ng treatment will re -start the fixed -dose 
CZP dosing based on their current weight with [ADDRESS_887805] 
weight group after implementation of Protocol  Amendment 4, for the duration of the study 
(see Table  7-1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 192 of 280 Has been changed to:  
Study participants achieving clinical remission on medication (CRM), ie, after 6 months of 
continuous CID, may discontinue CZP treatment at the Investigator’s discretion foll owing 
consultation with the Sponsor to confirm remission status. Study participants who have 
discontinued CZP due to achieving CRM will be allowed to remain in the study and continue 
with scheduled study visits. Study participants not maintaining persisten t CID following 
achievement of CRM will be allowed to resume CZP treatment at any time at the 
Investigator’s discretion and consultation with the Sponsor. If a study participant is on 
concomitant MTX treatment, the Investigator may decide to decrease and u ltimately 
discontinue the MTX dose after complete discontinuation of CZP. Study participants not 
maintaining persistent CID following achievement of CRM and resuming treatment will 
restart the fixed -dose CZP dosing based on their current weight with [ADDRESS_887806] weight group after implementation of Protocol Amendment 4, for the 
duration of the study (see Table  7-1). 
Change #18  
Section 7.2.1 Proced ure for dose change (Protocol Amendment 4), the first sentence:  
With Protocol Amendment 4, the treatment dose in the study will be reduced by 50% for all 
weight groups.  
Has been changed to:  
With Protocol Amendment 4, the maintenance dose in the study will be reduced by 50% for 
all weight groups (not applicable for study participants enrolled on the reduced CZP dose 
regimen per Protocol Amendment  5). 
Change #19  
Section 7.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]), first bullet 
“MTX, if being used” the fourth and fifth points in the list:  
 During the study, the MTX dose may be decreased, but not discontinued. 
Methotrexate may be discontinued only for documented reasons of intolerance or 
toxicity, or in study participants who achieve CRM a nd only after discontinuation of 
CZP.  
 Study participants who do not achieve persistent CRM status can reinitiate therapy 
with MTX.  
Have been changed to:  
 During the study, the MTX dose may be decreased, but not discontinued. 
Methotrexate may be discontinued only for documented reasons of intolerance or 
toxicity, or in study participants who achieve CRM (persistent CID over a period of 6 
months, as defined in Section 11.10) and only after discontinuation of CZP.  
 Study participants who do not maint ain persistent CID following achievement of 
CRM can reinitiate therapy with MTX.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 193 of 280 Change #[ADDRESS_887807] sentence : 
Additional assessments of the CZP plasma concentration af ter the change in dose will be 
performed to ensure that the 50% dose reduction will result in plasma concentrations within 
the target range of those observed in adults.  
Has been changed to:  
Continued analysis of CZP plasma concentrations (including additio nal assessments for study 
participants undergoing a dose reduction with Protocol Amendment 4) will be performed to 
confirm that the 50% dose reduction will result in plasma concentrations within the target 
range of those observed in adults.  
Change #21  
Section 10.1.8 Ongoing safety data review and oversight, second paragraph, the fourth 
sentence:  
In addition, a Data and Safety Monitoring Board (DSMB) will periodically review all 
emerging safety data (see Section 13.7).  
Has been changed to:  
In addition, a Da ta and Safety Monitoring Board (DSMB) will periodically review emerging 
safety and efficacy data (see Section 13.7).  
Change #22  
Section [IP_ADDRESS].[ADDRESS_887808] and second sentences:  
Per exclusion criterion 11c, LTB infection is defined as a positive TB test (IGRA or [COMPANY_003]) 
and chest imaging without positive findings for TB along with the absence of signs, 
symptoms, or physical findings suggestive of TB infection. If available, smears an d cultures 
of secretions or tissues should also be negative.  
Have been changed to:  
Latent TB infection is defined as a positive TB test (IGRA or [COMPANY_003]) and chest imaging 
without positive findings for TB along with the absence of signs, symptoms, or physical  
findings suggestive of TB infection. If available, smears and cultures of secretions or tissues 
should also be negative (refer to exclusion criterion 11c).  
Change #23  
Section [IP_ADDRESS].1  Latent tuberculosis infection, the fourth sentence:  
Study participan ts who have received prophylactic therapy for LTB infection for at least 4 
weeks prior to enrollment (initiation of CZP treatment at Baseline) and are committed to 
completing the full course of therapy, may be considered for study participation.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 194 of 280 Has been c hanged to:  
Study participants who have received prophylactic therapy for LTB infection for at least 4 
weeks prior to initiation or continuation of CZP treatment and who are committed to 
completing the full course of therapy, may be considered for study par ticipation or can 
continue on the study.  
Change #24  
Section [IP_ADDRESS].1  Latent tuberculosis infection, the text under “ LTB infection and active 
TB identified during study ”: 
During the study, study participants who develop evidence of LTB infection or active  TB 
must immediately discontinue further administration of IMP, be scheduled for the Early 
Discontinuation Visit and Final Visit, and referred to a TB specialist for evaluation. Evidence 
of LTB infection is defined as study participant’s IGRA test converts  to positive or 
indeterminate (and confirmed indeterminate on repeat), or [COMPANY_003] converts to positive (this only 
applies for regions or sites where UCB has determined [COMPANY_003] may be used for screening and 
follow -up), or the study participant’s questionnaire or hi story and physical examination 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, 
in addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the study participant should be  carefully assessed by a TB specialist for active TB 
(see Section  [IP_ADDRESS]). Study participants diagnosed with active TB or LTB infection should 
receive appropriate TB or prophylaxis therapy respectively per local and UCB guidelines as 
described above. Any  presumptive diagnosis or diagnosis of LTB infection or active TB is a 
reportable event; refer to Section  10.2.[ADDRESS_887809] be followed.  
Has been changed to:  
During the study, study participants who develop evidence of LTB infection or active TB 
must immediately stop further administration of study medication and be referred to an 
appropriate TB specialist (pulmonologist and infectious disease specialist) for further 
evaluation (see Section  [IP_ADDRESS]). Evidence of LTB infection is defined as study participant’s 
IGRA test converts to positive or indeterminate (and confirmed indeterminate on repeat), or 
[COMPANY_003] con verts to positive, or the study participant’s questionnaire or history and physical 
examination indicates that TB infection or exposure may have occurred. Evidence of active 
TB includes, in addition to the aforementioned tests, signs and symptoms of organ 
involvement. In either situation, the study participant should be carefully assessed by a TB 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887810] for active TB. Study participants diagnosed with active TB or LTB infection should 
receive appropriate TB or prophylaxis therapy. In case a TB specialis t excludes an active TB 
the study participant can proceed with the study medication no earlier than 4 weeks after the 
start of an appropriate prophylactic therapy.  
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event, and 
confirme d active TB has to be reported as an SAE (please see Section  10.2.2 Procedures for 
reporting SAEs for details). The Investigator is to complete and submit the TB follow -up 
form provided.  
The study participant should be transferred to the care of their phy sician and managed 
according to the best available standard of care. Study participants identified as having 
converted to active TB during the study must be withdrawn and scheduled to return for the 
Early Discontinuation Visit as soon as possible but no la ter than the next scheduled study 
visit.  
The study participant should be encouraged to complete the Final Visit [ADDRESS_887811] after 3, 9, and 12 months of start date of anti -TB treatment, including hematological and 
biochemical safety parameters, x -ray evolution data, and TB diagnostic procedures used to 
follow up and confirm recovery of TB . 
Change #[ADDRESS_887812] paragraph:  
Study participants achieving CRM, ie, after 6 months of CID, may discontinue CZP treatment 
at the Investigator’s discretion following consultation with the S ponsor to confirm remission 
status. Study participants will remain in the study and continue with scheduled study visits. 
Study participants not achieving persistent CID will be allowed to resume CZP treatment at 
any time at the Investigator’s discretion. If a study participant is on concomitant MTX 
treatment, the Investigator may decide to decrease and ultimately discontinue the MTX dose 
after complete discontinuation of CZP. Study participants not achieving persistent CID and 
resuming treatment will resta rt the fixed -dose CZP dosing based on their current weight with 
[ADDRESS_887813] weight group, 
who will receive t he treatment dose Q4W following implementation of Protocol Amendment 
4.  
Has been changed to:  
Study participants achieving CRM, ie, after 6 months of continuous CID, may discontinue 
CZP treatment at the Investigator’s discretion following consultation with  the Sponsor to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887814] discontinued CZP due to achieving 
CRM will be allowed to remain in the study and continue with scheduled study visits. Study 
participants not maintaining persistent CID following achieve ment of CRM will be allowed 
to resume CZP treatment at any time at the Investigator’s discretion and consultation with the 
Sponsor. If a study participant is on concomitant MTX treatment, the Investigator may decide 
to decrease and ultimately discontinue t he MTX dose after complete discontinuation of CZP. 
Study participants not maintaining persistent CID following achievement of CRM and 
resuming treatment will restart the fixed -dose CZP dosing based on their current weight with 
[ADDRESS_887815] weight group, 
who will receive the maintenance dose Q4W following implementation of Protocol 
Amendment 4.  
Change #[ADDRESS_887816] 
paragraph:  
Subgroups defined by [CONTACT_658337]. Two CZP dosing regimen 
subgroups will be defined as follows:  
 Original  CZP dose regimen: includes all study participants in the SS who began treatment 
in accordance with the original  dosing regimen defined for the study (3 loading doses of 
CZP at Weeks 0, 2, and 4 [minimum=100mg Q2W, maximum=400mg Q2W] followed 
by a maintena nce dose for the duration of the study [minimum=50mg Q2W, 
maximum=200mg Q2W]). This subgroup includes all study participants who began the 
study with this CZP dose regimen and received 1 or more doses of this regimen, 
regardless of any subsequent switch to  the reduced CZP dose regimen.  
 Reduced CZP dose regimen: includes all study participants in the SS who began 
treatment in accordance with the reduced dosing regimen defined for the study (3 loading 
doses of CZP at Weeks 0, 2, and 4 [minimum=50mg Q2W, maxim um=200mg Q2W] 
followed by a maintenance dose for the duration of the study [minimum=50mg Q4W, 
maximum=100mg Q2W]).  
Change #27  
Section 13.2.2 Multicenter studies:  
Approximately 55 centers are planned to enroll 125 study participants into this study. The 
enrollment per site is limited to a maximum of 10 study participants.  
Has been changed to:  
Approximately 55 centers are planned to enroll 156 study participants into this study. The 
enrollment per site is limited to a maximum of 12 study participants.  
Change #28 
Section 13.3 Planned safety analyses:  
The incidence of AEs will be assessed as primary safety variable in this study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 197 of 280 Safety summaries will include presentations of AEs, extent of exposure, laboratory values 
(hematology and biochemistry), vital signs,  concomitant medications and procedures, and 
autoantibody (ANA and anti -dsDNA antibodies) concentrations. Urinalysis results will be 
listed. Tanner stages will be presented by [CONTACT_17203]. Growth as measured by [CONTACT_658338] t o a comparative population and this may include an assessment 
of any change after treatment with CZP.  
Selected safety summaries will be presented overall and by [CONTACT_658303], as well as 
by [CONTACT_654] (2 to 5 years, 6 to 11 years, and 12 to 17 years), by  [CONTACT_658304], and by 
[CONTACT_14181]-CZP antibody status. Safety summaries will be based upon the SS (study participants 
who were enrolled and took at least 1 dose of study medication).  
Has been changed to:  
The incidence of AEs will be assessed as primary saf ety variable in this study. The primary 
summaries of safety will include all study participants in the SS, regardless of CZP dose. 
Safety variables will be summarized overall and separately for the 2 CZP dose regimens 
(original CZP dose regimen, reduced CZ P dose regimen).  
Safety summaries will include presentations of AEs, extent of exposure, laboratory values 
(hematology and biochemistry), vital signs, concomitant medications and procedures, and 
autoantibody (ANA and anti -dsDNA antibodies) concentrations.  Urinalysis results will be 
listed. Tanner stages will be presented by [CONTACT_17203]. Growth as measured by [CONTACT_658302] a comparative population and this may include an assessment 
of any change after treatment with CZP.  
For AEs, the exposure -adjusted incidence rate (EAIR) will also be calculated. For EAIR, the 
numerator will be the total number of study participants experiencing a particular AE. The 
denominator will be study participant -years, ie, the total summation of indi vidual study 
participant -years at risk up to the first occurrence of the given AE for study participants with 
that AE, plus the total study participant -years at risk for those study participants not 
experiencing that AE.  
For the original CZP dose regimen subgroup, in addition to the overall presentation of AEs, 
AEs will be summarized separately for the periods of exposure to original and reduced CZP 
dose regimens. Additionally, the frequency and percentage of AEs reported during the first 
16 weeks of study  medication exposure will be summarized separately for the 2 CZP dose 
regimens (original CZP dose regimen, reduced CZP dose regimen). This analysis will be 
repeated, excluding any study participants who switched from the original to the reduced 
CZP dose re gimen prior to Week 16. Selected safety summaries will be presented overall and 
by [CONTACT_658303], as well as by [CONTACT_654] (2 to 5 years, 6 to 11  years, and 12  to 17 years), 
by [CONTACT_658304], and by [CONTACT_14181] -CZP antibody status.  
Change #[ADDRESS_887817] and fourth 
paragraphs:  
In the Bayesian approach, the distributions of PK parameters estimated from adult data (from 
the PopPK analysis in C87068) will be incorporated as prior information in the model to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 198 of 280 estimate pediatric PK parameters. This combination of prior knowledge and sparse pediatric 
data will be analyzed within Winbugs.  
The meta -analysis will be performed by [CONTACT_658339] (C87068).  
Have been changed to:  
In the Bayesian approach, the distributions of PK parameters estimated from adult data (from 
the PopPK analysis in C87068 and CL0153) will be incorporated as prior information in the 
model to estimate pediatric PK parameters. This combination of prior knowledge and sparse 
pediatric data will be analyzed within Winbugs.  
The meta -analysis will be performed by [CONTACT_658339] (C87068 and 
CL0153).  
Change #30  
Section 13.4 Planned PK, PD, and immunological variable analysis, the eighth paragraph:  
Certolizumab pegol plasma concentration data will be tabulated and summarized for each 
visit on which samples were taken (geometric mean, arithmetic mean, minimum, maximum, 
standard deviation and % coefficient of variation). Plasma concentration time curves will be 
plotted, overall, by [CONTACT_658336], and by [CONTACT_14181] -CZP antibody status. Subgr oup analyses 
will include an analysis of the study participants enrolled and treated up to the Week 16 
timepoint under the original treatment dosing regimen.  
Has been changed to:  
Certolizumab pegol plasma concentration data will be tabulated and summarized  by [CONTACT_658340] ( original  CZP dose regimen or reduced CZP dose regimen) for each visit on which 
samples were taken (geometric mean, arithmetic mean, minimum, maximum, standard 
deviation and % coefficient of variation). Plasma concentration time curves wil l be plotted 
separately for study participants who began treatment according to the original  CZP dose 
regimen or the reduced CZP dose regimen, overall, by [CONTACT_658336], and by [CONTACT_14181] -CZP 
antibody status. Subgroup analyses will include an analysis of the study participants enrolled 
and treated up to the Week 16 timepoint under the original maintenance dosing regimen.  
Change #[ADDRESS_887818] paragraph:  
All effica cy and health outcomes variables results will be presented overall and separately for 
the 2 CZP dose regimens ( original  CZP dose regimen, reduced CZP dose regimen).  
Change #32  
Section 13.7 Planned interim analysis and data monitoring, the fifth paragraph:  
The CZP plasma concentrations will be monitored on an ongoing basis following the change 
in dose regimen to confirm they are within the adult range.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 199 of 280 Has been changed to:  
The CZP plasma concentrations will be monitored on an ongoing basis following the chan ge 
in dose regimen to confirm they are within the targeted adult range.  
Change #[ADDRESS_887819] paragraph:  
A DSMB will periodically review all emerging safety data. The DSMB members will be 
independent  of the Sponsor and Investigators. The DSMB members will be informed by [CONTACT_658330] (or designee) of all SAEs at the time of expedited reporting and 
will review periodically all emerging safety data (eg, SAEs, AEs, safety laboratory data ). 
Based on the safety data, the DSMB can recommend modifying/stoppi[INVESTIGATOR_10098].  
Has been changed to:  
A DSMB will periodically review emerging safety and efficacy data. The DSMB members 
will be independent of the Sponsor and Investigators. The DSMB member s will be informed 
by [CONTACT_658341] (or designee) of all SAEs at the time of expedited reporting 
and will periodically review emerging safety data (eg, SAEs, AEs, safety laboratory data) and 
efficacy data, as applicable, during the course of the study. Based on the safety data, the 
DSMB can recommend modifying/stoppi[INVESTIGATOR_10098].  
Change #[ADDRESS_887820] paragraph:  
Based upon the ICH guideline for the assessment of safety, it is planned to enroll a suf ficient 
number of study participants to this study to have a minimum of [ADDRESS_887821] 12 months 
continuous exposure to CZP. Assuming a dropout rate of approximately 20%, this means that 
125 study participants would need to be enrolled. Further assuming  a Screening failure rate of 
25%, it is planned to screen 167 study participants.  
Has been changed to:  
Based upon the ICH guideline for the assessment of safety, it is planned to enroll a sufficient 
number of study participants to this study to have a mini mum of [ADDRESS_887822] 12 months 
continuous exposure to CZP. Assuming a dropout rate of approximately 20%, it was 
originally determined that 125 study participants would need to be enrolled. At the time of 
Protocol Amendment 5, 78 study participants had been enrolled according to the original  
CZP dose regimen, and it is planned to enroll a further 78 study participants on the reduced 
CZP dose regimen, so that a comparable number of study participants on the reduced CZP 
dose regimens can be analyzed. Thus,  the total number of study participants planned to be 
enrolled will be increased to 156 study participants. Assuming a Screening failure rate of 
25%, it is planned to screen 195 study participants in total.  
Change #[ADDRESS_887823] sentence:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887824] that the planned sample size of 125 study participants is adequate for PK assessment 
purposes.  
Has been changed to : 
Prior to the start of study conduct, simulations using the adult population PK model in 
pediatric study participants with JIA suggested that the planned sample size of 125 study 
participants was adequate for PK assessment purposes.  
Change #36  
Section 13 .8 Determination of sample size, the following has been added at the end of the 
section:  
Data from all 156 study participants will be included in the final PopPK analysis, and 
therefore should allow CL/F and V/F to be determined with sufficient precision.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 201 of 280 17.16  Protocol Amendment 6  
Rationale for the amendment  
The primary purpose of this administrative  amendment is to update the packaging and 
labeling sections of the protocol to account for a new presentation of the prefilled syringe 
(PFS).  
In addition, administrative changes have been made to move the Sponsor declaration page to 
the back of the document to comply with the new electronic signature [CONTACT_41705], to update 
study personnel, and to correct typographical errors.  
Modifications and chan ges 
Global change  
The terms “Treatment Period” and treatment dose” were changed globally to “Maintenance 
Period” and “maintenance dose ” with RA0043 Protocol Amendment 5. However, in text that 
refers to the overall open -label Treatment Period in the study,  which includes a Loading and a 
Maintenance Period, the term “Treatment Period” should still be used. This has been 
corrected throughout the protocol.  
Specific changes  
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 20 Jan 2014. The changes are displayed in the order of 
appearance.  
Change #1  
The SPONSOR DECLARATION page was removed from page 2 and added as a new section 
at the back of the document:  
[ADDRESS_887825] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
Change #[ADDRESS_887826] details  of the  Study Physician : 
Name:   
[CONTACT_2761]:  [ADDRESS_887827]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887828] been changed to:  
Name:   
[CONTACT_2761]:  Chemin du Foriest  
B - 1420 Braine -l’Alleud  
Belgium  
Phone:  
Fax: 
Change #[ADDRESS_887829] details of the Clinical Trial 
Biostatistician : 
Name:   
[CONTACT_2761]:  [ADDRESS_887830]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
Have been changed to:  
Name:   
[CONTACT_2761]:  [ADDRESS_887831]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003]  
Phone:  
Fax: 
Change #[ADDRESS_887832] OF ABBREVIATIONS, the following abbreviation has been added:  
GMP  Good Manufacturing Practice  
Change #5  
Section 7.3 Packaging:  
Each site will receive uniquely numbered PFS of CZP 200mg/m L. The PFS will be packaged 
in individual protective containers (clamshell). Each clamshell will be packaged in an 
individual carton.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887833] the IXRS at each visit in order to obtain the PFS number(s) (MED ID) to 
be dispensed to a specific study participant.  
Has been changed to:  
Certolizumab pegol is packaged and labeled according to Good Manufacturing Practice 
(GMP) guid elines and applicable laws or regulations. They are suitably packaged in such a 
way as to protect the IMPs from deterioration during transport and storage.  
Change #6  
Section 7.4 Labeling:  
Clinical drug supplies will be labeled in accordance with the curren t International Conference 
on Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good 
Manufacturing Practice and will include any locally required statements. Where necessary, 
labels will be translated into the local language.  
All PFS will be inserted into a labeled individual container (clamshell). The label of an 
individual container has 2 sections. The tear -off section will be removed and attached to the 
source document at the time of study medication administration to the study participa nt and 
the main section will remain affixed to the individual container.  
Prefilled syringes used for administration will be labeled with the same unique identifier 
(MED ID) as on the individual container. Cartons containing the clamshells will also be 
labeled with the same unique identifier (MED ID) as on the individual container.  
Name, address, and phone number of the Investigator will be included on the study 
participant identification card (see  Section 14.2).  
Has been changed to:  
Clinical drug supplies w ill be labeled in accordance with the current International Conference 
on Harmonization (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will 
include any locally required statements. If necessary, labels will be translated into the local 
langua ge. Details on Labeling will be provided in the Pharmacy manual.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 204 of 280 17.17  Protocol Amendment 7  
Rationale for the amendment  
The primary purpose of this substantial amendment is to update the protocol in accordance 
with current UCB TB detection procedures, including the introduction of yearly TB testing 
and the extension of the prophylactic TB treatment duration from 4  to 8 weeks. Furthermore, 
it has been clarified that long -term efficacy data from study participants who withdraw from 
the study after Week  56 or initia te any rescue medication use after Week 56 will be analyzed 
“as observed” and will no longer be imputed as nonresponse or missing.  
Moreover, a section on “Suspected transmission of an infectious agent via a medicinal 
product” has been added in accordance with current company standards.  
In addition, study contact [CONTACT_658342].  
Modifications and changes  
Global changes  
The following changes have been made throughout the protocol:  
 Yearly TB testing and prophylactic TB treatment duration of [ADDRESS_887834] been made to the eligibility criteria in Section 6 
(eg, Exclusion Criterion #11) and the description of  Screening procedures for TB 
infection at study entry (Sec tion [IP_ADDRESS].1) because enrollment in the study is complete 
at the time of this protocol amendment.  
 References to UCB Drug Safety have been changed to UCB Patient Safety.  
Specific changes  
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 17 Sep 2015. The changes are displayed in the order of 
appearance.  
Change #1  
Under SERIOUS ADVERSE EVENT REPORTING, the fax numbers for SAE reporting in 
the US and Canada:  
Serious adverse event reporting (24h )  
 Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003]:  +[PHONE_299]  
Canada:  +[PHONE_1063]  
 E-mail  Global: [EMAIL_2443]   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887835] been changed to:  
Serious adverse event reporting (24h)  
 Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003] and Canada:  +[PHONE_299] or +[PHONE_300]  
 E-mail  Global: [EMAIL_2443]   
Change #2  
Section 2 INTRODUCTION, second paragraph, the second sentence:  
Juvenile idiopathic arthritis is the most commonly diagnosed rheumatic disease affecting 
children less than  16 years of age with a prevalence of approximately 100 in 100,000.  
Has been changed to:  
Juvenile idiopathic arthritis is the most commonly diagnosed rheumatic disease affecting 
children less than 16  years of age with a prevalence of approximately 100 in 100,000 (Zitelli 
et al, 2012).  
Change #3  
Section 5.2 Schedule of study assessments, Table 5 -1, entries for “TB screening and chest x -
ray” and “TB questionnaire” and the associated footnotes “i” and “n” have been updated 
(new information in italics  and bold ): 
Table  5-1 Schedule of study assessments  
Study period  Screening  Baseline        
Week  -4 to 0(a) 0 … 4, 8, 12, 
16, (17(u)), 
20, 24  32 and every 
8 weeks 
thereafter  … Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a) 1 2  5 to 10  11 onwards    FV 
…         
TB screening(n) and 
chest x -ray(o) X    X(n)    
TB questionnaire  X X  X(i) X(i)  X(i)  
…         
i TB questionnaire to be completed at Weeks 12 and 24, every 16 weeks thereafter, and Early Discontinuation/End 
of Treatment. If the Investigator suspects reactivation of latent  TB or active TB, TB testing and/or a chest x -ray 
should be performed  as outline d in Section [IP_ADDRESS] . 
n TB screening if not performed within 3 months of Screening: Interferon -gamma release assay (IGRA) testing 
(QuantiFERON®) is required to be performed by [CONTACT_658249] 5 to 17 years of 
age. [COMPANY_003] testi ng is mandatory for study participants from 2 to 4 years of age in this study unless written 
documentation of BCG vaccination is available (refer to Section  6.2 [exclusion criterion 11] and Section  10.7.9). 
Following implementation of Protocol Amendment 7,  IGRA testing (QuantiFERON) should be done once a 
year (approximately every 48 weeks) for all study participants from 5 to 17 years of age. For study participants 
from 2 to 4 years of age,  both IGRA and [COMPANY_003] testing should be performed once a year (approxi mately every 
48 weeks). In cases where written documentation of BCG vaccination is available or previous [COMPANY_003] test was 
positive, only IGRA should be performed (Section [IP_ADDRESS]).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 206 of 280 Change #[ADDRESS_887836] paragraph:  
Rescue medication use is defined as any initiation of treatment or increase in dose of a 
medication used to treat JIA (in addition to the IMP) that is considered to impact the efficacy 
analyses. A study participant requiring rescue medication after first a dministration of IMP is 
considered as a treatment failure from that time point forward for the purpose of efficacy 
analyses.  
Has been changed to:  
Rescue medication use is defined as any initiation of treatment or increase in dose of a 
medication used to t reat JIA (in addition to the IMP) that is considered to impact the efficacy 
analyses. A study participant requiring rescue medication after first administration of IMP is 
considered as a treatment failure from that time point forward for the purpose of eff icacy 
analyses. Exception: A study participant initiating rescue medication use after the Week 56 
visit will not be considered a treatment failure and the efficacy data will be analyzed as 
observed without imputation.  
Change #5  
Section 8.5 Visits 11 and co ntinuing (Week 32 and every 8 weeks thereafter), a new bullet 
has been added as sixth bullet:  
 TB screening once a year (approximately every 48 weeks)  
Change #6  
Section 10.1 Adverse events, the following section has been added:  
10.1.[ADDRESS_887837]  
For the purposes of reporting, any suspected transmission of an infectious agent via the study 
medication should be considered as an SAE; such cases must be reported immediately, 
recorded in the AE module of the CRF, and followed as any other SAE. Any organism, virus, 
or infectious particle (eg, prion protein transmitting transmissible spongiform 
encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.  
Change #7  
Section 10.6 Laboratory measurements, a new paragraph has been added as 12th paragraph:  
During the study and upon implementation of Protocol Amendment 7, IGRA testing should 
be done once a year (approximately every 48 weeks) for all study participants from 5 to 17 
years of age. For study participants from 2 to 4 years of age, both IGRA and [COMPANY_003] testing 
should be performed once a year (approximately every 48 weeks). In cases where written 
documentation of BCG vaccination is available or previous [COMPANY_003] test was positive, only 
IGRA sho uld be performed (Section [IP_ADDRESS]).  
Change #8  
Section 10.6 Laboratory measurements, Table 10 -2 Laboratory measurements, the entry “TB 
screening” and the associated footnote “d”:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 207 of 280 TB screening(d): IGRA (ages 5 -17 years ), [COMPANY_003] (ages 2 -4 years)  
d IGRA testin g is required at Screening for all study participants aged 5 to 17 years; [COMPANY_003] testing is required for 
all study participants aged 2 to 4 years (except for study participants with documented BCG vaccination).  
Have been changed to:  
TB screening(d): IGRA, [COMPANY_003]  
d For TB testing refer to Section 10.7.9.  IGRA is performed by [CONTACT_6626].  
Change #9  
Section [IP_ADDRESS].1, the section heading:  
[IP_ADDRESS].1   Latent tuberculosis infection   
Has been changed to:  
[IP_ADDRESS].1   Latent TB infection at study entry  
Change #10  
Section [IP_ADDRESS].[ADDRESS_887838] and second 
sentences:  
At Screening, study participants who have recently (defined as no more than 12 months prior 
to Screening) completed a full course of prophylaxis for LTB infection may be considered for 
study participation. Study participants who have received prophylactic therapy for LTB 
infection for at least [ADDRESS_887839] been changed to:  
At Screening , study participants who have recently (defined as no more than 12 months prior 
to Screening) completed a full course of prophylaxis for L TB infection may be considered for 
study participation. Study participants who have received prophylactic therapy for LTB 
infection for at least 4 weeks prior to initiation of CZP treatment and who are committed to 
completing the full course of therapy, ma y be considered for study participation.  
Change #[ADDRESS_887840] 
paragraph:  
In case a TB specialist excludes an active TB the study participant can proceed with the study 
medication no earlier than [ADDRESS_887841] been changed to:  
Section [IP_ADDRESS].[ADDRESS_887842] excludes an active TB the study participan t can proceed with the study 
medication no earlier than 8 weeks after the start of an appropriate prophylactic therapy.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 208 of 280 Change #12  
Section [IP_ADDRESS].2 Latent TB infection and active TB identified during study, the second 
paragraph:  
Any presumptive diagnosis  or diagnosis of a TB infection is a reportable event, and 
confirmed active TB has to be reported as an SAE (please see Section  10.2.2  Procedures for 
reporting SAEs for details). The Investigator is to complete and submit the TB follow -up 
form provided.  
Has been changed to:  
Any confirmed diagnosis of a latent or active TB infection is a reportable event. Both cases 
have to be reported as AE of Interest and must be captured on an SAE report form (please 
tick the appropriate AE of Interest and/or SAE field(s)  on the form to clearly indicate level of 
seriousness) and provided to the Sponsor in accordance with SAE reporting requirements (see 
Section  10.2.2 Procedures for reporting SAEs for details).  
Change #13  
Section [IP_ADDRESS] TB screening and testing, a new sub section has been added; subsequent 
subsections (for chest x -ray, IGRA test, and [COMPANY_003] skin test) have been renumbered:  
[IP_ADDRESS].[ADDRESS_887843] of the study, the TB assessment by [CONTACT_658343] a year 
(approximately every 48 weeks). The test results will be report ed as positive, negative, or 
indeterminate. Positive or indeterminate results must be reviewed by [CONTACT_658344], radiologist, or a pulmonologist. If the assessment by [CONTACT_658345] e previously negative at Screening and 
not treated for LTB infection, the study participant may not continue study treatment without 
further evaluation by a TB specialist, prophylactic TB treatment, and discussion with the 
Medical Monitor, if LTB infection  is identified.  
If active TB is identified, the study participant must undergo appropriate study -specified 
withdrawal procedures.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887844] and IGRA sh ould 
be repeated once a year (approximately every 48 weeks). If both tests are negative the study 
participant may continue in the study. The study participant should immediately discontinue 
study medication intake if [ADDRESS_887845] might be positive due 
to BCG vaccination; however, if the [COMPANY_003] skin test is not performed or positive in a pediatric 
study participants <5 years of age, it will not be allowed that the study participant continues 
in the study without written approval from a physician with experti se in pediatric TB.  
Change #14  
Section [IP_ADDRESS].[ADDRESS_887846] x -ray, the following paragraph has been added at the end of the 
section:  
Additional chest x -ray or other imaging test should be performed when positive signs and 
symptoms indicate pulmonary infection,  including potential TB infection, or when close 
exposure to persons with TB is documented.  
Change #15  
Section [IP_ADDRESS].3 Interferon -gamma release assay (IGRA test):  
The IGRA (QuantiFERON®-TB GOLD In -Tube test) is the protocol -required method of 
screening for TB in study participants from [ADDRESS_887847] be done during the protocol -defined Screening window.  
Has been changed to:  
The IGRA (QuantiFERON®-TB GOLD In -Tube test) is the protocol -required method of 
screening for TB and will be pe rformed at the central laboratory. If the result of the IGRA 
test is indeterminate, the test may be repeated once. If positive or indeterminate on retest, the 
study participant may not be enrolled without further evaluation and treatment, as well as 
discus sion by [CONTACT_658346]. The retest must 
be done during the protocol -defined Screening window. During the study, TB screening with 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 210 of 280 IGRA will be repeated once yearly, ie, approximately every 48 weeks (after imple mentation 
of Protocol Amendment 7).  
Change #16  
Section  [IP_ADDRESS].4 Tuberculin Purified Protein Derivative ([COMPANY_003] skin test):  
In study participants from 2 to 4 years of age (except for study participants 2 to 4 years of age 
with a written documentation of BCG vaccination), the [COMPANY_003] skin test must be administered 
during Screening or within the 3 months prior to Screening in accordance with the 
instructions below.  
Has been changed to:  
In study participants from 2 to 4 years of age (except for study participants 2 to 4 years of age 
with a written documentation of BCG vaccination), the [COMPANY_003] skin test must be administered 
during Screening or within the 3 months prior to Screening and once yearly during the study, 
ie, approximately every 48 weeks (after implementation o f Protocol Amendment 7) in 
accordance with the instructions below.  
Change #17  
Section  [IP_ADDRESS] TB questionnaire (evaluation of signs and symptoms associated with TB and 
guidelines for evaluating exposure risk), second paragraph, the last 2 sentences:  
Any presumptive diagnosis or diagnosis of LTB infection or active TB is a reportable event; 
refer to Section  10.2.[ADDRESS_887848] been changed to:  
Any confirmed diagnosis of a laten t or active TB infection is a reportable event; refer to 
Section  10.2.2 for details).  
Change #[ADDRESS_887849] 3 paragraphs:  
For all binary efficacy endpoints assessing response, study participants who withdra w early 
will be considered as non -responders from that time point onwards.  
For continuous efficacy endpoints, missing assessments will be imputed using the last 
observation carried forward (LOCF) approach. These summaries will be supported by 
[CONTACT_658309] (OC) analyses.  
Data collected after the taking of rescue medication will be treated as missing for continuous 
efficacy endpoints and non -response for binary efficacy endpoints in all analyses except 
where specifically stated otherwise. See Section  7.8.[ADDRESS_887850] of medications which would 
result in data at only the next scheduled visit (and not all subsequent visits) being treated as 
missing/non -response. These data will then be imputed as for any other missing data.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887851] been changed to:  
For all bin ary efficacy endpoints assessing response, study participants who withdraw early 
will be considered as non -responders from that time point onwards. The exception is efficacy 
data for study participants who withdraw after Week 56: Per Protocol Amendment  7, these 
will not be imputed (as nonresponse or missing) and will be analyzed as observed.  
For continuous efficacy endpoints, missing assessments will be imputed using the last 
observation carried forward (LOCF) approach. These summaries will be supported by 
[CONTACT_658309] (OC) analyses. Per Protocol Amendment  7, missing assessments after Week [ADDRESS_887852] of medications which would 
result in data at only the next scheduled visit (and not all subsequent visits) being treated as 
missing/non -response. These data will then be imputed as for any other missing data.  The 
exception is any rescue medication use that is initiated after Week 56:  Per Protocol 
Amendment  7, efficacy data after any rescue medication use initiated af ter Week 56 will not 
be imputed (as nonresponse or missing) and will be analyzed as observed.  
Change #19  
Section 16 REFERENCES, the following publication has been added:  
Zitelli B, McIntire S, Nowalk A. Zitelli and Davis’ Atlas of pediatric physical diagno sis, 6th 
edition. Chapter 7: Rheumatology, Section: Juvenile Idiopathic Arthritis. Elsevier Health 
Sciences, 2012, 264.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 212 of 280 17.18  Protocol Amendment 8  
Rationale for the amendment  
The primary purpose of this substantial amendment is to reduce the study participant s’ 
burden by [CONTACT_658347] -site visits, safety sampling, and efficacy assessments.  
The frequency of on -site visits will be reduced from every [ADDRESS_887853] completed the visit for Week 180. As before, on -site CZP 
administration between scheduled visits is offered as needed.  
The frequency of safety sampling (blood sampling and urinalysis) will be extended from 
every 8 weeks to every 16 weeks to reduce study participants’ burden in line with the updated 
on-site CZP administration schedule. Safety data collected previously during the study and 
close evaluation by [CONTACT_658348].   
This longer interval will also be implemented for efficacy assessments to further reduce the 
study participants’ burden and will be appropriate to describe the long -term efficacy of CZP.  
In addition, blood samples to determine CZP plasma concentrations a nd anti -CZP antibodies 
will no longer be collected in the study to further reduce study participants’ burden. 
Pharmacokinetic data from this study (assayed with an ELISA technique) will not be used for 
submission to the FDA to complete the Pediatric Resear ch Equity Act commitment, primarily 
due to some deficiencies detected on the bioanalytical assay used. UCB determined that 
further collection of additional samples to determine CZP plasma concentrations and anti -
CZP antibodies would be of limited utility a nd an undue burden on the study participants. 
There is also limited value in collecting anti -CZP antibody and CZP plasma concentration 
data after >[ADDRESS_887854] been  made throughout the protocol:  
 Study contact [CONTACT_579684].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 213 of 280  Safety laboratory assessments (including urinalysis), efficacy assessments, and on -site 
CZP administration frequency has been changed from every 8 weeks to every 
16 weeks.  
 Cessation of  samples for CZP plasma concentration and anti -CZP antibodies has been 
implemented.  
 Updated PK analysis section as the previous ELISA technique will no longer be used 
and the samples need to be re -assayed using a new MSD assay.  
 Reference to Week 56 interi m analysis removed as this interim analysis is no longer 
necessary following the . 
 Tanner stage assessment frequency has been updated from every [ADDRESS_887855] not reached Tanner stage V.  
 
Specific changes   
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 22 Sep 2016. The changes are displayed in the order of 
appearance.  
Change #[ADDRESS_887856] Manager : 
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
[LOCATION_013]  
Phone:  
Fax: 
Has been changed to:  
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
[LOCATION_013]  
Phone:  
Fax: 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 214 of 280 Change #[ADDRESS_887857] details  of the  Clinical Trial Biostatistician : 
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_887858]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003] 
Phone:  
Fax: 
Has been changed to:  
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_887859]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003] 
Phone:  
Fax: 
 
Change #3  
SERIOUS ADVERSE EVENT REPORTING, global email : 
Serious adverse event reporting (24h)  
 Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003] and  Canada:  +[PHONE_299] or +[PHONE_300]  
 E-mail  Global: [EMAIL_2443]   
Has been changed to:  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  [PHONE_301] 21  
[LOCATION_003] and Canada:  +[PHONE_299] or +[PHONE_300]  
E-mail  Global: [EMAIL_311]   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 215 of 280 Change #[ADDRESS_887860] completed the 
Week  24 (Visit  10) assessments, as well as after all active study participants have completed 
the Week 56 (Visit  14) assessments. The study will continue until the approval of the 
marketing application for the polyarticular -course JIA indication in the study participant’s 
country or region, or until discontinuation of the study based on the Week 16 a nalysis of 
response, or until further notice from UCB.  
Has been changed to:  
A full interim analysis will be performed after all active study participants have completed 
the Week  24 (Visit  10) assessments. The study will continue until the approval of the 
marketing application for the polyarticular -course JIA indication in the study participant’s 
country or region, or until discontinuation of the study based on the Week 16 analysis of 
response, or until further notice from UCB.  
 
Change #5  
Section 1, Summary,  eighth paragraph  
Certolizumab pegol will be administered as a fixed dose based on weight throughout the 
study consisting of 3  loading doses at Weeks 0, 2, and 4 (minimum=50mg every 2 weeks 
[Q2W], maximum=200mg Q2W) followed by a maintenance dose (minimum=50mg every 
4 weeks [Q4W], maximum=100mg Q2W). Prior to implementation of Protocol 
Amendments  4 and 5, the minimum and maximum loading doses in the study were 
CZP 100mg Q2W and CZP  400mg Q2W, respectively, and the minimum and maximum 
maintenance do ses were CZP  50mg Q2W and CZP  200mg Q2W, respectively. Interim 
analysis of PK data will compare plasma concentration data from this study with CZP plasma 
concentrations observed previously in adult study participants with rheumatoid arthritis (RA). 
This CZ P plasma concentration analysis will be done on an ongoing basis throughout the 
study, starting when [ADDRESS_887861] completed Week  12 
(Visit  7). Interim CZP plasma concentration data available at the time of Protocol 
Amend ment  3 indicated that no change to the dosing algorithm was required. The protocol 
stated that if future analyses indicate that plasma concentrations of JIA study participants are 
outside of the exposure range observed in previous adult RA studies, the dos ing algorithm 
may be changed via a protocol amendment.  
Has been changed to:  
Certolizumab pegol will be administered as a fixed dose based on weight throughout the 
study consisting of 3  loading doses at Weeks 0, 2, and 4 (minimum=50mg every 2 weeks 
[Q2W], m aximum=200mg Q2W) followed by a maintenance dose (minimum=50mg every 
4 weeks [Q4W], maximum=100mg Q2W). Prior to implementation of Protocol 
Amendments  [ADDRESS_887862] ively, and the minimum and maximum 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 216 of 280 maintenance doses were CZP  50mg Q2W and CZP  200mg Q2W, respectively. Interim 
analysis of PK data will compare plasma concentration data from this study with CZP plasma 
concentrations observed previously in adult study par ticipants with rheumatoid arthritis (RA). 
Interim analysis of CZP plasma concentrations was started when 6  study participants in 1  of 
the age groups completed Week  12 (Visit  7). Interim CZP plasma concentration data 
available at the time of Protocol Amendm ent 3 indicated that no change to the dosing 
algorithm was required. The protocol stated that if future analyses indicate that plasma 
concentrations of JIA study participants are outside of the exposure range observed in 
previous adult RA studies, the dosi ng algorithm may be changed via a protocol amendment.  
 
Change #6  
Section 4.3, Other variables, other safety variables, bullet 3  
 Assessments of study participants’ developmental stages and growth (height, weight) will 
be performed to determine Tanner stages  at Baseline, every 24  weeks thereafter, and the 
Early Discontinuation/End of Treatment Visit (weight at every visit through Final Visit).  
Has been changed to:  
 Assessments of study participants’ developmental stages and growth (height, weight) will 
be perf ormed to determine Tanner stages at Baseline, every 24  weeks thereafter, and the 
Early Discontinuation/End of Treatment Visit (weight at every visit through Final Visit). 
Following Protocol Amendment 8, Tanner stages assessment will be performed every [ADDRESS_887863] not reached Tanner stage V.  
 
Change #7  
Section 4.3, Other variables, other efficacy and health outcomes variables, bullets 15 
and 16; and Section 13.5 Planned efficacy and health outcomes analyses, bulle ts 16 and 
17 
 Change from Baseline in FPS-R (child -reported, ages 5  to 11 years), daily during the first 
week of treatment ; Weeks 4, 12, 16, and 24 ; and then every 8 weeks  thereafter through 
the Early Discontinuation/End of Treatment Visit.  
 Change from Bas eline in JIA Pain VAS, daily during the first 7 days of the study (acute 
and standard versions); and at Weeks 4, 12, 16, and 24; and then every 8 weeks thereafter 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
partici pants ages [ADDRESS_887864] been changed to:  
 Change from Baseline in FPS-R (child -reported, ages 5  to 11 years), daily during the first 
week of treatment ; Weeks 4, 12, 16, and 24 ; and then every 8 weeks  thereafter through 
the Early Discontinuation/End of Treatment Visit. Following Protocol Amendment 8, 
change from Baseline on FPS -R is assessed every 16 weeks.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 217 of 280  Change from Baseline in JIA Pain VAS, daily during the first 7 days of the study (acute 
and standard versions); and at Weeks 4, 12, 16, and 24; an d then every 8 weeks thereafter 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
participants ages 12 to 17 years.  Following Protocol Amendment 8, change from Baseline 
in JIA Pain VAS is assessed every 16 weeks.  
 
Change  #8 
Section 5.1, Study description, fifth paragraph  
Full interim analyses will be performed:  
 After all active study participants have completed the Week  24 (Visit 10) assessments  
 After all active study participants have completed the Week 56 (Visit 14) a ssessments  
Has been changed to:  
A full interim analysis will be performed after all active study participants have completed 
the Week  24 (Visit 10) assessments.  
 
Change #[ADDRESS_887865] completed Week  12 (Visit 7).  
Has been changed to:  
Interim analysis of PK data will compare CZP plasma concentration data from this study with 
plasma concentrations observed previously in adult study participants with RA. Interim 
analysis of CZP plasma concentrations was started when 6  study participants i n 1 of the age 
groups completed Week  12 (Visit 7).  
 
Change #10  
Section 5.1, Study description  
The following text was added:  
Pharmacokinetic data from this study (assayed with an enzyme -linked immunosorbent assay 
[ELISA] technique) will not be used for sub mission to the Food and Drug Administration 
(FDA) to complete the Pediatric Research Equity Act commitment, primarily due to some 
deficiencies detected on the bioanalytical assay used. UCB determined that further collection 
of additional samples to determi ne CZP plasma concentrations and anti -CZP antibodies 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 218 of 280 would be of limited utility and an undue burden on the study participants. Following Protocol 
Amendment 8, these samples will no longer be collected.  
For the final analysis at the end of the study, UCB will reanalyze all the available samples 
with sufficient volume with a new Meso Scale Discovery (MSD) bioanalytical assay that is 
fully validated and that meets current regulatory standards. This PK data, from the re -assayed 
samples, will be used for final  study reporting and thus will not be compared to the 
previously reported RA adult concentrations, as a different bioanalytical technique was used.  
 
Change #11  
Section 5.2, Schedule of study assessments, Table 5 -1, CZP plasma concentrations and 
anti-CZP an tibodies row  
Study period    
Week  Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a)  FV 
…   
CZP plasma concentrations and anti -CZP antibodies  X X 
…   
Has been changed to:  
Study period    
Week  Early Disc/ 
End of 
Treatment  Final 
Visit(c) 
Visit (+/ -3 days)(a)  FV 
…   
CZP plasma concentrations and anti -CZP antibodies    
…   
 
Change #12  
Section 5.2, Schedule of study assessments, Table 5 -1, footnotes f, q, r, and v  
f Height and Tanner stages to be measured at Weeks 24 and 48, every 24 weeks thereafter and at Early 
Discontinuation/End of Treatment.  
q  For study participants ages [ADDRESS_887866] week (Baseline and Day 1 to Day 
7, to be collected at Week 1). In addition, to be completed at Weeks 4, 12, 16, 24, and then every 8  weeks 
thereafter through the End of Treatment/Early Discontinuation Visit.  
r  For study participants ages [ADDRESS_887867] week (at 
Baseline and Day 1 to Day 7, to be collected at W eek 1). In addition, standard VAS version to be completed at 
Baseline, Weeks 4, 12, 16, 24, and then every 8  weeks thereafter through the End of Treatment/Early 
Discontinuation Visit for study participants ages [ADDRESS_887868] been changed to:  
f Height and Tanner stages to be measured at Weeks 24 and 48, every 24 weeks thereafter (Tanner stages will 
be measured every [ADDRESS_887869] not reached Tanner stage V following 
Protocol Amendment 8) and at Early Discontinuation/End of Treatment.  
q For study participants ages [ADDRESS_887870] week (Baseline and Day 1 to Day 
7, to be collected a t Week 1). In addition, to be completed at Weeks 4, 12, 16, 24, and then every 8  weeks 
thereafter (every 16 weeks following Protocol Amendment 8) through the End of Treatment/Early 
Discontinuation Visit.  
r  For study participants ages [ADDRESS_887871] week (at 
Baseline and Day 1 to Day 7, to be collected at Week 1). In addition, standard VAS version to be completed at 
Baseline, Weeks 4, 12, 16, 24, and then every 8  weeks thereafter (every 16 weeks follow ing Protocol 
Amendment 8) through the End of Treatment/Early Discontinuation Visit for study participants ages 12 to 17 
years.  
v CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 32, 40, and 48 and every 24 
weeks thereafter. For stud y participants already enrolled and treated prior to the implementation of Protocol 
Amendment 4 and hence undergoing a reduction of their dose, additional PK samples will be collected prior to 
dosing at the visit the dose change occurs and at the next 3 si te visits following the dose change, ie, additional 
PK samples will be collected at the Unscheduled Visits or at the regular visits if not already planned per 
regular schedule. Afterwards, the regular PK sampling schedule applies. Following Protocol Amendm ent 8, 
samples for CZP plasma concentration and anti -CZP antibodies will no longer be collected.  
 
Change #13  
Section 5.2, Schedule of study assessments, Table 5 -1, footnote z was added:  
z  Following Protocol Amendment 8, on -site CZP administration, safety  sampling, and efficacy assessment 
frequency changes to every 16 weeks instead of every 8 weeks, if administration at home is feasible. The 
option to come to the site for CZP administration between scheduled visits is available as needed.  
 
Change #14  
Section 5.3, Schematic diagram, footnote a was added:  
a Following Protocol Amendment 8, visits will be every 16 weeks instead of every 8 weeks.  
 
Change #15  
Section 8.5, section heading  
Visits 11 and continuing (Week 32 and every 8 weeks thereafter)  
Has been changed to:  
Visits 11 and continuing (Week 32 and every 8 weeks thereafter [every 16 weeks following 
Protocol Amendment 8])  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 220 of 280 Change #16  
Section 8.5, Visits 11 and continuing, bullets 2, 4, and 28  
 Height (Week 48 and every 24 weeks thereafter)  
 Tanner stages  (except growth; Week 48 and every 24 weeks thereafter)  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 32, 40, and 48 and every 
24 weeks thereafter , OR if a dose change is performed at th e current  visit OR if the study 
participant ’s dose was chan ged during [ADDRESS_887872] 3 visits  following Protocol 
Amendment 4) 
Have been changed to:  
 Height (Week 48 and every 24 weeks thereafter [every 48 weeks following Protocol 
Amendment 8])  
 Tanner stages (except growth; Week 48 and every 24 weeks thereafter [ever y [ADDRESS_887873] not reached Tanner stage V following Protocol 
Amendment 8])  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 32, 40, and 48 and every 
24 weeks thereafter , OR if a dose change is performed at th e current  visit OR if the study 
participant ’s dose was changed during [ADDRESS_887874] 3 visits  following Protocol 
Amendment 4; following Protocol Amendment 8, these samples will no longer be 
collected ) 
 
Change #17  
Section 8.7, Early Discontinuation/End of Trea tment Visit, second to last bullet  
 CZP plasma concentrations and anti -CZP antibodies  
Has been changed to:  
 CZP plasma concentrations and anti -CZP antibodies ( following Protocol Amendment 8, 
these samples will no longer be collected)  
 
Change #[ADDRESS_887875] bullet  
 CZP plasma concentrations and anti -CZP antibodies  
Has been changed to:  
 CZP plasma concentrations and anti -CZP antibodies ( following Protocol Amendment 8, 
these samples will no longer be collected)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 221 of 280 Change #19  
Section 9, Assessme nt of Pharmacokinetics and Immunological Variables  
The following text was added:  
Following Protocol Amendment 8, blood samples for determination of CZP plasma 
concentrations and anti -CZP antibodies will not be collected throughout the remainder of the 
study.  
 
Change #[ADDRESS_887876] paragraph  
Hematology , biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32, every 8 weeks thereafter, the Early Discontinuation/End of 
Treatment Visit, and the Final Visit [ADDRESS_887877] dose of study medicatio n. At 
Week 1, only CRP and PK samples will be collected and at Week 2, only CRP samples will 
be collected. In addition, hematology, biochemistry, and CRP samples will be collected at 
Unscheduled Visits related to the dose change implemented with Protocol A mendment  4. 
Has been changed to:  
Hematology, biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32, every 8 weeks thereafter (every 16 weeks following Protocol 
Amendment 8), the Early Discontinuation/ End of Treatment Visit, and the Final Visit 
[ADDRESS_887878] dose of study medication. At Week 1, only CRP and PK samples will 
be collected and at Week 2, only CRP samples will be collected. In addition, hematology, 
biochemistry, and CRP samples wil l be collected at Unscheduled Visits related to the dose 
change implemented with Protocol Amendment  4. 
 
Change #21  
Section 10.7.2, Growth (height and weight), first paragraph  
Height will be recorded at Screening, Baseline, every 24 weeks thereafter, and th e Early 
Discontinuation/End of Treatment Visit. Height will be recorded after the shoes have been 
removed. Height should preferably be measured with a wall -mounted stadiometer.  
Has been changed to:  
Height will be recorded at Screening, Baseline, every 24 w eeks thereafter (every 48 weeks 
following Protocol Amendment 8), and the Early Discontinuation/End of Treatment Visit. 
Height will be recorded after the shoes have been removed. Height should preferably be 
measured with a wall -mounted stadiometer.  
 
Change #22 
Section 10.7.3, Tanner stages  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 222 of 280 Assessments of study participants’ developmental stages on external genitalia and pubic hair 
(boys) and on breast and pubic hair (girls) will be performed to determine Tanner stages 
(Marshall and Tanner, 1969; Marshall and  Tanner, 1970). These assessments will be 
performed at Baseline, every 24 weeks thereafter, and the Early Discontinuation/End of 
Treatment Visit.  
Has been changed to:  
Assessments of study participants’ developmental stages on external genitalia and pubic hair 
(boys) and on breast and pubic hair (girls) will be performed to determine Tanner stages 
(Marshall and Tanner, 1969; Marshall and Tanner, 1970). These assessments will be 
performed at Baseline, every 24 weeks thereafter, and the Early Discontinuation/ End of 
Treatment Visit. Following Protocol Amendment 8, the assessments will be performed every 
[ADDRESS_887879] not reached Tanner stage V.  
 
Change #23  
Section 11.12, Faces Pain Scale -Revised (FPS -R), second paragraph  
The FPS-R is provided in Appendix 17.4. The FPS -R will be administered at Baseline and 
then daily during the first week of the study; at  Weeks 4, 12, 16, and 24; and then every 
8 weeks thereafter through the Early Discontinuation/End of Treatment Visit . The 
questionnaire should be checked by [CONTACT_658290].  
Has been changed to:  
The FPS -R is provided in Appendix 17.4. The FPS -R will be administered at Baseline and 
then daily during the first week of the study; at  Weeks 4, 12, 16, and 24; and then every 
8 weeks thereafter (every 16 weeks following Protocol Amendment 8) through the Early 
Discontinuation/End of Treatment Visit . The questionnaire should be checked by [CONTACT_658349].  
 
Change #24  
Section 11.13, Patient’s Assessment of Arthritis Pain (JIA Pain VAS), second  paragraph  
Both versions of the JIA Pain VAS are provided in Appendix 17.5 and Appendix 17.6. The 
Pain (VAS) will be completed at Baseline (acute and standard versions), daily during the first 
week of treatment (acute version); Weeks 4, 12, 16, and 24; and then every 8 weeks 
thereafter through the Early Discontinuation/End of Treatment Visit (standard version). The 
scale should be checked by [CONTACT_658290].  
Has been changed to:  
Both versions of the JIA Pain VAS are provided in Appendix 17.5 and Appendix 17.6. The 
Pain (VAS) will be completed at Baseline (acute and st andard versions), daily during the first 
week of treatment (acute version); Weeks 4, 12, 16, and 24; and then every 8 weeks 
thereafter (every 16 weeks following Protocol Amendment 8) through the Early 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 223 of 280 Discontinuation/End of Treatment Visit (standard versio n). The scale should be checked by 
[CONTACT_658290].  
 
Change #25  
Section 11.14, Fatigue Assessment Scale (NRS), fourth paragraph  
The Fatigue Assessment Scale is provided in Appendix 17.7. The Fatigue Assessment Scale 
will be assessed at Baseline, Weeks 1, 2, 4, 8, then every 8 weeks thereafter, and the Early 
Discontinuation/End of Treatment Visit. Preferably, the same parent/caregiver should 
complete the scale for each visit. The scale will not be completed if the study participant is 
not living with a parent/caregiver at least part -time, ie, the parent/caregiver is not able to 
answer the question appropriately. The scale should be chec ked by [CONTACT_658289].  
Has been changed to:  
The Fatigue Assessment Scale is provided in Appendix 17.7. The Fatigue Assessment Scale  
will be assessed at Baseline, Weeks 1, 2, 4, 8, 16, 24, 32, then every 8 weeks thereafter (every 
16 weeks following Protocol Amendment 8) , and the Early Discontinuation/End of Treatment 
Visit. Preferably, the same parent/caregiver should complete the scal e for each visit. The 
scale will not be completed if the study participant is not living with a parent/caregiver at 
least part -time, ie, the parent/caregiver is not able to answer the question appropriately. The 
scale should be checked by [CONTACT_658350] r completeness.  
 
Change #[ADDRESS_887880] modeling 
(NONMEM) software.  
In the Bayesian approach, the distributions of PK parameters estimated from adult data (from 
the PopPK analysis in C87068 and CL0153) will be incorporated as prior information in the 
model to estimate pediatric PK parameters. This combination of prior knowledge and sparse 
pediatric data will be analyzed within Winbugs.  
The meta -analysis will be performed by [CONTACT_658351] (C87068 and 
CL0153).  
Have been changed to:  
Plasma concentrations will be used to build a PopPK model with the nonlinear mixed -effect 
modeling (NONMEM) software.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 224 of 280 A meta -analysis was previously performed by [CONTACT_233563] p ediatric data to the adult data in a 
PopPK analysis within NONMEM (C87068 and CL0153) for the Week 24 interim analysis 
(with ELISA data).  
Change #27  
Section 13.4, Planned PK, PD, and immunological variable analysis  
The following text was added:  
For the fin al analysis, UCB will be re -assaying all available PK samples (ie, for which 
sufficient volume is available) with a newly developed MSD bioanalytical assay. The data 
from the re -assayed RA0043 PK samples will be used to build a PopPK model.  
 
Change #28  
Section 13.5, Planned efficacy and health outcomes analyses, bullets 16 and 17  
 Change from Baseline on FPS -R (child -reported, for study participants ages 5 to 11 
years), daily during the first 7 days of treatment; Weeks 4, 12, 16, and 24; and then every 
8 wee ks thereafter through the Early Discontinuation/End of Treatment Visit.  
 Change from Baseline in JIA Pain VAS, daily during the first week of the study (acute 
and standard versions); Weeks 4, 12, 16, and 24; and then every 8 weeks thereafter 
through the Ea rly Discontinuation/End of Treatment Visit (standard version) for study 
participants ages [ADDRESS_887881] been changed to:  
 Change from Baseline on FPS -R (child -reported, for study participants ages 5 to 11 
years), daily during the first 7 days of treatment; Weeks 4, 12, 16, and 24; and then every 
8 weeks thereafter through the Early Discontinuation/End of Treatment Visit. Following 
Protocol Amendment 8, change from Baseline on FPS -R is assessed every 16 weeks.  
 Change from Baseline in JIA Pain VAS, daily during the first week of the study (acute 
and standard versions); Weeks 4, 12, 16, and 24; and then every 8 weeks thereafter 
through the Early Discontinuation/End of Treatment Visit (standard version) for study 
participants ages 12 to 17 years. Following Protocol Amendment 8, change from Baseline 
in JIA Pain VAS is assessed every 16 weeks.  
 
Change #[ADDRESS_887882] completed Week  12 (Visit 7).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 225 of 280 Has been changed to:  
Interim analysis of PK data will compare CZP plasma concentration data from this stud y with 
CZP plasma concentrations observed previously in adult study participants with RA. Interim 
analysis of CZP plasma concentrations was started when 6  study participants in 1  of the age 
groups completed Week  12 (Visit 7).  
 
Change #30  
Section 13.7, Pla nned interim analysis and data monitoring, fifth paragraph  
The CZP plasma concentrations will be monitored on an ongoing basis following the change 
in dose regimen to confirm they are within the targeted adult range.  
Has been changed to:  
For the Week [ADDRESS_887883] to the adult RA concentrations range.  
 
Change #31  
Section 13.7, Planned interim analysis and data monitoring, eighth paragraph  
The following text was removed:  
A second full interim analysis of all safety and efficacy endpoints will be performed based 
upon 56 weeks of exposure (Visit 14).  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887884] plasma concentrations of CZP and anti -CZP antibodies analyzed 
using the ECLIA method . In addition, PK and ADA samples (for which sufficient volume is 
available) c ollected in this study prior to Protocol Amendment [ADDRESS_887885] been made throughout the protocol:  
 ‘Subject’ was changed to ‘study participant’.  
 Study contact [CONTACT_579684].  
 Updated  primary PK endpoints and primary safety endpoints to be more specific.  
 An additional 30 study participants will be enrolled on the original dose regimen.  
 Updated exclusion criteria to align with current clinical guidelines. The updated 
exclusion criteria are specific for the newly enrolled study participants and will not 
count as protocol deviations for study participants enrolled prior to Protocol 
Amendment 9.  
 The rationale for study design and selection of dose section was restructured for 
clarity and t o describe the rationale for adding the 30 study participants on the original 
CZP dose.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 227 of 280  Withdrawal criteria were updated to encourage study participants to remain in the 
study in the event of study medication discontinuation.  
 Study participants on the red uced CZP dose regimen will be able to switch to the 
original CZP dose regimen at the discretion of the Investigator.  
 Sampling for CZP plasma concentration and anti -CZP antibodies will occur for study 
participants enrolled following Protocol Amendment 9.  
 Updated statistical considerations section to reflect that study participants on the 
reduced CZP dose can switch dose regimens to the original CZP dose.  
 Updated safety analysis section to reflect updated primary safety endpoints of 
incidence of serious TEAEs  and TEAEs leading to permanent withdrawal of IMP . 
 Updated PK analysis section to reflect updated primary PK endpoints of CZP plasma 
concentrations and anti -CZP antibody levels at Week 16 and Week 48 .  
 Updated interim analysis section to reflect previous i nterim analyses and the analyses 
to be conducted with the newly enrolled study participants on the original CZP dose.  
 Removed the Week 16 futility analysis and the Week 56 analysis  
 Assessment and management of TB and TB risk factors has been updated to re flect 
current UCB guidelines.  
Specific changes   
This section displays the modifications in this amendment compared with the previous 
version of the protocol dated 24 Jun 2019. The changes are displayed in the order of 
appearance.  
Change #[ADDRESS_887886] details  of the  Sponsor Study Physician : 
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Chemin du Foriest  
B - 1420 Braine -l’Alleud  
Belgium  
Phone:  
Fax: 
Has been changed to:  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  UCB  
[ADDRESS_887887]  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 228 of 280 Slough  
SL1 3WE   
Phone:  
Fax: 
Change #[ADDRESS_887888] details  of the  Clinical Trial Biostatistician : 
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_887889]  
Suite  
Raleigh, NC [ZIP_CODE]  
[LOCATION_003] 
Phone:  
Fax: 
Has been changed to:  
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB  
[ADDRESS_887890]  
Slough  
SL1 3WE  
Phone:   
Fax: N/A 
Change #3  
Section 1,  paragraph 4 and 5 : 
Approximately 195 subjects will be screened to enroll 156 subjects in this study. The study 
consists of a Screening Period of up to 4 weeks; eligible subjects will then enter an open -label 
Treatment Period which will continue until the approval of the marketing application for the 
indication of polyarticular -course JIA in the subject’s country or region or until further notice 
from UCB. A Final Visit will be conducted [ADDRESS_887891] dose of study medication.  
A minimum of 10 subjects will be enrolled on the reduced CZP dose regimen (Protocol 
Amendment 5) in each weight range of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), 
and ≥40kg (≥88lb). A minimum of 10 subjects will be enrolled in each age category of 2 to 
5 years, 6 to 11 years, and 12 to 17 years, irrespective of the dose regimen. A minimum of 
25 subjects will be enrolled who receive CZP as monotherapy (ie, subjects with established 
intolerability or inadequate  response to MTX),  irrespective of the dose regimen . A minimum 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 229 of 280 of 10 subjects with ERA will be enrolled, irrespective of the dose regimen. Each of these 
categories is assessed independently.  
Has been changed to:  
Approximately [ADDRESS_887892] anned to be screened to enroll 156 study 
participants in this study, as follows:  
 A minimum of 10 study participants will be enrolled on the reduced CZP dose regimen 
(Protocol Amendment 5) in each weight range of 10 to <20kg (22 to <44lb), 20 to <40kg 
(44 to <88lb), and ≥40kg (≥88lb).  
 A minimum of 10 study participants will be enrolled in each age category of 2 to 5 years, 
6 to 11 years, and 12 to 17 years, irrespective of the dose regimen.  
 A minimum of 25 study participants will be enrolled who receive CZP as monotherapy 
(ie, study participants with established intolerability or inadequate response to MTX), 
irrespective of the dose regimen.  
 A minimum of [ADDRESS_887893] 5 study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), and ≥40kg (≥88lb) following 
Protocol Amendment 9.  
Change #4  
Section 1,  paragraph 6, was removed : 
An interim analysis of the American College of Rheumatology Pediatric 30% (PedACR30) 
response rate will be performed after all active subjects have completed the Week 16 (Visit  8) 
assessments. The study will be discontinued if less than 50% of the study popula tion enrolled 
on the reduced CZP dose regimen (Protocol Amendment 5) achieves a PedACR30 response 
at Week 16.  
Change #5  
Section 1,  paragraph 7: 
A full interim analysis will be performed after all active subjects have completed the 
Week  24 (Visit  10) assess ments. The study will continue until the approval of the marketing 
application for the polyarticular -course JIA indication in the subject’s country or region, or 
until discontinuation of the study based on the Week 16 analysis of response, or until further  
notice from UCB.  
Has been changed to:  
A full interim analysis will be performed after all active study participants have completed 
the Week  24 (Visit  10) assessments.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 230 of 280 Change #6  
Section 1,  paragraph 8: 
Certolizumab pegol will be administered as a fixed dose based on weight throughout the 
study consisting of 3 loading doses at Weeks 0, 2, and 4 (minimum=50mg every 2 weeks 
[Q2W], maximum=200mg Q2W) followed by a maintenance dose (minimum=50mg every 4 
weeks [Q4W], maximum=100mg Q2W). Prior to implementation  of Protocol Amendments 4 
and 5, the minimum and maximum loading doses in the study were CZP 100mg Q2W and 
CZP 400mg Q2W, respectively, and the minimum and maximum maintenance doses were 
CZP 50mg Q2W and CZP 200mg Q2W, respectively. Interim analysis of PK data will 
compare plasma concentration data from this study with CZP plasma concentrations observed 
previously in adult subjects with rheumatoid arthritis (RA). Interim analysis of CZP plasma 
concentrations was started when 6 subjects in 1 of the age group s completed Week 12 (Visit 
7). Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The protocol stated that if 
future analyses indicate that plasma concentration s of JIA subjects are outside of the 
exposure range observed in previous adult RA studies, the dosing algorithm may be changed 
via a protocol amendment.  
Has been changed to:  
Certolizumab pegol will be administered as a fixed dose based on weight throughout  the 
study consisting of 3  loading doses at Weeks 0, 2, and 4, followed by [CONTACT_65119] 
Q2W. The original minimum and maximum loading doses in the study were CZP 100mg 
Q2W and CZP  400mg Q2W, respectively, and the original minimum and maximum 
maintenan ce doses were CZP  50mg Q2W and CZP  200mg Q2W, respectively. Based on an 
interim PopPK analysis of RA0043 data, the minimum and maximum loading doses in the 
study were adjusted to CZP 50mg Q2W and CZP  200mg Q2W, respectively, and the 
minimum and maximum mai ntenance doses were adjusted to CZP  50mg Q4W and 
CZP 100mg Q2W, respectively, following implementation of Protocol Amendments 4 and 5.  
Change #7  
Section 1, Summary  
The following text was added:  
However, it was later determined that there were deficiencies  detected with the use of the 
bioanalytical assay within RA0043, which rendered the PK data for the PopPK analysis and 
simulations that informed the dose reduction in Protocol Amendment 4 and 5 unusable from a 
regulatory standpoint. Accordingly, PK samples were no longer collected for study 
participants on the reduced CZP dose regimen following implementation of Protocol 
Amendment 8.  
An electrochemiluminescent immuno -assay (ECLIA) method, for which selectivity had 
previously been assessed in the RA matrix, has now been validated to meet the standards set 
in the regulatory guidance for analytical procedures and methods validations for drugs and 
biologics.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887894] 163 participants enrolled in RA0043, both the 
original an d reduced dose regimens showed safety profiles similar to the approved CZP dose 
regimen in the adult RA population. The overall clinical response in this analysis (taking both 
dose regimens into account) was PedACR30 and PedACR50 responses of 77.3% and 67. 5%, 
respectively at Week 12. The response from the original dose regimen was 75.6% for 
PedACR30 and 64.1% for PedACR50. PedACR50 response demonstrates a highly clinically 
relevant decrease in disease activity.  
Therefore, in order to adequately assess the e xposure levels and clinical experience of CZP in 
JIA at both the reduced and original CZP dose regimens and also adequately support the 
safety assessment of the original CZP dosing regimen, as more of the safety data collected in 
the study to date has been  on the reduced dose, [ADDRESS_887895] plasma concentrations of 
CZP and anti -CZP anti bodies analyzed using the ECLIA method. In addition, PK and ADA 
samples (for which sufficient volume is available) collected in this study prior to Protocol 
Amendment 9 will be analyzed with the ECLIA method. The collective ECLIA -based PK 
data for this stu dy will form the basis of any future CZP modeling and simulation work.  
Change #8  
Section 1,  paragraph 10: 
The primary objectives of the study are to evaluate the PK and safety including the 
immunogenicity of CZP administered subcutaneously (sc) in children  and adolescents with 
moderate to severe polyarticular -course JIA. The secondary objective of the study is to assess 
the effectiveness of CZP on the clinical response in children and adolescents with moderate 
to severe polyarticular -course JIA.  
Has been changed to:  
The primary objectives of the study are to evaluate the PK and safety including the 
immunogenicity of CZP administered subcutaneously (sc) in children and adolescents with 
moderate to severe polyarticular -course JIA. The primary PK and immunolo gical variables 
are CZP plasma concentrations and anti -CZP antibody levels at Week 16 and Week 48.  
Change #9  
Section 1,  paragraph 11: 
The primary safety variable is the incidence of adverse events (AEs). Other safety variables 
to be assessed are vital signs and measurements of laboratory parameters including 
hematology, biochemistry, and urinalysis. Physical examination findings (except joint 
examination) are recorded in the case report form (CRF) only at Screening. Subsequent 
physical examinations are performed to assess clinically significant changes and thus, only 
abnormal findings are recorded in the CRF as AEs. Tanner stages (except growth) and 
growth (height, weight) over the course of the study will be assessed. Autoantibody 
(antinuclear antibodie s [ANA] and anti -double -stranded deoxyribonucleic acid [anti -dsDNA] 
antibodies) concentrations will be evaluated.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 232 of 280 Has been changed to:  
The primary safety variables are the incidence of serious treatment -emergent adverse events 
(TEAEs) and TEAEs leading to permanent withdrawal of IMP. Other safety variables to be 
assessed are the incidence of TEAEs, vital signs and measurements of laboratory parameters 
including hematology, biochemistry, and urinalysis. Physical examination findings (except 
joint examination ) are recorded in the case report form (CRF) only at Screening. Subsequent 
physical examinations are performed to assess clinically significant changes and thus, only 
abnormal findings are recorded in the CRF as AEs. Tanner stages (except growth) and 
growt h (height, weight) over the course of the study will be assessed. Autoantibody 
(antinuclear antibodies [ANA] and anti -double -stranded deoxyribonucleic acid [anti -dsDNA] 
antibodies) concentrations will be evaluated. The secondary objective of the study is t o assess 
the effectiveness of CZP on the clinical response in children and adolescents with moderate 
to severe polyarticular -course JIA.  
Change #10  
Section 2, paragraph 2, second sentence : 
Juvenile idiopathic arthritis is the most commonly diagnosed rheuma tic disease affecting 
children less than 16  years of age with a prevalence of approximately 100 in 100,000 (Zitelli 
et al, 2012).  
Has been changed to:  
Juvenile idiopathic arthritis is the most commonly diagnosed rheumatic disease affecting 
children less th an 16  years of age with a prevalence of approximately 100 in 100,000 children 
(Zitelli et al, 2012).  
Change #[ADDRESS_887896] sentence : 
Other serious AEs that have been infrequently reported in patients treated with currently 
available TNF -antagonists including CZP include congestive heart failure, drug -induced 
lupus, new -onset psoriasis, seizures, demyelinating disorders, and pancytopenia.  
Has been changed to:  
Other serious AEs that have been infrequently reported in patients treated with c urrently 
available TNF -antagonists including CZP include congestive heart failure, drug -induced 
lupus, demyelinating disorders, and pancytopenia.  
Change #12  
Section 4.1.1 : 
Certolizumab pegol plasma concentrations and anti -CZP antibody concentrations will b e 
assessed and data will be summarized.  
Has been changed to:  
Certolizumab pegol plasma concentrations and anti -CZP antibody levels at Week 16 and 
Week 48 will be assessed and data will be summarized.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 233 of 280 Change #13  
Section 4.1.2, paragraph 1 : 
The primary safet y variable will be the incidence of AEs.  
Has been changed to:  
The primary safety variables will be the incidence of serious TEAEs and TEAEs leading to 
permanent withdrawal of IMP.  
Change #14  
Section 4.3: 
The following text was added:  
Other PK and immunological variables are:  
 Certolizumab pegol plasma concentrations and anti -CZP antibody levels at other study 
timepoints  
Other safety variables are:  
 Incidence of TEAEs, TEAEs of interest, TEAEs by [CONTACT_182811], TEAEs by [CONTACT_926], and 
TEAEs by [CONTACT_24109] o f exposure  
Change #15  
Section 4.3, fifth bullet : 
 Assessments of subjects’ developmental stages and growth (height, weight) will be 
performed to determine Tanner stages at Baseline, every 24  weeks thereafter, and the 
Early Discontinuation/End of Treatment V isit (weight at every visit through Final Visit). 
Following Protocol Amendment 8, Tanner stages assessment will be performed every 
[ADDRESS_887897] not reached Tanner stage V . 
Has been changed to:  
 Assessments of study particip ant’s developmental stages and growth (height, weight) will 
be performed to determine Tanner stages at Baseline, every 24  weeks thereafter, and the 
Early Discontinuation/End of Treatment Visit (weight at every visit through Final Visit). 
For study particip ants enrolled prior to Protocol Amendment [ADDRESS_887898] not reached Tanner stage V . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 234 of 280 Change #1 6 
Section 4.3, bullet 15 and 16 under ‘other efficacy and health outcome variables’ : 
 Change from Baseline in FPS-R (child -reported, ages 5  to 11 years), daily during the first 
week of treatment ; Weeks 4, 12, 16, and 24 ; and then every 8 weeks  thereafter through 
the Early Discontinuation/End of Treatm ent Visit . Following Protocol Amendment 8, 
change from Baseline on FPS -R is assessed every 16 weeks.  
 Change from Baseline in JIA Pain VAS, daily during the first 7 days of the study (acute 
and standard versions); and at Weeks 4, 12, 16, and 24; and then ev ery 8 weeks thereafter 
through the Early Discontinuation/End of Treatment Visit  (standard version) for subjects 
ages 12 to 17 years.  Following Protocol Amendment 8, change from Baseline in JIA Pain 
VAS is assessed every 16 weeks.  
Has been changed to:  
 Change from Baseline in FPS-R (child -reported, ages 5  to 11 years), daily during the first 
week of treatment ; Weeks 4, 12, 16, 24, and then every 8  weeks thereafter through the 
Early Discontinuation/End of Treatment Visit.  For study participants enrolled p rior to 
Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 
8 weeks following implementation of Protocol Amendment 8.  
 Change from Baseline in JIA Pain VAS, daily during the first 7 days of the study (acute 
and standard versions ); and at Weeks 4, 12, 16, 24, and then every 8  weeks thereafter 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
participants ages 12 to 17 years.  For study participants enrolled prior to Protocol 
Amendment 9, visit fr equency changes to every 16 weeks instead of every 8  weeks 
following implementation of Protocol Amendment 8.  
Change #1 7 
Section 5.1, paragraph 4  and 5 were removed : 
An interim analysis of the PedACR30 response rate will be performed after all active subjec ts 
have completed the Week 16 (Visit 8) assessments. If less than 50% of the study population 
enrolled on the reduced CZP dose regimen (Protocol Amendment 5) achieves a PedACR30 
response at Week 16, the study will be discontinued.  
A full interim analysis w ill be performed after all active subjects have completed the 
Week  24 (Visit 10) assessments.  
Change #18  
Section 5.1, paragraph 6 : 
A Screening Visit is used to initiate assessments of eligibility. Certolizumab pegol will be 
administered as a fixed dose based on weight throughout the study (see Table 7 -1). At 
Baseline (Week 0, Visit 2) eligible subjects will begin with 3 loading doses of CZP at Weeks 
0, 2, and 4 (minimum=50mg Q2W, maximum=200mg Q2W) followed by a maintenance 
dose for the duration of the study (minimum=50mg Q4W, maximum=100mg Q2W). Prior to 
implementation of Protocol Amendments 4 and 5, the minimum and maximum loading do ses 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 235 of 280 in the study were CZP 100mg Q2W and CZP 400mg Q2W, respectively, and the minimum 
and maximum maintenance doses were CZP 50mg Q2W and CZP 200mg Q2W, respectively. 
After Week 4 (Visit 5), home based CZP administration by [CONTACT_11867]/caregiver 
will be permitted between scheduled study visits.  
Has been changed to:  
A Screening Visit is used to initiate assessments of eligibility. Certolizumab pegol will be 
administered as a fixed dose based on weight throughout the study (see Table 7 -1 for doses 
administered and Section  5.4.2  for the rationale for the different dose regimens). At Baseline 
(Week 0, Visit 2) eligible study participants will begi n with 3 loading doses of CZP at Weeks 
0, 2, and 4 followed by a maintenance dose for the duration of the study. After Week 4 
(Visit  5), home -based CZP administration by [CONTACT_658248]/caregiver will be 
permitted between scheduled study vi sits. 
Change #19  
Section 5.1, paragraph 7 was removed:  
A minimum of 10 subjects will be enrolled on the reduced CZP dose regimen (Protocol 
Amendment 5) in each weight range of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), 
and ≥40kg (≥88lb). A minim um of 10 subjects will be enrolled in each age category of 2 to 
5 years, 6 to 11 years, and 12 to 17 years, irrespective of the dose regimen. A minimum of 
25 subjects will be enrolled who receive CZP as monotherapy (ie, subjects with established 
intolerabi lity or inadequate response to MTX) , irrespective of the dose regimen . A minimum 
of 10 subjects with ERA will be enrolled, irrespective of the dose regimen. Each of these 
categories is assessed independently.  
Change #20  
Section 5.1, paragraph 8:  
Interim analysis of PK data will compare CZP plasma concentration data from this study with 
plasma concentrations observed previously in adult subjects with RA . Interim analysis of 
CZP plasma concentrations was started when 6  subjects in 1  of the age groups comple ted 
Week  12 (Visit 7).  
Has been changed to:  
Interim analyses were performed as described in Section 13.7. A full interim analysis will be 
performed after all active study participants have completed the Week 24 (Visit 10) 
assessments.   
Change #21  
Section 5.1, paragraphs 8 and 9 were removed:  
The therapeutic plasma concentration of CZP in children and adolescents is expected to be 
similar to that required for the adult population (see Section 5.4.2 ). Interim CZP plasma 
concentration data available at the time of Protocol Amendment 3 indicated that no change to 
the dosing algorithm was required. The protocol stated that if future analyses indicate that 
plasma concentrations are outside of the exposure range observed in previous studies with 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 236 of 280 adults, the dosing algorithm may be changed via a protocol amendment. This study will 
continue during the PK analysis. All subjects assessed in this analysis will con tinue treatment 
after Week 12 (Visit 7).  
Results of an interim PopPK analysis conducted in Jun  [ADDRESS_887899] that for some subjects in RA0043 receiving the 
originally determined loading doses up to Week 4 (Visit 5), plasma concentrations are likely 
to exceed the range previously seen in adult subjects receiving CZP  400mg Q2W. 
Furthermore, plasma concentratio ns of subjects receiving the originally determined 
maintenance dose after Week 4 (Visit 5) are predicted to exceed the concentration range 
observed in adults receiving CZP  200mg Q2W. Based on these findings, the dosing regimen 
will be changed with Protocol  Amendments 4 and 5, and the doses to be administered will be 
reduced by 50% for all weight groups. This dose change is intended to achieve plasma 
concentrations that are similar to the effective concentrations observed in previous studies in 
adult subject s with RA. Continued analysis of CZP plasma concentrations (including 
additional assessments for subjects undergoing a dose reduction with Protocol Amendment 4) 
will be performed to confirm that the 50% dose reduction will result in plasma concentrations 
within the target range of those observed in adults.  
Change #2 2 
Section 5.1, paragraph 10:  
Pharmacokinetic data from this study (assayed with an enzyme -linked immunosorbent assay 
[ELISA] technique) will not be used for submission to the Food and Drug Admini stration 
(FDA) to complete the Pediatric Research Equity Act commitment, primarily due to some 
deficiencies detected on the bioanalytical assay used. UCB determined that further collection 
of additional samples to determine CZP plasma concentrations and an ti-CZP antibodies 
would be of limited utility and an undue burden on the subjects. Following Protocol 
Amendment 8, these samples will no longer be collected.  
Has been changed to:  
Pharmacokinetic data from this study that were assayed with an enzyme -linked 
immunosorbent assay (ELISA) technique will not be used for submission to the Food and 
Drug Administration (FDA) to complete the Pediatric Research Equity Act commitment, 
primarily due to deficiencies detected with the use of the bioanalytical assay within RA0043. 
All study participants enrolled following Protocol Amendment [ADDRESS_887900] plasma 
concentrations of CZP and anti -CZP antibodies analyzed using an ECLIA method that meets 
current regulatory standards. In addition, PK and ADA samples (for which sufficient volume 
is available) collected in this study prior to Protocol Amendment 9 will be analyzed with the 
ECLIA method.  The collective ECLIA -based PK data for this study will form the basis of 
any future CZP modeling and simulation work.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 237 of 280 Change # 23 
Section 5.1, paragraph 11 was removed:  
For the final analysis at the end of the study, UCB will reanalyze all the available samples 
with sufficient volume with a new Meso Scale Discovery (MSD) bioanalytical assay that is 
fully validated and that meets curre nt regulatory standards. This PK data, from the re -assayed 
samples, will be used for final study reporting and thus will not be compared to the 
previously reported RA adult concentrations, as a different bioanalytical technique was used.  
Change #24  
Section  5.1.1, paragraph 1, second sentence:  
Eligible subjects will subsequently initiate open -label treatment with CZP at Baseline (Week 
0, Visit  2) and be permitted to continue until the approval of the marketing application for the 
polyarticular -course JIA indication in the subject’s country or region, or until discontinuation 
of the study based on the Week 16 analysis of response, or until further notice from UCB.  
Has been changed to:  
Eligible study participants will subsequently initiate open -label treatme nt with CZP at 
Baseline (Week 0, Visit  2) and be permitted to continue until the approval of the marketing 
application for the polyarticular -course JIA indication in the study participant’s country or 
region, or until further notice from  UCB.  
Change #[ADDRESS_887901] sentence:  
Planned Last Subject, First Visit –  1Q/2Q 2015  
Has been changed to:  
Planned Last Study participant, First Visit – 3Q 2021  
Change #[ADDRESS_887902] sentence:  
Approximately 195 subjects will be screened at about 55 centers in order to enroll 
156 subjects in this study.  
Has been changed to:  
Approximately 195 study participants are planned to be screened at about 55 centers in order 
to enroll 156  study participants in this study, as follows:   
Chang e #27  
Section 5.1.2, paragraph 2 was moved to paragraph 6:  
The enrollment per site is limited to a maximum of 12 subjects.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 238 of 280 Change #28  
Section 5.1.2, bullet 1 : 
A minimum of 10 subjects will be enrolled on the reduced CZP dose regimen (Protocol 
Amendment 5) in each weight range of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), 
and ≥40kg (≥88lb)  
Has been changed to:  
A minimum of 10 study participants will be enrolled on the reduced CZP dose regimen in 
each weight range of 10 to <20kg (22 to <44lb), 20 t o <40kg (44 to <88lb), and ≥40kg 
(≥88lb) (See Section  7.2 for the doses administered in the study and Section  [IP_ADDRESS]  for the 
rationale for the reduced CZP dose regimen).  
Change #29  
Section 5.1.2, the following text was added:  
Recruitment based on all protocol amendments prior to Protocol Amendment [ADDRESS_887903] 5 study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88l b), and ≥40kg (≥88lb) (See Section  7.2 
for the doses administered in the study and Section  [IP_ADDRESS]  for the rationale for the original 
CZP dose regimen).   
Change #30  
Section 5.2, Schedule of study assessments, Table 5 -1, CZP plasma concentrations and 
anti-CZP antibodies row  
Study period     
Week  … 4, 8, 12, 16, 
(17(u)), 20, 
24  
Visit (+/ -3 days)(a)  5 to 10   
…    
CZP plasma concentrations and anti -CZP antibodies   x  
…    
Has been changed to:  
Study period     
Week  … 4, 8, 12, 16, 
(17(u)), 20, 
24 … 
Visit (+/ -3 days)(a)  5 to 10   
…    
CZP plasma concentrations   x  
Anti-CZP antibodies   x  
…    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 239 of 280 Change #31  
Section 5.2, Schedule of study assessments, Table 5 -1, footnote f  
Height and Tanner stages to be measured at Weeks 24 and 48, every 24 weeks thereafter 
(Tanner stages will be measured every [ADDRESS_887904] not reached 
Tanner stage V following Protocol Amendment 8) and at Early Discontinuation/End of 
Treatment.  
Has been changed to:  
Height stages to be measured at Week  24 and 48,  every 24 weeks thereafter  (for study 
participants enrolled prior to Protocol Amendment 9, Tanner stages assessment will be 
performed every [ADDRESS_887905] not reached Tanner stage V ) and at Early Discontinuation/End of Treatment.   
Change #32  
Section 5.2, Schedule of study assessments, Table 5 -1, footnote i  
TB questionnaire to be completed at Weeks 12 and 24, every 16 weeks thereafter, and Early 
Discontinuation/End of Treatment. If the Investigator suspects reactivation o f latent TB or 
active TB, TB testing and/or a chest x -ray should be performed as outlined in 
Section  [IP_ADDRESS].  
Has been changed to:  
TB questionnaire to be completed at Weeks 12 and 24 and every 16 weeks thereafter, and 
Early Discontinuation/End of Treatmen t. If the Investigator suspects reactivation of latent TB 
or active TB, TB testing and/or a chest x -ray should be performed as outlined in 
Section  10.7.9.   
Change #33  
Section 5.2, Schedule of study assessments, Table 5 -1, footnote I, sentence 2  
If the Inve stigator suspects reactivation of latent TB or active TB, TB testing and/or a chest 
x-ray should be performed as outlined in Section 10.7.9.  
Has been changed to:  
If the Investigator suspects latent TB or active TB, TB testing and/or a chest x -ray should be  
performed as outlined in Section 10.7.9.  
Change #[ADDRESS_887906] to be fasting.  
Has been changed to:  
Hematology/biochemistry/urinalysis will be performed by a central laboratory, except urine 
dipsticks, which will be done locally at the site.  Study participants do not have to be fasting.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 240 of 280 Change #3 5 
Section 5.2, Schedule  of study assessments, Table 5 -1, footnote k  
At Screening, laboratory testing includes testing for HBcAb, HBsAb, HBsAg, and HCVAb. 
In addition, HBV DNA is required for subjects with only positive HBcAb (negative HBsAg 
and HBsAb) or with only positive HBsAg . Retesting on 1 additional occasion within the 
Screening Period is allowed in case of isolated exclusionary laboratory results, if, in the 
Investigator’s opi[INVESTIGATOR_1649], the value is not reflective of the subject’s previous clinical and 
laboratory pattern. In ad dition, retesting within the Screening Period is allowed in case of 
reporting failure of laboratory results (eg, issues with transportation of samples) . 
Has been changed to:  
At Screening, laboratory testing includes testing for hepatitis B core antibody, h epatitis B 
surface antibody, hepatitis B surface antigen, hepatitis C virus antibody , and HIV 1/[ADDRESS_887907] will not be allowed in the study (except for 
anti-hepatitis B surface positive only, in case study participant is immune due to well -
documented hepatitis B vaccination or isolated false -positive anti -hepatitis B core test 
confirmed with a confirmatory test such as hepatitis B virus deoxyribonucleic acid [DNA]). 
A positive hepatitis C antibody test will be confirmed by a confirmatory test (such as 
hepatitis C virus ribonucleic acid [RNA]) and those with a positive confirmatory test w ill not 
be allowed in the study.   
Change #3 6 
Section 5.2, Schedule of study assessments, Table 5 -1, footnote n  
TB screening if not performed within 3 months of Screening: Interferon -gamma release assay 
(IGRA) testing (QuantiFERON®) is required to be performed by [CONTACT_658352] 5 to 17 years of age. [COMPANY_003] testing is mandatory for subjects from 2 to 4 years o f 
age in this study unless written documentation of BCG vaccination is available (refer to 
Section 6.2 [exclusion criterion 11] and Section 10.7.9). Following implementation of 
Protocol Amendment 7, IGRA testing (QuantiFERON) should be done once a year 
(approximately every 48 weeks) for all subjects from 5 to 17 years of age. For subjects from 
2 to 4 years of age, both IGRA and [COMPANY_003] testing should be performed once a year 
(approximately every 48 weeks). In cases where written documentation of BCG vaccination  
is available or previous [COMPANY_003] test was positive, only IGRA should be performed (Section 
[IP_ADDRESS]).  
Has been changed to:  
TB screening: Interferon -gamma release assay (IGRA) testing (QuantiFERON®) is required 
to be performed by [CONTACT_658249] [ADDRESS_887908] 
and IGRA testing at Screening is mandatory for study participants less than 5 years of age in 
this study unless written documentation of BCG vaccination is available (refer to Section 6.2 
[exclusion criterion 11]  and Section 10.7.9). Following implementation of Protocol 
Amendment 7, IGRA testing (QuantiFERON) should be done once a year (approximately 
every 48 weeks) for all study participants.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 241 of 280 Change #[ADDRESS_887909] radiograph (anterior -posterior view at minimum, but preferably anterior -posterior and 
lateral) must be taken if the subject has a positive IGRA/[COMPANY_003] testing at Screening or, if 
written documentation of BCG vaccination is available for subjects  ages [ADDRESS_887910]’s risk of exposure or infection with TB. If a 
subject has had a recent radiograph of the chest within approximately [ADDRESS_887911]/pulmonary physician who is specifically required to look 
for evidence of active TB or inactive TB. Refer to Section [IP_ADDRESS].[ADDRESS_887912] x -rays.  
Has been c hanged to:  
Chest radiographic imaging is done at Screening and results must be available at Baseline 
before first drug administration unless as chest x -ray or CT is available within 2 months prior 
to Screening .  
Change #[ADDRESS_887913] week (Baseline and Day 1 
to Day 7, to be collected at Week 1). In addition, to be completed at Weeks 4, 12, 16, 24, and 
then every 8  weeks thereafter (every  16 weeks following Protocol Amendment 8) through the 
End of Treatment/Early Discontinuation Visit.  
Has been changed to:  
For study participants ages [ADDRESS_887914] week (Baseline 
and Day 1 to Day 7, to be collected at Week  1). In addition, to be completed at Weeks 4, 12, 
16, 24, and then every 8  weeks thereafter ( for study participants enrolled prior to Protocol 
Amendment 9, visit frequency changes to every 16 weeks instead of every 8 weeks following 
implementation of Proto col Amendment 8 ) through the  End of Treatment/Early 
Discontinuation Visit.  
Change #[ADDRESS_887915] 
week (at Baseline and Day 1 to Day 7, to be collected at Week 1). In addition, standard VAS 
version to be completed at Baseline, Weeks 4, 12, 16, 24, and then every 8 weeks thereafter 
(every 16 weeks following Protocol Amendment 8) through the End of Treatment/Earl y 
Discontinuation Visit for subjects ages 12 to 17 years.  
Has been changed to:  
For study participants ages [ADDRESS_887916] week (at Baseline and Day 1 to Day 7, to be collected at Week 1). In addition,  standard 
VAS version to be completed at Baseline, Weeks 4, 12, 16, 24, and then every 8 weeks 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 242 of 280 thereafter ( for study participants enrolled prior to Protocol Amendment 9, visit frequency 
changes to every 16 weeks instead of every 8 weeks following implement ation of Protocol 
Amendment 8 ) through the End of Treatment/Early Discontinuation Visit for study 
participants ages 12 to 17 years.  
Change # 40 
Section 5.2, Schedule of study assessments, Table 5 -1, footnote u  
CZP plasma concentration and anti -CZP antibodie s to be measured at Weeks 4, 12, 16, and 
24. A postdose CZP plasma sample will be collected at approximately 5 to 7 days following 
the Week 16 Visit (ie, requires an additional clinic site visit for blood collection at Week 17). 
For subjects already enroll ed and treated prior to the implementation of Protocol Amendment 
4 and hence undergoing a reduction of their dose, additional PK samples will be collected 
prior to dosing at the visit the dose change occurs and at the next 3 site visits following the 
dose change, ie, additional PK samples will be collected at the Unscheduled Visits or at the 
regular visits if not already planned per regular schedule. Afterwards, the regular PK 
sampling schedule applies  
Has been changed to:  
CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 4, 12, 16, and 
24. A postdose CZP plasma sample will be collected at approximately 5 to 7 days following 
the Week 16 Visit (ie, requires an additional clinic site visit for blood collection at Week 17). 
Samples for CZ P plasma concentration and anti -CZP antibodies will be collected as separate 
samples.  
Change #4 1 
Section 5.2, Schedule of study assessments, Table 5 -1, footnote v  
CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 32, 40, and 48 
and every 24 weeks thereafter. For subjects already enrolled and treated prior to the 
implementation of Protocol Amendment 4 and hence undergoing a reduction of their dose, 
additional PK samples will be collected prior to dosing at the visit the dose change oc curs and 
at the next 3 site visits following the dose change, ie, additional PK samples will be collected 
at the Unscheduled Visits or at the regular visits if not already planned per regular schedule. 
Afterwards, the regular PK sampling schedule applies. Following Protocol Amendment 8, 
samples for CZP plasma concentration and anti -CZP antibodies will no longer be collected.  
Has been changed to:  
CZP plasma concentration and anti -CZP antibodies to be measured at Weeks 32, 40, 48, and 
every 24 weeks thereafte r for study participants enrolled following Protocol Amendment 9. 
For study participants enrolled prior to Protocol Amendment 9, samples for CZP plasma 
concentration and anti -CZP antibodies will no longer be collected. Samples for CZP plasma 
concentration and anti -CZP antibodies will be collected as separate samples.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 243 of 280 Change #4 2 
Section 5.2, Schedule of study assessments, Table 5 -1, footnote z  
Following Protocol Amendment 8, on -site CZP administration, safety sampling, and efficacy 
assessment frequency chang es to every 16 weeks instead of every 8 weeks, if administration 
at home is feasible. The option to come to the site for CZP administration between schedule d 
visits is available as needed . 
Has been changed to:  
For study participants enrolled prior to Proto col Amendment 9, on -site CZP administration, 
safety sampling, and efficacy assessment frequency changes to every 16 weeks instead of 
every 8 weeks following implementation of Protocol Amendment 8, provided that 
compliance is maintained with the CZP dosing schedule using at -home administration. The 
option to come to the site for CZP administration between scheduled visits is available as 
needed.  
Change #4 3 
Section 5.3, Schematic diagram, footnote a  
Following Protocol Amendment 8, visits will be every 16 weeks instead of every 8 weeks.  
Has been changed to:  
Following Week 32, visits will be every 8 weeks. For study participants enrolled prior to 
Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 8 weeks 
following implementation  of Protocol Amendment 8 .   
Change #4 4 
Section 5.3, Schematic diagram, footnote b has been added  
The futility analysis of PedACR30 after all study participants on the reduced CZP dose 
completed Week 16 has already been completed. A further futility analys is will not be 
performed using the additional study participants that will be enrolled on the original CZP 
dose regimen following the implementation of Protocol Amendment 9.  
Change #4 5 
Section 5.4.1, paragraph 3, sentence 3:  
In light of these results and the efficacy  of CZP demonstrated in the 4 adequate and well -
controlled studies in adult RA, it is appropriate to extrapolate these efficacy data to the 
intended JIA population if similar results are obtained for PK and safety in JIA as seen for 
adult RA. The opi[INVESTIGATOR_658242] -label PK/safety data is acceptable for additional members  of the 
class of TNF -antagonists.  
Has been changed to:  
Through extensive interactions between the FDA and external experts, culminating in a 
collaborative workshop in October 2019 entitled “Accelerating Drug Development for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 244 of 280 polyarticular Juvenile Idiopathic Arthritis (pJIA)”, a therapeutic bridging approach from RA 
to pJIA was strongly supported for TNF -α inhi bitors based on the relationship between RA 
and pJIA and the extensive knowledge of TNF -α inhibitors as therapeutic agents in these two 
populations. This approach (based on "Pharmacokinetic (PK) matching") directs that the 
therapeutic effect of TNF -α inhib itors (such as CZP) in pJIA patients can be expected if the 
pediatric systemic exposure for the drug is within the therapeutic range for adult RA patients.  
Change #4 6 
Section 5.4.1, the following text was added:  
Study RA0043 is being undertaken in support  of the pJIA Pediatric Research Equity Act 
(PREA) requirement for CZP. The pJIA development program for CZP will be based on PK 
data generated with the newly validated MSD ECLIA method for pediatric study participants 
in (Section 7.2 and Section 5.4.2). To  enable this approach, an additional 30 study 
participants will be enrolled in RA0043 following Protocol Amendment 9 at the original CZP 
dosing regimen.  
Central to application of this approach is the existence of a reference systemic exposure (PK) 
range w hich is associated with therapeutic benefit of the drug in adult RA population. A 
supporting adult reference PK dataset for "PK matching" in the pJIA program will also need 
to be based on data generated with the ECLIA method. Accordingly, a separate study is being 
undertaken in order to generate ECLIA -based CZP PK data for CZP in adults with RA.  
Change #4 7 
Section 5.4.2, the following text was added:  
The original minimum and maximum loading doses in the study were CZP 100mg Q2W and 
CZP 400mg Q2W, respectively, and the original minimum and maximum maintenance doses 
were CZP  50mg Q2W and CZP  200mg Q2W, respectively (see Section  [IP_ADDRESS]  for the 
rationale for the original CZP dose regimen). Based on an interim PopPK analysis of RA0043 
data, the minimum and maximum loading doses in the study were adjusted to CZP 50mg 
Q2W and CZP  200mg Q2W, respectively, and the minimum and maximum maintenance 
doses w ere adjusted to CZP  50mg Q4W and CZP  100mg Q2W, respectively, following 
implementation of Protocol Amendments 4 and 5 (see Section  [IP_ADDRESS]  for the rati onale for the 
reduced CZP dose regimen).  
However, it was later determined that there were deficiencies detected with the use of the 
bioanalytical assay within RA0043,  which rendered the PK data for the PopPK analysis and 
simulations that informed the dose  reduction in Protocol Amendment 4 and 5  unusable from a 
regulatory standpoint . Accordingly, PK samples were no longer collected for study 
participants on the reduced CZP dose regimen following implementation of Protocol 
Amendment 8.  
An ECLIA method, for which selectivity had previously been assessed in the RA matrix, has 
now been validated to meet the standards set in the regulatory guidance for analytical 
procedures and methods validations for drugs and biologics (FDA, Guidance for Industry – 
Bioanalytic al Method Validation, 2018). The ECLIA assay consists of a homogeneous 
bridging immunoassay on the MSD platform.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 245 of 280 Based on 24 -week interim results from RA0043 (Section  13.7), both the original and reduced 
dose regimens showed safety profiles similar to the approved CZP dose regimen in the adult 
RA population. The overall clinical response in the study (taking both dose regimens into 
account) was PedACR30  and PedACR50 responses of 77.3% and 67.5%, respectively at 
Week 12. The response from the original dose regimen was 75.6% for PedACR30 and 64.1% 
for PedACR50. PedACR50 response demonstrates a highly clinically relevant decrease in 
disease activity.  
Theref ore, in order to adequately assess the exposure levels and clinical experience of CZP in 
pJIA at both the reduced and original CZP dose regimens and also adequately support the 
safety assessment of the original CZP dosing regimen, as more of the safety dat a collected in 
the study to date has been on the reduced dose, [ADDRESS_887917] plasm a concentrations of 
CZP and anti -CZP antibodies analyzed using the ECLIA method. In addition, PK and ADA 
samples ( for which sufficient volume is available) collected in this study prior to Protocol 
Amendment  9 will be analyzed with the ECLIA method. The c ollective ECLIA -based PK 
data for this study will form the basis of any future CZP modeling and simulation work.  
Change #4 8 
Section 5.4.2, the Section [IP_ADDRESS] and Section [IP_ADDRESS] heading s were  added.  
Change #4 9 
Section 5.4.2, paragraph 3; the following text was moved to Section [IP_ADDRESS]:  
During the course of the study, results from the ongoing interim PK analysis and an interim 
PopPK analysis conducted in Jun  2013 indicated that plasma concentrations within the r ange 
previously seen in adult subjects receiving CZP 200mg Q2W would be achieved if the dose 
in RA0043 was reduced to 50% of the original dose used in the study. Therefore, the 
maintenance doses in this study will be reduced further with Protocol Amendment  4 so that 
subjects with body weights between 20 and <40kg (44 to <88lb) will receive CZP  50mg 
Q2W, and subjects with body weights of ≥40kg (≥88lb) will receive CZP  100mg Q2W (see 
Table 7 -1). The optimal maintenance dose estimated in the PopPK model for th e lowest 
weight group would be CZP  25mg Q2W, however, the lowest available dose size is 
CZP 50mg. Thus, subjects with body weights of 10  to <20kg (22 to <44lb) will receive 
CZP 50mg Q4W to achieve this 50% reduction. In addition, with Protocol Amendment 5,  the 
loading dose in the study will be reduced by 50% for newly enrolled subjects, so that subjects 
with body weights of 10 to <20kg (22 to <44lb) will receive CZP 50mg at Weeks 0, 2, and 4, 
subjects with body weights between 20 to <40kg (44 to <88lb) will  receive CZP  100mg at 
Weeks 0, 2, and 4, and subjects with body weights ≥40kg (≥88lb) will receive CZP  200mg at 
Weeks 0, 2, and 4.  
The rationale behind selecting the equivalent of the adult therapeutic dose is based on the 
following:  
 There is no metabolic rationale to expect a difference in the PK/PD of CZP in a younger 
population, particularly as there is no involvement of cytochrome P450.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 246 of 280  Evaluation of a previous anti -TNF antibody (CDP571, a whole antibody) in a pediatric 
population (administered iv) conf irmed that the PK and safety were similar to that of an 
adult population.  
 Doses in excess of CZP 400mg (up to CZP 800mg) have been administered to healthy 
adult subjects and subjects with RA without any dose -limiting toxicities being identified.  
 A conservative approach to dose reduction was chosen because the body weight of 
pediatric subjects may be influenced largely by [CONTACT_658353].  
Change # [ADDRESS_887918] sentence:  
The original choice of dose and the weight -based dose -adjustment algorithm, prior to 
Protocol Amendments 4 and 5, was supported by [CONTACT_658354]/PD exposure  response model 
developed in adult RA subjects, corrected for pediatric demographics (C87079 addendum 
[ADDRESS_887919] 2008).  
Has been changed to:  
The original choice of dose and the weight -based dose -adjustment algorithm was supported 
by [CONTACT_658355]/PD exposure response model developed in adult RA study participants, corrected for 
pediatric demographics (C87079 addendum [ADDRESS_887920] 2008).  
Change # 51 
Section 5.4.2, paragraph 4, sentence 5 was removed:  
The revised dose and weight -based dose adjustment algorithm was based on a PopPK 
analysis and simulation using data from [ADDRESS_887921] -Baseline plasma 
concentrations of CZP available prior to Protocol Amendments 4 and 5.  
Chan ge #5 2 
Section 5.4.2, the following text was added  within Section 5. 4.2.1: 
The original CZP dose regimen is the regimen that will be used for study participants 
enrolled following Protocol Amendment 9  
Change #5 3 
Section 5.4.2, the following text was added  within Section [IP_ADDRESS] : 
Interim CZP plasma concentration data available at the time of Protocol Amendment [ADDRESS_887922] been performed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 247 of 280 Change #5 4 
Section 5.4.2, the following text was added within Section [IP_ADDRESS]:  
However, it was later determined that there were deficiencies detected with the use of the 
bioanalytical assay within RA0043, which rendered the PK data for the PopPK analysis and 
simulations  that informed the dose reduction in Protocol Amendment 4 and 5 unusable from a 
regulatory standpoint. Study participants enrolled prior to the implementation of Protocol 
Amendment 9 can remain on the reduced CZP dose or may be switched to the original CZP  
dose at the  discretion of the Investigator and in consultation with the medical monitor.  
Additional dose changes are not allowed (Section 7.2.1).  
Change #5 5 
Section 6.2, exclusion criterion 11:  
Subjects with known TB infection, or at high risk of acquirin g TB infection, are excluded. 
Subjects with latent TB (LTB) infection that have not received a minimum of 4 weeks of 
prophylactic treatment are only eligible following prophylaxis:  
a. Known TB infection whether present or past is defined as:  
 Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] 
(pulmonary or extra -pulmonary)  
 History of active TB infection involving any organ system or findings in other 
organ systems consistent with TB infection  
 Any evidence by [CONTACT_658356] g modalities consistent with 
previously active TB infection that is not reported in the subject’s medical 
history  
b. High risk of acquiring TB infection is defined as:  
 Known exposure of Subject or Caregiver to another person with active TB 
infection within th e 3 months prior to Screening  
 Time spent in a healthcare delivery setting or institution where individuals 
infected with TB are housed and where the risk of transmission of infection to 
Subject or Caregiver is high  
c. Latent TB infection is defined as:  
Absenc e of signs, symptoms (ie, evidence of organ -specific involvement), or 
physical findings suggestive of TB infection with a positive interferon -gamma 
release assay (IGRA [QuantiFERON]) test (or [ADDRESS_887923] results) 
or positive [COMPANY_003] (where the PP D skin test is approved for use by [CONTACT_18338]; mandatory 
for ages 2 to 4  years in this study) or, if written documentation of Bacille 
Calmette -Guérin (BCG) vaccination is available for subjects ages [ADDRESS_887924] ’s risk of exposure or infection 
with TB, and a chest x -ray (or other imaging) without evidence of TB infection.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 248 of 280 Note: If available, respi[INVESTIGATOR_58918] (Centers of Disease Control and Prevention [ CDC] diagnosis of 
LTB infection, http://www.cdc.gov/TB/topic/testing/default.htm).  
Refer to Section 10.7.9 for additional information on TB definition and clinical signs, 
diagnosis, documentation, and treatment.  
Subjects with a history of or active infection with nontuberculous mycobacteria (NTMB) 
are excluded from this study.  
Has been changed to:  
Participant has:  
a. Known active TB disease  
b. History of active TB involving any organ system  
c. History of or current latent  tuberculosis infection (LTBI)  
d. High risk of exposure to TB infection  
e. Current nontuberculous mycobacterial (NTMB) infection or history of NTMB 
infection. For further information relating to definitions of known active TB, past 
history of TB, LTBI, high risk  of acquiring TB infection and NTMB infection refer to 
Section 10.7.9 (Assessment and management of TB and TB risk factors).  
Change #5 6 
Section 6.2, exclusion criterion 13:  
Subject with known concurrent viral hepatitis or known positivity for hepatitis B s urface 
antigen (HBsAg) or hepatitis C virus (HCV) antibody or known human immunodeficiency 
virus (HIV) infection. At Screening, a hepatitis panel result which indicates immunity due to 
hepatitis B vaccination is not considered an exclusion criterion.  
Has been changed to:  
Study participant has a history of or current hepatitis B or C virus or  HIV 1/2 or  has any of 
the following laboratory abnormalities during the screening period:  
a. Hepatitis B surface (HBs) antigen, hepatitis B core (HBc) antibody (except f or isolated, 
false -positive anti -HBc confirmed with a confirmatory test such as hepatitis B virus 
[HBV] -deoxyribonucleic acid [DNA] [refer to Table  5-1 footnote k and Section  10.6 
(Clinical Laboratory Tests) table footnote c]): Positive to any of these  
b. Hepatitis C virus (HCV) positive: defined as hepati tis C antibody (anti -HCV Ab) positive 
confirmed via a confirmatory test (for example, HCV polymerase chain reaction).  
c. HIV antigen or antibody: Positive to either test  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 249 of 280 Change #5 7 
Section 6.2, exclusion crit erion 17, sentence  2, 3, and 4 : 
For postmenarcheal female study participants not currently sexually active, the study 
participant and parent or legal representative should agree that the study participant will 
employ an effective means of birth control should the study participant become  sexually 
active. Adequate methods of birth control are: oral/parenteral/implantable hormonal 
contraceptives (stable at least 2 months prior to Screening (Visit 1) if initiated prior to 
entering the study) or a combination of barrier and spermicide. Study participants must agree 
to use adequate contraception during the study and for [ADDRESS_887925] dose of study 
medication (or longer if required by [CONTACT_427]).   
Has been changed to:  
For postmenarcheal female study participants not currentl y sexually active, the study 
participant and parent or legal representative should agree that the study participant will 
employ an effective means of birth control consistently and correctly should the study 
participant become sexually active. Effective me thods of birth control are: 
oral/parenteral/implantable hormonal contraceptives (stable at least 2 months prior to 
Screening (Visit 1) if initiated prior to entering the study) or a combination of barrier and 
spermicide. Study participants must agree to us e effective contraception during the study and 
for [ADDRESS_887926] dose of study medication (or longer  if required by [CONTACT_13125]).  
Change #5 9 
Section 6.3, paragraph 2, bullet 3 was removed:  
Subjects with LTB infection, indicated by [CONTACT_658357] e [COMPANY_003] skin test or positive IGRA test result 
(or TB questionnaire indicating an increased risk of exposure or infection with TB for 
subjects ages 2 to 4 years with documented BCG vaccination) and a chest imaging without 
evidence of TB infection at Screenin g, may be rescreened after initiation of treatment for 
latent TB. Prior to first study medication administration, TB treatment must have been 
ongoing for at least [ADDRESS_887927] be continued until completion of 9 months of 
therapy (refer to Section 10.7.9).  
Change # 60 
Section 6.4, the following text for Liver Chemistry Stoppi[INVESTIGATOR_658243]:  
Participants with potential drug -induced liver injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all concomitant medications and herbal supplements 
that are not medically necessary should be discontinued. The PDILI crit eria below require 
immediate and permanent discontinuation of IMP:  
 Participants with either of the following:  
- ALT or AST ≥5xULN  
- ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 250 of 280 The PDILI criterion below requires immediate discontinuation of IMP:  
 Participants with ALT or AST ≥3xULN who exhibit temporally associated symptoms 
of hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, 
and right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever 
(without clear alternative cause), rash, and eosinophilia (ie, >5%).  
The PDILI criterion below allows participants to continue on IMP at the discretion of the 
investigator:  
 Participants with ALT or AST ≥3xULN (and ≥2x baseline) and <5xULN, total 
bilirubin <[ADDRESS_887928], and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of 
hepatitis (eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section 17.[ADDRESS_887929] be discontinued immediately.  
Investigators should attempt to obtain information on participants in the case of IMP 
discontinuation to complete the final evaluation. P articipants with PDILI should not be 
withdrawn from the study until investigation and monitoring are complete. All results of 
these evaluations and observations, as well as the reason(s) for IMP discontinuation and 
participant withdrawal (if applicable), m ust be recorded in the source documents. The eCRF 
must document the primary reason for IMP discontinuation.  
Change # 61 
Section 6. 5, Withdrawal criteria, the following text was added:  
Study participants are free to withdraw from the study at any time, witho ut prejudice to their 
continued care. Where possible, study participants discontinuing study medication should be 
encouraged to remain in the study.  
A study participant may withdraw from the study at any time at his/her own request, or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons.  
If the study participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected bef ore such a withdrawal of consent.  
If a study participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records.  
See the Schedule of Activities for dat a to be collected at the time of study discontinuation and 
follow -up and for any further evaluations that need to be completed.  
Change # 62 
Section 6. 5, withdrawal criteria 3 and 4:  
3) Subject who develops active TB or NTMB infection during the study must b e withdrawn 
(refer to Section  10.7.9 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 251 of 280 4) Subject who prematurely discontinues treatment for LTB, or, in the opi[INVESTIGATOR_58901], is noncompliant with anti -TB therapy must be withdrawn.  
Has been changed to:  
A study participant considered as having either a suspected new LTBI or who develops active 
TB or NTMB infection during the study (including but not limited to, conversion 
demonstrated by [CONTACT_14234] -gamma release assay  (IGRA) or other diagnostic means) mus t be 
immediately discontinued from IMP (refer to Section  [IP_ADDRESS]  for further details).  
a. The study participant must be permanently withdrawn from the s tudy if further 
examinations result in a diagnosis of active TB, NTMB infection or if the study 
participant is diagnosed with LTBI. An Early Discontinuation visit must be scheduled as 
soon as possible, but not later than the next regular visit.  
b. Any confir med diagnosis or suspi[INVESTIGATOR_1884] a latent or active TB infection is a reportable 
event. Either type of infection must be reported as an adverse event of special interest 
(AESI) and must be captured on an AE report form, ticking the appropriate AESI and, if 
applicable, serious adverse event (SAE) field(s) on the form to clearly indicate the level 
of seriousness. A UCB TB follow -up form also must be completed. Confirmed active TB 
is an SAE and must be captured on an SAE report form and provided to the Sponsor in  
accordance with SAE reporting requirements. As with all SAEs, periodic follow -up 
reports should be completed as per protocol requirements until such time as the TB 
infection resolves.  
Change # 63 
Section 6. 5, withdrawal criteria 2, 3, 4, and 6:  
Subjects should be withdrawn from the study if any of the following events occur:  
2) Subject/caregiver is noncompliant with the study procedures or medications in the 
opi[INVESTIGATOR_12182].  
3) Subject who develops active TB or NTMB infection during the s tudy must be 
withdrawn (refer to Section  10.7.9 ).  
4) Subject who prematurely discontinues treatment for LTB, or, in the opi[INVESTIGATOR_58901], is noncompliant with anti -TB therapy must be withdrawn.  
5) Subject is found to be persistently noncompliant (missing 2 or more consecutive 
scheduled CZP doses or missing 3 or more doses over a 12 -month period), the 
Sponsor in conjunction with the Inv estigator will make a decision as to whether the 
subject should be withdrawn from the study (see Section 7.7).  
This rule does not apply when CZP is  discontinued if the subject is in CRM or if CZP 
is temporarily discontinued due to an AE. In the case of temporary discontinuation 
due to an AE, the Sponsor in conjunction with the Investigator will make a decision as 
to whether the subject should be with drawn from the study.  
6) Subject takes prohibited concomitant medications as defined in this protocol (see 
Section  7.8.3 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 252 of 280 Has been changed to:  
Study participants must be permanently  discontinued from study medication (but not 
necessarily from the study) if any of the following occurs:  
1. Study participant/caregiver is noncompliant with the study procedures or medications in 
the opi[INVESTIGATOR_540012].  
2. A study participant considered as having either a suspected new LTBI or who develops 
active TB or NTMB infection during the study (including but not limited to, conversion 
demonstrated by [CONTACT_14234] -gamma release assay  (IGRA) or other diagnost ic means) must 
be immediately discontinued from IMP (refer to Section  [IP_ADDRESS]  for further details).  
a) The study participant must be permanently withdrawn from the study if further 
examinations result in a diagnosis of active TB, NTMB infection or if the study 
participant is diagnosed with LTBI. An Early Discontinuation visit must be scheduled 
as soon as possible, but not later than the next regular visit.  
3. Study participant is found to be persistently noncompliant (missing 2 or more consecutive 
scheduled CZP doses or missing 3 or more doses over a 12 -month period), the Sponsor in 
conjunction with the Investigator will make a decision as to whether the study participant 
should be withdrawn from the study (see Section 7.7).  
This rule does not apply when CZP is discontinued if the study participant is in  CRM or if 
CZP is temporarily discontinued due to an AE. In the case of temporary discontinuation 
due to an AE, the Sponsor in conjunction with the Investigator will make a decision as to 
whether the study participant should be withdrawn from the study.  
4. Study participant takes prohibited concomitant medications as defined in this protocol 
(see Section  7.8.3 ). 
Change #6 4 
Section 6. 5, withdrawal criter ia 1 and 8:  
Subjects should be withdrawn from the study if any of the following events occur:  
1. Subject develops an illness that would interfere with continued participation (eg, 
malignancies).  
8. There is confirmation of a pregnancy during the study, as eviden ced by a positive 
pregnancy test.  
Has been changed to:  
Study participants may be discontinued from study medication (but not necessarily from the 
study) if any of the following occurs, but may be restarted after consultation with the Medical 
Monitor:  
1. Study  participant develops an illness that would interfere with continued participation (eg, 
malignancies).  
2. If there is a positive pregnancy test, study medication will be held. If there is confirmed 
pregnancy, study medication must be discontinued until end of  the pregnancy. In case the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887930] be further 
discontinued until end of breastfeeding.  
Change #6 5 
Section 6. 5, withdrawal criteria 7 and 9:  
Subjects should be withdrawn from the study  if any of the following events occur:  
7. Subject/legal representative withdraws consent.  
9. The Sponsor or a regulatory agency requests withdrawal of the subject..  
Has been changed to:  
Study participants should be withdrawn from the study if any of the followin g events occur:  
1. Study participant or legal representative withdraws his/her consent.  
2. The sponsor or a regulatory agency requests withdrawal of the study participant.  
Change #6 6 
Section 7.2, paragraph 1, sentence 1 and 2:  
Throughout the study, CZP dosing is  fixed dose based on weight  and given Q2W, with 
exception of the lowest weight group, who will receive the maintenance dose Q4W following 
implementation of Protocol Amendment 4. The range of exposures in each weight category is 
presented in Table 7-1. Subjects start with 3  loading doses of CZP at Weeks 0, 2, and 4 
(minimum=50mg Q2W, maximum=200mg Q2W) followed by a maintenance dose for the 
duration of t he study (minimum=50mg Q4W, maximum=100mg Q2W).  
Has been changed to:  
Throughout the study, CZP dosing is fixed dose based on weight  and given Q2W, with 
exception of the lowest weight group on the reduced CZP regimen who will receive the 
maintenance dose Q4 W. The loading dose, maintenance dose, and range of exposures in each 
weight category for both the original and reduced CZP regimens are presented in Table 7-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 254 of 280 Change #6 7 
Section 7.2, Table 7 -1, the following was added : 
Table  17-1 Dosing administration of CZPa  
Weight range  Loading dose – Weeks 0, 2, and 4  
(mg/kg dose range)  
IMP Description  Maintenance – Week 6 and onwards  
(mg/kg dose range)  
IMP Description  
Original CZP regimen  
10 to <20kg  
(22 to <44lb)  100mg Q2W  
(5-10mg/kg)  
1 x 0.5mL inj  50mg Q2W  
(2.5-5mg/kg)  
1 x 0.25 mL inj  
20 to <40kg  
(44 to <88lb)  200mg Q2W  
(5-10mg/kg)  
1 x 1mL inj  100mg Q2W  
(2.5-5mg/kg)  
1 x 0.5mL inj  
≥40kg  
(≥88lb)  400mg Q2W  
(<10mg/kg)  
2 x 1mL inj  200mg Q2W  
(<5mg/kg)  
1 x 1mL inj  
Change # 68 
Section 7.2, Table 7 -1, footnote a : 
Note that Table 7-1 describes the dosing administration of CZP after implementation of 
Protocol Amendments 4 and 5. Refer to Section 7.2.1 for the procedure to be taken for 
subjects already enrolled and treated prior to the implementation of Protocol Amendment 4, 
and who are undergoing a dose change  
Has been changed to:  
Note that the original CZP regimen describes the dosing administration of CZP prior to the 
implementation of Protocol Amendments 4 and 5 and for study participants enrolled 
following the implementation of P rotocol Amendment 9. The reduced CZP regimen describes 
the dosing administration of CZP after implementation of Protocol Amendments 4 and 5. 
Refer to Section 7.2.1 for the procedure to be taken for study participants who are undergoing 
a dose change.  
Change #6 9 
Section 7.2, paragraph 5, sentence 1 has been moved to the 4th sentence position:  
Prior to CZP administration at home, study participants/caregivers will be trained by [CONTACT_658358] 0.25m L, 0.5m L, and 1m L injections, as appropriate.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 255 of 280 Change # [ADDRESS_887931] sentence : 
Subjects not maintaining persistent CID following achievement of CRM and resuming 
treatment wi ll restart the fixed -dose CZP dosing based on their current weight with [ADDRESS_887932] weight group after implementation of Protocol Amendment 4, 
for the duration of the study.  
Has been changed to:  
Study participants not maintaining persistent CID following achievement of CRM and 
resuming treatment will restart the fixed -dose CZP dosing based on their current weight with 
[ADDRESS_887933] weight group on the reduced CZP regimen  for the 
duration of the study.  
Change # 71 
Section 7.2.1, paragraph 1:  
With Protocol Amendment 4, the maintenance dose in the study will be reduced by 50% for 
all weight groups (not applicable for subjects enrolled on the reduced CZP dose regimen per 
Protocol Amendment  5). 
Has been changed to:  
Following Protocol Amendment 9, study participants will only be enrolled on the original 
CZP dose regimen. With Protocol Amendment 4, the maintenance dose in the study was 
reduced by 50% for all weight groups (not applicable for study participants enrolled on the 
reduced CZP dose regimen per Protocol Amendment  5). Participants on the reduced CZP 
dose regimen can remain on the reduced CZP dose or may be switched to the original CZP 
dose regimen at the discretion of the Investigator  and in consultation with the medical 
monitor . Additional dose changes are not allowed. The procedure for d ose change is as 
follows . 
Change # [ADDRESS_887934] been deleted:  
 For subjects undergoing a dose change prior to or at Week 12 (Visit 8), and who 
return for regularly scheduled visits every 4 weeks for a period of 12 week s after the 
dose change, no additional Unscheduled Visits will be required.  
 For subjects undergoing a dose change after Week 12 (Visit 8), [ADDRESS_887935] undergoing a dose change 
at Week 20 (Visit 9) will return for a regularly scheduled visit at Week 24 (Visit 10), 
will require an additional Unscheduled Visit at Week 28, and will return for the next 
regularly scheduled  visit at Week 32 (Visit 11). A subject who is undergoing a dose 
change at  Week 40 (Visit 12) will require an Unscheduled Visit at Week 44, will 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 256 of 280 return for a regularly scheduled visit at Week 48 (Visit 13), and will require another 
Unscheduled Visit at Week 52.  
Change # 73 
Section 7.2.1 , bullet 2, sub -bullet 3, sentence 3 has bee n deleted : 
 For example, a subject undergoing the dose change at Week 42 at the clinic will 
return for an Unscheduled Visit at Week 46, then continue with the regular visit at 
Week 48 (Visit 13), and return for an additional Unscheduled Visit at Week 52 bef ore 
continuing with the regular Week 56 visit (Visit 14).  
Change # 74 
Section 7.2.1 , bullet 4 has been deleted : 
 A predose PK sample will be collected prior to administration of CZP at the visit the dose 
change occurs. Additional predose PK sampling after the change in dose will be 
performed at the next 3 site visits, ie, additional PK samples will be collected at the 
Unscheduled Visits or at the regular visit if not already planned per regular schedule.  
Change # 75 
Section 7.8.3 , paragraph 1 bullet 1 : 
 Nonbi ologic DMARDs (other than MTX; see Section 7.8.1) and biologic DMARDs (eg, 
anakinra, rilonacept, etanercept, adalimumab, infliximab, golimumab, rituximab, 
abatacept, tocilizumab, CZP other than study medication)  
Has been changed to:  
 Nonbiologic DMARDs (oth er than MTX; see Section 7.8.1) and biologic DMARDs  
Change # 76 
Section 7.9 (Lost to Follow up) was added : 
Change # 77 
Section 8.1, paragraph 1 sentence 1:  
Prior to any study activities and 4 days prior to the Baseline Visit (Visit 2), subjects and 
parent(s)/legal representative, as applicable, will be asked to read and sign an Informed 
Consent/Assent Form that has been approved by [CONTACT_2717]/IEC and which complies with 
regulatory requirements.  
Has been changed to:  
Prior to any study activities and at least 4 days prior to the Baseline Visit (Visit 2), study 
participants and parent(s)/legal representative, as applicable, will be asked to read and sign an 
Informed Consent/Assent Form that has been approved  by [CONTACT_2717]/IEC and which complies 
with regulatory  requirements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 257 of 280 Change # 78 
Section 8.1, paragraph 2 bullet 15 : 
Chest x -ray (only for subjects with positive IGRA or [COMPANY_003] testing)**  
Has been changed to:  
Chest radiographic imaging and results must be available at Baseline before first IMP 
administration unless a chest X -ray or CT scan is available from 2 months prior to Screening.   
Change # 79 
Section 8.1, paragraph 2 bullet 16 : 
TB screening if not performed within 3 months of Screening: [COMPANY_003] skin test for subjects from 
2 to 4  years of age (unless written documentation for BCG vaccination is available) or IGRA 
(to be performed by [CONTACT_6626]) for subjects from 5  to 17  years of age**  
Has been changed to:  
TB screening: TST and IGRA for study participants from 2 to 4  years of age (unless the study 
participant is located in a country with high TST positivity and/or written documentation for 
BCG vaccination is available) or IGRA (to be performed by [CONTACT_6626]) for study 
participants from [ADDRESS_887936] may be positive due to BCG 
vaccination, however, UCB will not  permit enrollment of pediatric study participants < 5 
years old into the study with out written  approval from a physician with expertise in pediatric 
TB**  
Change # 80 
Section 8.2  
 CZP plasma concentrations and anti -CZP antibodies  
Has been changed to:  
 CZP plasma concentrations  
 Anti-CZP antibodies  
Change # 81 
Section 8.3  
 CZP plasma concentrations and anti-CZP antibodies(Week 1 only)  
Has been changed to:  
 CZP plasma concentrations (Week 1 only)  
 Anti-CZP antibodies (Week 1 only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 258 of 280 Change # 82 
Section 8.4  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 4, 12, 16, and [ADDRESS_887937]’s dose was changed 
during [ADDRESS_887938] 3 visits following Protocol Amendment 4; predose.  
Subjects wil l return to the clinic site for a postdose CZP plasma sample  approximately 
5 to 7 days following the Week 16 visit .) 
Has been changed to:  
 CZP plasma concentrations (predose at Weeks 4, 12, 16, and 24.  
Study participants will return to the clinic site for a postdose CZP plasma sample  
approximately 5 to 7 days following the Week 16 visit .) 
 Anti-CZP antibodies (predose at Weeks 4, 12, 16, and 24)  
Change # [ADDRESS_887939] paragraph  
Documentation of the Week 16 and Week 24  assessment of all 6 core set measures of 
PedACR response (PRINTO/PRCSG standard joint examination, Physician’s Global 
Assessment of Disease Activity [VAS], CHAQ -parent reported, Parent’s Assessment of 
Arthritis Pain [VAS], Parent’s Global  Assessment of Ov erall Well -Being [VAS] and CRP) 
will be submitted to UCB or designee for immediate review of completeness, while the 
subject is still on site.  
Has been changed to:  
Documentation of the Week 24  assessment of all 6 core set measures of PedACR response 
(PRINT O/PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
UCB or desi gnee for immediate review of completeness, while the study participant is 
still on site.  
Change # 84 
Section 8.5, heading  
Visits 11 and continuing (Week 32 and every 8 weeks thereafter [every 16 weeks following 
Protocol Amendment 8])  
Has been changed to:  
Visits 11 and continuing (Week 32 and every 8 weeks thereafter)  
Change #8 5 
Section 8.5, the following paragraph has been added  
For study participants enrolled prior to Protocol Amendment 9, visit frequency changes to 
every 16 weeks instead of every 8 week s following implementation of Protocol 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 259 of 280 Amendment  8, provided that compliance is maintained with the CZP dosing schedule using 
at-home administration.  
Change #8 6 
Section 8.5, bullet 2  
Height (Week 48 and every 24 weeks thereafter [every 48 weeks following Protocol 
Amendment 8])  
Has been changed to:  
Height (Week 48 and every 24 weeks thereafter; for study participants enrolled prior to 
Protocol Amendment 9, height assessment will be performed every 48 weeks following 
Protocol Amendment 8)  
Change # 87 
Section 8.5, bullet 4  
Tanner stages (except growth; Week 48 and every 24 weeks thereafter [every [ADDRESS_887940] not reached Tanner stage V following Protocol Amendment 8])  
Has been changed to:  
Tanner stages (except growth; for study participants enrolled prior to Protocol Amendment 9, 
Tanner stages assessment will be performed every [ADDRESS_887941] not reached Tanner stage V)  
Change #8 8 
Section 8.5, bullet 6  
TB screening on ce a year (approximately every 48 weeks)  
Has been changed to:  
TB screening once a year (at least every  48 weeks)  
Change # 89 
Section 8.5, bullet 28  
 CZP plasma concentrations and anti -CZP antibodies (Weeks 32, 40, and [ADDRESS_887942] ’s dose was changed during [ADDRESS_887943] 3 visits  following Protocol Amendment 4; 
following Protocol Amendment 8, these samples will no longer be collected ) 
Has been changed to:  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendment 9 only; Weeks 32, 40, and 48 and every 24  weeks thereafter)  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only; Weeks 32, 40, and 48 a nd every 24  weeks thereafter)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 260 of 280 Change # 90 
Section 8.6.1, the following paragraph has been removed : 
Documentation of the Week 56  assessment of all 6 core set measures of PedACR response 
(PRINTO/ PRCSG standard joint examination, Physician’s Global Assessment of Disease 
Activity [VAS], CHAQ -parent reported, Parent’s Assessment of Arthritis Pain [VAS], 
Parent’s Global Assessment of Overall Well -Being [VAS] and CRP) will be submitted to 
UCB or design ee for immediate review of completeness, while the subject is still on site.  
Change # 91 
Section 8.6.1, the following sentence has been added:  
If required, study participants will return for an Unscheduled Visit to undergo the dose 
change.  
Change # 92 
Sectio n 8.6.1, the following assessment  has been removed:  
 CZP plasma concentrations and anti -CZP antibodies (predose)  
Change # 93 
Section 8.7, bullet 27:  
 CZP plasma concentrations and anti -CZP antibodies ( following Protocol Amendment 8, 
these samples will no longer be collected)  
Has been changed to:  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendment 9 only  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only)  
Change # 94 
Section 8.8, bullet 11:  
 CZP plasma concentrations and anti -CZP antibodies ( following Protocol Amendment 8, 
these samples will no longer be collected)  
Has been changed to:  
 CZP plasma concentrations (for study participants enrolled following Protocol 
Amendment 9 only)  
 Anti-CZP antibodies (for study participants enrolled following Protocol Amendment 9 
only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 261 of 280 Change #9 5 
Section 9, the following  paragraph has been deleted:  
Following Protocol Amendment 8, blood samples for determination of CZP plasma 
concentrations and anti -CZP antibodies will not be collected throughout the remainder of the 
study.  
Change #9 6 
Section 9, paragraph 1, the following sentence has been added:  
For study participants enrolled prior to Protocol Amendment 9, samples for CZP plasma 
concentration and anti -CZP antibodies will no longer be collected.  
Change #9 7 
Section 9, paragraph 3, has been  deleted:  
For subjects already enrolled and treated prior to the implementation of Protocol 
Amendment  4 and hence undergoing a reduction of their dose, additional PK samples will be 
collected prior to dosing at the visit the dose change occurs and at the next 3 site visits 
following the dose change, ie, additional PK samples will be collected at either Unscheduled 
Visits or regular visits if not already planned per reg ular schedule. Afterwards, the regular PK 
sampling schedule applies.  
Change # [ADDRESS_887944] been deleted:  
Plasma concentration data for CZP from this study will be compared with plasma 
concentrations observed previously in adult subjects with RA, as described in Section 13.7. 
This plasma concentration analysis will be done on an ongoing basis throughout the study, 
starting when [ADDRESS_887945] completed Week 12 (Visit 7).  
Interim CZP plasma concentrati on data available at the time of Protocol Amendment 3 
indicated that no change to the dosing algorithm was required. The protocol stated that i f 
future analyses indicate that plasma concentrations are outside of the exposure range of those 
observed in prev ious studies with adults, the dosing algorithm may be changed via a protocol 
amendment, and if necessary additional interim analyses including PopPK, may be 
performed. This study will continue during the PK analysis. All subjects assessed in this 
analysis will continue treatment after Week 12 (Visit 7).  
Results of an interim PopPK analysis conducted in Jun  [ADDRESS_887946] that for some subjects in RA0043 receiving the 
originally determined loading doses up to Week 4 (Visit 5), plasma concentrations are likely 
to exceed the range previously seen in adult subjects receiving CZP  400mg Q2W. 
Furthermore, plasma conc entrations of subjects receiving the originally determined 
maintenance dose after Week  4 (Visit 5) are predicted to exceed the concentration range 
observed in adults receiving CZP  200mg Q2W. Based on these findings, the dosing regimen 
will be changed with Protocol Amendments 4 and 5, and the doses to be administered will be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 262 of 280 reduced by 50% for all weight groups. This dose change is intended to achieve plasma 
concentrations that are similar to the effective concentrations observed in previous studies in 
adult  subjects with RA. Continued analysis of CZP plasma concentrations (including 
additional assessments for subjects undergoing a dose reduction with Protocol Amendment 4) 
will be performed to confirm that the 50% dose reduction will result in plasma concentr ations 
within the target range of those observed in adults.  
The final pediatric PopPK model will be combined with PD data (PedACR) and if the data 
allow, an exposure -response relationship will be derived.  
Change # 99 
Section 9, paragraph 9, sentence 1:  
Blood samples to determine plasma concentrations of CZP and anti -CZP antibodies will be 
analyzed by [CONTACT_2237].   
Has been changed to:  
Blood samples to determine plasma concentrations of CZP and anti -CZP antibodies will be 
analyzed by a specialty laboratory.  
Change # 100 
Section 9, paragraph 9, the following text has been added:  
All study participants enrolled following Protocol Amendment [ADDRESS_887947] plasma 
concentrations of CZP and anti -CZP antibodies analyzed using an ECLIA method that meets 
curre nt regulatory standards. In addition, PK and ADA samples (for which sufficient volume 
is available) collected in this study prior to Protocol Amendment  9 will be analyzed with the 
ECLIA method. The collective ECLIA -based PK data for this study will form th e basis of 
any future CZP modeling and simulation work . 
Change # 101 
Section 10.1.6  (Reporting requirements for events relating to TB) was added.  
Change # 102 
Section 10.1.7 , paragraph 1, sentence 2:  
The subject should be withdrawn from the study as soon as pregnancy is known and the 
following should be completed:  
 The subject should return for an Early Discontinuation Visit. If pregnancy is determined 
at a study visit, the subject is withdrawn from the study and all Early Discontinuation 
Visit assessments sho uld be completed at that visit.  
 The subject should immediately stop receiving the IMP at the first confirmation of the 
pregnancy but no later than as instructed at the Early Discontinuation Visit.  
 A Final Visit should be scheduled [ADDRESS_887948] has discontinued their IMP..   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 263 of 280 Has been changed to:  
Study medication must be discontinued as soon as pregnancy is known (by [CONTACT_368790]). Study participants can remain in the study under observation and should 
attend to scheduled visits regularly as their condition allows.   
Change # 103 
Section 10.3, heading:  
AEs of interest   
Has been changed to:  
AEs of special interest  
Change # 104 
Section 10.3, paragraph 1, sentence 1:  
An AE of interest is any AE which is listed in the European Risk Management Plan, or meets 
another commitment requiring nonstandard expedited reporting, even if the AE does not 
fulfill the expedited reporting criteria of “serious,” “unexpected,” and “assoc iated with the 
use of the drug.”  
Has been changed to:  
An AESI  interest is any AE which is listed in the European Risk Management Plan, or meets 
another commitment requiring nonstandard expedited reporting, even if the AE does not 
fulfill the expedited rep orting criteria of “serious,” “unexpected,” and “associated with the 
use of the drug.”  
Change # 105 
Section 10.3, paragraph 2:  
Adverse events of interest include:  
Has been changed to:  
Adverse events of special interest include:  
Change #10 6 
Section 10.3, paragraph 2, the following text has been added:  
 Potential Hy’s Law  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin 
in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality (ie, without waiting for any additional etiologic investigations to have been 
concluded). Follow -up information should be reported if an alternative etiology is identified 
during investigation and monitoring of the participant.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 264 of 280 Change # 107 
Section 10.5, Table 1 0-1: 
Preferred Term  
Juvenile arthritis  
Has been changed to:  
Preferred Term  
Juvenile idiopathic arthritis  
Change # 108 
Section 10.6, paragraph 1, sentence 1:  
Hematology, biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32, every 8 weeks thereafter (every 16 weeks following Protocol 
Amendment 8), the Early Discontinuation/End of Treat ment Visit, and the Final Visit 
[ADDRESS_887949] dose of study medication.  
Has been changed to:  
Hematology, biochemistry, and urinalysis samples will be collected at Screening, Baseline, 
Weeks 4, 8, 12, 16, 20, 24, 32 and every 8 weeks thereafter ( for study participant s enrolled 
prior to Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 8 
weeks following implementation of Protocol Amendment 8 ), the Early Discontinuation/End 
of Treatment Visit, and the Final Visit [ADDRESS_887950] do se of study medication. At 
Week 1, only CRP and PK samples will be collected and at Week  2, only CRP samples will 
be collected.  In addition, hematology, biochemistry, and CRP samples will be collected at 
Unscheduled Visits for study participants undergoing  a dose change (Section 7.2.1 and 
Section 8.6.1).  
Change # 109 
Section 10.6, paragraph 1, sentence 3:  
In addition, hematology, biochemistry, and CRP samples will be collected at Unscheduled 
Visits related to the dose change implemented with Protocol Amendme nt 4. 
Has been changed to:  
In addition, hematology, biochemistry, and CRP samples will be collected at Unscheduled 
Visits for study participants undergoing a dose change (Section 7.2.1 and Section 8.6.1).  
Change # 110 
Section 10.6, paragraph 9:  
If IGRA test ing is required to be performed by [CONTACT_6626] (for all subjects from 5 to 17 
years of age, see Section 6.2) additional blood sampling of approximately 3mL will be 
required at Screening.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 265 of 280 Has been changed to:  
The TB assessment by [CONTACT_658359] d to be performed by [CONTACT_6626]; additional 
blood sampling of approximately 3mL will be required at Screening.  
Change #1 11 
Section 10.6, paragraph 10:  
If the result of the IGRA is indeterminate, the test may be repeated once. The retest must be 
conducted in the allowable Screening window. Subjects with IGRA (performed ≤3 months 
prior to Screening) positive  or indeterminate and a chest x -ray confirmative of TB infection 
are excluded (see Section [IP_ADDRESS]).  
Has been changed to:  
If the result of the  IGRA test is indeterminate, the test may be repeated once. If positive or 
indeterminate on retest, the study participant must not be enrolled (Section [IP_ADDRESS]).  
Change # 112 
Section 10.6, paragraph 11 and 12  
For subjects from 2 to 4 years of age, [COMPANY_003] tes ting will be performed locally (except for 
subjects with documented BCG vaccination) as described in Section [IP_ADDRESS].4.  
During the study and upon implementation of Protocol Amendment 7, IGRA testing should 
be done once a year (approximately every 48 weeks) for all subjects from 5 to 17 years of 
age. For subjects from 2 to 4 years of age, both IGRA and [COMPANY_003] testing should be performed 
once a year (approximately every 48 weeks). In cases where written documentation of BCG 
vaccination is available or prev ious [COMPANY_003] test was positive, only IGRA should be performed.  
Has been changed to:  
For study participants from [ADDRESS_887951] and IGRA testing will be performed 
(except for study participants with documented BCG vaccination) as described in Section 
[IP_ADDRESS].2. In countries with high BCG vaccination or high TST positivity, only IGRA should 
be performed (Section [IP_ADDRESS].2). The TST may be positive due to BCG vaccination, 
however, UCB will not permit enrollment of pediatric study participants <5 years old into the 
study with written approval from a physician with expertise in pediatric TB. IGRA testing 
should be done once a year (approximately every 48 weeks) for all study participants.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 266 of 280 Change # 113 
Section 10.6, Table 10 -2: 
Hepatitis screening(c) 
HBcAb 
HBsAb  
HBsAg  
HCVAb  
HBV DNA, if applicable  
TB screening(d) 
IGRA,  
[COMPANY_003] 
Has been changed to:  
Hepatitis screening(c) 
HBcAb  
HBsAb  
HBsAg  
HCVAb  
HBV DNA, if applicable  
HCV RNA, if applicable  
TB screening(d) 
IGRA,  
TST 
HIV Screening  
HIV antigen or antibody  
Change # 114 
Section 10.6, Table 10 -2, footnote C:  
Subjects will be tested for hepatitis at Screening. HBV DNA is required for subjects with 
only positive HBcAb (negative HBsAg and HBsAb) or only positive HBsAg. A hepatitis 
panel result which indicates immunity due to hepatitis B vaccination is not considered an 
exclusion criterion.  
Has been changed to:  
At Screening, laboratory testing includes testing for hepatitis B core antibody, hepatitis B 
surface antibody, hepatitis B surface antigen, hep atitis C virus antibody , and HIV 1/[ADDRESS_887952] will not be allowed in the study (except for anti -
hepatitis B positive only, in case study participant is immune due to well -documented 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887953] such as hepatitis B virus deoxyribonucleic acid [HBV -DNA]). A positive hepatitis C 
antibody test will be confirmed by a confirmatory test (such as HCV RNA) and those with a 
positive confirmatory  test will not be allowed in the study.  
Change # 115 
Section 10.7.2, paragraph 1, sentence 1:  
Height will be recorded at Screening, Baseline , every 24 weeks thereafter (every 48 weeks 
following Protocol Amendment 8), and the Early Discontinuation/End of Tre atment Visit.  
Has been changed to:  
Height will be recorded at Screening, Baseline, every 24 weeks thereafter ( for study 
participants enrolled prior to Protocol Amendment 9, the height  assessment will be performed 
every 48 weeks following Protocol Amendmen t 8), and the Early Discont inuation/End of 
Treatment Visit.  
Change # 116 
Section 10.7.3, sentence 2:  
These assessments will be performed at Baseline, every 24 weeks thereafter, and the Early 
Discontinuation/End of Treatment Visit. Following Protocol Amendment 8, the assessments 
will be performed every [ADDRESS_887954] not reached Tanner stage 
V.  
Has been changed to:  
These assessments will be performed at Baseline and every 24 weeks thereafter, and the 
Early Discontinuation/End of Treatment Visit. For study participants enrolled prior to 
Protocol Amendment 9, Tanner stages assessment will be performed every [ADDRESS_887955] not reached Tanner 
stage V.  
Change # 117 
Section 10.7.6, sentence 2:  
If the subject is of reproductive potential and is sexually active, the method of birth control 
used will be recorded. Sexually active subjects (male and female) must use adequat e 
contraceptive measures (see Section 6.2, Exclusion Criterion 17).  
Has been changed to:  
If the study participant is of reproductive potential and is sexually active, the method of birth 
control used will be recorded. Sexually active study participants (male and female) must use 
effective contraceptive measures (see Section 6.2, Exclusion Criterion 17).  
Change #11 8 
Section 10.7.9, heading:  
Tuberculosis guidance, testing, and screening  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 268 of 280 Has been changed to:  
Assessment and management of TB and TB risk factors  
Change #11 9 
Section 10.7.9, the following text has been added:  
As TNF inhibitors are known to be associated with significant risk of reactivation of LTBI or 
previously treated active TB, appropriate rigorous precautions are being taken within the 
protocol  (see Section  6.2 [Exclusion Criterion 11] and Section  6.4  [Withdrawal Criterion  2]). 
Study participants  with known active TB disease, at high risk of acquiring TB infection, or 
with past or current LTBI or current or history of NTMB infection are excluded from the 
study.  
a. Known TB infection whether present or past is defined as:  
 Active TB infection or clinical signs and symptoms strongly suggestive of TB 
(pulmonary or extra pulmonary).  
 History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection.  
 Any evidence by [CONTACT_658360] 's medical history.  
b. High risk of acquiring TB infection is defined as:  
 Known close exposure (eg, sleepi[INVESTIGATOR_368739]) to another person with active 
TB infection within 3 months prior to Screening.  
 Time spent within 3 months prior to Screening in a healthcare delivery setting or 
institution where individuals infected with TB are housed or where the risk of 
transmission of infection is high.  
c. LTBI is def ined as an infection by [CONTACT_658281]:  
 A positive IGRA (or 2 indeterminate IGRAs), AND  
 Chest imaging (or other imaging) negative for TB infection, AND  
 Absence of signs, symptoms (eg, evidence of organ -specific involvement), or physical 
findings suggestive of TB infection.  
d. Pulmonary NTMB infection is defined as a group of lung infections caused by 
[CONTACT_658282].  
Change #1 20 
Section [IP_ADDRESS], Section [IP_ADDRESS], Section [IP_ADDRESS] have been removed  
Change #1 21 
Section [IP_ADDRESS], Section [IP_ADDRESS], Section [IP_ADDRESS], Section [IP_ADDRESS], Section [IP_ADDRESS], 
Section [IP_ADDRESS], Section [IP_ADDRESS] have been added.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 269 of 280 Change # [ADDRESS_887956] paragraph:  
Documentation of the assessment of all 6 core set measures will be submitted to UCB or 
designee for immediate review of completeness at Week 0 (Baseline), Week 16, Week 24, 
and Week  56, while the subject is still on site.  
Has been changed to:  
Documentation of the assessment of all 6 core set measures will  be submitted to UCB or 
designee for immediate review of completeness at Week 0 (Baseline) and Week 24, while the 
study participant is still on site.  
Change # [ADDRESS_887957] paragraph:  
These assessments are completed at Screening, Baseline, and ever y visit (including 
Unscheduled Visits that are related to the dose change implemented with Protocol 
Amendment  4) through the Early Discontinuation/End of Treatment Visit.  
Has been changed to:  
These assessments are completed at Screening, Baseline, and ever y visit (including 
Unscheduled Visits that are related to dose change) through the Early Discontinuation/End of 
Treatment Visit.  
Change #1 24 
Section 11.4, paragraph 2:  
The Physician’s Global Assessment of Disease Activity (VAS) will be completed at 
Screeni ng, Baseline, and every visit (including Unscheduled Visits that are related to the dose 
change implemented with Protocol Amendment  4) through the Early Discontinuation/End of 
Treatment Visit.  
Has been changed to:  
The Physician’s Global Assessment of Disea se Activity (VAS) will be completed at 
Screening, Baseline, and every visit (including Unscheduled Visits that are related to dose 
change) through the Early Discontinuation/End of Treatment Visit . 
Change # 125 
Section 11.5, paragraph 3, sentence 2:  
The CHAQ  will be completed by [CONTACT_7903]/caregivers at Screening, Baseline, and every 
visit (including Unscheduled Visits that are related to the dose change implemented with 
Protocol Amendment  4) through the Early Discontinuation/End of Treatment Visit..  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 270 of 280 Has been changed to:  
The CHAQ will be completed by [CONTACT_7903]/caregivers at Screening, Baseline, and every 
visit (including Unscheduled Visits that are related to dose change) through the Early 
Discontinuation/End of Treatment Visit.  
Change #12 6 
Section 11.7,  paragraph 2, sentence 2:  
The Parent’s Global Assessment of Overall Well -Being (VAS) will be completed at 
Screening, Baseline, and every visit (including Unscheduled Visits that are related to the dose 
change implemented with Protocol Amendment  4) through the Early Discontinuation/End of 
Treatment Visit.  
Has been changed to:  
The Parent’s Global Assessment of Overall Well -Being (VAS) will be completed at 
Screening, Baseline, and every visit (including Unscheduled Visits that are related to dose 
change) throu gh the Early Discontinuation/End of Treatment Visit.  
Change #12 7 
Section 11.8, sentence 2:  
Samples will be collected at Screening, Baseline, and every visit (including Unscheduled 
Visits that are related to the dose change implemented with Protocol Amendment  4) through 
the Early Discontinuation/End of Treatment Visit.  
Has been changed to:  
Samples will be collected at Screening, Baseline, and every visit (including Unscheduled 
Visits that are related to dose change) through  the Early Discontinuation/E nd of Treatment 
Visit. 
Change # [ADDRESS_887958] sentence:  
Subjects not maintaining persistent CID following achievement of CRM and resuming 
treatment will restart the fixed -dose CZP dosing based on their current weight with [ADDRESS_887959] weight group, who will 
receive the maintena nce dose Q4W following implementation of Protocol Amendment 4.  
Has been changed to:  
Study participants not maintaining persistent CID following achievement of CRM and 
resuming treatment will restart the fixed -dose CZP dosing based on their current weight with 
[ADDRESS_887960] weight group 
on the reduced dose regimen, who will receive the maintenance dose Q4W.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 271 of 280 Change # [ADDRESS_887961] paragraph, second sentence:  
The FPS -R will be administered at Baseline and then daily during the first week of the study; 
at Weeks 4, 12, 16, and 24; and then every 8  weeks thereafter (every 16 weeks following 
Protocol Amendmen t 8) through the Early Discontinuation/End of Treatment Visit . 
Has been changed to:  
The FPS -R will be administered at Baseline and then daily during the first week of the study; 
at Weeks 4, 12, 16, 24, and then every 8  weeks thereafter (for study participa nts enrolled 
prior to Protocol Amendment 9, visit frequency changes to every 16 weeks instead of every 8 
weeks following implementation of Protocol Amendment 8 ) through  the Early 
Discontinuation/End of Treatment Visit . 
Change # 130 
Section 11.13, second paragraph, second sentence:  
The Pain (VAS) will be completed at Baseline (acute and standard versions), daily during the 
first week of treatment (acute version); Weeks 4, 12, 16, and 24; and then every 8 weeks 
thereafter (every 16 weeks following Protocol Amendment 8) through the Early 
Discontinuation/End of Treatment Visit (standard version).  
Has been changed to:  
The Pain (VAS) will be completed at Baseline (acute and standard versions), daily during the 
first week of treatment (acute version); Weeks 4, 12 , 16, 24, and then every 8  weeks 
thereafter  (for study participants enrolled prior to Protocol Amendment 9, visit frequency 
changes to every 16 weeks instead of every 8 weeks following implementation of Protocol 
Amendment 8 ) through the Early Discontinuati on/End of Treatment Visit (standard version).  
Change #1 31 
Section 11.14, fourth paragraph, second sentence:  
The Fatigue Assessment Scale will be assessed at Baseline, Weeks 1, 2, 4, 8, 16, 24, 32, then 
every 8 weeks thereafter (every 16 weeks following Protocol Amendment 8) , and  the Early 
Discontinuation/End of Treatment Visit. Preferably, the same parent/caregiver should 
complete the scale for each visit.  
Has been changed to:  
The Fatigue Assessment Scale will be assessed at Baseline, Weeks 1, 2, 4, 8, and then every 
8 weeks thereafter  (for study participants enrolled prior to Protocol Amendment 9, visit 
frequency changes to every 16 weeks instead of every 8 weeks following implementation of 
Protocol Amendment 8 ) and the Early D iscontinuation/End of Treat ment Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 272 of 280 Change # 132 
Section 12.4, the following text has been added:  
A futility analysis of the PedACR30 response rate was performed after all active study 
participants on the reduced CZP dose had completed the Week 16 (Visit 8) assessments. If 
less than 50% of the study population enrolled on the reduced CZP dose regimen ( Protocol 
Amendment 5) achieved a PedACR30 response at Week 16, the study was to be 
discontinued. The futility analysis confirmed that ≥50% of the study population enrolled on 
the reduced CZP dose regimen achieved a PedACR30 response at Week 16. A further f utility 
analysis will not be performed using the additional participants that will be enrolled on the 
original CZP dose regimen following the implementation of Protocol Amendment 9.  
Change #1 33 
Section 13.2.1, paragraph 1, bullet 2:  
Reduced CZP dose regim en: includes all subjects in the SS who began treatment in 
accordance with the reduced dosing regimen defined for the study (3 loading doses of CZP at 
Weeks 0, 2, and 4 [minimum=50mg Q2W, maximum=200mg Q2W] followed by a 
maintenance dose for the duration o f the study  [minimum=50mg Q4W, maximum=100mg 
Q2W]).  
Has been changed to:  
Reduced CZP dose regimen: includes all study participants in the SS who began treatment in 
accordance with the reduced dosing regimen defined for the study (3 loading doses of CZP at 
Weeks 0, 2, and 4 [minimum=50mg Q2W, maximum=200mg Q2W] followed by a 
maintenance dose for the duration of the study [minimum=50mg Q4W, maximum=100mg 
Q2W]). This subgroup includes all study participants who began the study with this CZP 
dose regimen and re ceived 1 or more doses of this regimen, regardless of any subsequent 
switch to the original CZP dose regimen.  
Change #1 34 
Section 13.2.2:  
Approximately 55 centers are planned to enroll 156 subjects into this study. The enrollment 
per site is limited to a m aximum of 12 subjects.  
Has been changed to:  
Approximately 55 centers are planned to enroll the original 156 study participants into this 
study. A subset of these centers will be used to enroll the additional 30 study participants 
following Protocol Amendme nt 9. The enrollment per site is limited to a maximum of 
12 study participants.   
Change # 135 
Section 13.3, paragraph 1, sentence 1:  
The incidence of AEs will be assessed as primary safety variable in this study . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 273 of 280 Has been changed to:  
The incidence of serious TEAEs and TEAEs leading to permanent withdrawal of IMP  will be 
assessed as primary safety variables in this study. Other safety variables include the incidence 
of TEAEs, TEAEs of interest, TEAEs by [CONTACT_182811], TEAEs by [CONTACT_926], and TEAEs by 
[CONTACT_658361].  
Change #1 36 
Section 13.3, paragraph 4, sentence  1 and 2:  
For the original CZP dose regimen subgroup, in addition to the overall presentation of AEs, 
AEs will be summarized separately for the periods of exposure to original and reduced CZP 
dose regimens. Additionally, the frequency and percentage of AEs reported during the first 
16 weeks of study medication exposure will be summarized separately for the 2 CZP dose 
regimens ( original CZP dose regimen, reduced CZP dose regimen).  
Has been chang ed to:  
For the original CZP dose regimen subgroup, in addition to the overall presentation of AEs, 
AEs will be summarized separately for the periods of exposure to original CZP dose regimen 
and the reduced CZP dose regimen, in addition to exposure for stud y participants that 
switched from the reduced CZP dose regimen to the original CZP dose regimen following 
Protocol Amendment  9. 
Change #13 7 
Section 13.4, paragraph 1:  
Certolizumab pegol plasma concentrations and anti -CZP antibody concentrations will be 
assessed as primary variables in this study.  
Has been changed to:  
Certolizumab pegol plasma concentrations levels at Week 16 and Week 48 will be assessed 
as primary variables in this study. Other PK and immunological variables include CZP 
plasma concentrat ions at other study timepoints and anti -CZP antibody levels throughout the 
study.  
Change # 138 
Section 13.4, paragraph 2:  
Plasma concentrations will be used to build a PopPK model with the nonlinear mixed -effect 
modeling (NONMEM) software.  
Has been changed to: 
Plasma CZP concentrations will be used to build a PopPK model with the nonlinear mixed -
effect modeling (NONMEM) software. The model will be parameterized in terms of 
clearance, volume of distribution, and absorption rate constant. Details of the PopPK 
modeling procedures will be described in a separate data analysis plan. The pediatric PopPK 
model will be combined with PD data (PedACR) and if the data allow, an exposure response 
relationship will be derived. These modeling analyses and results will be r eported separately.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 274 of 280 Change # 139 
Section 13.4, paragraph 3, 4, 5, 6, and 7:  
A meta -analysis was previously performed by [CONTACT_658362] a 
PopPK analysis within NONMEM (C87068 and CL0153) for the Week 24 interim analysis 
(with ELISA data).  
For the final analysis, UCB will be re -assaying all available PK samples (ie, for which 
sufficient volume is available) with a newly developed MSD bioanalytical assay. The data 
from the re -assayed RA0043 PK samples will be used to build a PopP K model.  
The model will be parameterized in terms of clearance, volume of distribution, and 
absorption rate constant. Details of the PopPK modeling procedures will be described in a 
separate data analysis plan. Analyses and results will be reported in a se parate report.  
The pediatric PopPK model will be combined with PD data (PedACR) and if the data allow, 
an exposure -response relationship will be derived.  
Individual  anti-CZP antibody concentrations will be listed and the incidence of anti -CZP 
positive (>2. 4units/mL)  subjects will be summarized by [CONTACT_658363] (all subjects, 2 to 5 years, 6 to 11 years, and 12 to 17 years). In addition 
safety and efficacy profiles by [CONTACT_658364].  
Certolizumab pegol plasma concentration data will be tabulated and summarized by [CONTACT_658340] ( original  CZP dose regimen or reduced CZP dose regimen) for each visit on which 
samples were taken (geometric mean, arithmetic mean, minimum, maximum, standard 
deviation and % coefficient of variation). Plasma concentration time curves will be plotted 
separately for subjects who began treatment according to the original  CZP dose regimen or 
the reduced CZP dose regimen, overall, by [CONTACT_658336], and by [CONTACT_14181] -CZP antibody 
status.  Subgroup analyses will include an analysis  of the subjects enrolled and treated up to 
the Week 16 timepoint under the original maintenance  dosing regimen.  
Has been changed to:  
All study participants enrolled following Protocol Amendmen t [ADDRESS_887962] plasma CZP 
concentrations and anti -CZP antibodies analyzed using the ECLIA method. In addition, PK 
and ADA samples (for which sufficient volume is available) collected in this study prior to 
Protocol Amendment 9 will be analyzed with the ECLI A method.  
Data from the ECLIA method will constitute the study's main PK and anti -CZP antibody 
evaluations. As such, PK and anti -CZP antibody data generated with the original ELSIA 
method will be reported as Listings. Plasma CZP concentration data generat ed by [CONTACT_658305] (geometric mean, arithmetic mean, minimum, 
maximum, standard deviation and % coefficient of variation) by [CONTACT_658306] (original 
CZP dose regimen or reduced CZP dose regimen) for each PK samplin g visit. Plasma 
concentration time curves will be plotted, along with respective individual anti -CZP antibody 
titers where available, separately for study participants who began treatment according to the 
original CZP dose regimen or the reduced CZP dose r egimen, overall, and by [CONTACT_658307]. Subgroup analyses will include study participants enrolled with Protocol 
Amendment 9 and those treated up to the Week 16 timepoint under the original maintenance 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 275 of 280 dosing regimen. Where available, individual ECLI A-based anti -CZP antibody data will be 
tabulated by [CONTACT_658308] (all study participants, 2 to 5 years, 6 to 
11 years, and 12 to 17 years). In addition, safety and efficacy profiles by [CONTACT_658365] (or 
titer categories) may be in vestigated.   
Change # 140 
Section 13.5, paragraph 5, bullets 14 and 15:  
 Change from Baseline on FPS -R (child -reported, for subjects ages 5 to 11 years), daily 
during the first 7 days of treatment; Weeks 4, 12, 16, and 24; and then every 8 weeks 
thereafter through the Early Discontinuation/End of Treatment Visit . Following Protocol 
Amendment 8, change from Baseline on FPS -R is assessed every 16 weeks.  
 Change from Baseline in JIA Pain VAS, daily during the first week of the study (acute 
and standard versions) ; Weeks 4, 12, 16, and 24; and then every 8 weeks thereafter 
through the Early Discontinuation/End of Treatment Visit (standard version) for subjects 
ages 12 to 17 years. Following Protocol Amendment 8, change from Baseline in JIA Pain 
VAS is assessed ever y 16 weeks.  
Has been changed to:  
 Change from Baseline on FPS -R (child -reported, for study participants ages 5 to 11 
years), daily during the first 7 days of treatment; Weeks 4, 12, 16, 24, and then every 
8 weeks thereafter ( for study participants enrolled prior to Protocol Amendment 9, visit 
frequency changes to every 16 weeks instead of every 8 weeks following implementation 
of Protocol Amendment 8 ) through the Early Discontinuation/End of Treatment Visit.   
 Change from Baseline in JIA Pain VAS, daily durin g the first week of the study (acute 
and standard versions); Weeks 4, 12, 16, 24, and then every 8  weeks thereafter ( for study 
participants enrolled prior to Protocol Amendment 9, visit frequency changes to every 16 
weeks instead of every 8 weeks following  implementation of Protocol Amendment 8 ) 
through the Early Discontinuation/End of Treatment Visit  (standard version) for study 
participants ages 12 to 17 years.  
Change #1 41 
Section 13.7, the following text was added:  
A futility analysis of the PedACR30 res ponse rate was performed after all active study 
participants enrolled on the reduced CZP dose had completed the Week 16 (Visit 8) 
assessments. If less than 50% of the study population enrolled on the reduced CZP dose 
regimen (Protocol Amendment 5) achieved  a PedACR30 response at Week 16, the study was 
to be discontinued. The futility analysis confirmed that ≥50% of the study population enrolled 
on the reduced CZP dose regimen achieved a PedACR30 response at Week 16. Given the 
descriptive nature of the data presentations, there were no statistical implications of this 
interim analysis. A further futility analysis will not be performed using the additional subjects 
that will be enrolled on the original CZP dose regimen following the implementation of 
Protocol Amendment 9.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 276 of 280 In addition to the futility analysis, several interim analyses were planned, including interim 
analyses of PK data, and full interim analyses of PK, immunogenicity, safety, and efficacy 
endpoints, as described below.  
Change #1 42 
Section 13.7,  paragraph 1 and 2, the following text was removed:  
Interim analysis of PK data will compare CZP plasma concentration data from this study with 
CZP plasma concentrations observed previously in adult subjects with RA. Interim analysis 
of CZP plasma concentr ations was started when 6  subjects in 1  of the age groups completed 
Week  12 (Visit 7).   
Comparisons will be made between the Week 12 geometric mean and median values for the 
pediatric and adult subjects, as well as between the individual pediatric data and  the adult 5th 
and 95th percentile and minimum and maximum observed values.  
Change # 143 
Section 13.7, paragraph 3:  
If the pediatric plasma concentrations demonstrate that the geometric mean and median 
concentrations are below the adult 5th percentile or ab ove the 95th percentile, the PK data 
will be used to re -evaluate the weight -based dose adjustment algorithm for pediatric subjects. 
Interim CZP plasma concentration data available at the time of Protocol Amendment 3 
indicated that no change to the dosing a lgorithm was required. The protocol stated that if 
future interim analyses, which may include PopPK, indicate that plasma concentrations of 
JIA subjects are outside of the exposure range observed in previous adult RA studies, a 
revised pediatric dose algor ithm will be derived. Any change in dose regimen will require a 
protocol amendment prior to implementation.  
Based on results of an interim PopPK analysis conducted in Jun 2013 described in Section 
5.1, the dosing regimen will be changed with Protocol Amendments 4 and 5, and the doses to 
be administered will be reduced by 50% for all weight groups. This change is intended to 
achieve plasma concentrations similar to the effective concentrations observed in previous 
studies in adult subjects with RA.  
Has been changed to:  
Per original protocol, if the pediatric plasma concentrations demonstrate that the geometric 
mean and median concentrations are below the adult 5th percentile or above the 95th 
percentile, the PK data will be used to re -evaluate the weight -based dose adjustment 
algorithm for pediatric study  participants. Interim CZP plasma concentration data available at 
the time of Protocol Amendment 3 indicated that no change to the dosing algorithm was 
required. The protocol stated that if future interim  analyses, which may include PopPK,  
indicate that plasma concentrations of JIA study participants are outside of the exposure 
range observed in previous adult RA studies, a revised pediatric dose algorithm will be 
derived. Any change in dose regimen will r equire a protocol amendment prior to 
implementation.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 277 of 280 An interim analysis of PK data conducted following Protocol Amendment 3 compared CZP 
plasma concentration data from this study with CZP plasma concentrations observed 
previously in adult study participants with RA. Interim analysis of CZP plasma 
concentrations was started when 6  study participants in 1  of the age groups completed 
Week  12 (Visit 7). Comparisons were made between the Week 12 geometric mean and 
median values for the pediatric and a dult study participants, as well as between the individual 
pediatric data and the adult 5th and 95th percentile and minimum and maximum observed 
values.  
Based on results of this interim PopPK analysis (also described in Section  5.1), the dosing 
regimen was changed with Protocol Amendments 4 and 5, and the doses to be administered 
were reduced by 50% for all weight groups. This change was intended to ac hieve plasma 
concentrations similar to the effective concentrations observed in previous studies in adult 
study participants with RA.  
Change # 144 
Section 13.7, paragraph 5, 6, 7:  
For the Week [ADDRESS_887963] completed the Week 16 (Visit 8) assessments, an interim 
analysis of PedACR30 response rates will be performed and the study w ill be discontinued if 
less than 50% of the study population enrolled on the reduced CZP dose regimen (Protocol 
Amendment 5) achieves a PedACR30 response at Week 16. Given the descriptive nature of 
the data presentations, there are no statistical implicati ons of this interim analysis.  
After the last subject has reached the Week 24 Visit (Visit 10), the database will be cut and a 
full interim analysis of all safety and efficacy endpoints will be performed based upon 
24 weeks of exposure for each individual (or all data for those cases who withdrew before 
this timepoint).  
Has been changed to:  
An interim analysis of PK, immunogenicity, safety, and efficacy endpoints was performed 
after all active study participants that were enrolled and treated prior to implementation of 
Protocol Amendment 9 had completed the Week  24 (Visit 10) assessments, and the results 
were reported separately. An interim analysis, including all enrolled participants, f or all PK, 
immunogenicity, safety, and efficacy endpoints will be performed after all active study 
participants, including those enrolled following the implementation of Protocol 
Amendment  9, have completed the Week  24 (Visit 10) assessments.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   27 Apr 2020  
Clinical Study Protocol  Certolizumab pegol  RA0043  
   
Confidential  Page 278 of 280 Change # 145 
Section 13.8, paragraph 1:  
Based upon the ICH guideline for the assessment of safety, it is planned to enroll a sufficient 
number of subjects to this study to have a minimum of [ADDRESS_887964] 12 months 
continuous exposure to CZP. Assuming a dropout rate of approximately 20%, it was 
originally determined that 125 subjects would need to be enrolled. At the time of Protocol 
Amendment 5, 78 subjects had been enrolled according to the original CZP dose regimen, 
and it is planned to enroll a further 78 subjects  on the reduced CZP dose regimen, so that a 
comparable number of subjects on the reduced CZP dose regimens can be analyzed. Thus, the 
total number of subjects planned to be enrolled will be increased to 156 subjects. Assuming a 
Screening failure rate of 25 %, it is planned to screen 195 subjects in total.  
Has been changed to:  
Based upon the ICH guideline for the assessment of safety, it is planned to enroll a sufficient 
number of study participants to this study to have a minimum of [ADDRESS_887965] 12 mont hs 
continuous exposure to CZP. Assuming a dropout rate of approximately 20%, it was 
originally determined that 125 study participants would need to be enrolled. At the time of 
Protocol Amendment 5, 78 study participants had been enrolled according to the o riginal 
CZP dose regimen, and it was planned to enroll a further 78 study participants on the reduced 
CZP dose regimen, so that a comparable number of study participants on the reduced CZP 
dose regimens could be analyzed. Thus, the total number of study pa rticipants planned to be 
enrolled was increased to 156 study  participants. Assuming a Screening failure rate of 25%, it 
is planned to screen 195 study participants in total.   
Change # 146 
Section 13.8, the following text has been added:  
With Protocol Amendment 9, an additional [ADDRESS_887966] 5 study participants in each weight range 
of 10 to <20kg (22 to <44lb), 20 to <40kg (44 to <88lb), and ≥40kg (≥88lb).  
Change #14 7 
Section 16, the following reference has been added:  
FDA Guidance for Industry – Bioanalytical Method Validation. 2018.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_887967].  
Investigator:  
 
 
__________________________________  
Printed Name   
 
 
__________________________________  
Date/Signature  
[CONTACT_207346]. 
UCB   [ADDRESS_887968] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: [INVESTIGATOR_20116]0043-protocol-amend-9
Version: 1 . 0
Document Number: CLIN-000151233
Title: RA0043 - Protocol Amendment 9 - Phase 3 - Open-label
Approved Date: [ADDRESS_887969]: ApprovedName: 
[CONTACT_18469]: Medical
Date of Signature: 27-Apr-2020 17:14:30 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Subject Matter Expert
Date of Signature: 27-Apr-2020 17:57:24 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 27-Apr-2020 18:03:16 GMT[PHONE_006]
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 